US20090258922A1 - Compound exhibiting pgd2 receptor antagonist - Google Patents

Compound exhibiting pgd2 receptor antagonist Download PDF

Info

Publication number
US20090258922A1
US20090258922A1 US12/413,503 US41350309A US2009258922A1 US 20090258922 A1 US20090258922 A1 US 20090258922A1 US 41350309 A US41350309 A US 41350309A US 2009258922 A1 US2009258922 A1 US 2009258922A1
Authority
US
United States
Prior art keywords
cooh
optionally substituted
formula
group represented
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/413,503
Inventor
Norihiko Tanimoto
Yoshiharu Hiramatsu
Susumu Mitsumori
Masanao Inagaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to US12/413,503 priority Critical patent/US20090258922A1/en
Publication of US20090258922A1 publication Critical patent/US20090258922A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Prostaglandin D 2 (PGD 2 ), a metabolite derived from arachidonic acid through PGG 2 and PGH 2 , is known to have a variety of potent biological activities.
  • PGD 2 is involved in biological actions such as sleep induction and hormone secretion in the central nervous system, inhibition of platelet aggregation, contraction of airway smooth muscle, and relaxation or constriction of vascular smooth muscle in the peripheral tissue (Pharmacol. Rev. (1994) 46, 205-229).
  • PGD 2 is the major metabolite of arachidonic acid produced by mast cells and can cause strong bronchoconstriction, increased vascular permeability, and migration of inflammatory cells such as eosinophils. From these findings, PGD 2 is considered to be deeply involved in the pathogenesis in allergic diseases such as asthma.
  • DP receptor is known as a PGD 2 receptor and antagonists against its receptor are described in WO 98/25915, WO 01/66520, WO 01/79169 and the like.
  • PGD 2 antagonistic activity of the above compounds has not been described in them.
  • PGD 2 also binds TXA 2 receptor in high concentration range (more than 1 ⁇ M) (Eur. J. Pharmacol. (1992) 226, 149-156; Br. J. Pharmacol. (1991) 103, 1883-1888 etc., 2) antagonists against TXA 2 receptor which have weak receptor affinity for DP receptor show the same depression effect (Int. Arch. Allergy Immunol.
  • the inventors of the present invention find out new compounds having a selective CRTH2 receptor antagonistic activity but not having a TXA 2 receptor antagonistic activity.
  • R 4 , R 5 , R 6 and R 7 are each independently hydrogen, halogen, haloalkyl, carboxy, alkyloxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, a group represented by the formula: —S(O)pR 8 wherein p is an integer from 0 to 2 and R 8 is alkyl or optionally substituted aryl, a group represented by the formula: —NR 9 R 10 wherein R 9 and R 10 are each independently hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl or acyl, or a group represented by the formula: —OR 11 wherein R 11 is hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl, alkanesulfonyl
  • R 20 is hydrogen or alkyl
  • R 21 is hydrogen or halogen; but excluding compounds 3-(4-chlorophenylsulfonylamino)-9-(2-carboxymethyl)-1,2,3,4-tetrahydrocarbazole, its ethyl ester, 3-(4-chlorophenylsulfonylaminoethyl)indolel-acetic acid, and 3-(4-chlorophenylsulfonylaminopropyl)indole acetic acid; or R 13 is hydrogen, alkyl, aralkyl, acyl or a group represented by the formula: —OR 16 wherein R 16 is hydrogen or alkyl, and R 14 is hydrogen or alkyl: or a group represented by the formula:
  • R 17 is hydrogen or alkyl
  • Z 1 is —CH 2 —, —C( ⁇ O)—, —C( ⁇ NOH)—, or —C( ⁇ NOMe)-
  • Z 2 is a group represented by the formula: —S( ⁇ O)s- wherein s is an integer from 0 to 2, a group represented by the formula: —N(—R 22 )— wherein R 22 is hydrogen, alkyl, alkyloxycarbonyl or acyl, or a group represented by the formula: —CR 18 R 19 — wherein R 18 and R 19 are each independently hydrogen, alkyl or aryl; or R 18 and R 19 are taken together to form a group represented by the formula: —(CH 2 )t- wherein t is an integer from 2 to 5; R 1 and R 15 are as defined above; and a group represented by the formula:
  • Y, E, R 20 and R 21 are as defined above; a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • this invention relates to the following II) to XV).
  • Z 3 is ⁇ C(—R 7 )—; R 4 , R 5 , R 6 and R 7 are as defined in I); Z 4 is —C(—R 2 ) ⁇ ; R 2 is as defined in I); R 15 is hydrogen; and R 3 is a group represented by the formula: —(CH 2 )n-N(—Y)—SO 2 —Ar wherein n is an integer from 1 to 3; Y is hydrogen, alkyl, alkenyl, optionally substituted aryl, optionally substituted aralkyl, or optionally substituted heteroarylalkyl; and Ar is optionally substituted aryl or optionally substituted heteroaryl, a group represented by the formula:
  • Y and Ar are as defined in I), and R 20 and R 21 are hydrogen, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • R 3 is a group represented by the formula: —(CH 2 )n-N(—Y)—SO 2 —Ar wherein n is 2 or 3; Y is hydrogen, alkyl, alkenyl, or aralkyl; and Ar is as defined in I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • R 3 is a group represented by the formula:
  • Y is hydrogen, alkyl, alkenyl or aralkyl; and R 20 , R 21 and Ar are as defined in I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • IX) A compound as described in any one of I) to VIII), wherein R 1 is carboxy, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • X) A compound as described in any one of I) to IX), wherein R 4 , R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • XI) A compound as described in any one of I) to X), wherein R 2 is hydrogen or alkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • XII) A pharmaceutical composition containing a compound, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof as described in any one of I) to XI).
  • XIII) A pharmaceutical composition as described in XII), which is used for an antagonist against the CRTH2 receptor.
  • XIV) A method for treating a disease relating to the CRTH2 receptor, which comprises administrating a compound as described in I).
  • XV) Use of the compound as described in I) for the preparation of a pharmaceutical composition for treating a disease relating to the CRTH2 receptor.
  • halogen means fluoro, chloro, bromo, and iodo. Fluoro, chloro, and bromo are preferred as halogen.
  • alkyl employed alone or in combination with other terms includes a straight- or branched chain monovalent hydrocarbon group having 1 to 8 carbon atom(s).
  • alkyl examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, and the like.
  • C1 to C6 alkyl is preferred.
  • C1 to C3 alkyl is more preferred.
  • cycloalkyl employed alone or in combination with other terms includes a mono cycloalkyl having 3 to 8 carbon atom.
  • examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • C3 to C6 cycloalkyl is preferred.
  • alkenyl employed alone or in combination with other terms includes a straight- or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and one or more double bond(s).
  • alkenyl examples include vinyl, allyl, 1-propenyl, 2-propenyl, crotonyl, isopentenyl, a variety of butenyl isomers and the like.
  • C2 to C6 alkenyl is preferred.
  • C2 to C4 alkenyl is more preferred.
  • alkynyl employed alone or in combination with other terms includes a straight or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and one or more triple bond(s).
  • alkynyl examples include ethynyl, 1-propynyl, 2-propynyl and the like.
  • C2 to C6 alkynyl is preferred.
  • C2 to C4 alkynyl is more preferred.
  • aryl employed alone or in combination with other terms includes monocyclic or condensed ring aromatic hydrocarbons. Examples of aryl are phenyl, 1-naphtyl, 2-naphtyl, anthryl, and the like. Phenyl, 1-naphtyl, and 2-naphtyl are preferred. Phenyl is more preferred.
  • aralkyl employed alone or in combination with other terms includes the above mentioned “alkyl” substituted with the above mentioned one or more “aryl” at any possible position.
  • examples of the aralkyl are benzyl, phenylethyl (e.g., 2-phenylethyl), phenylpropyl (e.g., 3-phenylpropyl), naphthylmethyl (e.g., 1-naphthylmethyl and 2-naphthylmethyl), anthrylmethyl (e.g., 9-anthrylmethyl), and the like.
  • Benzyl, 2-phenylethyl, 1-naphthylmethyl and 2-naphthylmethyl are preferred.
  • Benzyl and 2-phenylethyl are more preferred.
  • aralkyl herein used includes the above mentioned “alkyl” substituted with the above mentioned one or more “aryl” at any possible position.
  • examples of the aralkyl are benzyl, phenylethyl (e.g., 2-phenylethyl), phenylpropyl (e.g., 3-phenylpropyl), naphthylmethyl (e.g., 1-naphthylmethyl and 2-naphthylmethyl), anthrylmethyl (e.g., 9-anthrylmethyl), and the like.
  • Benzyl, 2-phenylethyl, 1-naphthylmethyl and 2-naphthylmethyl are preferred.
  • Benzyl and 2-phenylethyl are more preferred.
  • arylalkenyl herein used includes the above mentioned “alkenyl” substituted with the above mentioned one or more “aryl” at any possible position.
  • Examples of the arylalkenyl are phenylallyl, naphthylallyl, and the like.
  • non-aromatic heterocyclic group includes a 5 to 7 membered non-aromatic ring which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring, and the 5 to 7 membered non-aromatic ring may be condensed with two or more rings.
  • non-aromatic heterocyclic group examples include pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl), pyrrolinyl (e.g., 3-pyrrolinyl), imidazolidinyl (e.g., 2-imidazolidinyl), imidazolinyl (e.g., imidazolinyl), pyrazolidinyl (e.g., 1-pyrazolidinyl, 2-pyrazolidinyl), pyrazolinyl (e.g., pyrazolinyl), piperidyl (e.g., piperidino, 2-piperidyl), piperazinyl (e.g., 1-piperazinyl), indolynyl (e.g., 1-indolynyl), isoindolinyl (e.g., isoindolinyl), morpholinyl (e.g., morpholino, 3-morpholin
  • heteroaryl employed alone or in combination with other terms includes a 5 to 6 membered aromatic heterocyclic group which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring.
  • the aromatic heterocyclic group may be fused with the above mentioned cycloalkyl, above mentioned aryl, above mentioned non-aromatic heterocyclic group, and other heteroaryl at any possible position.
  • the heteroaryl which is a monocyclic or fused ring may be bonded at any possible position.
  • heteroaryl examples include pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl 3-thienyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl), isothiazolyl (e.g., 3-isothiazolyl), isoxazolyl (e.g., 3-isoxazolyl), oxazolyl (e.g., 2-oxazolyl), thiazolyl (e.g., 2-thiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl (e.g., 2-pyrazinyl), pyrimid
  • Thienyl, benzothienyl, dibenzothienyl, benzodioxolyl, oxazolyl, and the like are preferred as heteroaryl of Ar.
  • heteroarylalkyl herein used includes the above-mentioned “alkyl” substituted with the above-mentioned one or more “heteroaryl” at any possible position.
  • heteroarylalkyl examples include thienylalkyl, furylalkyl, pyrrolylalkyl, imidazolylalkyl, pyrazolylalkyl, thiazolylalkyl, isothiazolylalkyl, isoxazolylalkyl, oxazolylalkyl, pyridylalkyl, and the like.
  • Thienylmethyl e.g., 2-thienylmethyl
  • thienylethyl e.g., 2-(thiophen-2-yl)ethyl
  • furylmethyl e.g., 2-furylmethyl
  • furylethyl e.g., 2-(furan-2-yl)ethyl
  • pyrrolylmethyl e.g., 2-pyrrolylmethyl
  • pyrrolylethyl e.g., 2-(pyrrol-2-yl)ethyl
  • imidazolylmethyl e.g., 2-imidazolylmethyl, 4-imidazolylmethyl
  • imidazolylethyl e.g., 2-(imidazol-2-yl)ethyl
  • pyrazolylmethyl e.g., 3-pyrazolylmethyl
  • pyrazolylethyl e.g., 2-(pyrazol-3-yl)ethyl
  • Thienylmethyl is preferred as heteroaryl of Y.
  • alkyloxy herein used are methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy, and the like. Methyloxy, ethyloxy, n-propyloxy, isopropyloxy and n-butyloxy are preferred. C1 to C3 alkyloxy is more preferred.
  • alkylthio herein used are methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, and the like. Methylthio, ethylthio, n-propylthio, isopropylthio and n-butylthio are preferred. C1 to C3 alkylthio is more preferred.
  • aryloxy phenyloxy, naphthyloxy, and the like are exemplified as “aryloxy.”
  • arylthio phenylthio, naphthylthio, and the like are exemplified as “arylthio.”
  • arylazo phenylazo, naphthylazo, and the like are exemplified as “arylazo.”
  • alkyloxycarbonyl herein used are methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl and the like. Methyloxycarbonyl and ethyloxycarbonyl are preferred. C1 to C3 alkyloxycarbonyl are more preferred.
  • acyl employed alone or in combination with other terms includes alkylcarbonyl in which alkyl group is the above-mentioned “alkyl” and arylcarbonyl in which aryl group is the above-mentioned “aryl”.
  • alkyl and aryl may be substituted respectively with substituents exemplified in the following “optionally substituted alkyl” and “optionally substituted aryl”.
  • Examples of the acyl are acetyl, propyonyl, butyloyl, benzoyl, and the like.
  • haloalkyl employed alone or in combination with other terms includes the above-mentioned “alkyl” which is substituted with the above-mentioned “halogen” at 1 to 8 positions, preferably, at 1 to 5.
  • examples of the haloalkyl are trifluoromethyl, trichloromethyl, difluoroethyl, trifluoroethyl, dichloroethyl, trichloroethyl, chloromethyl, and the like. Preferable is trifluoromethyl.
  • acyloxy herein used are acetyloxy, propionyloxy, benzoyloxy and the like.
  • alkanesulfonyl herein used are methanesulfonyl, ethanesulfonyl, n-propanesulfonyl, isopropanesulfonyl, n-butanesulfonyl, isobutanesulfonyl, sec-butanesulfonyl, tert-butanesulfonyl, and the like. Methanesulfonyl and ethanesulfonyl are preferred.
  • arylsulfonyl herein used are phenylsulfonyl, naphthylsulfonyl, and the like.
  • aralkylsulfonyl examples are benzylsulfonyl, phenylethylsulfonyl, and the like.
  • heteroarylsulfonyl herein used is pyrrolylsulfonyl or the like.
  • the term “optionally substituted amino” employed alone or in combination with other terms includes amino which may be substituted with one or two of the above-mentioned “alkyl”, above-mentioned “aryl”, above-mentioned “aralkyl”, above-mentioned “heteroaryl”, above-mentioned “heteroarylalkyl”, above-mentioned “acyl”, above-mentioned “alkyloxycarbonyl” and/or “alkanesulfonyl”.
  • Examples of the optionally substituted amino are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino, benzylamino, acetylamino, benzoylamino, methyloxycarbonylamino, methanesulfonylamino, and the like.
  • Preferable are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino, acetylamino, methanesulfonylamino.
  • aminocarbonyl examples include aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, diethylaminocarbonyl, benzylamino, acetylamino, methanesulfonylaminocarbonyl and the like.
  • aminocarbonyl methylaminocarbonyl, dimethylaminocarbonyl, and methanesulfonylaminocarbonyl.
  • the term “optionally substituted ureide” includes ureide substituted with one or more of the above-mentioned “alkyl”, above-mentioned “aryl”, above-mentioned “aralkyl”, above-mentioned “heteroaryl”, above-mentioned “heteroarylalkyl” or above-mentioned “acyl”.
  • substituents of “optionally substituted alkyl” are cycloalkyl, alkenyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, optionally substituted non-aromatic heterocyclic group, aryloxy (e.g., phenyloxy), aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • alkyloxy, hydroxy, optionally substituted amino, aryloxy, and the like are substituents of “optionally substituted alkyl” for R 4 , R 5 , R 6 , and R 7 .
  • substituents of “optionally substituted cycloalkyl” are alkyl, cycloalkyl, alkenyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, aryloxy (e.g., phenyloxy), aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • alkyl, halogen, and the like are alkyl, halogen, and the like as substituents of “optionally substituted cycloalkyl” for R 4 , R 5 , R 6 , and R 7 .
  • substituents of “optionally substituted alkenyl” are alkyl, cycloalkyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, aryl, aryloxy (e.g., phenyloxy), aralkyl, aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • halogen, aryl, and the like as substituents of “optionally substituted alkenyl” for R 4 , R 5 , R 6 , and R 7 .
  • substituents of “optionally substituted aryl”, “optionally substituted aralkyl”, “optionally substituted heteroaryl”, “optionally substituted arylsulfonyl”, “optionally substituted aralkylsulfonyl”, and “optionally substituted non-aromatic heterocyclic group” herein used are alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, alkyloxy, haloalkyloxy, aryloxy, aralkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, acyl, acyloxy, alkanesulfonyl, guanidino, an azo group, optionally substituted amino, optionally substituted aminocarbonyl, aryl which may be substituted with one or more of the substituents selected from Substituents group C, heteroaryl which may be
  • substituents are able to locate at one or more of any possible positions (Substituents group C: alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, alkyloxy, haloalkyloxy, aryloxy, aralkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, acyl, acyloxy, alkanesulfonyl, guanidino, an azo group, optionally substituted amino, and optionally substituted aminocarbonyl).
  • Substituents group C alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, alkyloxy, haloalkyloxy, aryloxy, aralkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy,
  • alkyl, alkyloxy, halogen, and the like are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R 4 , R 5 , R 6 , and R 7 .
  • alkyl, alkyloxy, halogen, and the like are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R 8 .
  • alkyl, alkyloxy, halogen, and the like are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R 9 and R 10 .
  • alkyl, alkyloxy, halogen, and the like are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R 11 .
  • alkyl, alkyloxy, halogen, and the like are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for Y.
  • alkyl, alkyloxy, aryloxy, halogen, benzyl, phenyl which may be substituted with substituents selected from Substituents group B, and the like as substituents of “optionally substituted aryl” for Ar (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, and benzyl).
  • alkyl, halogen, and the like are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R 4 , R 5 , R 6 , and R 7 .
  • alkyl, halogen, and the like are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R 9 and R 10 .
  • alkyl, halogen, and the like are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R 11 .
  • alkyl, alkyloxy, nitro, halogen, and the like are alkyl, alkyloxy, nitro, halogen, and the like as substituents of “optionally substituted aralkyl” for Y.
  • alkyl, alkyloxy, aryloxy, halogen, benzyl, phenyl which may be substituted with substituents selected from Substituents group B, and the like as substituents of “optionally substituted heteroaryl” for Ar (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, and benzyl).
  • alkyl and the like are substituents of “optionally substituted arylsulfonyl” for R 11 .
  • alkyl and the like are alkyl and the like as substituents of “optionally substituted aralkylsulfonyl” for R 11 .
  • the compounds represented by the formula (I) of the present invention can be synthesized by reacting the compounds represented by the following formula (IIa) to (IIk):
  • R 1 is alkyloxycarbonyl and the other symbols are as defined in I) or their salts with 1 to 5 eq. of a compound represented by the formula Ar—SO 2 —X 1 or E-SO 2 —X 1 wherein Ar and E are as defined in I), and X 1 is halogen in an inactive solvent at 0° C. to room temperature for 5 min. to several hours.
  • This reaction can be carried out in the presence of 1 to 5 eq. of a base.
  • Triethylamine, pyridine, potassium carbonate, sodium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide and the like are preferred as a base.
  • Pyridine, acetonitrile, dichloromethane, tetrahydrofuran (THF) and the like are preferred as an inactive solvent, and they can be used themselves or mixed solvents with water.
  • the compound wherein Y is alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl can be synthesized by reacting with Y-X 2 wherein X 2 is halogen, optionally substituted alkanesulfonyloxy or optionally substituted arylsulfonyloxy in an inactive solvent such as THF, diethylether, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetonitrile, acetone, toluene and the like in the presence of a base such as sodium hydroxide, potassium hydroxide, potassium t-butoxide, potassium carbonate and the like at 0° C.
  • a base such as sodium hydroxide, potassium hydroxide, potassium t-butoxide, potassium carbonate and the like at 0° C.
  • the compound wherein Y is alkyl, alkenyl, optionally substituted aralkyl and the like can be synthesized by reactive amination.
  • the above compound can be synthesized by reacting the compound represented by the formula (IIa), (IIb), or (IIe) wherein Y is hydrogen with corresponding aldehyde or ketone in a solvent such as THF, dichloromethane and the like in the presence of 1 to 5 eq. of sodium borohydride, sodium cyanotrihydroborate or triacetoxyborohydride at 0° C. to 80° C. for 30 min. to several hours.
  • This reaction can be carried out in the presence of 0.1 to 5 eq. of an acidic catalyst such as hydrochloric acid, acetic acid, p-toluenesulfonic acid and the like.
  • an acidic catalyst such as hydrochloric acid, acetic acid, p-toluenesulfonic acid and the like.
  • the compound represented by the formula (I) can be synthesized by the above-mentioned sulfonylation.
  • the compound represented by the formula (I) wherein R 1 is carboxy can be synthesized by acidic hydrolysis or alkali hydrolysis of ester in accordance with the usual hydrolysis condition after the above mentioned reaction.
  • the compound represented by the formula (IIe) can be synthesized by the method described in JP-A-8-169879 and the like.
  • the compounds represented by the formula (IIa) to (IIk) can be synthesized using the compounds represented by the following formula (IIIa) to (IIIk) as a starting material.
  • the compounds represented by the formula (IIa) to (IIk), their salts of inorganic acid such as hydrochloric acid, sulfuric acid and the like or organic acid such as acetic acid, trifluoroacetic acid and the like can be synthesized in accordance with the following processes 1) to 3);
  • the indole derivatives having an alkyloxycarbonylmethyl group on its nitrogen atom is synthesized by reacting the obtained compound in the above process with 1 to 5 eq. of a compound represented by the formula: X 1 —CH 2 CO 2 R 12 wherein X 1 is halogen and R 12 is alkyl in an inactive solvent such as pyridine, acetonitrile, dichloromethane, THF, DMF, DMSO, acetone, methylethylketone, methylisobutylketone and the like in the presence of 1 to 5 eq. of a base such as sodium hydride, potassium hydride, potassium t-butoxide, potassium carbonate and the like at 0 to 100° C.
  • a base such as sodium hydride, potassium hydride, potassium t-butoxide, potassium carbonate and the like at 0 to 100° C.
  • phase transfer catalyst such as tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, benzyltriethylammonium chloride, benzyltributylammonium chloride and the like may be added to the above reaction mixture.
  • the compounds represented by the formula (IIIc) and (IIId), and the compounds represented by the formula (IIIa), (IIIb), and (IIIe) wherein Y is not hydrogen can be introduced into the compound of the formula (I) by the above mentioned sulfonylation and alkyloxycarbonylmethylation of nitrogen atom on the indole ring without protection of an amino group.
  • the compound represented by the formula (I) is a compound having a selective antagonistic activity against CRTH2 receptor but not having an antagonistic activity against TXA 2 receptor. Especially, the compounds represented by the following formula (Ia) to (Ie) are preferred as such a compound.
  • R 1 is carboxy or optionally substituted aminocarbonyl
  • R 2 is hydrogen or alkyl
  • R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR 11 wherein R 11 is alkyl
  • Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or more substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy, and nitro);
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from
  • R 1 is carboxy or optionally substituted aminocarbonyl
  • R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR 11 wherein R 11 is alkyl
  • Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or ore substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy and nitro);
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group A, biphenyl which may be substituted with one or more substituents selected from Substituents group A,
  • R 1 is carboxy or optionally substituted aminocarbonyl
  • R 2 is hydrogen or alkyl
  • R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR 11 wherein R 11 is alkyl
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B, or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl; m is 1, 2, or 3; r is 0 or 1; and x is 0, 1, or 2, a prodrug, a
  • R 1 is carboxy or optionally substituted aminocarbonyl
  • R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR 11 wherein R 11 is alkyl
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl); m is 1 or 2; and y is 1 or 2, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof
  • R 1 is carboxy or optionally substituted aminocarbonyl
  • R 5 , R 6 and R 7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR 11 wherein R 11 is alkyl
  • Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or more substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy and nitro); and
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • solvate includes, for example, solvates with organic solvents, hydrates, and the like.
  • a solvate may coordinate with an arbitrary number of organic solvent molecules.
  • a hydrate may coordinate with an arbitrary number of water molecules.
  • a hydrate is preferred.
  • the term “compound of the present invention” herein used includes a pharmaceutically acceptable salt.
  • the salt is exemplified by a salt with alkali metals (e.g., lithium, sodium, potassium, and the like), alkaline earth metals (e.g., magnesium, calcium, and the like), ammonium, organic bases, amino acids, mineral acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and the like), or organic acids (e.g., acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like).
  • alkali metals e.g., lithium, sodium, potassium, and the like
  • alkaline earth metals e.g., magnesium, calcium, and the like
  • ammonium organic bases
  • amino acids e.g., mineral acids (e.g., hydrochloric acid, hydrobromic acid,
  • Prodrug is a derivative of the compound having a group which can be decomposed chemically or metabolically, and such prodrug is a compound according to the present invention which becomes pharmaceutically active by means of solvolysis or by placing the compound in vivo under a physiological condition.
  • the method of both selection and manufacture of appropriate prodrug derivatives is described in, for example. Design of Prodrugs, Elsevier, Amsterdam, 1985).
  • prodrugs such as an ester derivative which is prepared by reacting a basal acid compound with a suitable alcohol, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a carboxylic group.
  • esters as prodrugs are methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester, N,N-diethylglycolamido ester, and the like.
  • prodrugs such as an acyloxy derivative which is prepared by reacting a basal hydroxy compound with a suitable acyl halide or a suitable acid anhydride, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a hydroxy group.
  • acyloxy derivatives as prodrugs are —OCOC 2 H 5 , —OCO(t-Bu), —OCOC 15 H 31 , —OCO(m-COONa-Ph), —COCH 2 CH 2 COONa, —OCOCH(NH 2 )CH 3 , —OCOCH 2 N(CH 3 ) 2 , and the like.
  • prodrugs such as an amide derivative which is prepared by reacting a basal amino compound with a suitable acid halide or a suitable acid anhydride are exemplified when the compounds according to present invention have an amino group.
  • Particularly preferred amide as prodrugs are —NHCO(CH 2 ) 20 CH 3 , —NHCOCH(NH 2 )CH 3 , and the like.
  • the compound of the present invention is not restricted to any particular isomers but includes all possible isomers and racemic modifications.
  • the pharmaceutical composition of the present invention may be used as a treating and/or preventing agent for allergic diseases having a relation to eosinophils, such as asthma, allergic rhinitis, allergic dermatitis, morbilli papulosi (guinea worm disease and the like), vasculitis, polyarteritis, dermal eosinophilic granuloma, autoimmune disease (e.g., multiple sclerosis, graft rejection, etc.), simple pulmonary eosinophilia, histiocytosis (Histiocytosis), pneumonia, aspergillosis, pleurisy, sarcoidosis, idiopathic pulmonary fibrosis, eosinophilic leucocytosis, filariasis, schistosomiasis, trichiniasis, coccidioidomycosis,
  • allergic diseases having a relation to eosinophils such as asthma, allergic rhinit
  • the compound of the present invention When the compound of the present invention is administered to a person for the treatment of the above diseases, it can be administered orally as powder, granules, tablets, capsules, pilulae, and liquid medicines, or parenterally as injections, suppositories, percutaneous formulations, insufflation, or the like.
  • An effective dose of the compound is formulated by being mixed with appropriate medicinal admixtures such as excipient, binder, penetrant, disintegrators, lubricant, and the like if necessary.
  • Parenteral injections are prepared by sterilizing the compound together with an appropriate carrier.
  • the dosage varies with the conditions of the patients, administration route, their age, and body weight.
  • the dosage can generally be between 0.1 to 100 mg/kg/day, and preferably 1 to 20 mg/kg/day for adult.
  • the membrane fraction prepared with CRTH2-transfected K562 cells was used for a binding assay.
  • a binding-reaction solution 50 mM Tris/HCl, pH 7.4, 10 mM MgCl 2
  • the membrane fraction (0.06 mg) and 3 nM [ 3 H]PGD 2 (172 Ci/mmol) were added, and the mixture was reacted at room temperature for 60 min.
  • the mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured.
  • the specific-binding ratio was calculated by subtracting the non-specific binding ratio which is the radioactivity similarly measured in the presence of 10 ⁇ M PGD 2 from the total binding.
  • the inhibitory activity of each compound was expressed as the concentration required for 50% inhibition (IC 50 ), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%. The results are shown below.
  • the human CRTH2-transfected K562 cells were suspended at 2 ⁇ 10 6 cells/ml in assay buffer (10 mM HEPES buffer, pH 7.4, 0.1% Bovine serum albumin), and were incubated with Fura-2 AM (2 ⁇ M) for 60 min at room temperature. After washing cells were resuspended again with assay buffer, incubated at 37° C., and then treated with various concentrations of compounds for 2 min. The emitted fluorescence was measured on a calcium analyzer (CAF-110) after addition of PGD 2 . The antagonistic activity of each compound at 1 ⁇ M was expressed as percent inhibition of the calcium mobilization in drug-untreated cells. The results are shown below.
  • Granules are prepared using the following ingredients.
  • the compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve.
  • Corn starch is made pass through a 120 mesh sieve. They are mixed by a twin shell blender.
  • An aqueous solution of HPC-L (low mucosity hydroxypropylcellulose) is added to the mixture and the resulting mixture is kneaded, granulated (by the extrusion with pore size 0.5 to 1 mm mesh), and dried.
  • the dried granules thus obtained are sieved by a swing sieve (12/60 mesh) to yield the granules.
  • Powders for filling capsules are prepared using the following ingredients.
  • the compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve.
  • Corn starch is made pass through a 120 mesh sieve.
  • These ingredients and magnesium stearate are mixed by a twin shell blender. 100 mg of the 10-fold trituration is filled into a No. 5 hard gelatin capsule.
  • Granules for filling capsules are prepared using the following ingredients.
  • the compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve.
  • Corn starch is made pass through a 120 mesh sieve.
  • an aqueous solution of HPC-L is added to the mixture and the resulting mixture is kneaded, granulated, and dried. After the dried granules are lubricated, 150 mg of that are filled into a No. 4 hard gelatin capsule.
  • Tablets are prepared using the following ingredients.
  • the compound represented by the formula (I), lactose, microcrystal cellulose, and CMC-Na (carboxymethylcellulose sodium salt) are made pass through a 60 mesh sieve and then mixed.
  • the resulting mixture is mixed with magnesium stearate to obtain the mixed powder for the tablet formulation.
  • the mixed powder is compressed to yield tablets of 150 mg.
  • the pharmaceutical composition and the compound of the present invention show superior CRTH2 receptor antagonistic activity and are useful for an agent for treating or preventing allergic diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound having CRTH2 receptor antagonism, represented by the following formula (I). The compound is useful for the treatment of allergic diseases having a relation to eosinophils and the like.
A compound of the formula (I):
Figure US20090258922A1-20091015-C00001
wherein
a group represented by the formula:
Figure US20090258922A1-20091015-C00002
is a group represented by the formula:
Figure US20090258922A1-20091015-C00003
and the like, R1 is carboxy and the like, R3 is —(CH2)n-N(—Y)—SO2—Ar and the like, the other symbols are as defined in claim 1.

Description

    TECHNICAL FIELD
  • This invention relates to a new compound having CRTH2 receptor antagonistic activity.
  • BACKGROUND ART
  • Prostaglandin D2 (PGD2), a metabolite derived from arachidonic acid through PGG2 and PGH2, is known to have a variety of potent biological activities. For example, PGD2 is involved in biological actions such as sleep induction and hormone secretion in the central nervous system, inhibition of platelet aggregation, contraction of airway smooth muscle, and relaxation or constriction of vascular smooth muscle in the peripheral tissue (Pharmacol. Rev. (1994) 46, 205-229). In addition, PGD2 is the major metabolite of arachidonic acid produced by mast cells and can cause strong bronchoconstriction, increased vascular permeability, and migration of inflammatory cells such as eosinophils. From these findings, PGD2 is considered to be deeply involved in the pathogenesis in allergic diseases such as asthma.
  • Formerly, only DP receptor is known as a PGD2 receptor and antagonists against its receptor are described in WO 98/25915, WO 01/66520, WO 01/79169 and the like.
  • However, it was suggested that there would be other PGD2 receptors different from DP receptor because BW-245C which is a selective agonist against DP receptor did not have activity for eosinphil infiltration (J. Immunol. (1992) 148, 3536-3542; Invest. Opthalmol. Vis. Sci. (1990) 31, 138-146; Br. J. Pharmacol. (1985) 85, 367-375; J. Pharmacol. Exp. Ther. (1995) 275, 611-617 etc.). Recently, it was reported that CRTH2 receptor is the other PGD2 receptor and PGD2 causes wandering of eosinophils and basophils vir this receptor (J. Exp. Med. (2001) 193, 255-261).
  • An antagonist against thromboxane A2 (TXA2) receptor and a platelet aggregation inhibitor having similar structure to a compound of the present invention are described in JP-A-61-249960, JP-A-62-198659, JP-A-62-249969, JP-A-2-193965, JP-A-3-151360, JP-A-4-230363, JP-A-4-234846, JP-A-4-257578, JP-A-8-157471, JP-A-8-245587, DE 3909600, Eur. J. Med. Chem., (1991) 26(8), 821-827. However, PGD2 antagonistic activity of the above compounds has not been described in them.
  • It is described in JP-A-3-151360 that 3-(4-chlorophenylsulfonylamino)-9-(2-carboxymethyl)-1,2,3,4-tetrahydrocarbazole and its ethyl ester have TXA2 antagonistic activity and TXA2 synthetase inhibitory activity. However, concrete value of the activities is not described in the document.
  • It is described in Eur. J. Med. Chem., 1991, 26(8), 821-827 that 3-(4-chlorophenylsulfonylaminoethyl)indole-1-acetic acid and 3-(4-chlorophenylsulfonylaminopropyl)indole-1-acetic acid have antagonistic activity against TXA2/PGH2 receptor.
  • It is described that 3-(4-fluorophenylsulfonamide)-1,2,3,4-tetrahydro-9-carbazole propionic acid is useful for therapeutic agent for allergic dermatitis, allergic dermatitis vir delayed type allergy reaction, and psoriasis in JP-A-7-175991, WO 97/44031, JP-A-11-106337 and JP-A-11-116477. It is described in JP-A-11-322600 that the above compound has depression activity for Chemokine production. Further, it is described in J. Allergy Clin. Immunol. (1992) 89, 1119-1126 that there is possibility that the above compound will have PGD2 antagonistic activity via DP receptor because it shows a depression effect against bronchus constriction caused PGD2. However, according to 1) PGD2 also binds TXA2 receptor in high concentration range (more than 1 μM) (Eur. J. Pharmacol. (1992) 226, 149-156; Br. J. Pharmacol. (1991) 103, 1883-1888 etc., 2) antagonists against TXA2 receptor which have weak receptor affinity for DP receptor show the same depression effect (Int. Arch. Allergy Immunol. 1992, 98, 239-246, and 3) selective DP receptor antagonists does not show a depression effect against bronchus constriction caused PGD2 (Br. J. Pharmacol. (1989) 96, 291-300), it is known time that the above depression effect is caused by depressing the reaction via thromboxane receptor and the above compound does not have direct DP receptor antagonistic activity at the present.
  • It is described in EP 1170594 that 4 compounds selectively binds CRTH2 receptor in comparison with DP receptor. However, the structures of the compounds are not similar to the compound of the present invention and details such as binding activities are not described.
  • DISCLOSURE OF INVENTION
  • The inventors of the present invention find out new compounds having a selective CRTH2 receptor antagonistic activity but not having a TXA2 receptor antagonistic activity.
  • The present invention relates to
  • I) a compound of the formula (I):
  • Figure US20090258922A1-20091015-C00004
  • wherein
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00005
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00006
  • wherein Z3 is ═N— or ═C(—R7)—;
    R4, R5, R6 and R7 are each independently hydrogen, halogen, haloalkyl, carboxy, alkyloxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, a group represented by the formula: —S(O)pR8 wherein p is an integer from 0 to 2 and R8 is alkyl or optionally substituted aryl, a group represented by the formula: —NR9R10 wherein R9 and R10 are each independently hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl or acyl, or a group represented by the formula: —OR11 wherein R11 is hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl, alkanesulfonyl, optionally substituted arylsulfonyl, optionally substituted aralkylsulfonyl, or haloalkyl;
    R1 is carboxy, alkyloxycarbonyl, optionally substituted aminocarbonyl or tetrazolyl;
    Z4 is —N= or —C(—R2)═; R2 is hydrogen, alkyl or halogen;
    R15 is hydrogen or alkyl;
    R3 is a group represented by the formula: —(CH2)n —N(—Y)—SO2—Ar wherein n is an integer from 1 to 3; Y is hydrogen, alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl or optionally substituted arylalkenyl; and Ar is optionally substituted aryl or optionally substituted heteroaryl,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00007
  • wherein r is an integer from 0 to 2; x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted aralkyl or optionally substituted arylalkenyl,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00008
  • wherein x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted aralkyl or optionally substituted arylalkenyl,
    a group represented by the formula: —CR23R24—CR25R26—(CH2)y-N(—Y)—SO2—Ar wherein Ar and Y are as defined above; y is 0 or 1; one of R23 or R24 is alkyl, the other is hydrogen, alkyl, or aryl; or R23 and R24 are taken together to form a group represented by the formula: —(CH2)t- wherein t is an integer from 2 to 5; R25 and R26 are each independently hydrogen or alkyloxyalkyl,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00009
  • wherein Y and Ar are as defined above, or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00010
  • wherein Y and Ar are as defined above and u is 1 or 2; or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00011
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00012
  • wherein y is an integer from 1 to 3, and m, p, Y and Ar are as defined above,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00013
  • wherein m, y and Ar are as defined above, or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00014
  • wherein Y and Ar are as defined above; R20 is hydrogen or alkyl; and R21 is hydrogen or halogen; but excluding compounds 3-(4-chlorophenylsulfonylamino)-9-(2-carboxymethyl)-1,2,3,4-tetrahydrocarbazole, its ethyl ester, 3-(4-chlorophenylsulfonylaminoethyl)indolel-acetic acid, and 3-(4-chlorophenylsulfonylaminopropyl)indole acetic acid; or
    R13 is hydrogen, alkyl, aralkyl, acyl or a group represented by the formula: —OR16 wherein R16 is hydrogen or alkyl, and R14 is hydrogen or alkyl: or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00015
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00016
  • wherein q is an integer from 0 to 3; R17 is hydrogen or alkyl; Z1 is —CH2—, —C(═O)—, —C(═NOH)—, or —C(═NOMe)-; Z2 is a group represented by the formula: —S(═O)s- wherein s is an integer from 0 to 2, a group represented by the formula: —N(—R22)— wherein R22 is hydrogen, alkyl, alkyloxycarbonyl or acyl, or a group represented by the formula: —CR18R19— wherein R18 and R19 are each independently hydrogen, alkyl or aryl; or R18 and R19 are taken together to form a group represented by the formula: —(CH2)t- wherein t is an integer from 2 to 5;
    R1 and R15 are as defined above; and
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00017
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00018
  • wherein Y, E, R20 and R21 are as defined above;
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • Further, this invention relates to the following II) to XV).
  • II) A compound as described in I), wherein a group represented by the formula:
  • Figure US20090258922A1-20091015-C00019
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00020
  • wherein Z3 is ═C(—R7)—; R4, R5, R6 and R7 are as defined in I);
    Z4 is —C(—R2)═; R2 is as defined in I);
    R15 is hydrogen; and
    R3 is a group represented by the formula: —(CH2)n-N(—Y)—SO2—Ar wherein n is an integer from 1 to 3; Y is hydrogen, alkyl, alkenyl, optionally substituted aryl, optionally substituted aralkyl, or optionally substituted heteroarylalkyl; and Ar is optionally substituted aryl or optionally substituted heteroaryl,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00021
  • wherein r is an integer from 0 to 2; x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl or optionally substituted heteroaryl; or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00022
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00023
  • wherein y is an integer from 1 to 3, and m, p, Y and Ar are as defined above,
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00024
  • wherein m, y and Ar are as defined above, or
    a group represented by the formula:
  • Figure US20090258922A1-20091015-C00025
  • wherein Y and Ar are as defined in I), and R20 and R21 are hydrogen,
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    III) A compound as described in I) or II), wherein Y is alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    IV) A compound as described in II), wherein R3 is a group represented by the formula: —(CH2)n-N(—Y)—SO2—Ar wherein n is 2 or 3; Y is hydrogen, alkyl, alkenyl, or aralkyl; and Ar is as defined in I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    V) A compound as described in II), wherein R3 is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00026
  • wherein m is 1; r is 0; x is 2; a broken line represents the presence or absence of a bond; and E is as defined in II), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    VI) A compound as described in II), wherein a group represented by the formula:
  • Figure US20090258922A1-20091015-C00027
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00028
  • wherein m is 2; p is 0; y is 1; Y is hydrogen, alkyl, alkenyl or aralkyl; and Ar is as defined in I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    VII) A compound as described in II), wherein a group represented by the formula:
  • Figure US20090258922A1-20091015-C00029
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00030
  • wherein m is 1 or 2; y is 1 or 2; and Ar is as defined in II), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    VIII) A compound as described in II), wherein a group represented by the formula:
  • Figure US20090258922A1-20091015-C00031
  • is a group represented by the formula:
  • Figure US20090258922A1-20091015-C00032
  • wherein Y is hydrogen, alkyl, alkenyl or aralkyl; and R20, R21 and Ar are as defined in I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    IX) A compound as described in any one of I) to VIII), wherein R1 is carboxy, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    X) A compound as described in any one of I) to IX), wherein R4, R5, R6 and R7 are each independently hydrogen, halogen, alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    XI) A compound as described in any one of I) to X), wherein R2 is hydrogen or alkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
    XII) A pharmaceutical composition containing a compound, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof as described in any one of I) to XI).
    XIII) A pharmaceutical composition as described in XII), which is used for an antagonist against the CRTH2 receptor.
    XIV) A method for treating a disease relating to the CRTH2 receptor, which comprises administrating a compound as described in I).
    XV) Use of the compound as described in I) for the preparation of a pharmaceutical composition for treating a disease relating to the CRTH2 receptor.
  • The following compounds are included in the compounds represented by the formula (I).
  • Figure US20090258922A1-20091015-C00033
    Figure US20090258922A1-20091015-C00034
  • wherein each symbol in the above structures is as defined in I).
  • The details of the present invention are as follows.
  • In the present specification, the term “halogen” means fluoro, chloro, bromo, and iodo. Fluoro, chloro, and bromo are preferred as halogen.
  • In the present specification, the term “alkyl” employed alone or in combination with other terms includes a straight- or branched chain monovalent hydrocarbon group having 1 to 8 carbon atom(s). Examples of alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, and the like. C1 to C6 alkyl is preferred. C1 to C3 alkyl is more preferred.
  • In the present specification, the term “cycloalkyl” employed alone or in combination with other terms includes a mono cycloalkyl having 3 to 8 carbon atom. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. C3 to C6 cycloalkyl is preferred.
  • In the specification, the term “alkenyl” employed alone or in combination with other terms includes a straight- or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and one or more double bond(s). Examples of the alkenyl are vinyl, allyl, 1-propenyl, 2-propenyl, crotonyl, isopentenyl, a variety of butenyl isomers and the like. C2 to C6 alkenyl is preferred. C2 to C4 alkenyl is more preferred.
  • In the specification, the term “alkynyl” employed alone or in combination with other terms includes a straight or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and one or more triple bond(s). Examples of the alkynyl are ethynyl, 1-propynyl, 2-propynyl and the like. C2 to C6 alkynyl is preferred. C2 to C4 alkynyl is more preferred.
  • In the present specification, the term “aryl” employed alone or in combination with other terms includes monocyclic or condensed ring aromatic hydrocarbons. Examples of aryl are phenyl, 1-naphtyl, 2-naphtyl, anthryl, and the like. Phenyl, 1-naphtyl, and 2-naphtyl are preferred. Phenyl is more preferred.
  • The term “aralkyl” employed alone or in combination with other terms includes the above mentioned “alkyl” substituted with the above mentioned one or more “aryl” at any possible position. Examples of the aralkyl are benzyl, phenylethyl (e.g., 2-phenylethyl), phenylpropyl (e.g., 3-phenylpropyl), naphthylmethyl (e.g., 1-naphthylmethyl and 2-naphthylmethyl), anthrylmethyl (e.g., 9-anthrylmethyl), and the like. Benzyl, 2-phenylethyl, 1-naphthylmethyl and 2-naphthylmethyl are preferred. Benzyl and 2-phenylethyl are more preferred.
  • The term “aralkyl” herein used includes the above mentioned “alkyl” substituted with the above mentioned one or more “aryl” at any possible position. Examples of the aralkyl are benzyl, phenylethyl (e.g., 2-phenylethyl), phenylpropyl (e.g., 3-phenylpropyl), naphthylmethyl (e.g., 1-naphthylmethyl and 2-naphthylmethyl), anthrylmethyl (e.g., 9-anthrylmethyl), and the like. Benzyl, 2-phenylethyl, 1-naphthylmethyl and 2-naphthylmethyl are preferred. Benzyl and 2-phenylethyl are more preferred.
  • The term “arylalkenyl” herein used includes the above mentioned “alkenyl” substituted with the above mentioned one or more “aryl” at any possible position. Examples of the arylalkenyl are phenylallyl, naphthylallyl, and the like.
  • In the present specification, the term “non-aromatic heterocyclic group” includes a 5 to 7 membered non-aromatic ring which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring, and the 5 to 7 membered non-aromatic ring may be condensed with two or more rings. Examples of the non-aromatic heterocyclic group are pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl), pyrrolinyl (e.g., 3-pyrrolinyl), imidazolidinyl (e.g., 2-imidazolidinyl), imidazolinyl (e.g., imidazolinyl), pyrazolidinyl (e.g., 1-pyrazolidinyl, 2-pyrazolidinyl), pyrazolinyl (e.g., pyrazolinyl), piperidyl (e.g., piperidino, 2-piperidyl), piperazinyl (e.g., 1-piperazinyl), indolynyl (e.g., 1-indolynyl), isoindolinyl (e.g., isoindolinyl), morpholinyl (e.g., morpholino, 3-morpholinyl), and the like.
  • In the present specification, the term “heteroaryl” employed alone or in combination with other terms includes a 5 to 6 membered aromatic heterocyclic group which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring. The aromatic heterocyclic group may be fused with the above mentioned cycloalkyl, above mentioned aryl, above mentioned non-aromatic heterocyclic group, and other heteroaryl at any possible position. The heteroaryl which is a monocyclic or fused ring may be bonded at any possible position. Examples of the heteroaryl are pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl 3-thienyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl), isothiazolyl (e.g., 3-isothiazolyl), isoxazolyl (e.g., 3-isoxazolyl), oxazolyl (e.g., 2-oxazolyl), thiazolyl (e.g., 2-thiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl (e.g., 2-pyrazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), tetrazolyl(e.g., 1H-tetrazolyl), oxadiazolyl (e.g., 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,3,4-thiadiazolyl), indolizinyl (e.g., 2-indolizinyl, 6-indolizinyl), isoindolyl (2-isoindolyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl), indazolyl (e.g., 3-indazolyl), purinyl (e.g., 8-purinyl), quinolizinyl (e.g., 2-quinolizinyl), isoquinolyl (e.g., 3-isoquinolyl), quinolyl (e.g., 2-quinolyl, 5-quinolyl), phthalazinyl (e.g., 1-phthalazinyl), naphthyridinyl (e.g., 2-naphthyridinyl), quinolanyl (2-quinolanyl), quinazolinyl (e.g., 2-quinazolinyl), cinnolinyl (e.g., 3-cinnolinyl), pteridinyl (e.g., 2-pteridinyl), carbazolyl (e.g., 2-carbazolyl, 4-carbazolyl), phenanthridinyl (e.g., 2-phenanthridinyl, 3-phenanthridinyl), acridinyl (e.g., 1-acridinyl, 2-acridinyl), dibenzofuranyl (e.g., 1-dibenzofuranyl, 2-dibenzofuranyl), benzimidazolyl (e.g., 2-benzimidazolyl), benzisoxazolyl (e.g., 3-benzisoxazolyl), benzoxazolyl (e.g., 2-benzoxazolyl), benzoxadiazolyl (e.g., 4-benzoxadiazolyl), benzisothiazolyl (e.g., 3-benzisothiazolyl), benzothiazolyl (e.g., 2-benzothiazolyl), benzofuryl (e.g., 3-benzofuryl), benzothienyl (e.g., 2-benzothienyl), dibenzothienyl (e.g., 2-dibenzothienyl), benzodioxolyl (e.g., 1,3-benzodioxolyl) and the like.
  • Thienyl, benzothienyl, dibenzothienyl, benzodioxolyl, oxazolyl, and the like are preferred as heteroaryl of Ar.
  • The term “heteroarylalkyl” herein used includes the above-mentioned “alkyl” substituted with the above-mentioned one or more “heteroaryl” at any possible position. Examples of the heteroarylalkyl are thienylalkyl, furylalkyl, pyrrolylalkyl, imidazolylalkyl, pyrazolylalkyl, thiazolylalkyl, isothiazolylalkyl, isoxazolylalkyl, oxazolylalkyl, pyridylalkyl, and the like. Thienylmethyl (e.g., 2-thienylmethyl), thienylethyl (e.g., 2-(thiophen-2-yl)ethyl), furylmethyl (e.g., 2-furylmethyl), furylethyl (e.g., 2-(furan-2-yl)ethyl), pyrrolylmethyl (e.g., 2-pyrrolylmethyl), pyrrolylethyl (e.g., 2-(pyrrol-2-yl)ethyl), imidazolylmethyl (e.g., 2-imidazolylmethyl, 4-imidazolylmethyl), imidazolylethyl (e.g., 2-(imidazol-2-yl)ethyl), pyrazolylmethyl (e.g., 3-pyrazolylmethyl), pyrazolylethyl (e.g., 2-(pyrazol-3-yl)ethyl), thiazolylmethyl (e.g., 2-thiazolylmethyl), thiazolylethyl (e.g., 2-(thiazol-2-yl)ethyl), isothiazolylmethyl (e.g., 3-isothiazolylmethyl), isoxazolylmethyl (e.g., 3-isoxazolylmethyl), oxazolylmethyl (e.g., 2-oxazolylmethyl), oxazolylethyl (e.g., 2-(oxazol-2-yl)ethyl), pyridylmethyl (e.g., 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl), pyridylethyl (e.g., 2-pyridylethyl) and the like are exemplified.
  • Thienylmethyl is preferred as heteroaryl of Y.
  • The term “alkyloxy” herein used are methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy, and the like. Methyloxy, ethyloxy, n-propyloxy, isopropyloxy and n-butyloxy are preferred. C1 to C3 alkyloxy is more preferred.
  • The term “alkylthio” herein used are methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, and the like. Methylthio, ethylthio, n-propylthio, isopropylthio and n-butylthio are preferred. C1 to C3 alkylthio is more preferred.
  • In the present specification, phenyloxy, naphthyloxy, and the like are exemplified as “aryloxy.”
  • In the present specification, phenylthio, naphthylthio, and the like are exemplified as “arylthio.”
  • In the present specification, phenylazo, naphthylazo, and the like are exemplified as “arylazo.”
  • The term “alkyloxycarbonyl” herein used are methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl and the like. Methyloxycarbonyl and ethyloxycarbonyl are preferred. C1 to C3 alkyloxycarbonyl are more preferred.
  • In the present specification, the term “acyl” employed alone or in combination with other terms includes alkylcarbonyl in which alkyl group is the above-mentioned “alkyl” and arylcarbonyl in which aryl group is the above-mentioned “aryl”. “Alkyl” and “aryl” may be substituted respectively with substituents exemplified in the following “optionally substituted alkyl” and “optionally substituted aryl”. Examples of the acyl are acetyl, propyonyl, butyloyl, benzoyl, and the like.
  • In the present specification, the term “haloalkyl” employed alone or in combination with other terms includes the above-mentioned “alkyl” which is substituted with the above-mentioned “halogen” at 1 to 8 positions, preferably, at 1 to 5. Examples of the haloalkyl are trifluoromethyl, trichloromethyl, difluoroethyl, trifluoroethyl, dichloroethyl, trichloroethyl, chloromethyl, and the like. Preferable is trifluoromethyl.
  • Examples of the term “acyloxy” herein used are acetyloxy, propionyloxy, benzoyloxy and the like.
  • Examples of the term “alkanesulfonyl” herein used are methanesulfonyl, ethanesulfonyl, n-propanesulfonyl, isopropanesulfonyl, n-butanesulfonyl, isobutanesulfonyl, sec-butanesulfonyl, tert-butanesulfonyl, and the like. Methanesulfonyl and ethanesulfonyl are preferred.
  • Examples of the term “arylsulfonyl” herein used are phenylsulfonyl, naphthylsulfonyl, and the like.
  • Examples of the term “aralkylsulfonyl” herein used are benzylsulfonyl, phenylethylsulfonyl, and the like.
  • Example of the term “heteroarylsulfonyl” herein used is pyrrolylsulfonyl or the like.
  • In the present specification, the term “optionally substituted amino” employed alone or in combination with other terms includes amino which may be substituted with one or two of the above-mentioned “alkyl”, above-mentioned “aryl”, above-mentioned “aralkyl”, above-mentioned “heteroaryl”, above-mentioned “heteroarylalkyl”, above-mentioned “acyl”, above-mentioned “alkyloxycarbonyl” and/or “alkanesulfonyl”. Examples of the optionally substituted amino are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino, benzylamino, acetylamino, benzoylamino, methyloxycarbonylamino, methanesulfonylamino, and the like. Preferable are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino, acetylamino, methanesulfonylamino.
  • Examples of the term “optionally substituted aminocarbonyl” herein used are aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, diethylaminocarbonyl, benzylamino, acetylamino, methanesulfonylaminocarbonyl and the like. Preferable are aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, and methanesulfonylaminocarbonyl.
  • In the present specification, the term “optionally substituted ureide” includes ureide substituted with one or more of the above-mentioned “alkyl”, above-mentioned “aryl”, above-mentioned “aralkyl”, above-mentioned “heteroaryl”, above-mentioned “heteroarylalkyl” or above-mentioned “acyl”.
  • The substituents of “optionally substituted alkyl” are cycloalkyl, alkenyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, optionally substituted non-aromatic heterocyclic group, aryloxy (e.g., phenyloxy), aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • Preferable are alkyloxy, hydroxy, optionally substituted amino, aryloxy, and the like as substituents of “optionally substituted alkyl” for R4, R5, R6, and R7.
  • The substituents of “optionally substituted cycloalkyl” are alkyl, cycloalkyl, alkenyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, aryloxy (e.g., phenyloxy), aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • Preferable are alkyl, halogen, and the like as substituents of “optionally substituted cycloalkyl” for R4, R5, R6, and R7.
  • The substituents of “optionally substituted alkenyl” are alkyl, cycloalkyl, alkyliden, hydroxy, alkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, haloalkyl, haloalkyloxy, optionally substituted amino, optionally substituted aminocarbonyl, acyl, acyloxy, aryl, aryloxy (e.g., phenyloxy), aralkyl, aralkyloxy (e.g., benzyloxy), alkanesulfonyl, guanidino, an azo group, and the like. These substituents are able to locate at one or more of any possible positions.
  • Preferable are halogen, aryl, and the like as substituents of “optionally substituted alkenyl” for R4, R5, R6, and R7.
  • The substituents of “optionally substituted aryl”, “optionally substituted aralkyl”, “optionally substituted heteroaryl”, “optionally substituted arylsulfonyl”, “optionally substituted aralkylsulfonyl”, and “optionally substituted non-aromatic heterocyclic group” herein used are alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, alkyloxy, haloalkyloxy, aryloxy, aralkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, acyl, acyloxy, alkanesulfonyl, guanidino, an azo group, optionally substituted amino, optionally substituted aminocarbonyl, aryl which may be substituted with one or more of the substituents selected from Substituents group C, heteroaryl which may be substituted with one or more of the substituents selected from Substituents group C, non-aromatic heterocyclic group which may be substituted with one or more of the substituents selected from Substituents group C, aralkyl which may be substituted with one or more of the substituents selected from Substituents group C, optionally substituted ureide, and the like. These substituents are able to locate at one or more of any possible positions (Substituents group C: alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, alkyloxy, haloalkyloxy, aryloxy, aralkyloxy, mercapto, alkylthio, halogen, nitro, cyano, carboxy, alkyloxycarbonyl, acyl, acyloxy, alkanesulfonyl, guanidino, an azo group, optionally substituted amino, and optionally substituted aminocarbonyl).
  • Preferable are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R4, R5, R6, and R7.
  • Preferable are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R8.
  • Preferable are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R9 and R10.
  • Preferable are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for R11.
  • Preferable are alkyl, alkyloxy, halogen, and the like as substituents of “optionally substituted aryl” for Y.
  • Preferable are alkyl, alkyloxy, aryloxy, halogen, benzyl, phenyl which may be substituted with substituents selected from Substituents group B, and the like as substituents of “optionally substituted aryl” for Ar (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, and benzyl).
  • Preferable are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R4, R5, R6, and R7.
  • Preferable are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R9 and R10.
  • Preferable are alkyl, halogen, and the like as substituents of “optionally substituted aralkyl” for R11.
  • Preferable are alkyl, alkyloxy, nitro, halogen, and the like as substituents of “optionally substituted aralkyl” for Y.
  • Preferable are alkyl, alkyloxy, aryloxy, halogen, benzyl, phenyl which may be substituted with substituents selected from Substituents group B, and the like as substituents of “optionally substituted heteroaryl” for Ar (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, and benzyl).
  • Preferable are alkyl and the like as substituents of “optionally substituted arylsulfonyl” for R11.
  • Preferable are alkyl and the like as substituents of “optionally substituted aralkylsulfonyl” for R11.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • The compounds represented by the formula (I) of the present invention can be synthesized by reacting the compounds represented by the following formula (IIa) to (IIk):
  • Figure US20090258922A1-20091015-C00035
    Figure US20090258922A1-20091015-C00036
  • wherein R1 is alkyloxycarbonyl and the other symbols are as defined in I) or their salts with 1 to 5 eq. of a compound represented by the formula Ar—SO2—X1 or E-SO2—X1 wherein Ar and E are as defined in I), and X1 is halogen in an inactive solvent at 0° C. to room temperature for 5 min. to several hours. This reaction can be carried out in the presence of 1 to 5 eq. of a base. Triethylamine, pyridine, potassium carbonate, sodium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide and the like are preferred as a base. Pyridine, acetonitrile, dichloromethane, tetrahydrofuran (THF) and the like are preferred as an inactive solvent, and they can be used themselves or mixed solvents with water.
  • When Y is hydrogen in the above synthesized compound, the compound wherein Y is alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl can be synthesized by reacting with Y-X2 wherein X2 is halogen, optionally substituted alkanesulfonyloxy or optionally substituted arylsulfonyloxy in an inactive solvent such as THF, diethylether, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetonitrile, acetone, toluene and the like in the presence of a base such as sodium hydroxide, potassium hydroxide, potassium t-butoxide, potassium carbonate and the like at 0° C. to 80° C. for 30 min. to several hours. Further, the compound wherein Y is alkyl, alkenyl, optionally substituted aralkyl and the like can be synthesized by reactive amination. For example, the above compound can be synthesized by reacting the compound represented by the formula (IIa), (IIb), or (IIe) wherein Y is hydrogen with corresponding aldehyde or ketone in a solvent such as THF, dichloromethane and the like in the presence of 1 to 5 eq. of sodium borohydride, sodium cyanotrihydroborate or triacetoxyborohydride at 0° C. to 80° C. for 30 min. to several hours. This reaction can be carried out in the presence of 0.1 to 5 eq. of an acidic catalyst such as hydrochloric acid, acetic acid, p-toluenesulfonic acid and the like. After the reaction, the compound represented by the formula (I) can be synthesized by the above-mentioned sulfonylation.
  • The compound represented by the formula (I) wherein R1 is carboxy can be synthesized by acidic hydrolysis or alkali hydrolysis of ester in accordance with the usual hydrolysis condition after the above mentioned reaction.
  • The compound represented by the formula (IIe) can be synthesized by the method described in JP-A-8-169879 and the like.
  • The compounds represented by the formula (IIa) to (IIk) can be synthesized using the compounds represented by the following formula (IIIa) to (IIIk) as a starting material.
  • Figure US20090258922A1-20091015-C00037
    Figure US20090258922A1-20091015-C00038
  • wherein each symbol is as defined in I) and Q is hydrogen.
  • The compounds represented by the formula (IIa) to (IIk), their salts of inorganic acid such as hydrochloric acid, sulfuric acid and the like or organic acid such as acetic acid, trifluoroacetic acid and the like can be synthesized in accordance with the following processes 1) to 3);
  • 1) An amino group of the compound represented by the formula (IIIa)˜(IIIk) wherein Q is hydrogen is protected with amino protecting group such as t-butoxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl and the like in accordance with the method described in PROTECTIVE GROUP IN ORGANIC SYNTHESIS, JOHN WILEY & SONS, INC. and the like.
  • 2) The indole derivatives having an alkyloxycarbonylmethyl group on its nitrogen atom is synthesized by reacting the obtained compound in the above process with 1 to 5 eq. of a compound represented by the formula: X1—CH2CO2R12 wherein X1 is halogen and R12 is alkyl in an inactive solvent such as pyridine, acetonitrile, dichloromethane, THF, DMF, DMSO, acetone, methylethylketone, methylisobutylketone and the like in the presence of 1 to 5 eq. of a base such as sodium hydride, potassium hydride, potassium t-butoxide, potassium carbonate and the like at 0 to 100° C. for 1 h to 20 h. 0.1 to 1 eq. of a phase transfer catalyst such as tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, benzyltriethylammonium chloride, benzyltributylammonium chloride and the like may be added to the above reaction mixture.
  • 3) Q, an amino protective group, is deprotected by the usual deprotecting reaction.
  • The compounds represented by the formula (IIIc) and (IIId), and the compounds represented by the formula (IIIa), (IIIb), and (IIIe) wherein Y is not hydrogen can be introduced into the compound of the formula (I) by the above mentioned sulfonylation and alkyloxycarbonylmethylation of nitrogen atom on the indole ring without protection of an amino group.
  • The compound represented by the formula (I) is a compound having a selective antagonistic activity against CRTH2 receptor but not having an antagonistic activity against TXA2 receptor. Especially, the compounds represented by the following formula (Ia) to (Ie) are preferred as such a compound.
  • A compound of the formula (Ia):
  • Figure US20090258922A1-20091015-C00039
  • wherein R1 is carboxy or optionally substituted aminocarbonyl;
    R2 is hydrogen or alkyl;
    R5, R6 and R7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR11 wherein R11 is alkyl;
    Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or more substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy, and nitro); Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl); and
    n is 1, 2, or 3,
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • A compound represented by the formula (Ib):
  • Figure US20090258922A1-20091015-C00040
  • wherein R1 is carboxy or optionally substituted aminocarbonyl;
    R5, R6 and R7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR11 wherein R11 is alkyl;
    Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or ore substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy and nitro);
    Ar is phenyl which may be substituted with one or more substituents selected from Substituents group A, biphenyl which may be substituted with one or more substituents selected from Substituents group A, thienyl which may be substituted with one or more substituents selected from Substituents group A, or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: halogen, alkyl, alkyloxy, aryloxy, hydroxy, and benzyl);
    m is 1 or 2;
    p is 0 or 1; and
    y is 0, 1, or 2,
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • A compound represented by the formula (Ic):
  • Figure US20090258922A1-20091015-C00041
  • wherein R1 is carboxy or optionally substituted aminocarbonyl;
    R2 is hydrogen or alkyl;
    R5, R6 and R7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR11 wherein R11 is alkyl;
    Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B, or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl;
    m is 1, 2, or 3;
    r is 0 or 1; and
    x is 0, 1, or 2,
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • A compound represented by the formula (Id):
  • Figure US20090258922A1-20091015-C00042
  • wherein R1 is carboxy or optionally substituted aminocarbonyl;
    R5, R6 and R7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR11 wherein R11 is alkyl;
    Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl);
    m is 1 or 2; and
    y is 1 or 2,
    a prodrug, a pharmaceutically acceptable salt, or a solvate thereof
  • A compound represented by the formula (Ie):
  • Figure US20090258922A1-20091015-C00043
  • wherein R1 is carboxy or optionally substituted aminocarbonyl;
    R5, R6 and R7 are each independently hydrogen, halogen, alkyl, or a group represented by the formula: —OR11 wherein R11 is alkyl;
  • Y is hydrogen, alkyl, alkenyl, phenyl, phenylalkyl which may be substituted with one or more substituents selected from Substituents group A, naphthylalkyl which may be substituted with one or more substituents selected from Substituents group A, or thienylalkyl which may be substituted with one or more substituents selected from Substituents group A (Substituents group A: alkyl, alkyloxy and nitro); and
  • Ar is phenyl which may be substituted with one or more substituents selected from Substituents group B, biphenyl which may be substituted with one or more substituents selected from Substituents group B, thienyl which may be substituted with one or more substituents selected from Substituents group B or dibenzothienyl which may be substituted with one or more substituents selected from Substituents group B (Substituents group B: alkyl, alkyloxy, aryloxy, halogen, hydroxy, and benzyl), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
  • The term “solvate” includes, for example, solvates with organic solvents, hydrates, and the like. A solvate may coordinate with an arbitrary number of organic solvent molecules. A hydrate may coordinate with an arbitrary number of water molecules. A hydrate is preferred.
  • The term “compound of the present invention” herein used includes a pharmaceutically acceptable salt. The salt is exemplified by a salt with alkali metals (e.g., lithium, sodium, potassium, and the like), alkaline earth metals (e.g., magnesium, calcium, and the like), ammonium, organic bases, amino acids, mineral acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and the like), or organic acids (e.g., acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like). These salts can be formed by the usual method.
  • Prodrug is a derivative of the compound having a group which can be decomposed chemically or metabolically, and such prodrug is a compound according to the present invention which becomes pharmaceutically active by means of solvolysis or by placing the compound in vivo under a physiological condition. The method of both selection and manufacture of appropriate prodrug derivatives is described in, for example. Design of Prodrugs, Elsevier, Amsterdam, 1985). For instance, prodrugs such as an ester derivative which is prepared by reacting a basal acid compound with a suitable alcohol, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a carboxylic group. Particularly preferred esters as prodrugs are methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester, N,N-diethylglycolamido ester, and the like. For instance, prodrugs such as an acyloxy derivative which is prepared by reacting a basal hydroxy compound with a suitable acyl halide or a suitable acid anhydride, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a hydroxy group. Particularly preferred acyloxy derivatives as prodrugs —OCOC2H5, —OCO(t-Bu), —OCOC15H31, —OCO(m-COONa-Ph), —COCH2CH2COONa, —OCOCH(NH2)CH3, —OCOCH2N(CH3)2, and the like. For instance, prodrugs such as an amide derivative which is prepared by reacting a basal amino compound with a suitable acid halide or a suitable acid anhydride are exemplified when the compounds according to present invention have an amino group. Particularly preferred amide as prodrugs are —NHCO(CH2)20CH3, —NHCOCH(NH2)CH3, and the like.
  • The compound of the present invention is not restricted to any particular isomers but includes all possible isomers and racemic modifications.
  • The compounds of the present invention show excellent CRTH2 receptor antagonism as described in examples mentioned later. Therefore, the pharmaceutical composition of the present invention may be used as a treating and/or preventing agent for allergic diseases having a relation to eosinophils, such as asthma, allergic rhinitis, allergic dermatitis, morbilli papulosi (guinea worm disease and the like), vasculitis, polyarteritis, dermal eosinophilic granuloma, autoimmune disease (e.g., multiple sclerosis, graft rejection, etc.), simple pulmonary eosinophilia, histiocytosis (Histiocytosis), pneumonia, aspergillosis, pleurisy, sarcoidosis, idiopathic pulmonary fibrosis, eosinophilic leucocytosis, filariasis, schistosomiasis, trichiniasis, coccidioidomycosis, tuberculous, bronchogenic cancer, lymphoma, Hodgkin's disease and the like.
  • When the compound of the present invention is administered to a person for the treatment of the above diseases, it can be administered orally as powder, granules, tablets, capsules, pilulae, and liquid medicines, or parenterally as injections, suppositories, percutaneous formulations, insufflation, or the like. An effective dose of the compound is formulated by being mixed with appropriate medicinal admixtures such as excipient, binder, penetrant, disintegrators, lubricant, and the like if necessary. Parenteral injections are prepared by sterilizing the compound together with an appropriate carrier.
  • The dosage varies with the conditions of the patients, administration route, their age, and body weight. In the case of oral administration, the dosage can generally be between 0.1 to 100 mg/kg/day, and preferably 1 to 20 mg/kg/day for adult.
  • EXAMPLE
  • The following examples and experiments are provided to further illustrate the present invention and are not to be construed as limiting the scope.
  • Abbreviations described below are used in the following examples.
  • Me: Methyl
  • Et: Ethyl
  • iPr: isopropyl
  • Ph: Phenyl
  • Boc: t-butoxycarbonyl
  • THF: tetrahydrofuran
  • MeOH: Methanol
  • Naphthyl: naphthyl
  • Benzyl: benzyl
  • Thienyl: thienyl
  • Biphenyl: biphenyl
  • Dibenzothiophene: dibenzothiophene
  • Example 1 Compound Ia-9 and Compound Ia-51
  • Figure US20090258922A1-20091015-C00044
  • Process 1
  • To a solution of tryptamine (1) (20 g, 0.125 mol) in dioxane (160 mL)-water (80 mL) was added a mixture of sodium carbonate (39.7 g, 0.374 mol) and di-tert-butyl dicarbonate (31.5 mL, 0.137 mol) in dioxane (20 mL) at ice-cooling and the resulting mixture was stirred for 2.5 h. After adding 2 mol/L hydrochloric acid to the reaction mixture, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated in vacuo to give a residue (42.49 g). 7.0 g of the residue was dissolved in methyl ethyl ketone (150 mL). To the mixture were added potassium carbonate (11.15 g, 80.7 mmol) and methyl bromoacetate (10.2 mL, 0.108 mol), and the resulting mixture was heated for 48 h at reflux. The mixture was diluted with ethyl acetate. The resulting mixture was washed with dilute hydrochloric acid and aqueous sodium hydrogencarbonate respectively, dried and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate 2:1) to give compound (2) (4.57 g; yield 51%).
  • Process 2
  • To a solution of Compound (2) (1.5 g, 4.5 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (10 mL) and the mixture was stirred for 10 min. at room temperature. The reaction mixture was concentrated in vacuo and neutralized with 2 mol/L aqueous sodium carbonate. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated in vacuo to give a residue (983 mg). 120 mg of the residue was dissolved in dichloromethane (3 mL). To a solution were added triethylamine (0.108 mL, 0.775 mmol) and 4-fluorobenzenesulfonylchloride (121 mg, 0.622 mmol) and the resulting mixture was stirred for 2 h at room temperature. The mixture was diluted with ethyl acetate, washed with dilute hydrochloric acid and aqueous sodium hydrogencarbonate respectively, dried, and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate=3:2) to give compound (3) (99 mg; yield 46%).
  • Process 3
  • To a solution of compound (3) (99 mg, 0.254 mmol) in MeOH (1.5 mL)-THF (1.5 mL) was added 2 mol/L aqueous sodium hydroxide (0.76 mL, 1.52 mmol) and the resulting mixture was stirred for 5.5 h at room temperature. The mixture was acidified with dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried, and concentrated in vacuo to give compound (Ia-9) (79 mg; yield 83%). The physical property of the compound is shown in Table 12.
  • Process 4
  • To a solution of compound (3) (132 mg, 0.339 mmol) in N,N-dimethylformamide (2 ml) were added benzyl bromide (48 μL, 0.407 mmol) and potassium carbonate (70 mg, 0.509 mmol) and the resulting mixture was stirred for 21.5 h at 50° C. The reaction mixture was poured in water and extracted with ethyl acetate. The organic layer was washed with brine, dried, and concentrated in vacuo. The residue was dissolved in MeOH (2 mL)-THF (2 mL). To the solution was added 2 mol/L aqueous sodium hydroxide (1.1 mL, 2.2 mmol) and the mixture was stirred for 5 h at room temperature. The resulting mixture was diluted with water and washed with diethyl ether. The aqueous layer was acidified with dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried, and concentrated in vacuo to give compound (Ia-51) (175 mg; yield 99%). The physical property of the compound is shown below.
  • Example 2 Compound Ib-20 and Compound Ib-29
  • Figure US20090258922A1-20091015-C00045
  • Process 1
  • To a solution of (3R)-3-amino-1,2,3,4-tetrahydrocarbozole (4) (3.33 g, 17.9 mmol) described in JP-A-62-198659 in 1,4-dioxane (33 mL) was added di-tert-butyl dicarbonate (4.1 g, 18.8 mmol) and the resulting mixture was stirred for 2 h at room temperature. The residue obtained by vacuum concentration was dissolved in methyl ethyl ketone (52 mL). To the mixture were added potassium carbonate (4.52 g, 32.7 mmol), benzyltriethylammonium chloride (0.74 g, 3.26 mmol), and methyl bromoacetate (5.00 g, 32.7 mmol) and the mixture was heated for 4 h at reflux. The insoluble residue was filtered off and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate, washed with water, dried, and concentrated in vacuo. The residue was crystallized from hexane-diethyl ether to give compound (5) (4.36 g; yield 68%, mp. 127-130° C.).
  • Process 2
  • To a solution of compound (5) (4.25 g, 11.9 mmol) in ethyl acetate (12 mL) was added 4 mol/L hydrochloric acid-ethyl acetate (12 mL, 48.0 mmol) and the resulting mixture was stirred for 2 h at room temperature. The precipitated crystalline was filtered off and washed with ethyl acetate to give compound (6) (3.44 g; yield 98%).
  • Process 3
  • To a solution of compound (6) (295 mg, 1.0 mmol) in THF (6 mL) were added triethylamine (0.30 g, 3.0 mmol) and 2-thiophenesulfonyl chloride (296 mg, 1.62 mmol), and the resulting mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric acid and water, dried over magnesium sulphate, and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to give compound (7) (379 mg; yield 94%).
  • Process 4
  • To a solution of compound (7) (371 mg, 0.917 mmol) in MeOH (1.2 mL)-THF (1.2 mL) was added 4 mol/L aqueous sodium hydroxide (0.6 mL, 2.4 mmol) and the resulting mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with water, acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulphate, and concentrated in vacuo to give compound (+)-Ib-20 (343 mg; yield 91%).
  • Process 5
  • To a solution of compound (7) (243 mg, 0.622 mmol) in N,N-dimethylformamide (2 mL) were added potassium carbonate (0.26 g. 1.87 mmol) and methyl iodide (0.27 g, 1.90 mmol) and the resulting mixture was stirred for 2.5 h at room temperature. The reaction mixture was diluted with ethyl acetate, washed with water, dried, and concentrated in vacuo. The residue was dissolved in MeOH (1 mL)-THF (1 mL). To the mixture was added 4 mol/L aqueous sodium hydroxide (0.4 mL, 1.6 mmol) and the mixture was stirred for 3 h at room temperature. The reaction mixture was diluted with water, acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water, dried, and concentrated in vacuo. The residue was crystallized form hexane-ethyl acetate to give compound (+)-Ib-29 (217 mg; yield 88%). The physical property of the compound is shown below.
  • Example 3 Compound Ic-14
  • Figure US20090258922A1-20091015-C00046
  • Process 1
  • To a solution of compound (8) (610 mg, 3.28 mmol, Synthesis, 443 (1997)) in THF (6 mL) were added triethylamine (0.50 g, 4.92 mmol) and 4-fluorobenzenesulfonyl chloride (0.70 g, 3.60 mmol), and the resulting mixture was stirred for 1.5 h at room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric acid and water respectively, dried, and concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (toluene-ethyl acetate=5:1) to give compound (9) (856 mg; yield 76%).
  • Process 2
  • To a solution of compound (9) (800 mg, 2.32 mmol) in methyl ethyl ketone (8 mL) were added potassium carbonate (0.96 g, 6.96 mmol), benzyltriethylammonium chloride (106 mg, 0.464 mmol), and methyl bromoacetate (1.06 g, 6.96 mmol), and the resulting mixture was heated for 2.5 h at reflux. The reaction mixture was diluted with water and extracted with toluene. The organic layer was washed with water, dried, and concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (toluene-ethyl acetate=5:1) and obtained material was dissolved in MeOH (2.8 ml)-THF (1.4 ml). To the solution was added 4 mol/L aqueous sodium hydroxide (1.4 mL, 5.6 mmol) and the mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with water, acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water, dried, and concentrated in vacuo. The resulting residue was crystallized from hexane-ethyl acetate to give compound Ic-14 (717 mg; yield 79%). The physical property of the compound is shown below.
  • Example 4 Compound Id-2
  • Figure US20090258922A1-20091015-C00047
  • Process 1
  • To a solution of compound (10) (1.25 g, 4.59 mmol) in methyl ethyl ketone (20 mL) prepared by the method described in Journal of Organic Chemistry, 62, 2676 (1997) were added potassium carbonate (1.9 g, 13.77 mmol), methyl bromoacetate (1.74 mL, 18.36 mmol), and benzyltriethylammonium chloride (209 mg, 0.92 mmol), and the resulting mixture was heated for 20 h at reflux. The mixture was diluted with ethyl acetate, washed with water and brine respectively, dried, and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane-ethyl acetate, 3:1) to give compound (11) (1.18 g; yield 75%).
  • Process 2
  • To a solution of compound (11) (355 mg, 1.03 mmol) in diethyl ether (0.5 mL) was added 4 mol/L hydrochloric acid-ethyl acetate (2.06 mL, 8.24 mmol), and the resulting mixture was stirred for 3 h at room temperature. The precipitated hydrochloric acid salt was filtered off, washed with diethyl ether, and dissolved in THF (3 mL). To this mixture were added triethylamine (0.37 mL, 2.66 mmol) and 4-fluorobenzenesulfonyl chloride (365 mg, 1.88 mmol). The resulting mixture was stirred for 16 h at room temperature, diluted with ethyl acetate, washed with dilute hydrochloric acid and aqueous sodium hydrogencarbonate respectively, dried, and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate 2:1). The product material was dissolved in MeOH (8 mL)-THF (4 mL). To the mixture was added 1 mol/L aqueous sodium hydroxide (1.8 mL, 1.8 mmol) and the resulting mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with water and washed with diethyl ether. To the aqueous layer was added dilute hydrochloric acid and the precipitated crystalline was filtered off, washed with water, and dried to give compound Id-2 (192 mg; yield 48%). The physical property of the compound is shown below.
  • Example 5 Compound Ie-2 and Compound Ie-5
  • Figure US20090258922A1-20091015-C00048
  • Process 1
  • To a solution of compound (12) (509 mg, 2 mmol) prepared by the method described in JP-A-8-169879 in THF (10 mL) were added triethylamine (0.84 mL, 6 mmol) and 4-fluorobenzenesulfonyl chloride (506 mg, 2.6 mmol), and the resulting mixture was stirred for 19 h at room temperature. The mixture was diluted with ethyl acetate, washed with dilute hydrochloric acid and aqueous sodium hydrogencarbonate respectively, dried and concentrated in vacuo. The residue was subjected to silica gel column chromatography (toluene:ethyl acetate=4:1) to give compound (13) (725 mg; yield 88%).
  • Process 2
  • To a solution of compound (13) (309 mg, 0.75 mmol) in MeOH (6 mL)-THF (3 mL) was added 1 mol/L aqueous sodium hydroxide (1.9 mL, 1.9 mmol) and the resulting mixture was stirred for 21 h at room temperature. The mixture was acidified with dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried, and concentrated in vacuo. The residue was crystallized from ethyl acetate-hexane to give compound Ie-2 (287 mg; yield 96%). The physical property of the compound is shown below.
  • Process 3
  • To a solution of compound (13) (363 mg, 0.88 mmol) in N,N-dimethylformamide (3.6 ml) were added methyl iodide (250 mg, 1.76 mmol) and potassium carbonate (182 mg, 1.32 mmol), and the resulting mixture was stirred for 19 h at room temperature. The reaction mixture was poured into water, extracted with ethyl acetate-hexane (1:2). The organic layer was washed with brine, dried, concentrated in vacuo. The residue was dissolved in MeOH-THF (2:1). To the mixture was added 1 mol/L aqueous sodium hydroxide (1.8 mL, 1.8 mmol) and the resulting mixture was stirred for 26 h at room temperature. The mixture was diluted with water and washed with diethyl ether. The aqueous layer was acidified with dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried, and concentrated in vacuo. The residue was crystallized from hexane to give compound Ie-5 (293 mg; yield 84%). The physical property of the compound is shown below.
  • Example 6 Compound Ih-1
  • Figure US20090258922A1-20091015-C00049
  • Process 1
  • The mixture of p-nitrophenylhydrazine (12) (15.0 g, 97.9 mmol) and cyclohexanone (10.15 ml, 97.9 mmol) in acetic acid (45 ml) was heated and stirred for 20 minutes at 60° C. To the reaction mixture was added conc. hydrochloric acid (15 ml) and the resulting mixture was heated for 1.5 h at reflux. To the reaction mixture was added water (50 ml), heated for 10 minutes at reflux, and allowed to cool to room temperature. The precipitated crystal was filtered off, washed with water, and recrystallized from ethanol-water to give 6-nitrotetrahydrocarbazole (13) (17.0 g; yield 80%).
  • Process 2
  • The mixture of compound (13) (6.80 g, 31.44 mmol), methyl bromoacetate (8.93 ml, 94.32 mmol), potassium carbonate (13 g, 94 mmol), benzyltriethylammonium chloride (1.43 g, 6.28 mmol) in methyl ethyl ketone (100 ml) was heated for 1 h at reflux. The reaction mixture was concentrated in vacuo and the resulting residue was diluted with ethyl acetate, washed with water, dried, and concentrated in vacuo. The residue was recrystallized from ethyl acetate-hexane to give compound (14) (7.93 g; yield 87%).
  • Process 3
  • The mixture of compound (14) (7.92 g, 27.47 mmol) and palladium hydroxide (20% wt, 1.0 g) in THF (70 ml) and MeOH (14 ml) was stirred for 7 h under hydrogen atmosphere. After removing the catalyst, the reaction mixture was concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to give compound (15) (5.89 g; yield 83%).
  • Process 4
  • To a solution of compound (15) (3.89 g, 15.0 mmol) in THF (30 ml) were added triethylamine (4.18 ml, 30 mmol) and 4-fluorobenzenesulfonyl chloride (3.07 g, 15.8 mmol), and the resulting mixture was stirred for 1 h at room temperature. To the reaction mixture was added dilute hydrochloric acid and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried, and concentrated in vacuo. The residue was crystallized from ethyl acetate-hexane to give compound (16) (5.93 g; yield 95%).
  • Process 5
  • To a solution of compound (16) (350 mg, 0.84 mmol) in MeOH (4 ml)-THF (2 ml) was added 2 mol/L aqueous sodium hydroxide (1 mL, 2 mmol) and the resulting mixture was stirred for 15 h at room temperature. To the reaction mixture was added dilute hydrochloric acid and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried, and concentrated in vacuo. The residue was crystallized from ethyl acetate-hexane to give compound Ih-1 (268 mg; yield 79%). The physical property of the compound is shown below.
  • The compounds which were shown in the following Tables were synthesized in a manner similar to those described in Examples 1 to 6.
  • TABLE 1
    Figure US20090258922A1-20091015-C00050
    No R1 R2 R4 R5 R6 R7 R15 n Y Ar
    Ia-1 COOH H H H H H H 1 H C6H5
    Ia-2 COOH H H H H H H 1 H 4-F—C6H4
    Ia-3 COOH H H H H H H 1 Me C6H5
    Ia-4 COOH H H H H H H 1 Me 4-F—C6H4
    Ia-5 COOH H H H H H H 1 CH2C6H5 C6H5
    Ia-6 COOH H H H H H H 1 CH2C6H5 4-F—C6H4
    Ia-7 COOH H H H H H H 2 H C6H5
    Ia-8 COOH H H H H H H 2 H 2-F—C6H4
    Ia-9 COOH H H H H H H 2 H 2-F—C6H4
    Ia-10 COOH H H H H H H 2 H 2-Me—C6H4
    Ia-11 COOH H H H H H H 2 H 4-Me—C6H4
    Ia-12 COOH H H H H H H 2 H 4-OMe—C6H4
    Ia-13 COOH H H H H H H 2 H 2-thienyl
    Ia-14 COOH H H H H H H 2 H 3-thienyl
    Ia-15 COOH H H H H H H 2 H 4-F-biphenyl
    Ia-16 COOH H H H H H H 2 H C6H4—4-OC6H5
    Ia-17 COOH H H H H H H 2 H dibenzothiophene-3-yl
    Ia-18 COOH Me H H H H H 2 H C6H5
    Ia-19 COOH Me H H H H H 2 H 2-F—C6H4
    Ia-20 COOH Me H H H H H 2 H 4-F—C6H4
    Ia-21 COOH Me H H H H H 2 H 2-thienyl
    Ia-22 COOH Me H H H H H 2 H 3-thienyl
    Ia-23 COOH H H H H Me H 2 H C6H5
    Ia-24 COOH H H H H Me H 2 H 2-F—C6H5
    Ia-25 COOH H H H H Me H 2 H 4-F—C6H5
  • TABLE 2
    Figure US20090258922A1-20091015-C00051
    No R1 R2 R4 R5 R6 R7 R15 n Y Ar
    Ia-26 COOH H H H H Me H 2 H 4-OMe—C6H4
    Ia-27 COOH H H H H Me H 2 H 3-thienyl
    Ia-28 COOH H H OMe H H H 2 H 4-F—C6H4
    Ia-29 COOH H H OMe H H H 2 H 2-thienyl
    Ia-30 COOH H H Cl H H H 2 H C6H5
    Ia-31 COOH H H Cl H H H 2 H 2-F—C6H4
    Ia-32 COOH H H Cl H H H 2 H 4-F—C6H4
    Ia-33 COOH H H Cl H H H 2 H 4-OMe—C6H4
    Ia-34 COOH H H F H H H 2 H C6H5
    Ia-35 COOH H H F H H H 2 H 2-F—C6H4
    Ia-36 COOH H H F H H H 2 H 4-F—C6H4
    Ia-37 COOH H H H F H H 2 H 4-F—C6H5
    Ia-38 COOH H H H H H H 2 Me C6H5
    Ia-39 COOH H H H H H H 2 Me 4-F—C6H4
    Ia-40 COOH H H H H H H 2 Me 3-thienyl
    Ia-41 COOH Me H H H H H 2 Me 4-F—C6H4
    Ia-42 COOH H H H H Me H 2 Me 4-F—C6H4
    Ia-43 COOH H H OMe H H H 2 Me 4-F—C6H4
    Ia-44 COOH H H Cl H H H 2 Me 4-F—C6H4
    Ia-45 COOH H H F H H H 2 Me 4-F—C6H4
    Ia-46 COOH H H H F H H 2 Me 4-F—C6H5
    Ia-47 COOH H H H H H H 2 CH2CH═CH2 4-F—C6H4
    Ia-48 COOH H H H H H H 2 iPr 4-F—C6H4
    Ia-49 COOH H H H H H H 2 C6H5 4-F—C6H4
    Ia-50 COOH H H H H H H 2 CH2C6H5 C6H5
    Ia-51 COOH H H H H H H 2 CH2C6H5 4-F—C6H4
    Ia-52 CONHMs H H H H H H 2 CH2C6H5 4-F—C6H4
  • TABLE 3
    Figure US20090258922A1-20091015-C00052
    No R1 R2 R4 R5 R6 R7 R15 n Y Ar
    Ia-53 COOH H H H H H H 2 CH2C6H5 4-OMe—C6H4
    Ia-54 COOH H H H H H H 2 CH2C6H5 3-thienyl
    Ia-55 COOH Me H H H H H 2 CH2C6H5 4-F—C6H4
    Ia-56 COOH H H H H Me H 2 CH2C6H5 4-F—C6H4
    Ia-57 COOH H H OMe H H H 2 CH2C6H5 4-F—C6H4
    Ia-58 COOH H H Cl H H H 2 CH2C6H5 4-F—C6H4
    Ia-59 COOH H H F H H H 2 CH2C6H5 4-F—C6H4
    Ia-60 COOH H H H F H H 2 CH2C6H5 4-F—C6H5
    Ia-61 COOH H H H H H H 2 CH2C6H4—2-Me 4-F—C6H4
    Ia-62 COOH H H H H H H 2 CH2C6H4—4-OMe 4-F—C6H4
    Ia-63 COOH H H H H H H 2 CH2C6H4—4-NO2 4-F—C6H4
    Ia-64 COOH H H H H H H 2 CH2-1-naphthyl 4-F—C6H4
    Ia-65 COOH H H H H H H 2 CH2-2-thienyl 4-F—C6H4
    Ia-66 COOH H H H H H H 2 CH2CH2C6H5 4-F—C6H4
    Ia-67 COOH H H H H H H 3 H C6H5
    Ia-68 COOH H H H H H H 3 H 2-F—C6H4
    Ia-69 COOH H H H H H H 3 H 4-F—C6H4
    Ia-70 COOH H H H H H H 3 H 2-Me—C6H4
    Ia-71 COOH H H H H H H 3 H 4-Me—C6H4
    Ia-72 COOH H H H H H H 3 H 4-OMe—C6H4
    Ia-73 COOH H H H H H H 3 H 2-thienyl
    Ia-74 COOH H H H H H H 3 H C6H4—4-OC6H5
    Ia-75 COOH Me H H H H H 3 H C6H5
    Ia-76 COOH Me H H H H H 3 H 4-F—C6H4
    Ia-77 COOH H H Cl H H H 3 H C6H5
    Ia-78 COOH H H Cl H H H 3 H 2-F—C6H4
  • TABLE 4
    Figure US20090258922A1-20091015-C00053
    No R1 R2 R4 R5 R6 R7 R15 n Y Ar
    Ia-79 COOH H H Cl H H H 3 H 4-F—C6H4
    Ia-80 COOH H H H H H H 3 Me C6H5
    Ia-81 COOH H H H H H H 3 Me 4-F—C6H4
    Ia-82 COOH H H H H H H 3 Me 3-thienyl
    Ia-83 COOH Me H H H H H 3 Me 4-F—C6H4
    Ia-84 COOH H H H H H H 3 CH2C6H5 C6H5
    Ia-85 COOH H H H H H H 3 CH2C6H5 4-F—C6H4
    Ia-86 COOH H H H H H H 3 CH2C6H5 3-thienyl
    Ia-87 COOH H H H H H H 2 CH2CH2C6H5 4-Me—C6H4
    Ia-88 COOH H H H H H H 2 H 4-Cl—C6H4
    Ia-89 COOH H H F H H H 2 H 4-OMe—C6H4
    Ia-90 COOH H H F H H H 2 H 2-thienyl
    Ia-91 COOH H H H H H H 2 CH2CH2C6H5 2-thienyl
    Ia-92 COOH H H Cl H H H 2 CH2CH2C6H5 4-F—C6H4
    Ia-93 COOH H H H H H H 2 CH2CH═CHC6H5 4-F—C6H4
    Ia-94 COOH H H H H H H 2 CH2CH2CH2C6H5 4-F—C6H4
    Ia-95 COOH H H F H H H 2 H 4-Me—C6H4
    Ia-96 COOH H H F H H H 2 H 2-naphthyl
    Ia-97 COOH H H F H H H 2 H 4-NO2—C6H4
    Ia-98 COOH H H F H H H 2 H 1-naphthyl
    Ia-99 COOH H H F H H H 2 H 4-CN—C6H4
    Ia-100 COOH H H OH H H H 2 H 2-F—C6H4
    Ia-101 COOH H F H H H H 2 H 4-F—C6H4
    Ia-102 COOH H F H H H H 2 Me 4-F—C6H4
    Ia-103 COOH H F H H H H 2 CH2C6H5 4-F—C6H4
    Ia-104 COOH H H Cl H H Me 2 H 4-F—C6H4
  • TABLE 5
    Figure US20090258922A1-20091015-C00054
    No R1 R2 R4 R5 R6 R7 R15 n Y Ar
    Ia-105 COOH H H Cl H H Me 2 Me 4-F—C6H4
    Ia-106 COOH H H Cl H H Me 2 CH2C6H5 4-F—C6H4
  • TABLE 6
    Figure US20090258922A1-20091015-C00055
    No R1 R5 R6 R7 y m p Y Ar
    Ib-1 COOH H H H 1 1 0 H C6H5
    Ib-2 COOH H H H 1 1 0 H 4-F—C6H4
    Ib-3 COOH H H H 1 1 0 H 4-Me—C6H4
    Ib-4 COOH H H H 1 1 0 H 2-thienyl
    Ib-5 COOH H H H 1 1 0 Me C6H5
    Ib-6 COOH H H H 1 1 0 Me 4-F—C6H4
    Ib-7 COOH H H H 1 1 0 Me 4-Me—C6H4
    Ib-8 COOH H H H 1 1 0 Me 2-thienyl
    Ib-9 COOH H H H 1 1 0 Et C6H5
    Ib-10 COOH H H H 1 1 0 CH2C6H5 C6H5
    Ib-11 COOH H H H 1 1 0 CH2C6H5 4-F—C6H4
    Ib-12 COOH H H H 1 1 0 CH2C6H5 4-Me—C6H4
    Ib-13 COOH H H H 1 1 0 CH2C6H5 2-thienyl
    Ib-14 COOH H H H 1 2 0 H C6H5
    Ib-15 COOH H H H 1 2 0 H 2-F—C6H4
    Ib-16 COOH H H H 1 2 0 H 4-F—C6H4
    Ib-17 COOH H H H 1 2 0 H 4-Cl—C6H4
    Ib-18 COOH H H H 1 2 0 H 4-Me—C6H4
    Ib-19 COOH H H H 1 2 0 H 4-OMe—C6H4
    Ib-20 COOH H H H 1 2 0 H 2-thienyl
  • TABLE 7
    Figure US20090258922A1-20091015-C00056
    No R1 R5 R6 R7 y m p Y Ar
    Ib-21 COOH H H H 1 2 0 H 3-thienyl
    Ib-22 COOH H H H 1 2 0 H 5-benzyl-
    2-thienyl
    Ib-23 COOH H H H 1 2 0 Me C6H5
    Ib-24 COOH H H H 1 2 0 Me 2-F—C6H4
    Ib-25 COOH H H H 1 2 0 Me 4-F—C6H4
    Ib-26 COOH H H H 1 2 0 Me 4-Cl—C6H4
    Ib-27 COOH H H H 1 2 0 Me 4-Me—C6H4
    Ib-28 COOH H H H 1 2 0 Me 4-OMe—C6H4
    Ib-29 COOH H H H 1 2 0 Me 2-thienyl
    Ib-30 COOH H H H 1 2 0 Me 3-thienyl
    Ib-31 COOH H H H 1 2 0 Me 5-benzyl-
    2-thienyl
    Ib-32 COOH H H H 1 2 0 Et 4-F—C6H4
    Ib-33 COOH H H H 1 2 0 Et 4-OMe—C6H4
    Ib-34 COOH H H H 1 2 0 CH2C6H5 4-Me—C6H4
    Ib-35 COOH Cl H H 1 2 0 H C6H5
    Ib-36 COOH Cl H H 1 2 0 H 4-F—C6H4
    Ib-37 COOH Cl H H 1 2 0 H 4-Me—C6H4
    Ib-38 COOH Cl H H 1 2 0 H 4-OMe—C6H4
    Ib-39 COOH Cl H H 1 2 0 H 3-thienyl
    Ib-40 COOH Cl H H 1 2 0 Me C6H4
    Ib-41 COOH Cl H H 1 2 0 Me 4-F—C6H4
    Ib-42 COOH Cl H H 1 2 0 Me 4-Me—C6H4
    Ib-43 COOH Cl H H 1 2 0 Me 4-OMe—C6H4
    Ib-44 COOH Cl H H 1 2 0 Me 3-thienyl
    Ib-45 COOH Cl H H 1 2 0 CH2C6H5 4-F—C6H4
    Ib-46 COOH F H H 1 2 0 H 4-F—C6H4
    Ib-47 COOH F H H 1 2 0 Me 4-F—C6H4
  • TABLE 8
    Figure US20090258922A1-20091015-C00057
    No R1 R5 R6 R7 y m p Y Ar
    Ib-48 COOH F H H 1 2 0 CH2C6H5 4-F—C6H4
    Ib-49 COOH H H H 1 2 0 H C6H5
    Ib-50 COOH H H H 2 1 0 H 2-F—C6H4
    Ib-51 COOH H H H 2 1 0 H 4-F—C6H4
    Ib-52 COOH H H H 2 1 0 H 4-Cl—C6H4
    Ib-53 COOH H H H 2 1 0 H 4-Me—C6H4
    Ib-54 COOH H H H 2 1 0 H 4-OMe—C6H4
    Ib-55 COOH H H H 2 1 0 H 2-thienyl
    Ib-56 COOH H H H 2 1 0 H 3-thienyl
    Ib-57 COOH H H H 2 1 0 Me C6H5
    Ib-58 COOH H H H 2 1 0 Me 4-F—C6H4
    Ib-59 COOH H H H 2 1 0 Me 4-Me—C6H4
    Ib-60 COOH H H H 2 1 0 Me 2-thienyl
    Ib-61 COOH H H H 2 1 0 CH2C6H5 4-F—C6H4
    Ib-62 COOH H H H 2 2 0 H C6H5
    Ib-63 COOH H H H 2 2 0 H 4-F—C6H4
    Ib-64 COOH H H H 2 2 0 H 4-Cl—C6H4
    Ib-65 COOH H H H 2 2 0 H 4-Me—C6H4
    Ib-66 COOH H H H 2 2 0 H 4-OMe—C6H4
    Ib-67 COOH H H H 2 2 0 H 2-thienyl
    Ib-68 COOH H H H 2 2 0 Me C6H5
    Ib-69 COOH H H H 2 2 0 Me 4-F—C6H4
    Ib-70 COOH H H H 2 2 0 Me 4-Cl—C6H4
    Ib-71 COOH H H H 2 2 0 Me 4-Me—C6H4
    Ib-72 COOH H H H 2 2 0 Me 4-OMe—C6H4
    Ib-73 COOH H H H 2 2 0 Me 2-thienyl
    Ib-74 COOH H H H 2 2 0 CH2C6C4 C6H5
  • TABLE 9
    Figure US20090258922A1-20091015-C00058
    No R1 R5 R6 R7 y m p Y Ar
    Ib-75 COOH H H H 2 2 0 CH2C6H5 4-F—C6H4
    Ib-76 COOH H H H 0 2 1 H C6H5
    Ib-77 COOH H H H 0 2 1 H 4-F—C6H4
    Ib-78 COOH H H H 0 2 1 H 4-Cl—C6H4
    Ib-79 COOH H H H 0 2 1 H 4-Me—C6H4
    Ib-80 COOH H H H 0 2 1 H 4-
    OMe—C6H4
    Ib-81 COOH H H H 0 2 1 H 2-thienyl
    Ib-82 COOH H H H 0 2 1 Me C6H5
    Ib-83 COOH H H H 0 2 1 Me 4-F—C6H4
    Ib-84 COOH H H H 0 2 1 Me 4-Cl—C6H4
    Ib-85 COOH H H H 0 2 1 Me 4-Me—C6H4
    Ib-86 COOH H H H 0 2 1 Me 4-
    OMe—C6H4
    Ib-87 COOH H H H 0 2 1 Me 2-thienyl
    Ib-88 COOH H H H 0 2 1 CH2C6H5 C6H5
    Ib-89 COOH H H H 0 2 1 CH2C6H5 4-F—C6H4
    Ib-90 COOH H H H 1 1 1 H C6H5
    Ib-91 COOH H H H 1 1 1 H 4-F—C6H4
    Ib-92 COOH H H H 1 1 1 H 4-Cl—C6H4
    Ib-93 COOH H H H 1 1 1 H 4-Me—C6H4
    Ib-94 COOH H H H 1 1 1 H 4-
    OMe—C6H4
    Ib-95 COOH H H H 1 1 1 H 2-thienyl
    Ib-96 COOH H H H 1 1 1 Me C6H5
    Ib-97 COOH H H H 1 1 1 Me 4-F—C6H4
    Ib-98 COOH H H H 1 1 1 Me 4-Cl—C6H4
    Ib-99 COOH H H H 1 1 1 Me 4-Me—C6H4
    Ib-100 COOH H H H 1 1 1 Me 4-
    OMe—C6H4
    Ib-101 COOH H H H 1 1 1 Me 2-thienyl
  • TABLE 10
    Figure US20090258922A1-20091015-C00059
    No R1 R5 R6 R7 y m p Y Ar
    Ib-102 COOH H H H 1 1 1 CH2C6H5 C6H5
    Ib-103 COOH H H H 1 1 1 CH2C6H5 4-F—C6H4
  • TABLE 11
    Figure US20090258922A1-20091015-C00060
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00061
    Ar
    Ic-1 COOH H H H H H
    Figure US20090258922A1-20091015-C00062
    C6H5
    Ic-2 COOH H H H H H
    Figure US20090258922A1-20091015-C00063
    4-F—C6H4
    Ic-3 COOH H H H H H
    Figure US20090258922A1-20091015-C00064
    4-Me—C6H4
    Ic-4 COOH H H H H H
    Figure US20090258922A1-20091015-C00065
    2-thienyl
    Ic-5 COOH H H H H H
    Figure US20090258922A1-20091015-C00066
    C6H5
    Ic-6 COOH H H H H H
    Figure US20090258922A1-20091015-C00067
    4-F—C6H4
    Ic-7 COOH H H H H H
    Figure US20090258922A1-20091015-C00068
    4-Me—C6H4
    Ic-8 COOH H H H H H
    Figure US20090258922A1-20091015-C00069
    2-thienyl
    Ic-9 COOH Me H H H H
    Figure US20090258922A1-20091015-C00070
    4-F—C6H4
    Ic-10 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00071
    4-F—C6H4
    Ic-11 COOH H H F H H
    Figure US20090258922A1-20091015-C00072
    4-F—C6H4
  • TABLE 12
    Figure US20090258922A1-20091015-C00073
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00074
    Ar
    Ic-12 COOH H H H H H
    Figure US20090258922A1-20091015-C00075
    4-F—C6H4
    Ic-13 COOH H H H H H
    Figure US20090258922A1-20091015-C00076
    C6H5
    Ic-14 COOH H H H H H
    Figure US20090258922A1-20091015-C00077
    4-F—C6H4
    Ic-15 COOH H H H H H
    Figure US20090258922A1-20091015-C00078
    4-Me—C6H4
    Ic-16 COOH H H H H H
    Figure US20090258922A1-20091015-C00079
    2-theinyl
    Ic-17 COOH Me H H H H
    Figure US20090258922A1-20091015-C00080
    C6H5
    Ic-18 COOH Me H H H H
    Figure US20090258922A1-20091015-C00081
    4-F—C6H4
    Ic-19 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00082
    4-F—C6H4
    Ic-20 COOH H H F H H
    Figure US20090258922A1-20091015-C00083
    4-F—C6H4
    Ic-21 COOH H H H H H
    Figure US20090258922A1-20091015-C00084
    C6H5
    Ic-22 COOH H H H H H
    Figure US20090258922A1-20091015-C00085
    4-F—C6H4
    Ic-23 COOH H H H H H
    Figure US20090258922A1-20091015-C00086
    C6H5
    Ic-24 COOH H H H H H
    Figure US20090258922A1-20091015-C00087
    4-F—C6H4
    Ic-25 COOH H H H H H
    Figure US20090258922A1-20091015-C00088
    C6H5
    Ic-26 COOH H H H H H
    Figure US20090258922A1-20091015-C00089
    4-F—C6H4
    Ic-27 COOH H H H H H
    Figure US20090258922A1-20091015-C00090
    2-thienyl
  • TABLE 13
    Figure US20090258922A1-20091015-C00091
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00092
    Ar
    Ic-28 COOH H H H H H
    Figure US20090258922A1-20091015-C00093
    C6H5
    Ic-29 COOH H H H H H
    Figure US20090258922A1-20091015-C00094
    4-F—C6H4
    Ic-30 COOH H H H H H
    Figure US20090258922A1-20091015-C00095
    4-OMe—C6H4
  • TABLE 14
    Figure US20090258922A1-20091015-C00096
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00097
    Ar
    Ic-31 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00098
    2-thienyl
    Ic-32 COOH H H Me H H
    Figure US20090258922A1-20091015-C00099
    4-F—C6H4
    Ic-33 COOH H H Me H H
    Figure US20090258922A1-20091015-C00100
    4-Me—C6H4
    Ic-34 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00101
    C6H5
    Ic-35 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00102
    CH2C6H5
    Ic-36 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00103
    4-Cl—C6H4
    Ic-37 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00104
    4-Me—C6H4
    Ic-38 COOH H H F H H
    Figure US20090258922A1-20091015-C00105
    4-F—C6H4
    Ic-39 COOH Me H F H H
    Figure US20090258922A1-20091015-C00106
    2-thienyl
    Ic-40 COOH H H OMe H H
    Figure US20090258922A1-20091015-C00107
    4-F—C6H4
    Ic-41 COOH H H OMe H H
    Figure US20090258922A1-20091015-C00108
    2-thienyl
  • TABLE 15
    Figure US20090258922A1-20091015-C00109
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00110
    Ar
    Ic-42 COOH H H OH H H
    Figure US20090258922A1-20091015-C00111
    4-F—C6H4
    Ic-43 COOH H H F H H
    Figure US20090258922A1-20091015-C00112
    nBu
    Ic-44 COOH H H F H H
    Figure US20090258922A1-20091015-C00113
    CH2═CHC6H5
    Ic-45 COOH H H F H H
    Figure US20090258922A1-20091015-C00114
    4-C6H5—C6H4
    Ic-46 COOH H H F H H
    Figure US20090258922A1-20091015-C00115
    Me
    Ic-47 COOH H H C6H5 H H
    Figure US20090258922A1-20091015-C00116
    4-F—C6H4
    Ic-48 COOH H H C6H5 H H
    Figure US20090258922A1-20091015-C00117
    nBu
    Ic-49 COOH H H C6H5 H H
    Figure US20090258922A1-20091015-C00118
    2-thienyl
    Ic-50 COOH H H F H H
    Figure US20090258922A1-20091015-C00119
    CH2CH2C6H5
    Ic-51 COOH H H H Cl H
    Figure US20090258922A1-20091015-C00120
    4-F—C6H4
     c-52 COOH H H H Cl H
    Figure US20090258922A1-20091015-C00121
    2-thienyl
    Ic-53 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00122
    4-F—C6H4
    Ic-54 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00123
    3-F—C6H4
    Ic-55 COOH Me H Cl H H
    Figure US20090258922A1-20091015-C00124
    4-F—C6H4
    Ic-56 COOH Me H Cl H H
    Figure US20090258922A1-20091015-C00125
    2-thienyl
    Ic-57 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00126
    nBu
    Ic-58 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00127
    4-CF3—C6H4
    Ic-59 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00128
    nBu
    Ic-60 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00129
    Octyl
  • TABLE 16
    Figure US20090258922A1-20091015-C00130
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00131
    Ar
    Ic-61 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00132
    1-naphthyl
    Ic-62 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00133
    4-NO2—C6H4
    Ic-63 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00134
    4-CN—C6H4
    Ic-64 COOH H Cl H H H
    Figure US20090258922A1-20091015-C00135
    4-F—C6H4
    Ic-65 COOH H Cl H H H
    Figure US20090258922A1-20091015-C00136
    2-thienyl
    Ic-66 COOH H Cl H H H
    Figure US20090258922A1-20091015-C00137
    nBu
    Ic-67 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00138
    5-benzyl-thiophen-2- yl
    Ic-68 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00139
    Quinolin-8-yl
    Ic-69 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00140
    3-thienyl
    Ic-70 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00141
    Benzo[b]thiophen-3-yl
    Ic-71 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00142
    2,4-diF—C6H3
    Ic-72 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00143
    Me
    Ic-73 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00144
    4-OMe-C6H4
    Ic-74 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00145
    CH2CH═CHC6H5
    Ic-75 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00146
    Pyridin3--yl
    Ic-76 COOH Me H H H H
    Figure US20090258922A1-20091015-C00147
    2-thienyl
    Ic-77 COOH Me H H H H
    Figure US20090258922A1-20091015-C00148
    nBu
    Ic-78 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00149
    5-Cl-thiophen-2-yl
    Ic-79 COOH H H Cl H H
    Figure US20090258922A1-20091015-C00150
    4-OH—C6H4
  • TABLE 17
    Figure US20090258922A1-20091015-C00151
    No R1 R2 R4 R5 R6 R7
    Figure US20090258922A1-20091015-C00152
    Ar
    Ic-80 COOH H H H H H
    Figure US20090258922A1-20091015-C00153
    4-F—C6H4
    Ic-81 COOH H H H H H
    Figure US20090258922A1-20091015-C00154
    4-OMe-C6H4
    Ic-82 COOH H H F H H
    Figure US20090258922A1-20091015-C00155
    4-F—C6H4
    Ic-83 COOH H H F H H
    Figure US20090258922A1-20091015-C00156
    4-F—C6H4
    Ic-84 COOH H H F H H
    Figure US20090258922A1-20091015-C00157
    4-F—C6H4
    Ic-85 COOH H H F H H
    Figure US20090258922A1-20091015-C00158
    4-OMe-C6H4
  • TABLE 18
    Figure US20090258922A1-20091015-C00159
    No y m R1 Ar
    Id-1 1 2 COOH C6H5
    Id-2 1 2 COOH 4-F—C6H4
    Id-3 1 2 COOH 2-thienyl
    Id-4 2 1 COOH C6H5
    Id-5 2 1 COOH 4-F—C6H4
    Id-6 2 1 COOH 2-thienyl
  • TABLE 19
    Figure US20090258922A1-20091015-C00160
    No R1 R4 R5 R6 R7 R20 R21 Y Ar
    Ie COOH H H H H H H H C6H5
    1
    Ie COOH H H H H H H H 4-F—C6H4
    2
    Ie- COOH H H H H H H H 2-thienyl
    3
    Ie- COOH H H H H H H Me C6H5
    4
    Ie- COOH H H H H H H Me 4-F—C6H4
    5
    Ie- COOH H H H H H H Me 2-thienyl
    6
    Ie- COOH H H H H H H CH2C6H5 C6H5
    7
    Ie- COOH H H H H H H CH2C6H5 4-F—C6H4
    8
    Ie- COOH H H H H H H CH2C6H5 2-thienyl
    9
    Ie- COOH H H F H H H H 4-F—C6H4
    10
    Ie- COOH H H Me H H H H 4-F—C6H4
    11
    Ie- COOH H H F H H H Me 4-F—C6H4
    12
    Ie- COOH H H F H H H CH2C6H5 4-F—C6H4
    13
    Ie- COOH H H Me H H H Me 4-F—C6H4
    14
    Ie- COOH H H H H Me H CH2C6H5 4-F—C6H4
    15
    Ie- COOH H F H H H H H 4-F—C6H4
    16
    Ie- COOH H F H H H H Me 4-F—C6H4
    17
    Ie- COOH H F H H H H Me 4-F—C6H4
    18
    Ie- COOH F H H H H H H 4-F—C6H4
    19
    Ie- COOH F H H H H H Me 4-F—C6H4
    20
    Ie- COOH F H H H H H CH2C6H5 4-F—C6H4
    21
    Ie- COOH H H H H H F H 4-F—C6H4
    22
    Ie- COOH H H H H H F Me 4-F—C6H4
    23
    Ie- COOH H H H H H F CH2C6H5 4-F—C6H4
    24
    Ie- COOH H H H F H H Me 4-F—C6H4
    25
    Ie- COOH H H H F H H CH2C6H5 4-F—C6H4
    26
    Ie- COOH H Br H H H H H 4-F—C6H4
    27
  • TABLE 20
    Figure US20090258922A1-20091015-C00161
    No R1 R2 R5 R23 R24 R25 R26 Z3 Y Ar
    If-1 COOH Me H Me Me H H ═CH— H 4-F—C6H4
    If-2 COOH Me H Me Me H H ═CH— Me 4-F—C6H4
    If-3 COOH Me H Me Me H H ═CH— CH2C6H5 4-F—C6H4
    If-4 COOH Me H Me H H H ═CH— H 4-F—C6H4
    If-5 COOH Me H Me H H H ═CH— Me 4-F—C6H4
    If-6 COOH Me H Me H H H ═CH— CH2C6H5 4-F—C6H4
    If-7 COOH H H —(CH2)4 H H ═CH— Me 4-F—C6H4
    If-8 COOH H H —(CH2)4 H H ═CH— CH2C6H5 4-F—C6H4
    If-9 COOH H H C6H5 H H H ═CH— H 4-F—C6H4
    If-10 COOH Me H C6H5 H H H ═CH— Me 4-F—C6H4
    If-11 COOH H H —(CH2)3 H H ═CH— H 4-F—C6H4
    If-12 COOH H H —(CH2)3 H H ═CH— CH2C6H5 4-F—C6H4
    If-13 COOH H H Me Me H H ═CH— H 4-F—C6H4
    If-14 COOH H H Me Me H H ═CH— Me 4-F—C6H4
    If-15 COOH H H Me Me H H ═CH— CH2C6H5 4-F—C6H4
    If-16 COOH H H H H CH2O H ═CH— H 4-F—C6H4
    Me
    If-17 COOH H Cl Me Me H H ═CH— H 4-F—C6H4
    If-18 COOH H Cl Me Me H H ═CH— Me 4-F—C6H4
    If-19 COOH H Cl Me Me H H ═CH— CH2C6H5 4-F—C6H4
    If-20 COOH H H H H H H ═N— CH2C6H5 4-F—C6H4
  • TABLE 21
    Figure US20090258922A1-20091015-C00162
    No R1 Z1 Z2 q Y Ar
    Ig-1 COOH —CH2 —CH2 0 H 4-F—C6H4
    Ig-2 COOH —CH2 —S— 1 H 4-F—C6H4
    Ig-3 COOH —CH2 —S— 1 Me 4-F—C6H4
    Ig-4 COOH —C(═O)— —CH2 1 Me 4-F—C6H4
    Ig-5 COOH —C(═O)— —CH(Et)- 1 Me 4-F—C6H4
    Ig-6 COOH —CH2 —N(COOEt)- 1 H 4-F—C6H4
    Ig-7 COOH —CH2 —N(COOEt)- 1 Me 4-F—C6H4
    Ig-8 COOH —CH2 —N(COOEt)- 1 H 4-OMe-C6H4
    Ig-9 COOH —CH2 —N(COOEt)- 1 Me 4-OMe-C6H4
    Ig-10 COOH —CH2 —N(COMe)- 1 Me 4-OMe-C6H4
    Ig-11 COOH —CH2 —CH2 2 H 4-F—C6H4
    Ig-12 COOH —CH2 —CH2 2 Me 4-F—C6H4
    Ig-13 COOH —CH2 —CH2 2 CH2C6H5 4-F—C6H4
    Ig-14 COOH —CH2 —CH2 2 Me 4-OMe-C6H4
    Ig-15 COOH —CH2 —CH2 2 Et 4-F—C6H4
    Ig-16 COOH —CH2 —CH2 2 Me 4-OH—C6H4
    Ig-17 COOH —CH2 —NH— 2 Me 4-F—C6H4
    Ig-18 COOH —CH2 —CH2 3 H 4-F—C6H4
    Ig-19 COOH —CH2 —CH2 3 Me 4-F—C6H4
    Ig-20 COOH —CH2 —CH2 3 CH2C6H5 4-F—C6H4
    Ig-21 COOH —CH2 —CH2 0 Me 4-F—C6H4
    Ig-22 COOH —CH2 —S(═O)— 1 H 4-F—C6H4
    Ig-23 COOH —CH2 —S(═O)— 1 Me 4-F—C6H4
    Ig-24 COOH —C(═O)— —NH— 2 H 4-OMe-C6H4
    Ig-25 COOH —C(═O)— —NH— 2 Me 4-OMe-C6H4
  • TABLE 22
    Figure US20090258922A1-20091015-C00163
    No R1 Z1 Z2 q Y Ar
    Ig-26 COOH —C(═NOH)— —CH2 1 Me 4-F—C6H4
    Ig-27 COOH —C(═NOMe)— —CH2 1 Me 4-F—C6H4
  • TABLE 23
    Figure US20090258922A1-20091015-C00164
    No R1 R17 R18 R19 Y Ar
    Ih-1 COOH H H H H 4-F—C6H4
    Ih-2 COOH H H H Me 4-F—C6H4
    Ih-3 COOH H H H CH2C6H5 4-F—C6H4
    Ih-4 COOH H H Me H 4-F—C6H4
    Ih-5 COOH H H Me Me 4-F—C6H4
    Ih-6 COOH H H Me CH2C6H5 4-F—C6H4
    Ih-7 COOH H H H Me 2-thienyl
    Ih-8 COOH H H H Me nBu
    Ih-9 COOH H H H CH2C6H5 2-thienyl
    Ih-10 COOH H H H CH2C6H5 nBu
    Ih-11 COOH H H H H 2-thienyl
    Ih-12 COOH H H H Me 4-OMe-C6H4
    Ih-13 COOH H H H H 4-OH—C6H4
    Ih-14 COOH H H H H 4-OMe-C6H4
    Ih-15 COOH H H H Me 4-OH—C6H4
    Ih-16 COOH H H Et H 4-F—C6H4
    Ih-17 COOH H H Et H 4-OMe-C6H4
    Ih-18 COOH H H Et Me 4-F—C6H4
    Ih-19 COOH H H Et Me 4-OMe-C6H4
  • TABLE 24
    Figure US20090258922A1-20091015-C00165
    No R1 R17 R18 R19 Y Ar
    Ih-20 COOH H H H H C6H5
    Ih-21 COOH H H H H 4-Me-C6H4
    Ih-22 COOH H H H Me C6H5
    Ih-23 COOH H H H Me 4-Me-C6H4
    Ih-24 COOH H H H Me CH2C6H5
    Ih-25 COOH H H H Me CH2CH═CHC6H5
    Ih-26 COOH H Me Me H 4-OMe-C6H4
    Ih-27 COOH H Me Me H 4-F—C6H4
    Ih-28 COOH H Me Me H 2-thienyl
    Ih-29 COOH H H H H CH2C6H5
    Ih-30 COOH H H H H CH2CH═CHC6H5
    Ih-31 COOH H Me Me Me 4-F—C6H4
    Ih-32 COOH H Me Me Me 4-OMe-C6H4
    Ih-33 COOH H Me Me Me 2-thienyl
    Ih-34 COOH H H C6H5 H 4-F—C6H4
    Ih-35 COOH H H C6H5 H 4-OMe-C6H4
    Ih-36 COOH H H C6H5 Me 4-F—C6H4
    Ih-37 COOH H H C6H5 Me 4-OMe-C6H4
    Ih-38 COOH H Et Et H 4-OMe-C6H4
    Ih-39 COOH H H H H 4-Cl—C6H4
    Ih-40 COOH H H H H 4-CF3—C6H4
    Ih-41 COOH H H H Me 4-Cl—C6H4
    Ih-42 COOH H H H Me 4-CF3—C6H4
    Ih-43 COOH H H H Me 3-thienyl
    Ih-44 COOH H H H Me 4-OCF3—C6H4
    Ih-45 COOH H Et Et Me 4-F—C6H4
    Ih-46 COOH H Et Et Me 4-OMe-C6H4
    Ih-47 COOH H —(CH2)5 H 4-F—C6H4
  • TABLE 25
    Figure US20090258922A1-20091015-C00166
    No R1 R17 R18 R19 Y Ar
    Ih-48 COOH H —(CH2)5 H 4-OMe-C6H4
    Ih-49 COOH H H H H 3-thienyl
    Ih-50 COOH H H Pr H 4-F—C6H4
    Ih-51 COOH H H tBu H 4-F—C6H4
    Ih-52 COOH H H Pr H 4-OMe-C6H4
    Ih-53 COOH H H tBu H 4-OMe-C6H4
    Ih-54 COOH H H H H 4-OCF3—C6H4
    Ih-55 COOH H —(CH2)5 Me 4-F—C6H4
    Ih-56 COOH H —(CH2)5 Me 4-OMe-C6H4
    Ih-57 COOH H H Pr Me 4-F—C6H4
    Ih-58 COOH H H tBu Me 4-F—C6H4
    Ih-59 COOH H H Pr Me 4-OMe-C6H4
    Ih-60 COOH H H tBu Me 4-OMe-C6H4
    Ih-61 COOH H H pentyl Me 4-F—C6H4
    Ih-62 COOH H H pentyl Me 4-OMe-C6H4
    Ih-63 COOH H H H Et 4-OMe-C6H4
    Ih-64 COOH H H H Pr 4-OMe-C6H4
    Ih-65 COOH H H H iBu 4-OMe-C6H4
    Ih-66 COOH H H H iPr 4-OMe-C6H4
    Ih-67 COOH H H H Et 4-F—C6H4
    Ih-68 COOH H H H Pr 4-F—C6H4
    Ih-69 COOH H H H allyl 4-F—C6H4
    Ih-70 COOH H H H propargyl 4-F—C6H4
    Ih-71 COOH H H H CH2CF3 4-F—C6H4
    Ih-72 COOH H H H CH2CH2OH 4-F—C6H4
    Ih-73 COOH H H H cyclo- 4-F—C6H4
    propylmethyl
    Ih-74 COOH H H H allyl 4-OMe-C6H4
  • TABLE 26
    Figure US20090258922A1-20091015-C00167
    No R1 R17 R18 R19 Y Ar
    Ih-75 COOH H H H 2-methylpropene 4-OMe-C6H4
    Ih-76 COOH H H H propargyl 4-OMe-C6H4
    Ih-77 COOH H H H cyclopropylmethyl 4-OMe-C6H4
    Ih-78 COOH H H H CH2CH2OH 4-OMe-C6H4
    Ih-79 COOH H H H cylcohexylmethyl 4-F—C6H4
    Ih-80 COOH H H H cyclohexylmethyl 4-OMe-C6H4
    Ih-81 COOH H H H CH2OMe 4-F—C6H4
    Ih-82 COOH H H H CH2OMe 4-OMe-C6H4
    Ih-83 COOH Me H H Me 4-F—C6H4
    Ih-84 COOH Me H H Me 4-OMe-C6H4
  • TABLE 27
    Figure US20090258922A1-20091015-C00168
    No R1 R5 Z4 Y Ar
    Ii-1 COOH Me —N═ H 4-F—C6H4
    Ii-2 COOH Me —CH═ H 4-F—C6H4
    Ii-3 COOH Me —CH═ Me 4-F—C6H4
  • TABLE 28
    Figure US20090258922A1-20091015-C00169
    No R1 R5 Y Ar
    Ij-1 COOH H H 4-F—C6H4
    Ij-2 COOH H Me 4-F—C6H4
    Ij-3 COOH H CH2C6H5 4-F—C6H4
  • TABLE 29
    Figure US20090258922A1-20091015-C00170
    No R1 R13 Z14 Y Ar
    Ik-1 COOH Me Me Me 4-F—C6H4
    Ik-2 COOH H Me Me 4-F—C6H4
    Ik-3 COOH Et Me H 4-F—C6H4
    Ik-4 COOH Pr Me H 4-F—C6H4
    Ik-5 COOH Et Me Me 4-F—C6H4
    Ik-6 COOH iPr Me Me 4-F—C6H4
    Ik-7 COOH Me Pr Me 4-F—C6H4
    Ik-8 COOH Et H Me 4-F—C6H4
    Ik-9 COOH Pr Me H 4-F—C6H4
    Ik-10 COOH Pr Me Me 4-F—C6H4
    Ik-11 COOH Et Pr H 4-F—C6H4
    Ik-12 COOH Et Pr H 2-thienyl
    Ik-13 COOH Et Pr Me 4-F—C6H4
    Ik-14 COOH Et Pr Me 2-thienyl
    Ik-15 COOH Pr Me H 4-OMe-C6H4
    Ik-16 COOH Pr Me Me 4-OMe-C6H4
    Ik-17 COOH Et Pr H 4-OMe-C6H4
  • TABLE 30
    Figure US20090258922A1-20091015-C00171
    No R1 R13 Z14 Y Ar
    Ik-18 COOH Et Pr Me 4-OMe-C6H4
    Ik-19 COOH CH2C6H5 Me Me 4-F—C6H4
    Ik-20 COOH CH2C6H5 Me Me 4-OMe-C6H4
    Ik-21 COOH iBu Me Me 4-F—C6H4
    Ik-22 COOH nBu Me H 4-F—C6H4
    Ik-23 COOH nBu Me H 4-OMe-C6H4
    Ik-24 COOH nBu Me Me 4-F—C6H4
    Ik-25 COOH nBu Me Me 4-OMe-C6H4
    Ik-26 COOH iBu Me H 4-OMe-C6H4
    Ik-27 COOH iBu Me Me 4-OMe-C6H4
    Ik-28 COOH Pr Me Et 4-OMe-C6H4
    Ik-29 COOH Pr Me Me 4-OH—C6H4
    Ik-30 COOH CH2C6H5 Me H 4-F—C6H4
    Ik-31 COOH Pr Me Me 4-OEt-C6H4
    Ik-32 COOH Pr Me proprgyl 4-OMe-C6H4
    Ik-33 COOH CH2C6H5 Me proprgyl 4-OMe-C6H4
    Ik-34 COOH iBu Me Me 4-F—C6H4
    Ik-35 COOH OMe Me Me 4-F—C6H4
    Ik-36 COOH OMe Me Me 4-OMe-C6H4
    Ik-37 COOH C(═O)Et Me Me 4-OMe-C6H4
    Ik-38 COOH C(═O)Et Me Et 4-OMe-C6H4
    Ik-39 COOH Pr Me Me C6H5
    Ik-40 COOH Pr Me Me 4-Me-C6H4
    Ik-41 COOH Pr Me Me 2-F—C6H4
    Ik-42 COOH Pr Me Me 4-Cl—C6H4
    Ik-43 COOH Pr Me Me 4-Br—C6H4
  • The physical properties of the compounds are shown below.
  • TABLE 31
    Compound
    No. Physical properties
    Ia-7 1H-NMR (CDCl3) δ 2.95 (m, 2H), 3.28 (m, 2H), 4.62 (br, 1H), 4.81 (s, 2H),
    6.84 (s, 1H), 7.06-7.22 (m, 3H), 7.38-7.72 (m, 4H), 7.71-7.74 (m, 2H); IR
    (CHCl3) 3480, 2953, 1731, 1603, 1469, 1447, 1409, 1329, 1162, 1093 cm−1;
    Ia-8 1H-NMR (CDCl3) δ 2.95 (t, J = 6.3 Hz, 2H), 3.31 (dt, J = 5.4 and 6.3 Hz, 2H),
    4.79 (t, J = 5.4 Hz, 1H), 4.84 (s, 2H), 6.90 (s, 1H), 6.99-7.22 (m, 5H), 7.41 (d,
    J = 7.8 Hz, 1H), 7.50 (m, 1H), 7.86 (m, 1H); IR (CHCl3) 3482, 3374, 2929,
    1732, 1601, 1475, 1453, 1411, 1384, 1335, 1266, 1169, 1156, 1126, 1077,
    1015 cm−1; Elemental analysis (C18H17FN2O4S•0.4H2O) Calcd. (%): C, 56.36;
    H, 4.68; N, 7.30; F, 4.95; S, 8.36 Found (%): C, 56.52; H, 4.67; N, 7.10; F,
    4.69; S, 8.30
    Ia-9 1H-NMR (CDCl3) δ 2.94 (m, 2H), 3.26 (m, 2H), 4.54 (t, J = 5.7 Hz, 1H),
    6.86 (s, 1H), 6.97-7.27 (m, 6H), 7.37 (d, J = 7.8 Hz, 1H), 7.65-7.69 (m, 2H),
    7.71-7.74 (m, 2H); IR (KBr) 3422, 3290, 2929, 1731, 1592, 1494, 1469, 1408, 1382,
    1328, 1292, 1237, 1166, 1152, 1092, 1013 cm−1; Elemental analysis
    (C18H17FN2O4S•0.5AcOEt) Calcd. (%): C, 57.13; H, 5.03; N, 6.66; F, 4.52; S,
    7.63 Found (%): C, 57.36; H, 5.07; N, 6.94; F, 4.58; S, 7.35
    Ia-12 1H-NMR (CDCl3) δ 2.92 (t, J = 6.6 Hz, 2H), 3.21-3.25 (m, 2H), 3.83 (s, 3H),
    4.50 (br, 1H), 4.80 (s, 2H), 6.80-6.82 (m, 3H), 7.06 (m, 1H), 7.18-7.23 (m, 2H),
    7.39 (d, J = 7.8 Hz, 1H), 7.60-7.65 (m, 2H); IR (CHCl3) 3481, 2967, 2945,
    2842, 1732, 1598, 1580, 1498, 1468, 1441, 1409, 1330, 1260, 1155, 1096,
    1047, 1030 cm−1; Elemental analysis (C19H20N2O5S•0.5AcOEt) Calcd. (%): C,
    58.32; H, 5.59; N, 6.48; S, 7.41 Found (%): C, 57.95; H, 5.40; N, 6.61; S, 7.73
    Ia-13 1H-NMR (CDCl3) δ 2.97 (t, J = 6.3 Hz, 2H), 3.35 (m, 2H), 4.62 (t, J = 5.7 Hz,
    1H), 4.82 (s, 2H), 6.86 (s, 1H), 7.00 (m, 1H), 7.11 (m, 1H), 7.19-7.26 (m, 2H),
    7.43-7.51 (m, 3H); IR (CHCl3) 3360, 2930, 1732, 1469, 1407, 1382, 1334,
    1158, 1092, 1069, 1048, 1016 cm−1; Elemental analysis
    (C16H16N2O4S2•0.4AcOEt) Calcd. (%): C, 52.89; H, 4.84; N, 7.01; S, 16.05
    Found (%): C, 52.93; H, 4.88; N, 7.04; S, 16.01
    Ia-14 1H-NMR (CDCl3) δ 2.94 (t, J = 6.3 Hz, 2H), 3.30 (dt, J = 6.0 and 6.3 Hz, 2H),
    4.61 (t, J = 6.0 Hz, 1H), 4.80 (s, 2H), 6.85 (s, 1H), 7.07-7.27 (m, 5H), 7.42 (d,
    J = 7.8 Hz, 1H), 7.84 (dd, J = 1.2 and 3.0 Hz, 1H); IR (CHCl3) 3481, 2930,
    1732, 1469, 1410, 1331, 1157, 1101, 1076, 1015 cm−1; Elemental analysis
    (C16H16N2O4S•0.1AcOEt) Calcd. (%): C, 52.77; H, 4.54; N, 7.51; S, 17.18
    Found (%): C, 52.39; H, 4.57; N, 7.40; S, 17.00
  • TABLE 32
    Compound
    No. Physical properties
    Ia-15 1H-NMR (CDCl3) δ 2.96 (t, J = 6.3 Hz, 2H), 3.29 (m, 2H), 4.56 (m, 1H),
    4.81 (s, 2H), 6.88 (s, 1H), 7.03 (m, 1H), 7.13-7.21 (m, 4H), 7.39 (d, J = 7.5 Hz, 1H),
    7.51-7.55 (m, 4H), 7.73-7.76 (m, 2H); IR (CHCl3) 2930, 1732, 1604, 1519,
    1469, 1408, 1331, 1160, 1096, 1047 cm−1; Elemental analysis
    (C24H21FN2O4S•0.5AcOEt) Calcd. (%): C, 62.89; H, 5.07; N, 5.83; F, 3.83; S,
    6.46 Found (%): C, 62.74; H, 4.97; N, 5.90; F, 3.82; S, 6.54
    Ia-16 1H-NMR (CDCl3) δ 2.94 (t, J = 6.9 Hz, 2H), 3.26 (m, 2H), 4.51 (br, 1H),
    4.81 (s, 2H), 6.86-6.94 (m, 3H), 7.03-7.11 (m, 3H), 7.19-7.24 (m, 3H), 7.37-7.63 (m,
    3H), 7.64-7.70 (m, 2H); IR (KBr) 3279, 3059, 2930, 1730, 1583, 1488, 1469,
    1410, 1382, 1327, 1298, 1245, 1152, 1094, 1013 cm−1; Elemental analysis
    (C24H22N2O5S•0.6AcOEt) Calcd. (%): C, 62.99; H, 5.37; N, 5.57; S, 6.37 Found
    (%): C, 62.99; H, 5.19; N, 5.77; S, 6.47
    Ia-17 1H-NMR (CDCl3) δ 2.92 (t, J = 6.3 Hz, 2H), 3.31 (m, 2H), 4.66 (m, 1H),
    4.73 (s, 2H), 6.80 (s, 1H), 6.91 (m, 1H), 7.06-7.11 (m, 2H), 7.28 (m, 1H),
    7.47-7.90 (m, 5H), 8.10 (dd, J = 2.7 and 6.3 Hz, 1H), 8.49 (s, 1H); IR (CHCl3) 3480,
    2929, 1732, 1670, 1616, 1586, 1468, 1428, 1411, 1377, 1330, 1158, 1077,
    1047, 1025, 1015 cm−1;
    Ia-20 1H-NMR (CDCl3) δ 2.31 (s, 3H), 2.95 (t, J = 6.0 Hz, 2H), 3.19 (dt, J = 6.0 and
    6.3 Hz, 2H), 4.37 (t, J = 6.3 Hz, 1H), 4.82 (s, 2H), 6.98-7.18 (m, 5H), 7.30 (d, J = 7.5 Hz,
    1H), 7.63-7.68 (m, 2H); IR (CHCl3) 2926, 1730, 1594, 1495, 1410,
    1375, 1335, 1292, 1167, 1154, 1093 cm−1
    Ia-25 1H-NMR (CDCl3) δ 2.62 (s, 3H), 2.90 (t, J = 6.3 Hz, 2H), 3.22 (t, J = 6.3 Hz,
    2H), 4.53 (br, 1H), 5.03 (s, 2H), 6.74 (s, 1H), 6.93-7.03 (m, 4H), 7.19 (m, 1H),
    7.64-7.69 (m, 2H); IR (CHCl3) 2940, 1729, 1594, 1495, 1465, 1438, 1408,
    1373, 1329, 1292, 1167, 1154, 1093, 1074, 1046, 1014 cm−1; Elemental
    analysis (C19H19FN2O4S•0.5H2O) Calcd. (%): C, 57.13; H, 5.05; N, 7.01; F,
    4.76; S, 8.03 Found (%): C, 57.15; H, 4.99; N, 6.74; F, 4.42; S, 7.72
    Ia-28 1H-NMR (CDCl3) δ 2.87-2.92 (m, 2H), 3.19-3.24 (m, 2H), 3.79 (s, 3H),
    4.59 (br, 1H), 4.77 (s, 2H), 6.78-7.11 (m, 6H), 6.63-7.68 (m, 2H); IR (CHCl3) 2942,
    2837, 1731, 1622, 1594, 1492, 1455, 1409, 1333, 1292, 1167, 1153, 1093,
    1051, 1014 cm−1; Elemental analysis (C19H19FN2O5S•0.2H2O) Calcd. (%): C,
    55.66; H, 4.77; N, 6.83; F, 4.63; S, 7.82 Found (%): C, 55.52; H, 4.87; N, 6.54;
    F, 4.45; S, 7.55
    Ia-32 1H-NMR (CDCl3) δ 2.87 (t, J = 6.3 Hz, 2H), 3.20-3.22 (m, 2H), 4.58 (br, 1H),
    4.77 (s, 2H), 6.89 (s, 1H), 6.98-7.18 (m, 5H), 7.62-7.67 (m, 2H); IR (CHCl3)
    3477, 2930, 1731, 1594, 1495, 1471, 1409, 1376, 1333, 1293, 1167, 1154,
    1093, 1073, 1046, 1014 cm−1
  • TABLE 33
    Compound
    No. Physical properties
    Ia-36 1H-NMR (CDCl3) δ 2.90 (t, J = 6.6 Hz, 2H), 3.23 (t, J = 6.6 Hz, 2H), 4.44 (br,
    1H), 4.83 (s, 2H), 6.93-7.13 (m, 6H), 7.68-7.72 (m, 2H); IR (KBr) 3290, 2664,
    2573, 1721, 1629, 1591, 1493, 1460, 1440, 1410, 1346, 1323, 1292, 1252,
    1090, 1049, cm−1; Elemental analysis (C18H16F2N2O4S•0.2AcOEt) Calcd. (%):
    C, 54.80; H, 4.31; N, 6.80; F, 9.22; S, 7.78 Found (%): C, 54.70; H, 4.27; N,
    6.68; F, 9.03; S, 7.81
    Ia-39 1H-NMR (CDCl3) δ 2.79 (s, 3H), 3.03 (t, J = 7.5 Hz, 2H), 3.34 (t, J = 7.5 Hz,
    2H), 4.85 (s, 2H), 6.95 (s, 1H), 7.12-7.23 (m, 5H), 7.55 (d, J = 8.1 Hz, 1H),
    7.74-7.79 (m, 2H); IR (CHCl3) 3482, 2928, 2865, 1732, 1594, 1495, 1469,
    1408, 1383, 1341, 1292, 1166, 1154, 1189, 1044, 1014 cm−1; Elemental
    analysis (C19H19FN2O4S•0.1AcOEt) Calcd. (%): C, 58.36; H, 5.00; N, 7.02; F,
    4.76; S, 8.03 Found (%): C, 58.64; H, 5.07; N, 6.90; F, 4.46; S, 7.90
    Ia-41 1H-NMR (CDCl3) δ 2.35 (s, 3H), 2.78 (s, 3H), 3.02 (t, J = 8.4 Hz, 2H), 3.22 (t,
    J = 8.4 Hz, 2H), 4.83 (s, 2H), 7.09-7.17 (m, 5H), 7.47 (d, J = 7.5 Hz, 1H),
    7.72-7.77 (m, 2H); IR (CHCl3) 2928, 2866, 1906, 1731, 1594, 1496, 1469,
    1416, 1376, 1341, 1292, 1166, 1154, 1090, 1046, 1013 cm−1; Elemental
    analysis (C20H21FN2O4S•0.3H2O) Calcd. (%): C, 58.61; H, 5.31; N, 6.83; F,
    4.64; S, 7.82 Found (%): C, 58.58; H, 5.11; N, 6.61; F, 4.32; S, 7.46
    Ia-42 1H-NMR (CDCl3) δ 2.62 (s, 3H), 2.78 (s, 3H), 2.99 (t, J = 7.8 Hz, 2H), 3.32 (t,
    J = 7.8 Hz, 2H), 5.06 (s, 2H), 6.83 (s, 1H), 6.95-7.17 (m, 4H), 7.37 (d, J = 7.8 Hz,
    1H), 7.74-7.78 (m, 2H); IR (CDCl3) 2933, 2869, 1731, 1594, 1495, 1463,
    1439, 1406, 1375, 1342, 1292, 1166, 1154, 1089, 1044, 1014 cm−1; Elemental
    analysis (C20H21FN2O4S) Calcd. (%): C, 59.39; H, 5.23; N, 6.93; F, 4.70; S,
    7.93 Found (%): C, 59.28; H, 5.26; N, 6.75; F, 4.45; S, 7.66
    Ia-43 1H-NMR (CDCl3) δ 2.79 (s, 3H), 3.00 (t, J = 7.8 Hz, 2H), 3.33 (t, J = 7.8 Hz,
    2H), 3.86 (s, 3H), 4.81 (s, 2H), 6.88-7.18 (m, 6H), 7.75-7.79 (m, 2H); IR
    (CHCl3) 2930, 1731, 1594, 1490, 1455, 1342, 1166, 1154, 1089, 1045, 1014 cm−1
    Ia-44 1H-NMR (CDCl3) δ 2.78 (s, 3H); 2.98 (t, J = 7.2 Hz, 2H), 3.32 (t, J = 7.2 Hz,
    2H), 4.83 (s, 2H), 7.01 (s, 1H), 7.11-7.20 (m, 3H), 7.47 (s, 1H), 7.74-7.79 (m,
    2H); IR (CHCl3) 3481, 2928, 2864, 1732, 1594, 1496, 1471, 1342, 1293, 1241,
    1166, 1154, 1089, 1072, 1041, 1014 cm−1
    Ia-45 1H-NMR (CDCl3) δ 2.78 (s, 3H), 2.97 (t, J = 6.9 Hz, 2H), 3.31 (t, J = 6.9 Hz,
    2H), 4.83 (s, 2H), 6.97-7.19 (m, 6H), 7.75-7.79 (m, 2H); IR (KBr) 2927, 1730,
    1626, 1592, 1489, 1458, 1338, 1293, 1236, 1153, 1087, 1039, 1013 cm−1;
    Elemental analysis (C19H18F2N2O4S•0.7MeOH) Calcd. (%): C, 54.92; H, 4.87;
    N, 6.50; F, 8.82; S, 7.44 Found (%): C, 55.19; H, 4.93; N, 6.33; F, 8.44; S, 7.24
  • TABLE 34
    Compound
    No. Physical properties
    Ia-47 1H-NMR (CDCl3) δ 2.98-3.03 (m, 2H), 3.38-3.43 (m, 2H), 3.84 (d, J = 6.3 Hz,
    2H), 4.01 (s, 2H), 5.13-5.18 (m, 2H), 5.64 (m, 1H), 6.81 (s, 1H), 7.07-7.15 (m,
    3H), 7.17-7.24 (m, 2H), 7.54 (d, J = 7.8 Hz, 1H), 7.76-7.82 (m, 2H); IR
    (CHCl3) 3503, 2928, 2869, 2656, 2558, 1770, 1733, 1594, 1495, 1469, 1342,
    1291, 1165, 1153 cm−1; Elemental analysis (C21H21FN2O4S•0.3H2O) Calcd.
    (%): C, 59.79; H, 5.16; F, 4.50; N, 6.64; S, 7.60 Found (%): C, 59.83; H, 4.91;
    F, 4.42; N, 6.67; S, 7.52
    Ia-48 1H-NMR (CDCl3) δ 1.05 (s, 3H), 1.07 (s, 3H), 3.12-3.18 (m, 2H), 3.31-3.36 (m,
    2H), 4.11 (m, 1H), 4.85 (s, 2H), 6.92 (s, 1H), 7.11-7.26 (m, 5H), 7.68 (d, J = 7.5 Hz,
    1H), 7.83-7.88 (m, 2H); IR (CHCl3) 3503, 2935, 2875, 2653, 2558,
    1733, 1594, 1494, 1468, 1334, 1291, 1187, 1150 cm−1; Elemental analysis
    (C21H23FN2O4S•0.2H2O) Calcd. (%): C, 59.76; H, 5.59; F, 4.50; N, 6.64; S, 7.60
    Found (%): C, 59.80; H, 5.44; F, 4.48; N, 6.65; S, 7.62
    Ia-51 1H-NMR (CDCl3) δ 2.82 (dd, J = 8.1 and 5.1 Hz, 2H), 3.36 (dd, J = 8.1 and 5.1 Hz,
    2H), 4.37 (s, 2H), 4.77 (s, 2H), 6.69 (s, 1H), 7.05-7.30 (m, 11H),
    7.79-7.84 (m, 2H); IR (CHCl3) 3282, 2928, 2871, 1732, 1594, 1496, 1469, 1407, 1384,
    1339, 1292, 1165, 1154, 1093, 1068, 1014 cm−1; Elemental analysis
    (C25H23FN2O4S•0.8H2O) Calcd. (%): C, 62.43; H, 5.16; N, 5.82; F, 3.95; S, 6.67
    Found (%): C, 62.43; H, 5.39; N, 5.64; F, 3.70; S, 6.38
    Ia-52 1H-NMR (CDCl3) δ 2.65 (t, J = 7.8 Hz, 2H), 3.24-3.28 (m, 2H), 3.36 (s, 3H),
    4.45 (s, 2H), 4.49 (s, 2H), 6.87-7.45 (m, 12H), 7.90-7.95 (m, 2H); IR (KBr)
    3434, 2926, 1592, 1494, 1469, 1405, 1380, 1335, 1293, 1234, 1152, 1069,
    1013 cm−1;
    Ia-55 1H-NMR (CDCl3) δ 2.13 (s, 3H), 2.78 (t, J = 8.1 Hz, 2H), 3.19 (t, J = 8.1 Hz,
    2H), 4.36 (s, 2H), 4.75 (s, 2H), 7.03-7.37 (m, 11H), 7.82-7.87 (m, 2H); IR
    (CHCl3) 2928, 2868, 1659, 1594, 1496, 1469, 1340, 1292, 1165, 1154, 1097,
    1015 cm−1; Elemental analysis (C26H25FN2O4S) Calcd. (%): C, 64.98; H, 5.24;
    N, 5.83; F, 3.95; S, 6.67 Found (%): C, 65.28; H, 5.24; N, 5.59; F, 3.64; S, 6.31
    Ia-56 1H-NMR (CDCl3) δ 2.58 (s, 3H), 2.79 (t, J = 7.8 Hz, 2H), 3.35 (t, J = 7.8 Hz,
    2H), 4.37 (s, 2H), 4.98 (s, 2H), 6.57 (s, 1H), 6.90-7.37 (m, 10H), 7.79-7.89 (m,
    2H); IR (CHCl3) 3482, 2934, 2871, 1731, 1594, 1496, 1455, 1439, 1406, 1341,
    1292, 1165, 1154, 1093, 1070, 1029, 1013 cm−1; Elemental analysis
    (C26H25FN2O4S) Calcd. (%): C, 64.98; 11, 5.24; N, 5.83; F, 3.95; S, 6.67 Found
    (%): C, 64.81; H, 5.26; N, 5.60; F, 3.75; S, 6.47
    Ia-57 1H-NMR (CDCl3) δ 2.79 (t, J = 7.5 Hz, 2H), 3.36 (t, J = 7.5 Hz, 2H), 3.79 (s,
    3H), 4.37 (s, 2H), 4.73 (s, 2H), 6.66 (s, 1H), 6.78-7.38 (m, 10H), 7.80-7.84 (m,
    2H); IR (CHCl3) 2937, 1732, 1593, 1491, 1455, 1340, 1292, 1165, 1154, 1093,
    1066, 1043, 1014 cm−1;
  • TABLE 35
    Compound
    No. Physical properties
    Ia-58 1H-NMR (CDCl3) δ 2.77 (t, J = 7.8 Hz, 2H), 3.31 (t, J = 7.8 Hz, 2H), 4.36 (s,
    2H), 4.75 (s, 2H), 6.74 (s, 1H), 7.04-7.32 (m, 10H), 7.81-7.86 (m, 2H); IR
    (CHCl3) 3481, 2929, 2868, 1732, 1594, 1496, 1471, 1410, 1386, 1341, 1292,
    1165, 1154, 1093, 1071, 1029, 1013 cm−1; Elemental analysis
    (C25H22ClNF2O4S) Calcd. (%): C, 59.94; H, 4.43; N, 5.59; Cl, 7.08; F, 3.79; S,
    6.40 Found (%): C, 59.65; H, 4.34; N, 5.48; Cl, 6.71; F, 3.62; S, 6.19
    Ia-59 1H-NMR (CDCl3) δ 2.77 (t, J = 8.1 Hz, 2H), 3.32 (t, J = 8.1 Hz, 2H), 4.36 (s,
    2H), 4.76 (s, 2H), 6.76 (s, 1H), 6.80-7.37 (m, 11H), 7.81-7.86 (m, 2H); IR
    (KBr) 3429, 2927, 1733, 1625, 1594, 1486, 1455, 1408, 1338, 1295, 1241,
    1209, 1199, 1166, 1154, 1137, 1097, 1070, 1028, 1014 cm−1; Elemental
    analysis (C25H22F2N2O4S•0.3AcOEt) Calcd. (%): C, 61.59; H, 4.81; N, 5.48; F,
    7.44; S, 6.28 Found (%): C, 61.98; H, 4.83; N, 5.31; F, 7.12; S, 6.13
    Ia-61 1H-NMR (CDCl3) δ 2.36 (s, 3H), 2.67-2.72 (m, 2H), 3.23-3.29 (m, 2H), 4.34 (s,
    2H), 4.74 (s, 2H), 5.70 (br s, 1H), 6.63 (s, 1H), 7.03 (m, 1H), 7.11-7.27 (m,
    9H), 7.81-7.88 (m, 2H); IR (CHCl3) 3502, 2929, 2868, 2656, 2558, 1732, 1594,
    1495, 1468, 1340, 1240 cm−1; Elemental analysis (C26H25FN2O4S•0.2H2O)
    Calcd. (%): C, 64.50; H, 5.29; F, 3.92; N, 5.79; S, 6.62 Found (%): C, 64.50; H,
    5.24; F, 3.78; N, 5.82; S, 6.61
    Ia-62 mp 108-110° C.; 1H-NMR (CDCl3) δ 2.75-2.80 (m, 2H), 3.28-3.34 (m, 2H),
    3.77 (s, 3H), 4.27 (s, 2H), 4.64 (s, 2H), 6.13 (br s, 1H), 6.63 (s, 1H), 6.80-6.82 (m,
    2H), 7.00-7.15 (m, 7H), 7.24 (m, 1H), 7.75-7.80 (m, 2H); IR (Nujol) 2726,
    1727, 1612, 1590, 1513, 1494, 1467, 1333, 1246, 1152 cm−1; Elemental
    analysis (C26H25FN2O5S•0.3H2O) Calcd. (%): C, 62.21; H, 5.14; F, 3.78; N,
    5.58; S, 6.39 Found (%): C, 62.26; H, 5.16; F, 3.56; N, 5.43; S, 6.21
    Ia-63 1H-NMR (CDCl3) δ 2.86 (t, J = 7.4 Hz, 2H), 3.42 (t, J = 7.4 Hz, 2H), 4.34 (s,
    2H), 4.80 (s, 2H), 5.35 (br s, 1H), 6.74 (s, 1H), 7.01 (m, 1H), 7.14-7.32 (m, 7H),
    7.83-7.87 (m, 2H), 7.98-8.01 (m, 2H); IR (Nujol) 2725, 1725, 1591, 1520,
    1493, 1465, 1377, 1345, 1235, 1153 cm−1
    Ia-64 mp 163-165° C.; 1H-NMR (CDCl3) δ 2.50-2.56 (m, 2H), 3.24-3.30 (m, 2H),
    4.64 (s, 2H), 4.75 (s, 2H), 6.48 (s, 1H), 6.95-7.07 (m, 3H), 7.11-7.22 (m, 3H),
    7.32-7.40 (m, 2H), 7.49-7.59 (m, 2H), 7.81-7.93 (m, 4H), 8.29-8.32 (m, 2H); IR
    (Nujol) 3105, 3061, 1736, 1592, 1492, 1465, 1343, 1333, 1239, 1221, 1170,
    1152 cm−1; Elemental analysis (C29H25FN2O4S) Calcd. (%): C, 67.43; H, 4.88;
    F, 3.68; N, 5.42; S, 6.21 Found (%): C, 67.20; H, 4.71; F, 3.51; N, 5.30; S, 6.04
  • TABLE 36
    Compound
    No. Physical properties
    Ia-65 1H-NMR (CDCl3) δ 2.94-2.99 (m, 2H), 3.41-3.46 (m, 2H), 4.57 (s, 2H), 4.79 (s,
    2H), 6.77-6.90 (m, 3H), 7.06-7.25 (m, 6H), 7.41 (d, J = 7.8 Hz, 1H),
    7.75-7.79 (m, 2H); IR (CHCl3) 3503, 2929, 2655, 2558, 1733, 1594, 1495, 1469, 1342 cm−1;
    Elemental analysis (C23H21FN2O4S2•0.6H2O) Calcd. (%): C, 57.15; H,
    4.63; F, 3.93; N, 5.80; S, 13.27 Found (%): C, 57.04; H, 4.48; F, 3.78, N, 5.63;
    S, 13.44
    Ia-66 1H-NMR (CDCl3) δ 2.82 (t, J = 8.0 Hz, 2H), 2.97-3.02 (m, 2H), 3.35-3.48 (m,
    4H), 4.79 (s, 2H), 5.99 (bs, 1H), 6.83 (s, 1H), 7.05-7.28 (m, 10H), 7.54 (d, J = 7.5 Hz,
    1H), 7.73-7.78 (m, 2H); IR (CHCl3) 3503, 2932, 2869, 2655, 2558,
    1733, 1594, 1496, 1468, 1334 cm−1; Elemental analysis
    (C26H25FN2O4S•0.5H2O) Calcd. (%): C, 63.79; H, 5.35; F, 3.88; N, 5.72; S, 6.55
    Found (%): C, 64.02; H, 5.29; F, 3.60, N, 5.75; S, 6.26
    Ia-69 1H-NMR (CDCl3) δ 1.86 (m, 2H), 2.75 (t, J = 6.3 Hz, 2H), 3.00 (m, 2H),
    4.58 (t, J = 5.7 Hz, 1H), 4.83 (s, 2H), 6.83 (s, 1H), 7.06-7.24 (m, 5H), 7.45 (d, J = 7.8 Hz,
    1H), 7.70-7.75 (m 2H); IR (CHCl3) 3780, 3369, 2936, 1732, 1594,
    1495, 1468, 1410, 1381, 1334, 1292, 1240, 1167, 1154, 1093, 1046, 1014 cm−1;
    Elemental analysis (C19H19FN2O4S•0.2AcOEt) Calcd. (%): C, 58.28; H, 5.09;
    N, 6.87; F, 4.66; S, 7.86 Found (%): C, 58.39; H, 5.14; N, 6.96; F, 4.52; S, 7.72
    Ia-74 1H-NMR (CDCl3) δ 1.83-1.91 (m, 2H), 2.75 (t, J = 7.2 Hz, 2H), 2.97-3.04 (m,
    2H), 4.56 (m, 1H), 4.82 (s, 2H), 6.82 (s, 1H), 6.95-7.12 (m, 5H), 7.19-7.25 (m,
    3H), 7.34-7.49 (m, 3H), 7.67-7.75 (m, 2H); IR (CHCl3) 3480, 2935, 1732,
    1584, 1488, 1469, 1412, 1376, 1332, 1298, 1246, 1154, 1095, 1045, 1022 cm−1;
    Elemental analysis (C25H24N2O5S•0.3H2O) Calcd. (%): C, 63.90; H, 5.28; N,
    5.96; S, 6.82 Found (%): C, 63.95; H, 5.51; N, 5.72; S, 6.39
    Ia-81 1H-NMR (CDCl3) δ 1.91 (m, 2H), 2.73 (s, 3H), 2.81 (t, J = 6.9 Hz, 2H), 3.60 (t,
    J = 7.2 Hz, 1H), 4.86 (s, 2H), 6.95 (s, 1H), 7.10-7.23 (m, 5H), 7.54 (d, J = 7.8 Hz,
    1H), 7.73 (m, 2H); IR (CHCl3) 3481, 2932, 2868, 1731, 1615, 1594, 1494,
    1468, 1407, 1378, 1342, 1292, 1166, 1154, 1090, 1014 cm−1
    Ia-85 1H-NMR (CDCl3) δ 1.68-1.77 (m, 2H), 2.56 (t, J = 6.9 Hz, 2H), 3.17 (t, J = 7.8 Hz,
    2H), 4.31 (s, 2H), 4.80 (s, 2H), 6.67 (s, 1H), 7.03-7.38 (m, 11H),
    7.71-7.77 (m, 2H); IR (CHCl3) 3481, 2931, 1732, 1594, 1495, 1468, 1339, 1292, 1165,
    1154, 1095, 1013 cm−1
    Ia-87 mp 125-126° C.; 1H-NMR (CDCl3) δ 2.39 (s, 3H), 2.81 (m, 1H), 2.99 (m, 1H),
    3.33-3.46 (m, 2H), 4.82 (s, 2H), 6.85 (s, 1H), 7.06-7.28 (m, 10H), 7.55 (d, J = 8.1 Hz,
    1H), 7.68 (d, J = 8.4 Hz, 2H); IR (Nujol) 3428, 3081, 3026, 2927,
    1713, 1598, 1468, 1325, 1241, 1191, 1149 cm−1; Elemental analysis
    (C27H28N2O4S) Calcd. (%): C, 68.04; H, 5.92; N, 5.88; S, 6.73 Found (%): C,
    68.07; H, 5.82; N, 5.95; S, 6.60
  • TABLE 37
    Compound
    No. Physical properties
    Ia-88 1H-NMR (CDCl3) δ 2.89 (t, J = 6.6 Hz, 2H), 3.21-3.27 (m, 2H), 4.53 (t, J = 6.6 Hz,
    1H), 4.81 (s, 2H), 6.92-7.02 (m, 3H), 7.13 (m, 1H), 7.30-7.34 (m, 2H),
    7.59-7.62 (m, 2H); IR (KBr) 3290, 3087, 2571, 1721, 1627, 1586, 1490, 1409,
    1346, 1323, 1251, 1225, 1163, 1092, 1048, 1013 cm−1; Elemental analysis
    (C18H26ClFN2O4S) Calcd. (%): C, 52.62; H, 3.93; N, 6.82; Cl, 8.63; F, 4.62; S,
    7.80 Found (%): C, 52.46; H, 3.85; N, 6.62; Cl, 8.25; F, 4.34; S, 7.64
    Ia-89 1H-NMR (CDCl3) δ 2.85 (t, J = 6.6 Hz, 2H), 3.19 (m, 2H), 3.84 (s, 3H),
    4.56 (br, 1H), 4.77 (s, 2H), 6.80-6.98 (m, 5H), 7.10 (m, 1H), 7.58-7.64 (m, 2H); IR
    (CHCl3) 2945, 2843, 1732, 1598, 1580, 1498, 1488, 1458, 1410, 1329, 1303,
    1260, 1180, 1155, 1096, 1029 cm−1; Elemental analysis
    (C19H19FN2O5S•0.4H2O) Calcd. (%): C, 55.17; H, 4.82; N, 6.77; F, 4.59; S, 7.75
    Found (%): C, 55.30; H, 4.81; N, 6.56; F, 4.33, S, 7.45
    Ia-90 1H-NMR (CDCl3) δ 2.91 (t, J = 6.3 Hz, 2H), 3.34-3.49 (m, 2H), 4.63 (t, J = 6.0 Hz,
    1H), 4.80 (s, 2H), 6.92-7.15 (m, 5H), 7.48-7.53 (m, 2H); IR (KBr) 3269,
    2655, 2565, 1728, 1626, 1584, 1488, 1459, 1433, 1324, 1241, 1096, 1073,
    1017 cm−1; Elemental analysis (C16H15FN2O4S2•0.3H2O) Calcd. (%): C, 49.55;
    H, 4.05; N, 7.22; F, 4.90; S, 16.54 Found (%): C, 49.89; H, 3.98; N, 6.98; F,
    4.54; S, 16.12
    Ia-91 mp 95-97° C.; 1H-NMR (CDCl3) δ 2.84 (m, 1H), 3.02 (m, 1H), 3.34-3.49 (m,
    2H), 4.83 (s, 2H), 6.88 (s, 1H), 7.04-7.29 (m, 9H), 7.52-7.59 (m, 3H); IR
    (Nujol) 3429, 3087, 3029, 2932, 1713, 1615, 1469, 1406, 1340, 1242, 1190,
    1151 cm−1; Elemental analysis (C24H24N2O4S2) Calcd. (%): C, 61.52; H, 5.16;
    N, 5.98; S, 13.69 Found (%): C, 61.39; H, 5.06; N, 5.78; S, 13.66
    Ia-92 mp 113-114.5° C.; 1H-NMR (CDCl3) δ 2.81 (m, 1H), 2.93 (m, 1H),
    3.35-3.42 (m, 2H), 4.79 (s, 2H), 6.88 (s, 1H), 7.07-7.29 (m, 9H), 7.45 (d, J = 2.1 Hz, 1H),
    7.77 (dd, J = 5.1, 8.7 Hz); IR (Nujol) 3423, 3028, 1720, 1591, 1494, 1470,
    1405, 1336, 1293, 1226, 1147, 1094 cm−1; Elemental analysis
    (C26H24ClFN2O4S) Calcd. (%): C, 60.64; H, 4.70; N, 5.44; Cl, 6.88; F, 3.69; S,
    6.23 Found (%): C, 60.54; H, 4.60; N, 5.29; Cl, 6.70; F, 3.56; S, 6.28
    Ia-93 mp 103-107° C.; 1H-NMR (CDCl3) δ 3.05 (m, 2H), 3.45 (m, 2H), 3.96 (d, J = 6.6 Hz,
    2H), 4.77 (s, 2H), 5.94 (dt, J = 6.6, 15.6 Hz), 6.37 (d, J = 15.6 Hz, 1H),
    6.84 (s, 1H), 7.01-7.33 (m, 10H), 7.49 (d, J = 8.1 Hz, 1H), 7.82 (dd, J = 4.8, 8.7 Hz,
    2H); IR (Nujol) 3456, 3058, 1725, 1591, 1493, 1469, 1405, 1334, 1292,
    1235, 1165, 1153, 1091 cm−1; Elemental analysis
    (C27H25FN2O4S•0.3H2O•0.3MeOH) Calcd. (%): C, 64.60; H, 5.32; N, 5.52; F,
    3.74; S, 6.32 Found (%): C, 64.58; H, 5.33; N, 5.47; F, 3.69; S, 6.53
  • TABLE 38
    Compound
    No. Physical properties
    Ia-94 mp 126-129° C.; 1H-NMR (CDCl3) δ 1.85 (m, 1H), 2.58 (t, J = 7.8 Hz, 2H),
    2.99 (m, 2H), 3.19 (t, J = 7.8 Hz, 2H), 3.39 (m, 2H), 4.80 (s, 2H), 6.86 (s, 1H),
    7.07-7.29 (m, 10H), 7.50 (d, J = 8.1 Hz, 1H), 7.75 (dd, J = 5.1, 9.0 Hz, 2H); IR
    (Nujol) 3404, 3056, 1724, 1591, 1492, 1471, 1413, 1340, 1290, 1232, 1154,
    1095 cm−1; Elemental analysis (C27H27FN2O4S) Calcd. (%): C, 65.57; H, 5.50;
    N, 5.66; F, 3.84; S, 6.48 Found (%): C, 65.48; H, 5.60; N, 5.56; F, 3.77; S, 6.35
    Ia-95 1H-NMR (CD3OD) δ 2.39 (s, 3H), 2.80 (t, J = 7.2 Hz, 2H), 3.10-3.16 (m, 2H),
    6.89 (m, 1H), 6.98-7.29 (m, 5H), 7.63-7.66 (m, 2H); IR (KBr) 3293, 2575,
    1721, 1628, 1598, 1491, 1459, 1440, 1407, 1321, 1252, 1224, 1187, 1092,
    1048 cm−1; Elemental analysis (C19H19FN2O4S•0.2H2O) Calcd. (%): C, 57.91;
    H, 4.96; N, 7.11; F, 4.82; S, 8.14 Found (%): C, 57.87; H, 4.98; N, 6.85; F,
    4.66, S, 7.93
    Ia-96 1H-NMR (CDCl3) δ 2.86 (t, J = 6.3 Hz, 2H), 3.25-3.32 (m, 2H), 4.64 (br, 1H),
    4.74 (s, 2H), 6.85-7.09 (m, 4H), 7.57-7.66 (m, 3H), 7.81-7.89 (m, 3H), 8.33 (s,
    1H); IR (KBr) 3281, 1713, 1625, 1588, 1487, 1456, 1411, 1325, 1239, 1216,
    1157, 1132, 1102, 1075 cm−1; Elemental analysis (C22H19FN2O4S•0.3H2O)
    Calcd. (%): C, 61.18; H, 4.57; N, 6.49; F, 4.40; S, 7.42 Found (%): C, 61.08;
    H, 4.56; N, 6.22; F, 4.09, S, 7.14
    Ia-97 1H-NMR (CD3OD) δ 2.82 (t, J = 6.3 Hz, 2H), 3.26-3.44 (m, 2H), 4.63 (t, J = 6.0 Hz,
    1H), 6.76-7.13 (m, 4H), 7.76-7.81 (m, 2H), 8.06-8.10 (m, 2H); IR
    (KBr) 3280, 3104, 2938, 1721, 1626, 1606, 1583, 1526, 1487, 1410, 1349,
    1310, 1254, 1225, 1164, 1092, 1047 cm−1; Elemental analysis
    (C18H16FN3O6S•0.2H2O) Calcd. (%): C, 50.87; H, 3.89; N, 9.89; F, 4.47; S, 7.54
    Found (%): C, 50.99; H, 3.86; N, 9.59; F, 4.19, S, 7.31
    Ia-98 1H-NMR (CDCl3) δ 2.73 (t, J = 6.3 Hz, 2H), 3.18-3.22 (m, 2H), 4.71 (t, J = 6.0 Hz,
    1H), 6.63 (s, 1H), 6.81-7.05 (m, 3H), 7.45-7.53 (m, 3H), 7.89 (d, J = 8.1 Hz,
    1H), 8.03 (d, J = 8.1 Hz, 1H), 8.22 (d, J = 5.4 Hz, 1H), 8.40 (d, J = 5.4 Hz,
    1H); IR (CDCl3) 1732, 1487, 1457, 1408, 1328, 1162, 1135, 1079, 1045 cm−1;
    Elemental analysis (C22H19FN2O4S•0.5H2O) Calcd. (%): C, 60.68; H, 4.63; N,
    6.43; F, 4.36; S, 7.36 Found (%): C, 60.65; H, 4.58; N, 6.26; F, 4.10, S, 7.20
    Ia-99 1H-NMR (CDCl3) δ 2.88 (t, J = 6.0 Hz, 2H), 3.24-3.28 (m, 2H), 4.35 (br, 1H),
    4.78 (s, 2H), 6.92-7.13 (m, 4H), 7.63 (d, J = 6.6 Hz, 2H), 7.79 (d, J = 6.6 Hz,
    2H); IR (KBr) 3269, 2655, 2565, 1728, 1626, 1584, 1488, 1459, 1433, 1324,
    1241, 1096, 1073, 1017 cm−1; Elemental analysis (C19H16FN3O4S2•0.4H2O)
    Calcd. (%): C, 55.85; H, 4.14; N, 10.28; F, 4.65; S, 7.85 Found (%): C, 55.91;
    H, 4.23; N, 9.89; F, 4.33, S, 7.40
  • TABLE 39
    Compound
    No. Physical properties
    Ia-100 1H-NMR (d6-DMSO) δ 2.68 (t, J = 6.9 Hz, 2H), 2.93-2.98 (m, 2H), 4.09 (br,
    1H), 4.81 (s, 2H), 6.59 (dd, J = 6.0 and 2.1 Hz, 1H), 6.70 (s, 1H), 7.00 (s, 1H),
    7.09 (d, J = 6.0 Hz, 1H), 7.36-7.42 (m, 2H), 7.78-7.87 (m, 3H), 8.70 (s, 1H); IR
    (KBr) 3431, 2927, 1732, 1626, 1591, 1494, 1465, 1407, 1322, 1292, 1231,
    1151, 1092, cm−1; Elemental analysis (C18H17FN2O5S•H2O) Calcd. (%): C,
    52.68; H, 4.67; N, 6.83; F, 4.63; S, 7.81 Found (%): C, 52.41; H, 4.72; N, 6.58;
    F, 4.38, S, 7.76
    Ia-101 1H-NMR (CD3OD) δ 2.91 (t, J = 6.9 Hz, 2H), 3.21 (t, J = 6.9 Hz, 2H), 6.63 (m,
    1H), 6.93 (s, 1H), 7.04-7.13 (m, 4H), 7.71-7.77 (m, 2H); IR (KBr) 3303, 1721,
    1633, 1592, 1557, 1494, 1466, 1440, 1409, 1327, 1290, 1253, 1235, 1190,
    1166, 1152, 1092, 1076, 1046 cm−1; Elemental analysis (C18H16F2N2O4S)
    Calcd. (%): C, 54.82; H, 4.09; N, 7.10; F, 9.63; S, 8.13 Found (%): C, 54.63; H,
    4.05; N, 6.97; F, 9.28; S, 7.87
    Ia-102 1H-NMR (CDCl3) δ 2.79 (s, 3H), 3.08 (t, J = 7.2 Hz, 2H), 3.35 (t, J = 7.2 Hz,
    2H), 4.83 (s, 2H), 6.74 (m, 1H), 6.92-7.17 (m, 5H), 7.74-7.79 (m, 2H); IR
    (CHCl3) 2931, 1732, 1630, 1594, 1557, 1496, 1460, 1408, 1374, 1341, 1292,
    1238, 1166, 1154, 1089, 1045 cm−1; Elemental analysis
    (C19H18F2N2O4S•0.4MeOH) Calcd. (%): C, 55.32; H, 4.69; N, 6.65; F, 9.02; S,
    7.61 Found (%): C, 55.52; H, 4.50; N, 6.45; F, 8.70, S, 7.31
    Ia-103 1H-NMR (CDCl3) δ 2.87 (t, J = 7.8 Hz, 2H), 3.43 (t, J = 7.8 Hz, 2H), 4.40 (s,
    2H), 4.60 (s, 2H), 6.62-7.36 (m, 12H), 7.77-7.81 (m, 2H); IR (CHCl3) 2930,
    1732, 1629, 1593, 1496, 1457, 1406, 1329, 1292, 1154, 1098 cm−1.
    Ia-104 1H-NMR (CDCl3) δ 1.83 (d, J = 7.2 Hz, 3H), 2.79-2.94 (m, 2H), 3.19-3.49 (m,
    2H), 4.55 (br, 1H), 5.07 (q, J = 7.5 Hz, 1H), 6.99-7.20 (m, 5H), 7.63-7.68 (m,
    2H); IR (CHCl3) 1725, 1594, 1495, 1466, 1409, 1331, 1292, 1167, 1153, 1092,
    1062 cm−1; Elemental analysis (C19H18ClFN2O4S•0.5H2O) Calcd. (%): C,
    52.60; H, 4.41; N, 6.46; Cl, 8.17; F, 4.38; S, 7.39 Found (%): C, 52.64; H, 4.36;
    N, 6.35; Cl, 7.95; F, 4.29, S, 7.42
    Ia-105 1H-NMR (CDCl3) δ 1.84 (d, J = 7.2 Hz, 3H), 2.97 (t, J = 8.1 Hz, 2H), 3.31 (t, J = 8.1 Hz,
    2H), 5.07 (q, J = 7.2 Hz, 1H), 7.13-7.19 (m, 5H), 7.46 (s, 1H),
    7.75-7.80 (m, 2H); IR (CHCl3) 1726, 1594, 1495, 1465, 1375, 1342, 1292, 1166,
    1154, 1090 cm−1; Elemental analysis (C20H20ClFN2O4S•0.3H2O) Calcd. (%): C,
    54.07; H, 4.67; N, 6.30; Cl, 7.98; F, 4.28; S, 7.22 Found (%): C, 54.09; H, 4.89;
    N, 5.99; Cl, 7.63; F, 4.03; S, 6.86
    Ia-106 1H-NMR (CDCl3) δ 1.78 (d, J = 7.5 Hz, 3H), 2.77 (t, J = 8.4 Hz, 2H), 3.32 (d, J = 8.4 Hz,
    2H), 4.71 (s, 1H), 5.01 (q, J = 7.5 Hz, 1H), 6.91 (s, 1H),
    7.08-7.7.38 (m, 10H), 7.82-7.87 (m, 2H); IR (CHCl3) 1725, 1594, 1496, 1465, 1341, 1292,
    1165, 1154, 1092, 1066 cm−1; Elemental analysis (C26H24ClFN2O4S•0.3H2O)
    Calcd. (%): C, 60.01; H, 4.76; N, 5.38; Cl, 6.81; F, 3.65; S, 6.16 Found (%): C,
    60.24; H, 4.65; N, 5.25; Cl, 6.51; F, 3.55; S, 6.04
  • TABLE 40
    Compound
    No. Physical properties
    Ib-2 1H-NMR (d6-DMSO) δ 2.54-2.68 (m, 2H), 2.89-3.06 (m, 2H), 3.35 (m, 1H),
    4.84 (s, 2H), 6.93-7.04 (m, 2H), 7.26-7.32 (m, 2H), 7.45-7.52 (m, 2H),
    7.92-7.97 (m, 2H), 8.36 (d, J = 7.8 Hz, 1H), 12.96 (br, 1H); IR (KBr) 3429, 3300,
    3061, 2913, 2856, 1725, 1592, 1494, 1458, 1432, 1409, 1382, 1340, 1291,
    1241, 1167, 1155, 1092, 1002 cm−1; Elemental analysis
    (C19H17FN2O4S•0.4H2O) Calcd. (%): C, 57.68; H, 4.54; N, 7.08; F, 4.80; S, 8.11
    Found (%): C, 57.89; H, 4.36; N, 6.76; F, 4.49; S, 7.77
    Ib-6 1H-NMR (CD3OD) δ 2.56-2.65 (m, 2H), 2.71 (s, 3H), 2.95-3.04 (m, 2H),
    4.75 (d, J = 18 Hz, 1H), 4.80 (d, J = 18 Hz, 1H), 5.36 (m, 1H), 6.96-7.08 (m, 2H),
    7.19-7.41 (m, 4H), 7.93-7.98 (m, 2H); IR (KBr) 3413, 2925, 2653, 2551, 1719,
    1706, 1616, 1592, 1493, 1461, 1404, 1378, 1335, 1291, 1234, 1151, 1087,
    1012 cm−1; Elemental analysis (C20H19FN2O5S•0.4AcOEt) Calcd. (%): C,
    59.27; H, 5.11; N, 6.40; F, 4.34; S, 7.33 Found (%): C, 59.03; H, 4.95; N, 6.34;
    F, 4.17; S, 7.29
    Ib-11 1H-NMR (CD3OD) δ 2.46-2.55 (m, 2H), 2.89-2.98 (m, 2H), 4.30 (d, J = 7.2 Hz,
    1H), 4.42 (d, J = 7.2 Hz, 1H), 4.50 (d, 12.0 Hz, 1H), 4.63 (d, J = 12.0 Hz,
    1H), 5.36 (m, 1H), 6.95-7.39 (m, 11H), 7.96-8.01 (m, 2H); IR (KBr) 3430,
    2927, 2859, 1728, 1591, 1493, 1457, 1404, 1381, 1340, 1292, 1236, 1208,
    1165, 1153, 1092, 1052, 1012 cm−1;
    Ib-16 mp 162-168° C.; 1H-NMR (d6-DMSO) δ 1.77 (m, 1H), 1.92 (m, 1H),
    2.46-2.78 (m, 4H), 3.41 (m, 1H), 4.80 (d, J = 18.6 Hz, 1H), 4.86 (d, J = 18.6 Hz, 1H),
    6.96 (m, 1H), 7.04 (m, 1H), 7.25 (d, J = 7.2 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H),
    7.40-7.48 (m, 2H), 7.90-7.97 (m, 3H), 12.95 (br, 1H); IR (Nujol)
    3261, 1734, 1590, 1493, 1469, 1444, 1329, 1188, 1168, 1153 cm−1;
    [α]D 24 + 60.4 ± 1.0° (c = 1.012, MeOH); Elemental analysis (C20H19FN2O4S) Calcd. (%): C, 59.69;
    H, 4.76; F, 4.72; N, 6.96; S, 7.97 Found (%): C, 59.51; H, 4.68; F, 4.57; N, 6.77;
    S, 7.78
    Ib-18 1H-NMR (d6-DMSO) δ 1.74 (m, 1H), 1.90 (m, 1H), 2.39 (s, 3H), 2.45-2.75 (m,
    4H), 3.30 (m, 1H), 4.79 (d, J = 19.2 Hz, 1H), 4.88 (d, J = 19.2 Hz, 1H), 6.96 (m,
    1H), 7.04 (m, 1H), 7.24 (d, J = 6.9 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 8.1 Hz,
    2H), 7.76 (d, J = 8.1 Hz, 2H), 7.82 (d, J = 6.6 Hz, 1H), 12.93 (br,
    1H); IR (KBr) 3272, 2924, 1728, 1617, 1598, 1468, 1434, 1382, 1319, 1156 cm−1;
    [α]D 23 + 76.2 ± 1.2° (c = 1.010, MeOH); Elemental analysis
    (C21H22N2O4S•0.5H2O) Calcd. (%): C, 61.90; H, 5.69; N, 6.87; S, 7.87 Found
    (%): C, 62.01; H, 5.45; N, 6.81; S, 7.76
  • TABLE 41
    Compound
    No. Physical properties
    Ib-20 1H-NMR (d6-DMSO) δ 1.78 (m, 1H), 1.94 (m, 1H), 2.48-2.80 (m, 4H), 3.47 (m,
    1H), 4.81 (d, J = 18.3 Hz, 1H), 4.87 (d, J = 18.3 Hz, 1H), 6.97 (m, H), 7.05 (m,
    1H), 7.19 (dd, J = 3.6, 5.1 Hz, 1H), 7.26-7.32 (m, 2H), 7.66 (dd, J = 1.5, 3.6 Hz,
    1H), 7.94 (dd, J = 1.5, 5.1 Hz, 1H), 8.12 (d, J = 6.9 Hz, 1H), 12.95 (br,
    1H); IR (KBr)
    3435, 3276, 2925, 1727, 1617, 1468, 1433, 1405, 1382, 1320, 1227, 1182, 1154 cm−1;
    [α]D 24 + 70.9 ± 1.1° (c = 1.010, MeOH); Elemental analysis
    (C18H18N2O4S2•0.5H2O) Calcd. (%): C, 54.12; H, 4.79; N, 7.01; S, 16.05 Found
    (%): C, 54.24; H, 4.58; N, 6.90; S, 16.14
    Ib-21 1H-NMR (d6-DMSO) δ 1.77 (m, 1H), 1.95 (m, 1H), 2.46-2.76 (m, 4H), 3.40 (m,
    1H), 4.80 (d, J = 18.6 Hz, 1H), 4.86 (d, J = 18.6 Hz, 1H), 6.96 (m, 1H),
    7.04 (m, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 5.1 Hz,
    1H), 7.78 (dd, J = 3.0, 5.1 Hz, 1H), 7.84 (d, J = 6.6 Hz, 1H), 8.20 (m, 1H),
    12.95 (br, 1H); IR (KBr)
    3271, 1728, 1616, 1468, 1433, 1382, 1319, 1206, 1183, 1153, 1101, 1075 cm−1;
    Elemental analysis (C18H18N2O4S2•0.4H2O) Calcd. (%): C, 54.36; H, 4.76; N,
    7.04; S, 16.13 Found (%): C, 54.36; H, 4.75; N, 6.92; S, 15.96
    Ib-22 1H-NMR (d6-DMSO) δ 1.76 (m, 1H), 1.93 (m, 1H), 2.45-2.76 (m, 4H), 3.41 (m,
    1H), 4.22 (s, 2H), 4.80 (d, J = 18.6 Hz, 1H), 4.86 (d, J = 18.6 Hz, 1H),
    6.95-7.07 (m, 3H), 7.20-7.37 (m, 7H), 7.48 (d, J = 3.6 Hz, 1H), 12.97 (br, 1H); IR
    (KBr) 3431, 3271, 2923, 1726, 1486, 1453, 1382, 1320, 1153 cm−1; Elemental
    analysis (C25H24FN2O4S2•0.3H2O) Calcd. (%): C, 61.78; H, 5.10; N, 5.76; S,
    13.12 Found (%): C, 61.76; H, 5.01; N, 5.67; S, 13.12
    Ib-25 mp 185-196° C.; 1H-NMR (d6-DMSO) δ 1.53 (m, 1H), 1.88 (m, 1H),
    2.48-2.85 (m, 4H), 2.83 (s, 3H), 4.12 (m, 1H), 4.85 (s, 2H), 6.98 (m, 1H), 7.06 (m, 1H),
    7.28-7.32 (m, 2H), 7.45-7.51 (m, 2H), 7.91-7.98 (m, 2H), 12.95 (br, 1H); IR
    (Nujol) 2683, 1715, 1592, 1490, 1465, 1473, 1335, 1288, 1167 cm−1;
    [α]D 24 + 95.0 ± 1.3° (c = 1.004, MeOH); Elemental analysis (C20H19FN2O4S) Calcd. (%):
    C, 60.56; H, 5.08; F, 4.56; N, 6.73; S, 7.70 Found (%): C, 60.34; H, 5.15;
    F, 4.33; N, 6.47; S, 7.43
    Ib-27 mp 154-160° C.; 1H-NMR (d6-DMSO) δ 1.50 (m, 1H), 1.85 (m, 1H), 2.42 (s,
    3H), 2.52-2.78 (m, 4H), 2.80 (s, 3H), 4.10 (m, 1H), 4.82 (d, J = 18.3 Hz, 1H),
    4.88 (d, J = 18.3 Hz, 1H), 6.97 (m, 1H), 7.05 (m, 1H), 7.28-7.32 (m, 2H),
    7.51 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H), 12.95 (br, 1H); IR (Nujol)
    2658, 1714, 1598, 1465, 1335, 1288, 1165 cm−1; [α]D 24 + 119.5 ± 1.6° (c = 1.012,
    MeOH); Elemental analysis (C22H24N2O4S) Calcd. (%): C, 64.06; H, 5.86; N,
    6.79; S, 7.77 Found (%): C, 64.02; H, 5.78; N, 6.75; S, 7.68
  • TABLE 42
    Compound
    No. Physical properties
    Ib-29 Mp 185-196° C.; 1H-NMR (d6-DMSO) δ 1.52 (m, 1H), 1.88 (m, 1H),
    2.53-2.82 (m, 4H), 2.86 (s, 3H), 4.11 (m, 1H), 4.82 (d, J = 18.3 Hz, 1H), 4.88 (d, J = 18.3 Hz,
    1H), 6.98 (m, 1H), 7.06 (m, 1H), 7.26-7.33 (m, 3H), 7.74 (dd, J = 1.5, 3.6 Hz,
    1H), 8.03 (dd, J = 1.5, 5.1 Hz, 1H), 12.93 (br, 1H); IR (Nujol)
    2683, 1715, 1592, 1490, 1465, 1473, 1335, 1288, 1167 cm−1;
    [α]D 24 + 95.0 ± 1.3° (c = 1.004, MeOH); Elemental analysis (C20H19FN2O4S) Calcd. (%): C, 60.56;
    H, 5.08; F, 4.56; N, 6.73; S, 7.70 Found (%): C, 60.34; H, 5.15; F, 4.33; N, 6.47;
    S, 7.43
    Ib-30 mp 175-180° C.; 1H-NMR (d6-DMSO) δ 1.36 (m, 1H), 1.88 (m, 1H), 2.52 (m, 1),
    2.64-2.86 (m, 3H), 2.83 (s, 3H), 4.11 (m, 1H), 4.85 (s, 2H), 6.98 (m, 1H),
    7.06 (m, 1H), 7.28-7.32 (m, 2H), 7.45 (dd, J = 1.2, 5.1 Hz, 1H), 7.83 (dd, J = 3.0,
    5.1 Hz, 1H), 8.31 (dd, J = 1.2, 3.0 Hz, 1H), 12.93 (br, 1H); IR (Nujol)
    3100, 2662, 1721, 1468, 1336, 1323, 1253, 1201, 1163, 1138 cm−1; Elemental
    analysis (C19H20N2O4S2) Calcd. (%): C, 56.42; H, 4.98; N, 6.93; S, 15.85
    Found (%): C, 56.34; H, 4.88; N, 6.85; S, 15.80
    Ib-31 mp 138-140° C.; 1H-NMR (d6-DMSO) δ 1.49 (m, 1H), 1.86 (m, 1H),
    2.49-2.77 (m, 4H), 2.81 (s, 3H), 4.02 (m, 1H), 4.25 (s, 2H), 4.85 (s, 2H), 6.96-7.08 (m,
    3H), 7.22-7.38 (m, 7H), 7.56 (d, J = 3.9 Hz, 1H), 12.97 (br, 1H); IR (Nujol)
    1712, 1468, 1449, 1431, 1410, 1380, 1341, 1238, 1154 cm−1; Elemental analysis
    (C26H26N2O4S2) Calcd. (%): C, 63.13; H, 5.30; N, 5.66; S, 12.97 Found (%): C,
    62.99; H, 5.26; N, 5.56; S, 13.00
    Ib-77 mp 160-172° C.; 1H-NMR (d6-DMSO) δ 2.50 (m, 1H), 2.80-3.06 (m, 6H),
    4.18 (d, J = 18.0 Hz, 1H), 4.88 (d, J = 18.0 Hz, 1H), 6.94-7.04 (m, 2H),
    7.27-7.31 (m, 2H), 7.41-7.48 (m, 2H), 7.85-7.91 (m, 3H), 12.95 (br, 1H); IR (Nujol)
    3387, 3352, 2653, 1722, 1593, 1494, 1459, 1402, 1330, 1289, 1235, 1156 cm−1;
    Elemental analysis (C20H19FN2O4S) Calcd. (%): C, 59.69; H, 4.76; F, 4.72; N,
    6.96; S, 7.97 Found (%): C, 59.40; H, 4.74; F, 4.60; N, 7.04; S, 7.91
    Ic-2 mp 142-143° C.; 1H-NMR (CDCl3) δ 2.42 (br s, 2H), 3.31 (t, J = 5.7 Hz, 2H),
    3.97 (br s, 2H), 4.87 (s, 2H), 6.21 (br s, 1H), 7.03 (s, 1H), 7.14-7.29 (m, 5H),
    7.75 (d, J = 7.8 Hz, 1H), 7.85 (dd, J = 4.8, 8.7 Hz, 2H); IR (KBr) 3348, 1770,
    1590, 1491, 1466, 1347, 1331, 1167, 1156, 1095 cm−1; Elemental analysis
    (C21H19FN2O4S) Calcd. (%): C, 60.86; H, 4.62; N, 6.76; F, 4.58; S, 7.74 Found
    (%): C, 60.94; H, 4.65; N, 6.65; F, 4.24; S, 7.70
    Ic-6 mp 189-194° C. (dec); 1H-NMR (CDCl3) δ 1.56 (m, 1H), 1.84 (m, 2H), 2.06 (m,
    1H), 2.40-2.54 (m, 2H), 3.24 (m, 1H), 3.70 (m, 1H), 3.94 (dd, J = 2.1, 11.7 Hz,
    1H), 4.84 (s, 2H), 6.88 (s, 1H), 7.13-7.26 (m, 5H), 7.63 (d, J = 7.8 Hz, 1H),
    7.76 (dd, J = 5.1, 9.0 Hz, 2H); IR (KBr) 3423, 1706, 1590, 1492, 1468, 1405,
    1332, 1288, 1240, 1148 cm−1; Elemental analysis (C21H21FN2O4S) Calcd. (%):
    C, 60.56; H, 5.08; N, 6.73; F, 4.56; S, 7.70 Found (%): C, 60.51; H, 5.12; N,
    6.63; F, 4.35; S, 7.56
  • TABLE 43
    Compound
    No. Physical properties
    Ic-8 mp 152-157° C.; 1H-NMR (CDCl3) δ 1.57 (m, 1H), 1.79-1.90 (m, 2H), 2.06 (m,
    1H), 2.53-2.65 (m, 2H), 3.26 (m, 1H), 3.70 (m, 1H), 3.94 (m, 1H), 4.84 (s, 2H),
    6.90 (s, 1H), 7.10-7.28 (4H, m), 7.51 (m, 1H), 7.58 (m, 1H), 7.64 (d, J = 7.8 Hz,
    1H); IR (Nujol) 3424, 3101, 3055, 2930, 1717, 1614, 1579, 1469, 1406,
    1337, 1243, 1164, 1146 cm−1; Elemental analysis (C19H20N2O4S2) Calcd. (%):
    C, 56.42; H, 4.98; N, 6.93; S, 15.85 Found (%): C, 56.37; H, 4.93; N, 6.83; S,
    15.68
    Ic-11 mp 212-214° C.; 1H-NMR (d6-DMSO) δ 1.41-1.96 (m, 4H), 2.27-2.42 (m, 2H),
    3.06 (m, 1H), 3.64-3.84 (m, 2H), 4.94 (s, 2H), 6.97 (td, J = 2.7, 9.0 Hz, 1H),
    7.23 (s, 1H), 7.31 (dd, J = 2.7, 10.2 Hz, 1H), 7.36 (dd, J = 4.5, 9.0 Hz, 1H),
    7.42-7.48 (m, 2H), 7.80-7.86 (m, 2H); IR (Nujol) 2654, 2558, 1709, 1624,
    1591, 1489, 1458, 1407, 1334, 1319, 1283, 1241, 1192, 1155 cm−1; Elemental
    analysis (C21H20F2N2O4S•0.2AcOEt) Calcd. (%): C, 57.92; H, 4.82; F, 8.40; N,
    6.20; S, 7.09 Found (%): C, 58.06; H, 4.67; F, 8.24; N, 6.36; S, 7.31
    Ic-14 mp 155-156° C.; 1H-NMR (d6-DMSO) δ 1.86 (m, 1H), 2.21 (m, 1H), 3.13 (dd, J = 8.4,
    9.6 Hz, 1H), 3.29-3.51 (m, 3H), 3.73 (dd, J = 7.2, 9.6 Hz, 1H), 4.89 (s,
    2H), 6.98 (m, 1H), 7.06 (s, 1H), 7.11 (m, 1H), 7.31 (m, 1H), 7.37 (d, J = 8.1 Hz,
    1H), 7.37 (d, J = 8.1 Hz, 1H), 7.42-7.49 (m, 2H), 7.88-7.95 (m, 2H),
    12.93 (br, 1H); IR (Nujol) 2662, 1732, 1712, 1587, 1490, 1469, 1341, 1333, 1241,
    1198, 1162, 1095 cm−1; Elemental analysis (C20H19FN2O4S) Calcd. (%): C,
    59.69; H, 4.76; F, 4.72; N, 6.96; S, 7.97 Found (%): C, 59.55; H, 4.66; F, 4.54;
    N, 6.83; S, 7.93
    Ic-16 mp 126-133° C.; 1H-NMR (d6-DMSO) δ 1.84 (m, 1H), 2.22 (m, 1H), 3.17 (dd, J = 8.7,
    9.9 Hz, 1H), 3.33-3.55 (m, 3H), 3.76 (dd, J = 7.5, 9.9 Hz, 1H), 4.91 (s,
    2H), 7.00 (m, 1H), 7.07 (s, 1H), 7.12 (m, 1H), 7.28-7.40 (m, 3H), 7.75 (dd, J = 1.5,
    3.9 Hz, 1H), 8.05 (dd, J = 1.5, 5.1 Hz, 1H), 12.92 (br, 1H); IR (Nujol)
    3230, 1752, 1726, 1469, 1333, 1211, 1146, 1098, 1030 cm−1; Elemental
    analysis (C18H18N2O4S2•0.2AcOEt) Calcd. (%): C, 55.33; H, 4.84; N, 6.86; S,
    15.71 Found (%): C, 55.08; H, 4.90; N, 6.83; S, 15.56
    Ic-18 mp 139-140° C.; 1H-NMR (d6-DMSO) δ 1.84-2.16 (m, 2H), 2.20 (s, 3H),
    3.30-3.76 (m, 5H), 4.88 (s, 2H), 6.77 (m, 2H), 7.02 (m, 1H), 7.31 (d, J = 8.1 Hz,
    1H), 7.50-7.64 (m, 2H), 7.94-8.08 (m, 2H); IR (Nujol) 3075, 2925, 2736, 2656,
    2561, 1725, 1590, 1468, 1375, 1351, 1291, 1241, 1152 cm−1
    Ic-22 mp 185-190° C. (dec); 1H-NMR (CDCl3) δ 2.65 (br t, 2H), 3.36 (t, J = 5.7 Hz,
    2H), 3.83 (br s, 2H), 4.78 (s, 2H), 6.10 (br s, 1H), 7.06 (s, 1H), 7.11-7.27 (m,
    5H), 7.77 (d, J = 8.1 Hz, 1H), 7.87 (dd, J = 5.1, 9.0 Hz, 2H); Elemental
    analysis (C21H19FN2O4S) Calcd. (%): C, 60.86; H, 4.62; N, 6.76; F, 4.58; S,
    7.74 Found (%): C, 60.59; H, 4.68; N, 6.57; F, 4.29; S, 7.46
  • TABLE 44
    Compound
    No. Physical properties
    Ic-24 mp 119-124° C. (dec); 1H-NMR (CDCl3) δ 1.86 (m, 2H), 2.11 (m, 2H), 2.45 (m,
    2H), 2.77 (m, 1H), 3.93 (m, 2H), 4.84 (s, 2H), 6.81 (s, 1H), 7.10 (m, 1H),
    7.21-7.27 (m, 4H), 7.51 (d, J = 8.1 Hz, 1H), 7.83 (dd, J = 5.1, 9.0 Hz, 2H); IR
    (KBr) 3422, 1715, 1593, 1493, 1467, 1349, 1333, 1240, 1168, 1154 cm−1;
    Elemental analysis (C21H21FN2O4S) Calcd. (%): C, 60.56; H, 5.08; N, 6.73; F,
    4.56; S, 7.70 Found (%): C, 60.48; H, 4.98; N, 6.67; F, 4.35; S, 7.55
    Ic-26 1H-NMR (CDCl3) δ 1.43-1.71 (m, 4H), 2.89 (m, 1H), 3.08 (m, 1H),
    3.34-3.49 (m, 2H), 3.92 (m, 1H), 4.86 (s, 2H), 6.93 (s, 1H), 7.15-7.26 (m, 5H), 7.79 (d, J = 7.8 Hz,
    1H), 7.87-7.91 (m, 2H); IR (KBr) 2927, 1727, 1591, 1493, 1468,
    1332, 1292, 1235, 1197, 1152, 1091, 1038 cm−1; Elemental analysis
    (C21H21FN2O4S•0.6H2O) Calcd. (%): C, 59.03; H, 5.24; N, 6.56; F, 4.45; S, 7.50
    Found (%): C, 59.38; H, 5.21; N, 6.42; F, 4.12, S, 7.11
    Ic-29 1H-NMR (CDCl3) δ 1.26-1.65 (m, 6H), 2.97-3.21 (m, 3H), 3.82 (m, 1H),
    4.36 (m, 1H), 4.82 (s, 2H), 6.86 (s, 1H), 6.99-7.26 (m, 5H), 7.61 (d, J = 4.8 Hz, 1H),
    7.69-7.74 (m, 2H); IR (KBr) 3426, 2936, 1728, 1591, 1494, 1468, 1330, 1289,
    1232, 1149, 1091 cm−1; Elemental analysis (C22H23FN2O4S•0.4H2O) Calcd.
    (%): C, 60.37; H, 5.48; N, 6.40; F, 4.34; S, 7.33 Found (%): C, 60.53; H, 5.49;
    N, 6.26; F, 3.97; S, 6.93
    Ic-30 mp 205-208° C.; 1H-NMR (d6-DMSO) δ 1.46-1.97 (m, 4H), 2.16-2.37 (m, 2H),
    3.07 (m, 1H), 3.64-3.83 (m, 2H), 3.84 (s, 3H), 4.93 (s, 2H), 7.05 (m, 1H),
    7.10-7.15 (m, 3H), 7.34 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 9.0 Hz,
    2H).
    Ic-31 mp 155-159° C.; 1H-NMR (d6-DMSO) δ 1.80 (m, 1H), 2.23 (m, 1H), 3.16 (dd, J = 8.7,
    9.3 Hz, 1H), 3.34-3.56 (m, 3H), 3.74 (dd, J = 7.5, 9.9 Hz, 1H), 4.93 (s,
    2H), 7.12 (dd, J = 2.1, 8.7 Hz, 1H), 7.16 (s, 1H), 7.28 (dd, J = 3.6, 5.1 Hz, 1H),
    7.38 (d, J = 8.7 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 7.74 (dd, J = 1.5, 3.6 Hz,
    1H), 8.03 (dd, J = 1.5, 5.1 Hz, 1H), 12.99 (br, 1H); IR (Nujol) 2669, 1745,
    1669, 1469, 1388, 1347, 1226, 1156, 1040 cm−1; Elemental analysis
    (C18H17ClN2O4S2) Calcd. (%): C, 50.88; H, 4.03; Cl, 8.34; N, 6.59; S, 15.09
    Found (%): C, 55.86; H, 3.92; Cl, 8.04; N, 6.58; S, 15.00
    Ic-32 mp 169-171° C.; 1H-NMR (d6-DMSO) δ 1.83 (m, 1H), 2.19 (m, 1H), 3.11 (dd, J = 8.7,
    9.3 Hz, 1H), 3.29-3.50 (m, 3H), 3.71 (dd, J = 7.5, 9.9 Hz, 1H), 4.84 (s,
    2H), 6.93 (dd, J = 1.5, 8.4 Hz, 1H), 7.00 (s, 1H), 7.13 (d, J = 1.5 Hz, 1H),
    7.19 (d, J = 8.4 Hz, 1H), 7.42-7.50 (m, 2H), 7.89-7.96 (m, 2H), 12.89 (br, 1H); IR
    (Nujol) 2663, 1730, 1708, 1588, 1492, 1463, 1342, 1243, 1198, 1160, 1096,
    1025 cm−1; Elemental analysis (C21H21FN2O4S) Calcd. (%): C, 60.56; H, 5.08;
    F, 4.56; N, 6.73; S, 7.70 Found (%): C, 60.49; H, 5.08; F, 4.27; N, 6.67; S, 7.40
  • TABLE 45
    Compound
    No. Physical properties
    Ic-33 mp 145-149° C.; 1H-NMR (d6-DMSO) δ 1.83 (m, 1H), 2.20 (m, 1H), 2.36 (s,
    3H), 3.16 (t, J = 9.0 Hz, 1H), 3.34-3.54 (m, 3H), 3.74 (dd, J = 7.5, 9.6 Hz, 1H),
    4.86 (s, 2H), 6.94 (dd, J = 1.5, 8.4 Hz, 1H), 7.01 (s, 1H), 7.17 (d, J = 1.5 Hz,
    1H), 7.20 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 3.9, 5.1 Hz, 1H), 7.75 (dd, J = 1.5,
    3.9 Hz, 1H), 8.05 (dd, J = 1.5, 5.1 Hz, 1H), 12.90 (br, 1H); IR (Nujol) 2662,
    1705, 1484, 1463, 1348, 1246, 1156, 1034 cm−1; Elemental analysis
    (C19H20N2O4S2) Calcd. (%): C, 56.42; H, 4.98; N, 6.93; S, 15.85 Found (%): C,
    56.33; H, 4.85; N, 6.84; S, 15.54
    Ic-34 mp 145-146° C.; 1H-NMR (d6-DMSO) δ 1.76 (m, 1H), 2.20 (m, 1H), 3.11 (t, J = 9.0 Hz,
    1H), 3.27-3.48 (m, 3H), 3.72 (dd, J = 7.5, 9.6 Hz, 1H), 4.90 (s, 2H),
    7.10 (s, 1H), 7.11 (dd, J = 1.8, 8.7 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.46 (d, J = 1.8 Hz,
    1H), 7.61-7.66 (m, 2H), 7.73 (m, 1H), 7.83-7.87 (m, 2H), 12.98 (br,
    1H); IR (Nujol) 2663, 1731, 1471, 1446, 1340, 1242, 1198, 1162, 1099, 1029 cm−1;
    Elemental analysis (C20H19ClN2O4S) Calcd. (%): C, 57.34; H, 4.57; Cl,
    8.46; N, 6.69; 5, 7.65 Found (%): C, 57.00; H, 4.48; Cl, 8.13; N, 6.71; S, 7.43
    Ic-35 1H-NMR (d6-DMSO) δ 1.97 (m, 1H), 2.30 (m, 1H), 3.08 (t, J = 9.0 Hz, 1H),
    3.29-3.59 (m, 3H), 3.68 (d, J = 8.1 Hz, 1H), 4.50 (d, J = 13.5 Hz, 1H), 4.56 (d,
    J = 13.5 Hz, 1H), 4.98 (s, 2H), 7.14 (dd, J = 1.8, 8.7 Hz, 1H), 7.29 (s, 1H),
    7.36-7.50 (m, 6H), 7.59 (d, J = 1.8 Hz, 1H), 13.01 (br, 1H); IR (KBr) 3439,
    2637, 1731, 1471, 1329, 1152 cm−1; Elemental analysis
    (C21H21ClN2O4S•0.6H2O) Calcd. (%): C, 56.84; H, 5.04; Cl, 7.99; N, 6.31; S,
    7.23 Found (%): C, 56.96; H, 4.81; Cl, 7.61; N, 6.34; S, 7.17
    Ic-36 mp 158-159° C.; 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.22 (m, 1H), 3.13 (t, J = 9.0 Hz,
    1H), 3.28-3.50 (m, 3H), 3.72 (dd, J = 7.5, 9.3 Hz, 1H), 4.91 (s, 2H),
    7.13 (dd, J = 1.8, 8.7 Hz, 1H), 7.16 (s, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.46 (d, J = 1.8 Hz,
    1H), 7.64-7.68 (m, 2H), 7.82-7.86 (m, 2H), 12.99 (br, 1H); IR (Nujol)
    2669, 1741, 1726, 1472, 1346, 1246, 1162, 1100, 1086, 1032 cm−1.
    Ic-37 mp 195-196° C.; 1H-NMR (d6-DMSO) δ 1.76 (m, 1H), 2.19 (m, 1H), 2.42 (s,
    3H), 3.08 (t, J = 9.0 Hz, 1H), 3.26-3.45 (m, 3H), 3.68 (dd, J = 7.5, 9.3 Hz, 1H),
    4.90 (s, 2H), 7.10 (s, 1H), 7.11 (dd, J = 1.8, 8.7 Hz, 1H), 7.37 (d, J = 8.7 Hz,
    1H), 7.42-7.44 (m, 4H), 7.71-7.74 (m, 2H), 12.98 (br, 1H); IR (Nujol) 2671,
    1728, 1470, 1347, 1249, 1199, 1158, 1097, 1030 cm−1; Elemental analysis
    (C21H21ClN2O4S) Calcd. (%): C, 58.26; H, 4.89; Cl, 8.19; N, 6.47; S, 7.41
    Found (%): C, 58.18; H, 4.87; Cl, 7.92; N, 6.40; S, 7.28
  • TABLE 46
    Compound
    No. Physical properties
    Ic-38 mp 166-168° C.; 1H-NMR (d6-DMSO) δ 1.81 (m, 1H), 2.20 (m, 1H), 3.10 (t, J = 9.0 Hz,
    1H), 3.27-3.50 (m, 3H), 3.72 (dd, J = 7.5, 9.3 Hz, 1H), 4.90 (s, 2H),
    6.95 (m, 1H), 7.15-7.19 (m, 2H), 7.34 (dd, J = 4.5, 9.0 Hz, 1H), 7.40-7.47 (m,
    2H), 7.85-7.94 (m, 2H), 12.96 (br, 1H); IR (Nujol) 2662, 1725, 1715, 1587,
    1457, 1341, 1333, 1237, 1198, 1160, 1096 cm−1; Elemental analysis
    (C20H18F2N2O4S) Calcd. (%): C, 57.14; H, 4.32; F, 9.04; N, 6.66; S, 7.63 Found
    (%): C, 57.15; H, 4.25; F, 8.79; N, 6.54; S, 7.57
    Ic-39 1H-NMR (d6-DMSO) δ 1.80 (m, 1H), 2.22 (m, 1H), 3.15 (t, J = 9.0 Hz, 1H),
    3.31-3.53 (m, 3H), 3.75 (dd, J = 7.5, 9.6 Hz, 1H), 4.92 (s, 2H), 6.96 (m, 1H),
    7.15 (s, 1H), 7.21 (dd, J = 2.4, 9.9 Hz, 1H), 7.28 (dd, J = 3.9, 4.8 Hz, 1H),
    7.35 (dd, J = 4.5, 9.0 Hz, 1H), 7.74 (dd, J = 1.2, 3.9 Hz, 1H), 8.03 (dd, J = 1.2, 4.8 Hz,
    1H), 12.97 (br, 1H); IR (KBr) 1729, 1626, 1580, 1486, 1457, 1403, 1344,
    1225, 1155 cm−1; Elemental analysis (C18H17FN2O4S2) Calcd. (%): C, 52.24;
    H, 4.29; F, 4.59; N, 6.77; S, 15.50 Found (%): C, 52.26; H, 4.22; F, 4.46; N,
    6.33; S, 15.47
    Ic-40 mp 157-160° C.; 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.21 (m, 1H), 3.10 (t, J = 9.0 Hz,
    1H), 3.30-3.50 (m, 3H), 3.71 (dd, J = 7.5, 9.6 Hz, 1H), 3.74 (s, 3H),
    4.83 (s, 2H), 6.75 (dd, J = 2.4, 8.7 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 7.00 (s,
    1H), 7.21 (d, J = 8.7 Hz, 1H), 7.40-7.48 (m, 2H), 7.88-7.95 (m, 2H), 12.90 (br,
    1H); IR (Nujol) 3204, 1742, 1718, 1622, 1586, 1493, 1452, 1338, 1331, 1224,
    1151, 1095, 1037, 1027 cm−1; Elemental analysis (C21H21FN2O5S) Calcd. (%):
    C, 58.32; H, 4.89; F, 4.39; N, 6.48; S, 7.41 Found (%): C, 58.02; H, 5.07; F,
    4.22; N, 6.30; S, 7.15
    Ic-41 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.23 (m, 1H), 3.14 (t, J = 9.0 Hz, 1H),
    3.30-3.52 (m, 3H), 3.75 (m, 1H), 3.75 (s, 3H), 4.85 (s, 2H), 6.76 (dd, J = 2.4,
    8.7 Hz, 1H), 6.92 (d, J = 2.4 Hz, 1H), 7.01 (s, 1H), 7.22 (d, J = 8.7 Hz, 1H),
    7.29 (dd, J = 3.9, 5.1 Hz, 1H), 7.75 (dd, J = 1.2, 3.6 Hz, 1H), 8.04 (dd, J = 1.2,
    5.1 Hz, 1H), 12.74 (br, 1H); IR (KBr) 1727, 1622, 1580, 1488, 1454, 1403,
    1345, 1226, 1155, 1031 cm−1; Elemental analysis (C19H20N2O5S2•0.2H2O)
    Calcd. (%): C, 53.81; H, 4.85; N, 6.61; S, 15.12 Found (%): C, 53.85; H, 4.87;
    N, 6.34; S, 15.01
    Ic-42 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.16 (m, 1H), 3.09 (t, J = 9.0 Hz, 1H),
    3.25-3.47 (m, 3H), 3.69 (dd, J = 7.5, 9.9 Hz, 1H), 4.79 (s, 2H), 6.63 (dd, J = 2.1,
    9.0 Hz, 1H), 6.72 (d, J = 2.1 Hz, 1H), 6.93 (s, 1H), 7.10 (d, J = 9.0 Hz,
    1H), 7.42-7.47 (m, 2H), 7.88-7.93 (m, 2H), (d, J = 8.7 Hz, 1H), 7.46 (d, J = 1.8 Hz,
    1H), 7.61-7.66 (m, 2H), 7.73 (m, 1H), 8.73 (br, 1H), 12.87 (br, 1H); IR
    (KBr) 3436, 1730, 1625, 1590, 1492, 1466, 1332, 1293, 1226, 1153, 1096 cm−1;
    Elemental analysis (C20H19FN2O5S•0.7H2O) Calcd. (%): C, 55.73; H, 4.77;
    F, 4.41; N, 6.50; S, 7.44 Found (%): C, 55.69; H, 4.68; F, 4.05; N, 6.28; S, 7.19
  • TABLE 47
    Compound
    No. Physical properties
    Ic-43 mp 119-123° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.5 Hz, 3H), 1.34-1.46 (m,
    2H), 1.60-1.79 (m, 2H), 2.03 (m, 1H), 2.36 (m, 1H), 3.02-3.65 (m, 6H),
    3.80 (dd, J = 7.5, 9.0 Hz, 1H), 4.96 (s, 2H), 6.98 (m, 1H), 7.33-7.44 (m, 3H),
    12.96 (br, 1H); IR (Nujol) 3254, 1751, 1626, 1583, 1488, 1456, 1318, 1299, 1274,
    1183, 1127, 1095, 1045 cm−1; Elemental analysis (C18H23FN2O4S) Calcd. (%):
    C, 56.53; H, 6.06; F, 4.97; N, 7.32; S, 8.38 Found (%): C, 56.46; H, 5.99; F,
    4.76; N, 7.19; S, 8.20
    Ic-44 mp 178-182° C.; 1H-NMR (d6-DMSO) δ 1.99 (m, 1H), 2.33 (m, 1H), 3.20 (t, J = 9.0 Hz,
    1H), 3.23-3.60 (m, 3H), 3.80 (dd, J = 7.5, 9.9 Hz, 1H), 4.91 (s, 2H),
    6.95 (m, 1H), 7.29 (s, 1H), 7.31-7.47 (m, 7H), 7.73-7.76 (m, 2H), 12.95 (br,
    1H); IR (Nujol) 1719, 1620, 1577, 1486, 1459, 1331, 1228, 1144, 1048, 1023 cm−1;
    Elemental analysis (C22H21FN2O4S) Calcd. (%): C, 61.67; H, 4.94; F,
    4.43; N, 6.54; S. 7.48 Found (%): C, 61.45; H, 4.92; F, 4.27; N, 6.40; S, 7.40
    Ic-45 mp 205-207° C.; 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.22 (m, 1H), 3.15 (t, J = 9.0 Hz,
    1H), 3.34-3.54 (m, 3H), 3.76 (dd, J = 7.5, 9.3 Hz, 1H), 4.88 (s, 2H),
    6.95 (m, 1H), 7.17 (s, 1H), 7.20 (dd, J = 2.4, 9.9 Hz, 1H), 7.32 (dd, J = 4.5, 9.0 Hz,
    1H), 7.43-7.56 (m, 3H), 7.76-7.79 (m, 2H), 9.93 (s, 4H), 12.93 (br, 1H); IR
    (Nujol) 1721, 1597, 1483, 1457, 1337, 1233, 1199, 1158 cm−1; Elemental
    analysis (C26H23FN2O4S) Calcd. (%): C, 65.26; H, 4.84; F, 3.97; N, 5.85; S,
    6.70 Found (%): C, 65.03; H, 4.85; F, 3.78; N, 5.72; S, 6.59
    Ic-46 mp 172-174° C.; 1H-NMR (d6-DMSO) δ 2.20 (m, 1H), 2.36 (m, 1H), 2.94 (s,
    3H), 3.16 (t, J = 9.0 Hz, 1H), 3.33-3.64 (m, 3H), 3.79 (dd, J = 7.2, 9.0 Hz, 1H),
    4.97 (s, 2H), 6.98 (m, 1H), 7.34 (s, 1H), 7.38 (dd, J = 4.2, 9.0 Hz, 1H),
    7.44 (dd, J = 2.4, 10.2 Hz, 1H), 12.98 (br, 1H); IR (Nujol) 1722, 1487, 1456, 1318,
    1233, 1196, 1141, 1042 cm−1; Elemental analysis (C15H17FN2O4S) Calcd. (%):
    C, 52.93; H, 5.03; F, 5.58; N, 8.23; S, 9.42 Found (%): C, 52.76; H, 4.96; F,
    5.39; N, 8.15; S, 9.20
    Ic-47 mp 171-173° C.; 1H-NMR (d6-DMSO) δ 1.88 (m, 1H), 2.26 (m, 1H), 3.17 (t, J = 9.3 Hz,
    1H), 3.34-3.57 (m, 3H), 3.76 (dd, J = 6.9, 9.3 Hz, 1H), 4.93 (s, 2H),
    7.12 (s, 1H), 7.32 (m, 1H), 7.39-7.48 (m, 6H), 7.63-7.68 (m, 3H), 7.89-7.96 (m,
    2H), 12.99 (br, 1H); IR (Nujol) 2668, 1736, 1592, 1493, 1476, 1347, 1335,
    1258, 1244, 1187, 1166, 1154 cm−1; Elemental analysis (C26H23FN2O4S)
    Calcd. (%): C, 65.26; H, 4.84; F, 3.97; N, 5.85; S, 6.70 Found (%): C, 65.29; H,
    4.84; F, 3.91; N, 5.75; S, 6.78
    Ic-48 mp 161-163° C.; 1H-NMR (d6-DMSO) δ 0.89 (t, J = 7.5 Hz, 3H), 1.34-1.46 (m,
    2H), 1.61-1.71 (m, 2H), 2.08 (m, 1H), 2.41 (m, 1H), 3.04-3.20 (m, 2H),
    3.27-3.58 (m, 3H), 3.68-3.86 (m, 2H), 4.99 (s, 2H), 7.29-7.33 (m, 2H), 7.42-7.48 (m,
    4H), 7.68-7.71 (m, 2H), 7.86 (s, 1H), 12.97 (br, 1H); IR (Nujol) 2666, 1715,
    1478, 1455, 1325, 1243, 1197, 1133, 1094, 1046 cm−1; Elemental analysis
    (C24H28N2O4S) Calcd. (%): C, 65.43; H, 6.41; N, 6.36; S, 7.28 Found (%): C,
    65.16; H, 6.37; N, 6.24; S, 7.29
  • TABLE 48
    Compound
    No. Physical properties
    Ic-49 mp 174-178° C.; 1H-NMR (d6-DMSO) δ 1.86 (m, 1H), 2.28 (m, 1H),
    3.18-3.57 (m, 4H), 3.78 (dd, J = 6.9, 9.3 Hz, 1H), 4.94 (s, 2H), 7.12 (s, 1H), 7.27 (dd, J = 3.9,
    5.1 Hz, 1H), 7.32 (m, 1H), 7.42-7.49 (m, 4H), 7.64-7.70 (m, 3H), 7.75 (dd,
    J = 1.5, 3.9 Hz, 1H), 8.02 (dd, J = 1.5, 5.1 Hz, 1H), 12.97 (br, 1H); IR (Nujol)
    2664, 1738, 1714, 1476, 1345, 1336, 1251, 1187, 1157, 1020 cm−1; Elemental
    analysis (C24H22N2O4S) Calcd. (%): C, 61.78; H, 4.75; N, 6.00; S, 13.74 Found
    (%): C, 61.73; H, 4.74; N, 5.90; S, 13.62
    Ic-50 mp 160-170° C.; 1H-NMR (d6-DMSO) δ 1.99 (m, 1H), 2.32 (m, 1H), 3.00 (t, J
    8.1 Hz, 1H), 3.17 (t, J = 9.0 Hz, 1H), 3.35-3.61 (m, 5H), 3.83 (dd, J = 7.5, 9.0 Hz,
    1H), 4.93 (s, 2H), 6.97 (m, 1H), 7.20-7.43 (m, 8H), 12.94 (br, 1H); IR
    (Nujol) 3617, 3498, 2625, 1739, 1713, 1488, 1458, 1327, 1224, 1147, 1135,
    1049 cm−1; Elemental analysis (C22H23FN2O4S•H2O) Calcd. (%): C, 58.91; H,
    5.62; F, 4.24; N, 6.25; S, 7.15 Found (%): C, 59.09; H, 5.51; F, 4.17; N, 6.12;
    S, 7.19
    Ic-51 mp 192-194° C.; 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.21 (m, 1H), 3.11 (t, J = 9.0 Hz,
    1H), 3.27-3.50 (m, 3H), 3.73 (dd, J = 7.5, 9.3 Hz, 1H), 4.89 (d, J = 18.3 Hz,
    1H), 4.95 (d, J = 18.3 Hz, 1H), 7.00 (dd, J = 1.5, 8.4 Hz, 1H), 7.11 (s, 1H),
    7.40-7.51 (m, 4H), 7.87-7.93 (m, 2H), 12.97 (br, 1H); IR (Nujol) 2641, 1736,
    1529, 1492, 1470, 1414, 1335, 1241, 1227, 1178, 1168, 1159 cm−1; Elemental
    analysis (C20H18ClFN2O4S) Calcd. (%): C, 54.98; H, 4.15; Cl, 8.11; F, 4.35; N,
    6.41; S, 7.34 Found (%): C, 54.95; H, 4.07; Cl, 7.91; F, 4.33; N, 6.40; S, 7.36
    Ic-52 Mp 224-226° C.; 1H-NMR (d6-DMSO) δ 1.81 (m, 1H), 2.22 (m, 1H), 3.15 (dd, J = 8.7,
    9.6 Hz, 1H), 3.34-3.53 (m, 3H), 3.75 (dd, J = 7.2, 9.6 Hz, 1H), 4.90 (d, J = 18.3 Hz,
    1H), 4.96 (d, J = 18.3 Hz, 1H), 7.01 (dd, J = 1.8, 8.4 Hz, 1H),
    7.12 (s, 1H), 7.29 (dd, J = 3.9, 5.1 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 1.8 Hz,
    1H), 7.74 (dd, J = 1.5, 3.9 Hz, 1H), 8.04 (dd, J = 1.5, 5.1 Hz, 1H),
    12.97 (br, 1H); IR (Nujol) 1729, 1472, 1341, 1327, 1236, 1200, 1157, 1032 cm−1;
    Elemental analysis (C18H17ClN2O4S2•AcOEt) Calcd. (%): C, 51.09; H, 4.33;
    Cl, 7.85; N, 6.21; S, 14.21 Found (%): C, 50.97; H, 4.22; Cl, 7.65; N, 6.31;
    S, 14.51
    Ic-53 Mp 133-136° C.; 1H-NMR (d6-DMSO) δ 1.93 (m, 1H), 2.30 (m, 1H),
    3.19-3.59 (m, 4H), 3.80 (m, 1H), 4.89 (d, J = 18.9 Hz, 1H), 4.95 (d, J = 18.9 Hz, 1H),
    7.12 (dd, J = 2.1, 8.7 Hz, 1H), 7.19 (s, 1H), 7.36-7.50 (m, 3H), 7.53 (d, J = 2.1 Hz,
    1H), 7.69-7.88 (m, 2H), 12.99 (brs, 1H); IR (Nujol) 3093, 2668, 2575,
    1714, 1598, 1472, 1416, 1376, 1351, 1304, 1263, 1248, 1223, 1189, 1164,
    1127, 1108 cm−1; Elemental analysis (C20H18ClFN2O4S) Calcd. (%): C, 54.98;
    H, 4.15; Cl, 8.11; F, 4.35; N, 6.41; S, 7.34 Found (%): C, 54.68; H, 4.01; Cl,
    7.81; F, 4.17; N, 6.38; S, 7.30
  • TABLE 49
    Compound
    No. Physical properties
    mp 162-165° C.; 1H-NMR (d6-DMSO) δ 1.82 (m, 1H), 2.20 (m, 1H),
    3.11-3.52 (m, 4H), 3.75 (dd, J = 7.2, 9.6 Hz, 1H), 4.92 (d, J = 18.6 Hz, 1H), 4.94 (d, J = 18.6 Hz,
    1H), 7.11 (dd, J = 2.1, 8.4 Hz, 1H), 7.16 (s, 1H), 7.37 (d, J = 8.4 Hz,
    1H), 7.48 (d, J = 2.1 Hz, 1H), 7.53-7.73 (m, 4H), 12.99 (brs, 1H); IR (Nujol)
    3084, 2667, 2573, 1710, 1590, 1472, 1415, 1390, 1378, 1345, 1304, 1267,
    1249, 1221, 1197, 1162, 1106 cm−1; Elemental analysis
    (C20H18ClFN2O4S•0.1AcOEt) Calcd. (%): C, 54.97; H, 4.25; Cl, 7.95; F,
    4.26; N, 6.29; S, 7.19 Found (%): C, 54.97; H, 4.11; Cl, 7.74; F, 4.36; N, 6.36;
    S, 7.25
    Ic-55 mp 193-197° C.; 1H-NMR (d6-DMSO) δ 1.94-2.02 (m, 2H), 2.21 (s, 3H),
    3.15-3.69 (m, 5H), 4.92 (s, 2H), 6.88 (d, J = 1.5 Hz, 1H), 7.02 (dd, J = 1.5, 8.7 Hz,
    1H), 7.38 (d, J = 8.7 Hz, 1H), 7.50-7.57 (m, 2H), 7.96-8.01 (m, 2H), 13.04 (br,
    1H); IR (Nujol) 1734, 1592, 1494, 1469, 1338, 1169, 1159 cm−1; Elemental
    analysis (C21H20ClFN2O4S) Calcd. (%): C, 55.94; H, 4.47; Cl, 7.86; F, 4.21; N,
    6.21; S, 7.11 Found (%): C, 55.78; H, 4.41; Cl, 7.59; F, 4.28; N, 6.25; S, 7.10
    Ic-56 mp 196-201° C.; 1H-NMR (d6-DMSO) δ 1.98-2.07 (m, 2H), 2.21 (s, 3H),
    3.24-3.40 (m, 2H), 3.45-3.55 (m, 2H), 3.65 (m, 1H), 4.93 (s, 2H), 7.02-7.05 (m, 2H),
    7.36-7.40 (m, 2H), 7.81 (dd, J = 1.5, 3.6 Hz, 1H), 8.13 (dd, J = 1.5, 5.1 Hz,
    1H), 13.06 (br, 1H); IR (Nujol) 3278, 1770, 1739, 1470, 1346, 1325, 1231,
    1221, 1159, 1089, 1059, 1027 cm−1; Elemental analysis (C19H19ClN2O4S2)
    Calcd. (%): C, 51.99; H, 4.36; Cl, 8.08; N, 6.38; S, 14.61 Found (%): C, 51.86;
    H, 4.34; Cl, 7.75; N, 6.36; S, 14.74
    Ic-57 mp 153-161° C.; 1H-NMR (d6-DMSO) δ 0.94 (t, J = 7.8 Hz, 3H), 1.39-1.52 (m,
    2H), 1.67-1.77 (m, 2H), 2.13 (m, 1H), 2.31 (m, 1H), 2.31 (s, 3H), 3.20 (m, 1H),
    3.33-3.43 (m, 3H), 3.54-3.76 (m, 3H), 4.96 (s, 2H), 7.07 (dd, J = 2.1, 9.0 Hz,
    1H), 7.41 (d, J = 9.0 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 13.06 (br, 1H); IR
    (Nujol) 3187, 1759, 1713, 1472, 1420, 1380, 1328, 1318, 1301, 1247, 1190,
    1142, 1114, 1049 cm−1; Elemental analysis (C19H25ClN2O4S) Calcd. (%): C,
    55.26; H, 6.10; Cl, 8.59; N, 6.78; S, 7.77 Found (%): C, 55.47; H, 6.10; Cl,
    8.36; N, 6.77; S, 7.54
    Ic-58 mp 180-183° C.; 1H-NMR (d6-DMSO) δ 1.85 (m, 1H), 2.24 (m, 1H),
    3.13-3.55 (m, 4H), 3.77 (dd, J = 7.5, 9.6 Hz, 1H), 4.90 (s, 2H), 7.11 (dd, J = 1.8, 8.7 Hz,
    1H), 7.19 (s, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.98 (d, J = 8.4 Hz,
    2H), 8.06 (d, J = 8.4 Hz, 2H), 12.95 (brs, 1H); IR (Nujol) 3092, 2730,
    2665, 2553, 1723, 1695, 1612, 1473, 1403, 1378, 1329, 1289, 1268, 1245,
    1233, 1189, 1163, 1140, 1106 cm−1; Elemental analysis (C21H18ClF3N2O4S)
    Calcd. (%): C, 51.80; H, 3.73; Cl, 7.28; F, 11.71; N, 5.75; S, 6.59 Found (%): C,
    51.65; H, 3.66; Cl, 7.02; F, 11.55; N, 5.76; S, 6.72
  • TABLE 50
    Compound
    No. Physical properties
    Ic-59 mp 136-142° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.2 Hz, 3H), 1.34-1.47 (m,
    2H), 1.59-1.72 (m, 2H), 2.02 (m, 1H), 2.36 (m, 1H), 3.03-3.68 (m, 6H),
    3.80 (dd, J = 7.5, 9.0 Hz, 1H), 4.97 (s, 2H), 7.13 (dd, J = 2.1, 8.7 Hz, 1H), 7.34 (s,
    1H), 7.41 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 2.1 Hz, 1H), 13.00 (brs, 1H); IR
    (Nujol) 3133, 3093, 2664, 2549, 1721, 1697, 1472, 1403, 1389, 1333, 1297,
    1277, 1242, 1231, 1199, 1146, 1100 cm−1; Elemental analysis
    (C18H23ClN2O4S) Calcd. (%): C, 54.20; H, 5.81; Cl, 8.89; N, 7.02; S, 8.04
    Found (%): C, 54.09; H, 5.74; Cl, 8.65; N, 7.00; S, 7.93
    Ic-60 mp 158-162° C.; 1H-NMR (d6-DMSO) δ 0.81-0.91 (m, 3H), 1.17-1.46 (m, 10H),
    1.58-1.74 (m, 2H), 2.02 (m, 1H), 2.35 (m, 1H), 3.01-3.68 (m, 6H), 3.80 (dd, J = 7.5,
    9.0 Hz, 1H), 4.97 (s, 2H), 7.13 (dd, J = 2.1, 8.7 Hz, 1H), 7.34 (s, 1H),
    7.41 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 2.1 Hz, 1H), 13.00 (brs, 1H); IR (Nujol)
    3135, 3094, 1720, 1695, 1471, 1403, 1391, 1378, 1333, 1285, 1230, 1199,
    1146, 1119 cm−1; Elemental analysis (C22H31ClN2O4S) Calcd. (%): C, 58.07;
    H, 6.87; Cl, 7.79; N, 6.16; S, 7.05 Found (%): C, 58.00; H, 6.82; Cl, 7.55; N,
    6.20; S, 6.99
    Ic-61 mp 220-223° C.; 1H-NMR (d6-DMSO) δ 1.92 (m, 1H), 2.29 (m, 1H),
    3.15-3.60 (m, 4H), 3.83 (dd, J = 7.5, 9.3 Hz, 1H), 4.86 (s, 2H), 7.09 (s, 1H), 7.10 (dd, J = 2.1,
    8.7 Hz, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H),
    7.63-7.77 (m, 3H), 8.11 (m, 1H), 8.16 (m, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.75 (d, J = 7.5 Hz,
    1H), 12.96 (brs, 1H); IR (Nujol) 3266, 3064, 3045, 1764, 1736, 1592,
    1565, 1506, 1471, 1430, 1404, 1385, 1345, 1329, 1266, 1203, 1187, 1161,
    1137, 1111 cm−1; Elemental analysis (C24H21ClN2O4S•0.2H2O) Calcd. (%): C,
    61.00; H, 4.56; Cl, 7.50; N, 5.93; S, 6.79 Found (%): C, 61.11; H, 4.57; Cl,
    7.33; N, 5.93; S, 6.63
    Ic-62 mp 195-198° C.; 1H-NMR (d6-DMSO) δ 1.88 (m, 1H), 2.24 (m, 1H),
    3.13-3.59 (m, 4H), 3.77 (dd, J = 7.2, 9.3 Hz, 1H), 4.89 (s, 2H), 7.09 (dd, J = 1.8, 8.7 Hz,
    1H), 7.18 (s, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.43 (d, J = 1.8 Hz, 1H), 8.06 (d, J = 9.0 Hz,
    2H), 8.35 (d, J = 9.0 Hz, 2H), 12.97 (brs, 1H); IR (Nujol) 3108, 3068,
    1738, 1606, 1530, 1472, 1414, 1401, 1376, 1348, 1320, 1303, 1261, 1238,
    1227, 1200, 1179, 1165, 1134, 1103 cm−1; Elemental analysis (C20H18ClN3O6S)
    Calcd. (%): C, 51.78; H, 3.91; Cl, 7.64; N, 9.06; S, 6.91 Found (%): C, 51.59;
    H, 3.81; Cl, 7.34; N, 8.87; S, 6.84
    Ic-63 1H-NMR (d6-DMSO) δ 1.83 (m, 1H), 2.22 (m, 1H), 3.12-3.83 (m, 5H), 4.83,
    4.87 (each s, total 2H), 7.06-7.19 (m, 2H), 7.31-7.43 (m, 2H), 7.89-8.16 (m,
    4H); IR (KBr) 3413, 3226, 3091, 2233, 1728, 1611, 1568, 1472, 1437, 1399,
    1344, 1282, 1218, 1161, 1107 cm−1.
  • TABLE 51
    Compound
    No. Physical properties
    Ic-64 Mp 205-206° C.; 1H-NMR (d6-DMSO) δ 1.92 (m, 1H), 2.19 (m, 1H), 3.10 (m,
    1H), 3.34-3.51 (m, 2H), 3.69-3.79 (m, 2H), 4.90 (d, J = 18.3 Hz, 1H), 4.96 (d, J = 18.3 Hz,
    1H), 7.03 (dd, J = 1.2, 7.8 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.23 (s,
    1H), 7.33 (dd, J = 1.2, 7.8 Hz, 1H), 7.39-7.45 (m, 2H), 7.85-7.91 (m, 2H),
    13.03 (br, 1H); IR (Nujol) 2662, 1723, 1589, 1491, 1476, 1447, 1350, 1332,
    1248, 1236, 1182, 1162, 1098, 1029 cm−1; Elemental analysis
    (C20H18ClFN2O4S) Calcd. (%): C, 54.98; H, 4.15; Cl, 8.11; F, 4.35; N, 6.41; S,
    7.34 Found (%): C, 55.04; H, 4.13; Cl, 7.79; F, 4.33; N, 6.42; S, 7.32
    Ic-65 mp 170-171° C.; 1H-NMR (d6-DMSO) δ 1.93 (m, 1H), 2.21 (m, 1H), 3.14 (m,
    1H), 3.37-3.54 (m, 2H), 3.72-3.83 (m, 2H), 4.91 (d, J = 18.6 Hz, 1H), 4.98 (d, J = 18.6 Hz,
    1H), 7.03 (dd, J = 1.2, 7.8 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.24 (s,
    1H), 7.26 (dd, J = 3.9, 5.1 Hz, 1H), 7.34 (dd, J = 1.2, 8.1 Hz, 1H), 7.70 (dd, J = 1.5,
    3.9 Hz, 1H), 8.01 (dd, J = 1.5, 5.1 Hz, 1H), 13.02 (br, 1H); IR (Nujol)
    3204, 1755, 1728, 1554, 1453, 1401, 1338, 1326, 1196, 1146, 1033 cm−1;
    Elemental analysis (C18H17ClN2O4S2) Calcd. (%): C, 50.88; H, 4.03; Cl, 8.34;
    N, 6.59; S, 15.09 Found (%): C, 50.87; H, 3.97; Cl, 8.10; N, 6.52; S, 14.89
    Ic-66 mp 169-171° C.; 1H-NMR (d6-DMSO) δ 0.88 (t, J = 7.2 Hz, 3H), 1.32-1.45 (m,
    2H), 1.59-1.69 (m, 2H), 2.08 (m, 1H), 2.35 (m, 1H), 2.99-3.14 (m, 2H),
    3.21 (dd, J = 8.4, 9.3 Hz, 1H), 3.38-3.54 (m, 2H), 3.88 (dd, J = 6.9, 9.6 Hz, 1H),
    4.04 (m, 2H), 5.00 (s, 2H), 7.06-7.14 (m, 2H), 7.37 (dd, J = 1.2, 7.5 Hz, 1H),
    7.44 (s, 1H), 13.06 (br, 1H); IR (Nujol) 2660, 1715, 1555, 1480, 1451, 1404,
    1327, 1246, 1182, 1140, 1096, 1041 cm−1; Elemental analysis
    (C18H23ClN2O4S) Calcd. (%): C, 54.20; H, 5.81; Cl, 8.89; N, 7.02; S, 8.04
    Found (%): C, 54.05; H, 5.76; Cl, 8.72; N, 7.00; S, 8.03
    Ic-67 mp 170-173° C.; 1H-NMR (d6-DMSO) δ 1.81 (m, 1H), 2.23 (m, 1H),
    3.11-3.49 (m, 4H), 3.70 (dd, J = 7.2, 9.6 Hz, 1H), 4.23 (s, 2H), 4.94 (s, 2H), 7.06 (d, J = 3.9 Hz,
    1H), 7.13 (dd, 2.1, 8.7 Hz, 1H), 7.18 (s, 1H), 7.21-7.36 (m, 5H),
    7.40 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.57 (d, J = 3.9 Hz, 1H),
    13.00 (brs, 1H); IR (Nujol) 3084, 3027, 2665, 2570, 1731, 1601, 1571, 1554, 1527,
    1494, 1472, 1442, 1415, 1380, 1344, 1244, 1198, 1156, 1113 cm−1; Elemental
    analysis (C25H23ClN2O4S2) Calcd. (%): C, 58.30; H, 4.50; Cl, 6.88; N, 5.44; S,
    12.45 Found (%): C, 58.15; H, 4.39; Cl, 6.64; N, 5.39; S, 12.35
  • TABLE 52
    Compound
    No. Physical properties
    Ic-68 mp 207-210° C.; 1H-NMR (d6-DMSO) δ 1.85 (m, 1H), 2.20 (m, 1H),
    3.17-3.57 (m, 3H), 3.88 (m, 1H), 4.13 (m, 1H), 4.88 (s, 2H), 7.09 (dd, J = 1.8, 8.7 Hz,
    1H), 7.14 (s, 1H), 7.31 (d, J = 1.8 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.70 (dd, J = 4.2,
    8.1 Hz, 1H), 7.76 (dd, J = 7.5, 8.1 Hz, 1H), 8.31 (dd, J = 1.5, 8.1 Hz,
    1H), 8.42 (dd, J = 1.5, 7.5 Hz, 1H), 8.56 (dd, J = 1.5, 8.1 Hz, 1H), 9.05 (dd, J = 1.5,
    4.2 Hz, 1H), 12.94 (brs, 1H); IR (Nujol) 3539, 3214, 3032, 2725, 2614,
    1768, 1747, 1726, 1611, 1596, 1561, 1493, 1470, 1419, 1378, 1362, 1338,
    1265, 1223, 1211, 1198, 1159, 1140, 1131, 1101 cm−1; Elemental
    analysis (C23H20ClN3O4S•0.5H2O) Calcd. (%): C, 57.68; H, 4.42; Cl, 7.40; N,
    8.77; S, 6.69 Found (%): C, 57.77; H, 4.32; Cl, 7.18; N, 8.76; S, 6.70
    Ic-69 mp 166-170° C.; 1H-NMR (d6-DMSO) δ 1.80 (m, 1H), 2.22 (m, 1H),
    3.09-3.51 (m, 4H), 3.73 (dd, J = 7.2, 9.3 Hz, 1H), 4.93 (s, 2H), 7.12 (dd, J = 1.8, 8.7 Hz,
    1H), 7.16 (s, 1H), 7.38 (d, J = 8.7 Hz, 1H), 7.46 (dd, J = 1.2, 5.1 Hz, 1H),
    7.48 (d, J = 1.8 Hz, 1H), 7.82 (dd, J = 3.0, 5.1 Hz, 1H), 8.33 (dd, J = 1.2, 3.0 Hz,
    1H), 12.95 (brs, 1H); IR (Nujol) 3112, 3087, 2669, 1743, 1710, 1667, 1469,
    1431, 1387, 1363, 1342, 1303, 1247, 1220, 1202, 1155, 1106 cm−1; Elemental
    analysis (C18H17ClN2O4S2) Calcd. (%): C, 50.88; H, 4.03; Cl, 8.34; N, 6.59; S,
    15.09 Found (%): C, 50.76; H, 3.92; Cl, 8.14; N, 6.53; S, 15.08
    Ic-70 mp 222-226° C.; 1H-NMR (d6-DMSO) δ 1.85 (m, 1H), 2.22 (m, 1H),
    3.13-3.60 (m, 4H), 3.82 (dd, J = 7.2, 9.3 Hz, 1H), 4.85 (s, 2H), 7.06 (s, 1H), 7.09 (dd,
    J = 2.1, 8.7 Hz, 1H), 7.33 (d, J = 8.7 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H),
    7.47-7.58 (m, 2H), 8.15 (m, 1H), 8.27 (m, 1H), 8.63 (s, 1H), 12.86 (brs, 1H); IR
    (Nujol) 3275, 3079, 1764, 1734, 1485, 1471, 1454, 1421, 1405, 1386, 1342,
    1320, 1304, 1260, 1241, 1221, 1186, 1159, 1158, 1147, 1114 cm−1; Elemental
    analysis (C22H19ClN2O4S2) Calcd. (%): C, 55.63; H, 4.03; Cl, 7.46; N, 5.90; S,
    13.50 Found (%): C, 55.46; H, 4.12; Cl, 7.17; N, 5.76; S, 13.27
    Ic-71 mp 166.5-168° C.; 1H-NMR (d6-DMSO) δ 1.95 (m, 1H), 2.30 (m, 1H),
    3.10-3.61 (m, 4H), 3.78 (m, 1H), 4.93 (s, 2H), 7.12 (dd, J = 1.8, 8.7 Hz, 1H),
    7.19-7.32 (m, 2H), 7.38 (d, J = 8.7 Hz, 1H), 7.48-7.59 (m, 2H), 7.90 (m, 1H),
    13.00 (brs, 1H); IR (Nujol) 3092, 3056, 2731, 2658, 2550, 1722, 1696, 1604, 1473,
    1426, 1403, 1384, 1340, 1272, 1233, 1206, 1196, 1163, 1120, 1103 cm−1.
    Ic-72 Mp 223-225° C.; 1H-NMR (d6-DMSO) δ 1.99 (m, 1H), 2.37 (m, 1H), 2.94 (s,
    3H), 3.16 (t, J = 9.0 Hz, 1H), 3.25-3.68 (m, 3H), 3.80 (dd, J = 7.5, 9.0 Hz, 1H),
    4.98 (s, 2H), 7.13 (dd, J = 2.1, 8.7 Hz, 1H), 7.34 (s, 1H), 7.40 (d, J = 8.7 Hz,
    1H), 7.70 (d, J = 2.1 Hz, 1H), 13.00 (br, 1H); IR (Nujol) 3275, 1764, 1744,
    1473, 1426, 1398, 1384, 1381, 1361, 1338, 1305, 1253, 1222, 1202, 1175,
    1150 cm−1; Elemental analysis (C15H17ClN2O4S•0.2AcOEt) Calcd. (%): C,
    50.68; H, 5.01; Cl, 9.47; N, 7.48; S, 8.56 Found (%): C, 50.48; H, 4.83; Cl,
    9.49; N, 7.68; S, 8.52
  • TABLE 53
    Compound
    No. Physical properties
    Ic-73 mp 196-198° C.; 1H-NMR (d6-DMSO) δ 1.76 (m, 1H), 2.19 (m, 1H), 3.07 (m,
    1H), 3.15-3.48 (m, 3H), 3.67 (dd, J = 7.5, 9.3 Hz, 1H), 3.85 (s, 3H), 4.90 (s,
    2H), 7.08-7.16 (m, 2H), 7.13 (d, J = 9.0 Hz, 2H), 7.37 (d, J = 9.0 Hz, 1H),
    7.44 (d, J = 1.8, 1H), 7.77 (d, J = 9.0 Hz, 2H), 12.98 (br, 1H); IR (Nujol) 3083, 3050,
    2667, 2572, 1728, 1593, 1574, 1497, 1473, 1444, 1415, 1381, 1340, 1307,
    1258, 1245, 1194, 1157, 1110 cm−1.
    Ic-74 mp 195-199° C.; 1H-NMR (d6-DMSO) δ 1.98 (m, 1H), 2.33 (m, 1H), 2.94 (s, 3H),
    3.16 (t, J = 9.0 Hz, 1H), 3.25-3.68 (m, 3H), 3.80 (dd, J = 7.5, 9.0 Hz, 1H),
    4.98 (s, 2H), 7.13 (dd, J = 2.1, 8.7 Hz, 1H), 7.34 (s, 1H), 7.40 (d, J = 8.7 Hz, 1H),
    7.70 (d, J = 2.1 Hz, 1H), 13.00 (brs, 1H); IR (Nujol) 3054, 3028, 2645, 2541,
    1716, 1616, 1576, 1494, 1470, 1448, 1408, 1381, 1336, 1301, 1261, 1228,
    1192, 1146, 1111 cm−1; Elemental analysis (C22H22ClN2O4S•0.2AcOEt) Calcd.
    (%): C, 59.20; H, 4.92; Cl, 7.66; N, 6.06; S, 6.93 Found (%): C, 59.32; H, 4.76;
    Cl, 7.41; N, 6.19; S, 6.94
    Ic-75 mp 190-193° C.; 1H-NMR (d6-DMSO) δ 1.83 (m, 1H), 2.24 (m, 1H), 3.16 (m,
    1H), 3.24-3.57 (m, 3H), 3.78 (dd, J = 7.2, 9.6 Hz, 1H), 4.88 (d, J = 18.2 Hz,
    1H), 4.94 (d, J = 18.2 Hz, 1H), 7.11 (dd, J = 1.8, 8.7 Hz, 1H), 7.18 (s, 1H),
    7.37 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 1.8 Hz, 1H), 7.63 (m, 1H), 8.24 (m, 1H),
    8.87 (dd, J = 1.8, 4.8 Hz, 1H), 9.00 (d, J = 1.8 Hz, 1H), 12.99 (brs, 1H); IR
    (Nujol) 3124, 3083, 3056, 2726, 2594, 2516, 1928, 1843, 1778, 1732, 1612,
    1589, 1567, 1553, 1473, 1416, 1357, 1335, 1325, 1273, 1254, 1232, 1210,
    1191, 1173, 1166, 1116 cm−1; Elemental analysis (C19H18ClN3O4S) Calcd. (%):
    C, 54.35; H, 4.32; Cl, 8.44; N, 10.01; S, 7.64 Found (%): C, 54.29; H, 4.31; Cl,
    8.20; N, 9.95; S, 7.43
    Ic-76 mp 105-107° C.; 1H-NMR (d6-DMSO) δ 1.94-2.20 (m, 2H), 2.29 (s, 3H),
    3.30-3.60 (m, 4H), 3.66 (m, 1H), 4.88 (s, 2H), 6.80-7.08 (m, 3H), 7.34 (d, J = 7.8 Hz,
    1H), 7.38 (dd, J = 3.6, 4.8 Hz, 1H), 7.80 (dd, J = 1.2, 3.6 Hz, 1H),
    8.14 (dd, J = 1.2, 5.1 Hz, 1H); IR (Nujol) 2924, 1748, 1693, 1611, 1467, 1376,
    1335, 1292, 1156 cm−1.
    Ic-77 mp 125-126° C.; 1H-NMR (d6-DMSO) δ 1.07 (t, J = 7.2 Hz, 3H), 1.38-1.52 (m,
    2H), 1.64 (m, 2H), 2.13 (m, 1H), 2.31 (m, 1H), 2.31 (s, 3H), 3.13-3.28 (m, 2H),
    3.22-3.80 (m, 5H), 4.92 (s, 2H), 6.94 (m, 2H), 7.35 (d, J = 7.5 Hz, 1H), 7.55 (d,
    J = 7.5 Hz, 1H); IR (Nujol) 3243, 3053, 2924, 1755, 1567, 1418, 1321, 1298,
    1275, 1180, 1143 cm−1; Elemental analysis (C19H26N2O4S) Calcd. (%): C,
    60.29; H, 6.92; N, 7.40; S, 8.47 Found (%): C, 59.80; H, 6.86; N, 7.29; S, 8.51
  • TABLE 54
    Compound
    No. Physical properties
    Ic-78 mp 140-142° C.; 1H-NMR (d6-DMSO) δ 1.84 (m, 1H), 2.28 (m, 1H),
    3.15-3.57 (m, 4H), 3.75 (m, 1H), 4.93 (s, 2H), 7.13 (dd, J = 1.8, 8.7 Hz, 1H), 7.22 (s, 1H),
    7.33 (d, J = 4.2 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 1.8 Hz, 1H),
    7.62 (d, J = 4.2 Hz, 1H), 12.90 (brs, 1H); IR (Nujol) 3091, 2670, 2577, 1726, 1567,
    1513, 1471, 1445, 1414, 1380, 1357, 1332, 1310, 1266, 1249, 1199, 1180,
    1155, 1112 cm−1; Elemental analysis (C18H16Cl2N2O4S2•0.05AcOEt) Calcd.
    (%): C, 47.13; H, 3.56; Cl, 15.29; N, 6.04; S, 13.83 Found (%): C, 46.95; H,
    3.47; Cl, 15.10; N, 6.11; S, 14.02
    Ic-79 mp 220-221° C.; 1H-NMR (d6-DMSO) δ 1.76 (m, 1H), 2.19 (m, 1H), 3.06 (t, J = 9.3 Hz,
    1H), 3.22-3.46 (m, 3H), 3.65 (dd, J = 7.5, 9.3 Hz, 1H), 4.91 (s, 2H),
    6.92-6.96 (m, 2H), 7.11 (dd, J = 2.1, 8.4 Hz, 1H), 7.13 (s, 1H), 7.37 (d, J = 8.4. Hz,
    1H), 7.47 (d, J = 2.1 Hz, 1H), 7.64-7.69 (m, 2H), 10.48 (br, 1H), 12.97 (br,
    1H); IR (Nujol) 3409, 1741, 1712, 1603, 1586, 1500, 1472, 1440, 1319, 1245,
    1151, 1094, 1028 cm−1; Elemental analysis (C20H19ClN2O5S) Calcd. (%): C,
    55.24; H, 4.40; Cl, 8.15; N, 6.44; S, 7.37 Found (%): C, 55.21; H, 4.52; Cl,
    7.62; N, 6.20; S, 7.14
    Ic-80 1H-NMR (CDCl3) δ 1.84-1.89 (m, 2H), 2.04-2.17 (m, 3H), 3.49-3.54 (m, 3H),
    4.88 (m, 1H), 5.12 (m, 1H), 7.09-7.45 (m, 5H), 7.85-8.08 (m, 3H), 8.30 (m,
    1H); IR (KBr) 3387, 1739, 1647, 1591, 1526, 1493, 1467, 1428, 1389, 1343,
    1292, 1236, 1152, 1092, 1066, 1011 cm−1; Elemental analysis
    (C21H19FN2O5S•1.0H2O) Calcd. (%): C, 56.24; H, 4.72; N, 6.25; F, 4.24; S, 7.15
    Found (%): C, 56.18; H, 4.56; N, 6.29; F, 4.11, S, 7.06
    Ic-81 1H-NMR (CDCl3) δ 1.43-1.68 (m, 4H), 2.88 (m, 1H), 3.09 (m, 1H),
    3.34-3.44 (m, 2H), 3.85 (s, 3H), 3.91 (m, 1H), 4.85 (s, 2H), 6.93-6.98 (m, 3H),
    7.20-7.26 (m, 3H), 7.80-7.83 (m, 3H); IR (KBr) 2945, 1728, 1596, 1497, 1468, 1331,
    1260, 1153, 1092, 1024 cm−1; Elemental analysis (C22H24N2O5S•0.5H2O)
    Calcd. (%): C, 60.40; H, 5.76; N, 6.40; S, 7.33 Found (%): C, 60.42; H, 5.78; N,
    6.27; S, 6.97
    Ic-82 1H-NMR (CDCl3) δ 1.86-2.20 (m, 4H), 3.45-3.55 (m, 2H), 4.91 (s, 2H),
    5.06 (m, 1H), 7.04-7.28 (m, 4H), 7.74 (m, 1H), 7.88 (m, 1H), 8.00 (dd, J = 2.4, 6.9 Hz,
    2H), 8.10 (s, 1H); IR (KBr) 3433, 2929, 1738, 1626, 1590, 1528, 1493,
    1394, 1344, 1293, 1233, 1153, 1092, 1062, 1010 cm−1;
    Ic-83 1H-NMR (CDCl3) δ 1.86-2.20 (m, 4H), 3.45-3.55 (m, 2H), 4.91 (s, 2H),
    5.06 (m, 1H), 7.04-7.28 (m, 4H), 7.74 (m, 1H), 7.88 (m, 1H), 8.00 (dd, J = 2.4, 6.9 Hz,
    2H), 8.10 (s, 1H); IR (KBr) 3433, 2929, 1738, 1626, 1590, 1528, 1493,
    1394, 1344, 1293, 1233, 1153, 1092, 1062, 1010 cm−1;
    [α]D 22 + 29.0 ± 0.7° (c = 1.001, MeOH)
    Ic-84 1H-NMR (CDCl3) δ 1.433-1.72 (m, 4H), 2.89 (dd, J = 9.3 and 14.4 Hz, 1H),
    3.10 (m, 1H), 3.27 (dd, J = 3.9 and 14.4 Hz, 1H), 3.41 (m, 1H), 3.87 (m, 1H),
    4.84 (s, 2H), 6.95-7.02 (m, 2H), 7.11-7.26 (m, 3H), 7.40 (dd, J = 2.4 and 9.6 Hz,
    1H), 7.85-7.91 (m, 2H); IR (CHCl3) 1729, 1593, 1493, 1456, 1348, 1292,
    1164, 1154, 1092 cm−1; [α]D 22 + 109.6 ± 1.5 (c = 1.003, MeOH)
  • TABLE 55
    Compound
    No. Physical properties
    Ic-85 1H-NMR (CDCl3) δ 1.43-1.66 (m, 4H), 2.87 (dd, J = 6.0 and 14.1 Hz, 1H),
    3.11 (m, 1H), 3.26 (dd, J = 3.3 and 14.1 Hz, 1), 3.82 (m, 1H), 3.86 (s, 3H), 4.83 (s,
    2H), 6.95-7.01 (m, 4H), 7.11 (dd, J = 3.9 and 8.7 Hz, 1H), 7.40 (dd, J = 2.4
    and 9.3 Hz, 1H), 7.73-7.83 (m, 2H); IR (CHCl3) 1730, 1626, 1597, 1578, 1497,
    1487, 1457, 1338, 1304, 1260, 1155, 1094, 1030 cm−1;
    [α]D 22 + 124.6 ± 1.6 (c = 1.002, MeOH)
    Id-2 mp 220-222° C.; 1H-NMR (CDCl3) δ 2.84 (t, J = 5.7 Hz, 2H), 3.57 (t, J = 5.7 Hz,
    2H), 4.42 (s, 2H), 4.67 (s, 2H), 7.05-7.25 (m, 5H), 7.35-7.43 (m, 1H),
    7.84-7.92 (m, 2H),; IR (CHCl3) 3428, 3048, 2927, 1727, 1595, 1494, 1467,
    1345, 1240, 1169, 1103 cm−1; Elemental analysis (C19H17FN2O4S) Calcd. (%):
    C, 58.75; H, 4.41; F, 4.89; N, 7.21; S, 8.26 Found (%): C, 58.58; H, 4.37; F,
    4.69; N, 7.13; S, 8.08
    Ie-2 mp 139-141° C.; 1H-NMR (CDCl3) δ 4.95 (s, 2H), 7.02-7.11 (m, 3H),
    7.18-7.25 (m, 2H), 7.34 (m, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.68-7.73 (m, 2H), 7.80 (d, J = 1.8 Hz,
    1H), 7.99 (d, J = 7.5 Hz, 1H); IR (Nujol) 3300, 3245, 3047, 1776,
    1736, 1688, 1590, 1493, 1466, 1335, 1285, 1163, 1152 cm−1; Elemental
    analysis (C20H15FN2O4S•0.6CH3CO2C2H5) Calcd. (%): C, 59.62; H, 4.42; F,
    4.21; N, 6.21; S, 7.11 Found (%): C, 59.45; H, 4.19; F, 4.14; N, 6.51; S, 7.02
    Ie-5 mp 188-191° C.; 1H-NMR (CDCl3) δ 3.28 (d, J = 1.5 Hz, 3H), 5.02 (s, 2H),
    7.09-7.33 (m, 6H), 7.49 (t, J = 7.8 Hz, 1H), 7.57-7.61 (m, 2H), 7.73 (d, J = 1.5 Hz,
    1H), 7.97 (d, J = 8.1 Hz, 1H); IR (Nujol) 3102, 3049, 2728, 1727, 1628,
    1591, 1491, 1292, 1228, 1210, 1173, 1150 cm−1; Elemental analysis
    (C21H17FN2O4S•0.2H2O) Calcd. (%): C, 60.63; H, 4.22; F, 4.57; N, 6.73; S, 7.71
    Found (%): C, 60.52; H, 4.13; F, 4.46; N, 6.82; S, 7.63
    Ie-8 mp 212-213° C.; 1H-NMR (d6-DMSO) δ 4.89 (s, 2H), 5.16 (s, 2H), 7.06 (dd, J = 8.4,
    2.1 Hz, 1H), 7.13-7.32 (m, 6H), 7.41-7.52 (m, 5H), 7.73-7.77 (m, 2H),
    7.84 (d, J = 1.8 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 13.05 (br s, 1H); IR (Nujol)
    3063, 3035, 2658, 1705, 1630, 1591, 1232, 1214, 1162 cm−1; Elemental
    analysis (C27H21FN2O4S) Calcd. (%): C, 66.38; H, 4.33; F, 3.89; N, 5.73; S,
    6.56 Found (%): C, 66.33; H, 4.26; F, 3.79; N, 5.80; S, 6.53
    Ie-10 mp 171-175° C.; 1H-NMR (d6-DMSO) δ 5.15 (s, 2H), 6.98-7.07 (m, 2H),
    7.32-7.47 (m, 4H), 7.74-7.81 (m, 3H), 8.05-8.10 (m, 2H), 10.10 (s, 1H); IR (Nujol)
    3621, 3313, 3107, 3070, 2727, 1737, 1702, 1636, 1603, 1592, 1490, 1330,
    1164, 1146 cm−1.
    Ie-11 mp 183-187° C.; 1H-NMR (d6-DMSO) δ 2.13 (s, 3H), 5.14 (s, 2H), 7.00-7.95 (m,
    10H), 9.61 (s, 1H); IR (Nujol) 3517, 3236, 3105, 3068, 2732, 1735, 1635,
    1607, 1591, 1494, 1408, 1335, 1270 cm−1; Elemental
    analysis (C21H17FN2O4S•0.4H2O) Calcd. (%): C, 60.10; H, 4.28; F, 4.53; N,
    6.68; S, 7.64 Found (%): C, 60.28; H, 4.47; F, 4.42 N, 6.54; S, 7.52
  • TABLE 56
    Compound
    No. Physical properties
    Ie-12 mp 201-203° C.; 1H-NMR (CDCl3) δ 3.26 (s, 3H), 4.95 (s, 2H), 6.95-7.02 (m,
    2H), 7.09-7.20 (m, 4H), 7.56-7.61 (m, 2H), 7.72 (m, 1H), 7.89 (m, 1H); IR
    (Nujol) 3106, 3067, 2744, 2657, 2558, 1734, 1635, 1605, 1592, 1495, 1483,
    1340, 1236 cm−1; Elemental analysis (C21H16F2N2O4S•0.2AcOEt) Calcd. (%):
    C, 58.44; H, 3.96; F, 8.48; N, 6.25; S, 7.16 Found (%): C, 58.49; H, 3.72; F,
    8.33 N, 6.37; S, 7.16
    Ie-13 mp 215-218° C.; 1H-NMR (CDCl3 + CD3OD) δ 4.82 (s, 2H), 4.86 (s, 2H),
    6.92-7.02 (m, 3H), 7.14-7.24 (m, 9H), 7.60-7.86 (m, 3H); IR (Nujol) 3066, 3036,
    2656, 1708, 1635, 1605, 1591, 1492, 1483, 1406, 1338, 1232 cm−1; Elemental
    analysis (C27H20F2N2O4S•0.2AcOEt) Calcd. (%): C, 63.70; H, 4.15; F, 7.25; N,
    5.34; S, 6.12 Found (%): C, 63.79; H, 4.04; F, 6.99; N, 5.31; S, 6.11
    Ie-14 mp 219-225° C.; 1H-NMR (CDCl3 + CD3OD) δ 2.56 (s, 3H), 3.24 (s, 3H), 4.95 (s,
    2H), 7.09-7.23 (m, 5H), 7.31 (m, 1H), 7.44 (m, 1H), 7.73-7.77 (m, 3H); IR
    (Nujol) 2742, 2656, 2560, 1727, 1711, 1632, 1605, 1590, 1495, 1483, 1412,
    1339, 1275 cm−1; Elemental analysis (C22H19FN2O4S•0.2AcOEt) Calcd. (%): C,
    61.67; H, 4.68; F, 4.28; N, 6.31; S, 7.22 Found (%): C, 61.82; H, 4.59; F, 4.00;
    N, 6.31; S, 7.14
    Ie-15 mp 194-197° C.; 1H-NMR (CDCl3 + CD3OD) δ 2.13 (s, 3H), 4.36 (d, J = 13.5 Hz,
    1H), 4.90 (s, 2H), 5.09 (d, J = 13.5 Hz, 1H), 7.07 (s, 1H), 7.13-7.24 (m, 10H),
    7.31 (m, 1H), 7.45 (t, J = 7.2 Hz, 1H), 7.73-7.78 (m, 2H); IR (Nujol) 3060,
    3032, 2739, 2644, 2557, 1715, 1633, 1604, 1593, 1494, 1478, 1414, 1342,
    1240 cm−1; Elemental analysis (C28H23FN2O4S•0.2AcOEt) Calcd. (%): C,
    66.50; H, 4.77; F, 3.65; N, 5.39; S, 6.16 Found (%): C, 66.74; H, 4.76; F,
    3.39; N, 5.37; S, 6.04
    Ie-16 mp 164-165° C.; 1H-NMR (d6-DMSO) δ 5.16 (s, 2H), 7.08 (dd, J = 1.8, 9.0 Hz,
    1H), 7.52-7.45 (m, 4H), 7.54 (dd, J = 4.2, 8.7 Hz, 1H), 7.75-7.79 (m, 2H),
    7.86 (d, J = 2.1 Hz, 1H), 7.95 (dd, J = 2.4, 9.3 Hz, 1H), 10.09 (s, 1H); IR (Nujol)
    3301, 3191, 3108, 1778, 1691, 1590, 1496, 1474, 1337, 1286 cm−1.
    Ie-17 mp 187-188° C.; 1H-NMR (CDCl3) δ 3.26 (s, 3H), 4.96 (s, 2H), 7.08-7.21 (m,
    6H), 7.55-7.61 (m, 3H), 7.66 (d, J = 0.9 Hz, 1H); IR (Nujol) 2747, 2650, 2566,
    2483, 1720, 1593, 1492, 1414, 1348, 1295, 1254 cm−1; Elemental analysis
    (C21H16F2N2O4S•0.2AcOEt) Calcd. (%): C, 58.44; H, 3.96; F, 8.48; N, 6.25; S,
    7.16 Found (%): C, 58.55; H, 3.77; F, 8.40; N, 6.23; S, 7.34
    Ie-18 mp 189-191° C.; 1H-NMR (CDCl3 + CD3OD) δ 4.82 (s, 2H), 4.89 (s, 2H),
    7.01 (dd, J = 1.8, 8.7 Hz, 1H), 7.14-7.27 (m, 10H), 7.56 (dd, J = 2.4, 9.0 Hz, 1H),
    7.59 (d, J = 1.8 Hz, 1H), 7.67-7.71 (m, 2H); IR (Nujol) 3089, 3074, 3033,
    2742, 2653, 2558, 1710, 1591, 1343, 1296 cm−1; Elemental analysis
    (C27H20F2N2O4S•0.1AcOEt) Calcd. (%): C, 63.86; H, 4.07; F, 7.37; N, 5.44; S,
    6.22 Found (%): C, 63.84; H, 3.95; F, 7.14; N, 5.31; S, 6.33
  • TABLE 57
    Compound
    No. Physical properties
    Ie-19 Mp 189-191° C.; 1H-NMR (d6-DMSO) δ 5.19 (s, 2H), 6.99 (m, 1H), 7.21 (dd, J = 2.1,
    9.0 Hz, 1H), 7.33-7.46 (m, 4H), 7.51 (d, J = 9.0 Hz, 1H), 7.75-7.79 (m,
    3H), 10.15 (s, 1H); IR (Nujol) 3262, 3103, 3061, 2661, 2558, 1715, 1640,
    1611, 1590, 1484, 1406, 1331, 1294 cm−1; Elemental analysis
    (C20H14F2N2O4S•0.1AcOEt) Calcd. (%): C, 57.62; H, 3.51; F, 8.94; N, 6.59; S,
    7.54 Found (%): C, 57.43; H, 3.26; F, 8.65; N, 6.46; S, 7.34
    Ie-20 Mp 214-217° C.; 1H-NMR (CDCl3) δ 3.27 (s, 3H), 5.00 (s, 2H), 6.92 (dd, J = 8.1,
    9.9 Hz, 1H), 7.06-7.17 (m, 3H), 7.23 (d, J = 8.7 Hz, 1H), 7.32 (dd, J = 2.1,
    8.7 Hz, 1H), 7.39 (m, 1H), 7.56-7.63 (m, 2H), 7.70 (d, J = 1.8 Hz, 1H); IR
    (Nujol) 3087, 2748, 2651, 2568, 2486, 1723, 1637, 1592, 1493, 1308, 1236 cm−1;
    Elemental analysis (C21H16F2N2O4S•0.1AcOEt) Calcd. (%): C, 58.52; H,
    3.86; F, 8.65; N, 6.38; S, 7.30 Found (%): C, 58.64; H, 3.61; F, 8.37; N, 6.39;
    S, 7.21
    Ie-21 Mp 209-213° C.; 1H-NMR (CDCl3 + CD3OD) δ 4.82 (s, 2H), 4.91 (s, 2H),
    6.90 (dd, J = 8.1, 9.9 Hz, 1H), 7.08-7.13 (m, 2H), 7.15-7.28 (m, 8H), 7.38 (m, 1H),
    7.65 (d, J = 1.8 Hz, 1H), 7.68-7.73 (m, 2H); IR (Nujol) 3063, 3033, 2659,
    1708, 1641, 1610, 1590, 1492, 1241 cm−1; Elemental analysis
    (C27H20F2N2O4S•0.1AcOEt) Calcd. (%): C, 63.86; H, 4.07; F, 7.37; N, 5.44; S,
    6.22 Found (%): C, 63.77; H, 3.90; F, 7.21; N, 5.45; S, 6.18
    Ie-22 mp 153-156° C.; 1H-NMR (CDCl3 + CD3OD) δ 5.13 (s, 2H), 6.92 (dd, J = 1.8,
    10.4 Hz, 1H), 7.04-7.12 (m, 2H), 7.25 (td, J = 0.6, 15.0 Hz, 1H), 7.32 (d, J = 8.4 Hz,
    1H), 7.49 (td, J = 1.2, 7.7 Hz, 1H), 7.55 (d, J = 1.8 Hz, 1H),
    7.72-7.77 (m, 2H), 7.96 (d, J = 7.5 Hz, 1H); IR (Nujol) 3236, 3109, 3073,, 3050, 2725,
    1761, 1732, 1641, 1610, 1591, 1497, 1375, 1288 cm−1; Elemental analysis
    (C20H14F2N2O4S•0.2AcOEt) Calcd. (%): C, 57.56; H, 3.62; F, 8.75; N, 6.45; S,
    7.39 Found (0%): C, 57.27; H, 3.39; F, 8.82; N, 6.58; S, 7.49
    Ie-23 1H-NMR (CDCl3) δ 3.25 (s, 3H), 5.22 (s, 2H), 6.91 (dd, J = 2.1, 12.9 Hz, 1H),
    7.09-7.16 (m, 2H), 7.28-7.33 (m, 2H), 7.48-7.54 (m, 2H), 7.56-7.62 (m, 2H),
    7.94 (d, J = 7.8 Hz, 1H); IR (Nujol) 3505, 3103, 3052, 2729, 2648, 1728, 1639,
    1589, 1494, 1297, 1238 cm−1; Elemental analysis (C21H16F2N2O4S•0.3H2O)
    Calcd. (%): C, 57.87; H, 3.84; F, 8.72; N, 6.43; S, 7.36 Found (%): C, 57.99; H,
    3.79; F, 8.55; N, 6.43; S, 7.07
    Ie-24 mp 199-201° C.; 1H-NMR (CDCl3 + CD3OD) δ 4.80 (s, 2H), 5.13 (s, 2H),
    6.76 (dd, J = 2.1, 13.2 Hz, 1H), 7.17-7.28 (m, 8H), 7.32 (d, J = 8.4 Hz, 1H), 7.44 (d,
    J = 2.1 Hz, 1H), 7.49 (m, 1H), 7.67-7.74 (m, 2H), 7.89 (d, J = 7.5 Hz, 1H); IR
    (Nujol) 3087, 3062, 3032, 2644, 2560, 2470, 1714, 1638, 1585, 1493, 1300,
    1249 cm−1; Elemental analysis (C27H20F2N2O4S•0.1AcOEt) Calcd. (%): C,
    63.86; H, 4.07; F, 7.37; N, 5.44; S, 6.22 Found (%): C, 64.07; H, 3.90; F, 7.17;
    N, 5.52; S, 6.10
  • TABLE 58
    Compound
    No. Physical properties
    Ie-25 mp 204-206° C.; 1H-NMR (CDCl3) δ 3.27 (s, 3H), 5.22 (s, 2H), 7.09-7.22 (m,
    6H), 7.56-7.61 (m, 2H), 7.71-7.74 (m, 2H); IR (Nujol) 3327, 3085, 3046, 2680,
    1774, 1637, 1592, 1578, 1339, 1242 cm−1; Elemental analysis
    (C21H16F2N2O4S•0.1AcOEt) Calcd. (%): C, 58.52; H, 3.86; F, 8.65; N, 6.38; S,
    7.30 Found (%): C, 58.60; H, 3.70; F, 8.51; N, 6.44; S, 7.46
    Ie-26 mp 194-197° C.; 1H-NMR (CDCl3) δ 4.81 (s, 2H), 5.13 (s, 2H), 7.00 (dd, J = 2.1,
    8.7 Hz, 1H), 7.07-7.25 (m, 11H), 7.62-7.69 (m, 3H); IR (Nujol) 3093,
    3066, 3040, 3023, 2657, 2561, 1722, 1593, 1581, 1493, 1294, 1236 cm−1;
    Elemental analysis (C27H20F2N2O4S) Calcd. (%): C, 64.02; H, 3.98; F, 7.50; N,
    5.53; S, 6.33 Found (%): C, 64.00; H, 3.98; F, 7.26; N, 5.49; S, 6.13
    Ie-27 mp 190-191° C.; 1H-NMR (CDCl3 + CD3OD) δ 4.92 (s, 2H), 7.03-7.09 (m, 2H),
    7.13-7.23 (m, 3H), 7.54 (dd, J = 1.8, 8.7 Hz, 1H), 7.68-7.73 (m, 3H), 8.10 (d, J = 1.8 Hz,
    1H); IR (Nujol) 3263, 3102, 3060, 2657, 1715, 1591, 1487, 1406,
    1335, 1286 cm−1.
    Ie-28 mp 200-202° C.; 1H-NMR (CDCl3 + CD3OD) δ 3.28 (s, 3H), 4.95 (s, 2H),
    7.11-7.29 (m, 5H), 7.54-7.61 (m, 3H), 7.69 (d, J = 1.8 Hz, 1H), 8.09 (d, J = 2.1 Hz);
    IR (Nujol) 3066, 2744, 2658, 2565, 1731, 1454, 1444, 1293, 1247, 1224 cm−1;
    Elemental analysis (C21H16BrFN2O4S•0.4AcOEt) Calcd. (%): C, 51.55; H,
    3.68; Br, 15.17; F, 3.61; N, 5.32; S, 6.09 Found (%): C, 51.74; H, 3.13; Br,
    14.82; F, 3.66; N, 5.60; S, 6.28
    If-1  1H-NMR (CDCl3) δ 1.56 (s, 6H), 2.43 (s, 3H), 3.20 (d, J = 5.7 Hz, 2H), 4.21 (t,
    J = 5.7 Hz, 1H), 4.82 (s, 2H), 6.85-6.98 (m, 3H), 7.13-7.15 (m, 2H), 7.35 (d, J = 8.1 Hz,
    1H), 7.49-7.53 (m, 2H); IR (KBr) 3505, 1728, 1594, 1495, 1478,
    1468, 1406, 1340, 1292, 1166, 1154, 1092, 1076 cm−1; Elemental analysis
    (C21H23FN2O4S•0.6H2O) Calcd. (%): C, 58.75; H, 5.68; N, 6.53; F, 4.43; S, 7.47
    Found (%): C, 58.83; H, 5.73; N, 6.32; F, 4.29, S, 7.24
    If-2  1H-NMR (CDCl3) δ 1.68 (s, 6H), 2.28 (s, 3H), 2.52 (s, 3H), 3.40 (s, 2H),
    4.83 (s, 2H), 7.05 (m, 1H), 7.13-7.18 (m, 4H), 7.71-7.77 (m, 3H); IR (CHCl3) 2976,
    2930, 1729, 1594, 1495, 1479, 1467, 1393, 1342, 1293, 1166, 1155, 1089,
    1015 cm−1; Elemental analysis (C22H25FN2O4S•0.2H2O) Calcd. (%): C, 60.59;
    H, 5.87; N, 6.42; F, 4.36; S, 7.35 Found (%): C, 60.57; H, 6.01; N, 6.31; F,
    4.26, S, 7.15
    If-3  1H-NMR (CDCl3) δ 1.58 (s, 6H), 2.10 (s, 3H), 3.71 (s, 2H), 3.96 (s, 2H),
    4.56 (s, 2H), 6.47 (d, J = 7.2 Hz, 2H), 6.95-7.15 (m, 8H), 7.56 (d, J = 8.4 Hz, 1H),
    7.72-7.77 (m, 2H); IR (CHCl3) 1729, 1594, 1495, 1479, 1467, 1342, 1292,
    1239, 1165, 1154, 1091, 1056 cm−1; Elemental analysis
    (C28H29FN2O4S•0.2MeOH) Calcd. (%): C, 65.77; H, 5.83; N, 5.44; F, 3.69; S,
    6.23 Found (%): C, 66.15; H, 5.98; N, 5.23; F, 3.40, S, 5.87
  • TABLE 59
    Compound
    No. Physical properties
    If-4 1H-NMR (CDCl3) δ 1.38 (d, J = 6.6 Hz, 3H), 2.29 (s, 3H), 3.07-3.36 (m, 3H),
    4.29 (d, J = 9.0 Hz, 1H), 4.81 (d, J = 5.1 Hz, 2H), 6.91-7.27 (m, 6H),
    7.54-7.59 (m, 2H); IR (CHCl3) 2976, 2930, 1729, 1594, 1495, 1479, 1467, 1393, 1342,
    1293, 1166, 1155, 1089, 1015 cm−1; Elemental analysis
    (C20H21FN2O4S•1.2MeOH) Calcd. (%): C, 57.49; H, 5.87; N, 6.32; F, 4.29; S,
    7.24 Found (%): C, 57.55; H, 5.65; N, 6.14; F, 4.22, S, 7.23
    If-5 1H-NMR (CDCl3) δ 1.48 (d, J = 6.9 Hz, 3H), 2.35 (s, 3H), 2.57 (s, 3H), 3.02 (m,
    1H), 3.36 (m, 1H), 3.65 (m, 1H), 4.82 (s, 2H), 7.04-7.17 (m, 5H), 7.58 (d, J = 8.7 Hz,
    1H), 7.68-7.73 (m, 2H); IR (CHCl3) 2976, 2930, 1729, 1594, 1495,
    1479, 1467, 1393, 1342, 1293, 1166, 1155, 1089, 1015 cm−1
    If-6 1H-NMR (CDCl3) δ 1.31 (d, J = 6.6 Hz, 3H), 2.17 (s, 3H), 3.15-3.23 (m, 2H),
    3.70 (q, J = 6.6 Hz, 1H), 4.17 (s, 2H), 4.76 (s, 2H), 6.96-7.23 (m, 10H), 7.40 (d,
    J = 7.8 Hz, 1H), 7.69-7.74 (m, 2H); IR (CHCl3) 2974, 2932, 2876, 1731, 1594,
    1496, 1468, 1409, 1339, 1292, 1240, 1165, 1153, 1089, 1022 cm−1; Elemental
    analysis (C27H27FN2O4S•1.1MeOH) Calcd. (%): C, 63.70; H, 5.97; N, 5.29; F,
    3.59; S, 6.05 Found (%): C, 64.02; H, 5.78; N, 5.20; F, 3.42, S, 5.70
    If-7 1H-NMR (CDCl3) δ 1.73-1.85 (m, 4H), 2.02-2.23 (m, 4H), 3.30 (s, 2H), 4.86 (s,
    1H), 6.91 (s, 1H), 7.04-7.21 (m, 5H), 7.60 (d, J = 8.1 Hz, 1H), 7.70-7.75 (m,
    2H); IR (CHCl3) 2961, 2874, 1594, 1494, 1468, 1340, 1292, 1240, 1155, 1089 cm−1;
    Elemental analysis (C23H25FN2O4S•0.2H2O) Calcd. (%): C, 61.65; H,
    5.71; N, 6.25; F, 4.24; S, 7.16 Found (%): C, 61.74; H, 5.93; N, 5.96; F, 3.93,
    S, 6.95
    If-8 1H-NMR (CDCl3) δ 1.65-1.80 (m, 4H), 2.00-2.09 (m, 4H), 3.64 (s, 2H), 3.80 (s,
    2H), 4.58 (s, 2H), 6.47 (s, 1H), 6.54 (d, J = 7.8 Hz, 2H), 6.97-7.15 (m, 7H),
    7.37-7.45 (m, 2H), 7.67-7.72 (m, 2H); IR (CHCl3) 2960, 2874, 1731, 1592,
    1495, 1468, 1339, 1292, 1239, 1165, 1154, 1092, 1022 cm−1.
    If-9 mp 117-120° C.; 1H-NMR (CDCl3) δ 3.50-3.69 (m, 2H), 4.34 (t, J = 7.5 Hz,
    1H), 4.58 (br t, J = 6.0 Hz, 1H), 4.80 (d, J = 18.3 Hz, 1H), 4.81 (d, J = 18.3 Hz,
    1H), 6.84 (s, 1H), 7.01 (m, 1H), 7.08 (t, J = 9.0 Hz, 2H), 7.17-7.30 (m,
    8H), 7.72 (dd, J = 5.1 9.0 Hz, 2H); IR (Nujol) 3351, 3295, 3063, 1727, 1706,
    1614, 1592, 1494, 1468, 1406, 1331, 1241, 1165, 1152 cm−1; Elemental
    analysis (C24H21FN2O4S•0.4AcOEt) Calcd. (%): C, 63.04; H, 5.00; N, 5.74; F,
    3.90; S, 6.57 Found (%): C, 62.73; H, 4.75; N, 5.77; F, 3.91; S, 6.58
  • TABLE 60
    Compound
    No. Physical properties
    If-10 mp 167-170° C.; 1H-NMR (CDCl3) δ 2.61 (s, 3H), 3.36 (dd, J = 7.8, 13.5 Hz,
    1H), 3.93 (dd, J = 7.8, 13.5 Hz, 1H), 4.55 (t, J = 7.8 Hz, 1H), 4.87 (s, 2H),
    7.06 (m, 1H), 7.10 (s, 1H), 7.13 (t, J = 9.0 Hz, 2H), 7.20-7.31 (m, 7H), 7.43 (br d, J = 8.1 Hz,
    1H), 7.70 (dd, J = 5.1, 9.0 Hz, 2H); IR (Nujol) 3429, 3030, 1722,
    1704, 1592, 1493, 1469, 1406, 1332, 1237, 1150, 1087 cm−1; Elemental
    analysis (C25H23FN2O4S) Calcd. (%): C, 64.36; H, 4.97; N, 6.00; F, 4.07; S,
    6.87 Found (%): C, 64.28; H, 4.93; N, 5.91; F, 3.85; S, 6.73
    If-11 1H-NMR (CDCl3) δ 2.00-2.41 (m, 6H), 3.30 (d, J = 6.0 Hz, 2H), 4.21 (t, J = 5.7 Hz,
    1H), 4.84 (s, 2H), 6.82-6.98 (m, 4H), 7.13-7.27 (m, 3H), 7.45-7.50 (m, 2H);
    IR (CHCl3) 2984, 2934, 2875, 1731, 1594, 1496, 1468, 1408, 1333, 1292,
    1240, 1167, 1154 cm−1; Elemental analysis (C21H21FN2O4S•0.4H2O) Calcd.
    (%): C, 59.53; H, 5.19; N, 6.61; F, 4.48; S, 7.57 Found (%): C, 59.49; H, 5.23;
    N, 6.35; F, 4.20, S, 7.34
    If-12 1H-NMR (CDCl3) δ 1.91-1.95 (m, 2H), 2.25-2.42 (m, 4H), 3.74 (s, 2H), 3.92 (s,
    2H), 4.70 (s, 2H), 6.53 (s, 1H), 6.67 (d, J = 8.1 Hz, 2H), 6.97-7.38 (m, 9H),
    7.62-7.67 (m, 2H); IR (CHCl3) 2932, 1731, 1593, 1495, 1468, 1333, 1292,
    1239, 1163, 1153, 1089 cm−1; Elemental analysis (C28H27FN2O4S•0.8H2O)
    Calcd. (%): C, 64.55; H, 5.53; N, 5.38; F, 3.65; S, 6.15 Found (%): C, 64.61; H,
    5.27; N, 5.08; F, 3.35, S, 5.87
    If-13 1H-NMR (CDCl3) δ 1.43 (s, 6H), 3.17 (d, J = 5.7 Hz, 2H), 4.20 (t, J = 6.0 Hz,
    1H), 4.83 (s, 2H), 6.85 (s, 1H), 6.90-6.97 (m, 3H), 7.21 (d, J = 3.6 Hz, 2H),
    7.32 (d, J = 8.4 Hz, 1H), 7.49-7.54 (m, 2H); IR (CHCl3) 2971, 2933, 2878,
    1731, 1594, 1496, 1467, 1408, 1386, 1331, 1292, 1239, 1194, 1167, 1154,
    1092, 1076 cm−1; Elemental analysis (C20H21FN2O4S•0.5H2O) Calcd. (%): C,
    58.10; H, 5.36; N, 6.78; F, 4.59; S, 7.76 Found (%): C, 58.05; H, 5.31; N, 6.55;
    F, 4.34, S, 7.58
    If-14 1H-NMR (CDCl3) δ 1.54 (s, 3H), 2.26 (s, 3H), 3.37 (s, 2H), 4.86 (s, 2H),
    6.89 (s, 1H), 7.07-7.22 (m, 5H), 7.69-7.77 (m, 3H); IR (CHCl3) 2974, 2929, 1731,
    1594, 1495, 1480, 1467, 1340, 1292, 1240, 1166, 1155, 1089, 1020 cm−1;
    Elemental analysis (C21H23FN2O4S•0.3H2O) Calcd. (%): C, 59.50; H, 5.61; N,
    6.61; F, 4.48; S, 7.56 Found (%): C, 59.59; H, 5.62; N, 6.39; F, 4.26, S, 7.42
    If-15 1H-NMR (CDCl3) δ 1.47 (s, 3H), 3.67 (s, 2H), 3.96 (s, 2H), 4.61 (s, 2H),
    6.51-6.54 (m, 3H), 6.95-7.15 (m, 7H), 7.37 (d, J = 4.8 Hz, 1H), 7.48 (d, J = 8.4 Hz,
    1H), 7.71-7.76 (m, 2H); IR (CHCl3) 2972, 2931, 1731, 1594, 1495, 1468, 1339,
    1292, 1239, 1165, 1154, 1091, 1056 cm−1.
  • TABLE 61
    Compound
    No. Physical properties
    If-16 1H-NMR (CDCl3) δ 2.91 (t, J = 6.3 Hz, 2H), 3.34-3.49 (m, 2H), 4.63 (t, J = 6.0 Hz,
    1H), 4.80 (s, 2H), 6.92-7.15 (m, 5H), 7.48-7.53 (m, 2H); IR (KBr) 3285,
    2232, 1729, 1627, 1582, 1488, 1414, 1324, 1250, 1159, 1092, 1047 cm−1;
    Elemental analysis (C16H15FN2O4S2•0.3H2O) Calcd. (%): C, 49.55; H, 4.05; N,
    7.22; F, 4.90; S, 16.54 Found (%): C, 49.89; H, 3.98; N, 6.98; F, 4.54, S, 16.12
    If-17 1H-NMR (CDCl3) δ 1.42 (s, 6H), 3.12 (s, 3H), 3.45 (br, 1H), 4.79 (s, 2H),
    6.90-7.24 (m, 6H), 7.51-7.56 (m, 2H); IR (KBr) 3283, 2966, 2926, 1736, 1590,
    1494, 1474, 1409, 1337, 1320, 1293, 1242, 1167, 1153 cm−1; Elemental
    analysis (C20H20ClFN2O4S•0.3H2O) Calcd. (%): C, 54.07; H, 4.67, N, 6.30; Cl,
    7.98; F, 4.28; S, 7.22 Found (%): C, 54.06; H, 4.65; N, 6.26; Cl, 7.79; F, 4.13,
    S, 7.12
    If-18 1H-NMR (CDCl3) δ 1.52 (s, 6H), 2.22 (s, 3H), 3.32 (s, 2H), 4.83 (s, 2H),
    6.92 (s, 1H), 7.14-7.21 (m, 4H), 7.63 (s, 1H), 7.74-7.78 (m, 2H); IR (CHCl3) 2974,
    2929, 1731, 1594, 1495, 1474, 1341, 1292, 1240, 1167, 1155, 1089, 1020 cm−1;
    Elemental analysis (C21H22ClFN2O4S•0.3H2O) Calcd. (%): C, 55.03; H, 4.97;
    N, 6.11; Cl, 7.74; F, 4.15; S, 7.00 Found (%): C, 55.36; H, 5.13; N, 5.90; Cl,
    7.34; F, 3.93; S, 7.00
    If-19 1H-NMR (CDCl3) δ 1.44 (s, 6H), 3.63 (s, 2H), 3.95 (s, 2H), 4.59 (s, 2H),
    6.43 (d, J = 7.8 Hz, 2H), 6.57 (s, 1H), 6.94-7.17 (m, 5H), 7.33-7.38 (m, 3H),
    7.75-7.80 (m, 2H); IR (CHCl3) 1732, 1594, 1495, 1475, 1341, 1292, 1165, 1154,
    1091, 1056 cm−1.
    If-20 1H-NMR (CDCl3) δ 3.05-3.10 (m, 2H), 3.51-3.56 (m, 2H), 4.44 (s, 2H), 5.00 (s,
    2H), 7.07-7.13 (m, 3H), 7.24-7.44 (m, 8H), 7.70-7.82 (m, 2H); IR (KBr) 1736,
    1622, 1589, 1509, 1492, 1455, 1320, 1230, 1162, 1148, 1096 cm−1; Elemental
    analysis (C24H22FN3O4S) Calcd. (%): C, 61.66; H, 4.74; N, 8.99; F, 4.06; S,
    6.86 Found (%): C, 61.53; H, 4.72; N, 8.91; F, 3.91, S, 6.53
    Ig-1  mp 217-219° C.; 1H-NMR (d6-DMSO) δ 2.36-2.79 (m, 6H), 4.80 (s, 2H),
    6.71 (dd, J = 2.1, 8.4 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H),
    7.31-7.37 (m, 2H), 7.69-7.74 (m, 2H), 9.83 (s, 1H), 13.00 (br, 1H); IR (Nujol)
    2926, 1725, 1592, 1492, 1476, 1347, 1237, 1149 cm−1; IR (Nujol) 3207, 2925,
    2853, 1738, 1587, 1464, 1150 cm−1; Elemental analysis (C19H17FN2O4S)
    Calcd. (%): C, 58.75; H, 4.41; F, 4.89; N, 7.21; S, 8.26 Found (%): C, 58.71; H,
    4.39; F, 4.65; N, 7.07; S, 8.03
    Ig-2  mp 223-226° C.; 1H-NMR (d6-DMSO) δ 2.80-2.88 (m, 2H), 2.94-3.00 (m, 2H),
    3.69 (s, 2H), 4.85 (s, 2H), 6.75 (dd, J = 1.8, 8.4 Hz, 1H), 7.12 (d, J = 1.8 Hz,
    1H), 7.23 (d, J = 8.4 Hz, 1H), 7.29-7.39 (m, 2H), 7.68-7.77 (m, 2H), 9.96 (br s,
    1H); IR (Nujol) 3228, 3105, 3070, 3047, 2924, 2854, 1734, 1590, 1467, 1332,
    1226, 1182, 1167, 1151 cm−1; Elemental analysis (C19H17FN2O4S2•0.3AcOEt)
    Calcd. (%): C, 54.28; H, 4.18; F, 4.43; N, 6.53; S, 14.94 Found (%): C, 54.05;
    H, 3.98; F, 4.29; N, 6.55; S, 14.92
  • TABLE 62
    Compound
    No. Physical properties
    Ig-3 mp 214-217° C.; 1H-NMR (d6-DMSO) δ 2.81-2.92 (m, 2H), 2.93-3.03 (m, 2H),
    3.17 (s, 3H), 3.70 (s, 2H), 4.92 (s, 2H), 6.72 (dd, J = 2.1, 8.7 Hz, 1H), 7.12 (d, J = 2.1 Hz,
    1H), 7.33 (d, J = 8.7 Hz, 1H), 7.38-7.48 (m, 2H), 7.56-7.64 (m, 2H),
    13.08 (br, 1H); IR (Nujol) 3103, 2923, 2742, 2656, 2554, 1724, 1591, 1478,
    1342, 1239, 1169, 1147 cm−1
    Ig-4 mp 218-220° C.; 1H-NMR (d6-DMSO) δ 2.05-2.18 (m, 2H), 2.43 (t, J = 6.3 Hz,
    2H), 2.90 (t, J = 6.0 Hz, 2H), 3.18 (s, 3H), 5.09 (s, 2H), 6.91 (dd, J = 2.1, 8.7 Hz,
    1H), 7.38-7.45 (m, 2H), 7.49 (d, J = 8.7 Hz, 1H), 7.57-7.62 (m, 2H),
    7.66 (d, J = 2.1 Hz, 1H); IR (Nujol) 3501, 3335, 2925, 2854, 1714, 1631, 1592,
    1473, 1454, 1343, 1265, 1239, 1172, 1152 cm−1; Elemental analysis
    (C21H19FN2O5S•H2O) Calcd. (%): C, 56.24; H, 4.72; F, 4.24; N, 6.25; S, 7.15
    Found (%): C, 56.18; H, 4.72; F, 4.14; N, 6.15; S, 7.07
    Ig-5 mp 220-222° C.; 1H-NMR (d6-DMSO) δ 0.94 (t, J = 7.5 Hz, 2H), 1.40-1.57 (m,
    1H), 1.72-2.00 (m, 2H), 2.19-2.40 (m, 2H), 2.80-3.06 (m, 2H), 3.18 (s, 3H),
    5.08 (s, 2H), 6.90 (dd, J = 2.1, 8.7 Hz, 1H), 7.38-7.45 (m, 2H), 7.48 (d, J = 8.7 Hz,
    1H), 7.57-7.62 (m, 2H), 7.68 (d, J = 2.1 Hz, 1H), 13.30 (br, 1H); IR (Nujol)
    2924, 2854, 1733, 1593, 1534, 1477, 1464, 1353, 1206, 1172 cm−1; Elemental
    analysis (C23H23FN2O5S) Calcd. (%): C, 60.25; H, 5.06; F, 4.14; N, 6.11; S,
    6.99 Found (%): C, 60.04; H, 5.15; F, 3.90; N, 6.07; S, 6.78
    Ig-6 mp 128-130° C.; 1H-NMR (d6-DMSO) δ 1.22 (t, J = 6.0 Hz, 3H), 2.67 (br t, 2H),
    3.72 (t, J = 6.0 Hz, 2H), 4.09 (q, J = 7.2 Hz, 2H), 4.47 (s, 2H), 4.84 (s, 2H),
    6.77 (dd, J = 1.8, 8.4 Hz, 1H), 7.07 (s, 1H), 7.26 (d, J = 9.0 Hz, 1H),
    7.31-7.37 (m, 2H), 7.70-7.75 (m, 2H), 9.88 (s, 1H), 13.00 (br 1H); IR (Nujol) 3187, 2925,
    2854, 1764, 1678, 1585, 1468, 1448, 1269, 1235, 1171, 1158 cm−1.
    Ig-7 mp 200-202° C.; 1H-NMR (d6-DMSO) δ 1.22 (t, J = 7.2 Hz, 3H), 2.71 (br t, 2H),
    3.18 (s, 3H), 3.74 (br t, 2H), 4.09 (q, J = 7.2 Hz, 2H), 4.49 (s, 2H), 4.92 (s, 2H),
    6.79 (dd, J = 1.8, 9.0 Hz, 1H), 7.10 (br, 1H), 7.35 (d, J = 8.4 Hz, 1H),
    7.39-7.45 (m, 2H), 7.56-7.62 (m, 2H), 13.00 (br 1H); IR (Nujol) 2925, 2854, 1697,
    1677, 1476, 1340, 1238, 1147 cm−1; Elemental analysis
    (C23H24FN3O6S•0.4H2O) Calcd. (%): C, 55.61; H, 5.03; F, 3.82; N, 8.46; S, 6.46
    Found (%): C, 55.58; H, 5.10; F, 3.71; N, 8.39; S, 6.41
    Ig-8 mp 229-232° C.; 1H-NMR (d6-DMSO) δ 1.22 (t, J = 6.9 Hz, 3H), 2.67 (br t, 2H),
    3.72 (t, J = 6.0 Hz, 2H), 3.77 (s, 3H), 4.06 (q, J = 7.2 Hz, 2H), 4.47 (s, 2H),
    4.85 (s, 2H), 6.69 (dd, J = 2.1, 8.7 Hz, 1H), 7.07 (d, J = 2.1 Hz, 1H),
    6.99-7.03 (m, 2H), 7.23 (d, J = 8.7 Hz, 1H), 7.59-7.63 (m, 2H); IR (Nujol) 3309, 3218,
    2925, 2853, 1741, 1644, 1598, 1491, 1259, 1247, 1155 cm−1.
  • TABLE 63
    Compound
    No. Physical properties
    Ig-9  mp 232-234° C.; 1H-NMR (d6-DMSO) δ 1.22 (t, J = 6.9 Hz, 3H), 2.71 (br t, 2H),
    3.13 (s, 3H), 3.74 (t, J = 5.7 Hz, 2H), 3.85 (s, 3H), 4.09 (q, J = 6.9 Hz, 2H),
    4.49 (s, 2H), 4.92 (s, 2H), 6.79 (dd, J = 1.8, 8.7 Hz, 1H), 7.08-7.11 (m, 3H),
    7.34 (d, J = 8.7 Hz, 1H), 7.43-7.47 (m, 2H); IR (Nujol) 3143, 2925, 2854,
    1722, 1690, 1598, 1497, 1472, 1229, 1163 cm−1; Elemental analysis
    (C24H27N3O7S) Calcd. (%): C, 57.47; H, 5.43; N, 8.38; S, 6.39 Found (%): C,
    57.48; H, 5.41; N, 8.28; S, 6.23
    Ig-10 mp 245-250° C.; 1H-NMR (d6-DMSO at 80° C.) δ 2.11 (s, 3H), 2.78 (br, 2H),
    3.14 (s, 3H), 3.80 (br, 2H), 3.85 (s, 3H), 4.55 (s, 2H), 4.85 (s, 2H), 6.80 (br d, J = 8.7 Hz,
    1H), 7.05-7.08 (m, 3H), 7.28 (d, J = 8.7 Hz, 1H), 7.47-7.51 (m, 2H); IR
    (Nujol) 2923, 2853, 1737, 1596, 1474, 1340, 1259, 1162 cm−1.
    Ig-11 mp 209-211° C.; 1H-NMR (d6-DMSO) δ 1.60-1.90 (m, 6H), 2.60-2.76 (m, 4H),
    4.87 (s, 2H), 6.69 (dd, J = 1.8, 8.7 Hz, 1H), 7.05 (d, J = 1.8 Hz, 1H), 7.17 (d, J = 8.7 Hz,
    1H), 7.31-7.38 (m, 2H), 7.70-7.75 (m, 2H), 9.80 (s, 1H), 12.90 (br,
    1H); IR (Nujol) 3220, 2922, 2854, 1733, 1593, 1482, 1323, 1194, 1149 cm−1;
    Elemental analysis (C21H21FN2O4S) Calcd. (%): C, 60.56; H, 5.08; F, 4.56; N,
    6.73; S, 7.70 Found (%): C, 60.48; H, 4.92; F, 4.32; N, 6.68; S, 7.56
    Ig-12 mp 157-160° C.; 1H-NMR (CDCl3) δ 1.70-1.93 (m, 6H), 2.66-2.79 (m, 4H),
    3.22 (s, 3H), 4.83 (s, 2H), 6.80 (dd, J = 1.8, 8.7 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H),
    7.08-7.16 (m, 3H), 7.57-7.63 (m, 2H); IR (Nujol) 2923, 2853, 1725, 1592,
    1480, 1346, 1235, 1148 cm−1; Elemental analysis (C22H23FN2O4S) Calcd. (%):
    C, 61.38; H, 5.39; F, 4.41; N, 6.51; S, 7.45 Found (%): C, 60.98; H, 5.42; F,
    4.10; N, 6.41; S, 7.43
    Ig-13 mp 155-157° C.; 1H-NMR (CDCl3) δ 1.60-1.92 (m, 6H), 2.60-2.74 (m, 4H),
    4.76 (s, 4H), 6.66 (dd, J = 1.8, 8.7 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 1.8 Hz,
    1H), 7.09-7.28 (m, 7H), 7.65-7.70 (m, 2H); IR (Nujol) 2923, 2854, 1726,
    1593, 1479, 1346, 1241, 1167, 1153 cm−1; Elemental analysis (C28H27FN2O4S)
    Calcd. (%): C, 66.39; H, 5.37; F, 3.75; N, 5.53; S, 6.33 Found (%): C, 66.39; H,
    5.40; F, 3.53; N, 5.51; S, 6.09
    Ig-14 mp 144-150° C.; 1H-NMR (d6-DMSO) δ 1.61-1.76 (m, 4H), 1.78-1.90 (m, 2H),
    2.60-2.76 (m, 4H), 3.13 (s, 3H), 3.84 (s, 3H), 4.93 (s, 2H), 6.64 (dd, J = 1.8, 8.4 Hz,
    1H), 7.02 (d, J = 1.8 Hz, 1H), 7.07-7.0 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H),
    7.45-7.49 (m, 2H); IR (Nujol) 2926, 2853, 1727, 1596, 1496, 1477, 1353,
    1256, 1243, 1162, 1151 cm−1; Elemental analysis (C23H26N2O5S) Calcd. (%):
    C, 62.42; H, 5.92; N, 6.33; S, 7.25 Found (%): C, 62.72; H, 5.83; N, 6.18; S,
    7.08
  • TABLE 64
    Compound
    No. Physical properties
    Ig-15 mp 151-155° C.; 1H-NMR (d6-DMSO) δ 0.97 (t, J = 6.9 Hz, 3H), 1.61-1.76 (m,
    4H), 1.78-1.90 (m, 2H), 2.62-2.76 (m, 4H), 3.60 (q, J = 6.9 Hz, 2H), 4.94 (s,
    2H), 6.58 (dd, J = 1.8, 8.4 Hz, 1H), 7.01 (d, J = 1.8 Hz, 1H), 7.28 (d, J = 8.4 Hz,
    1H), 7.38-7.45 (m, 2H), 7.63-7.68 (m, 2H); IR (Nujol) 2924, 2854, 1728,
    1592, 1478, 1345, 1233, 1170, 1143 cm−1; Elemental analysis (C23H26N2O5S)
    Calcd. (%): C, 62.14; H, 5.67; F, 4.27; N, 6.30; S, 7.21 Found (%): C, 61.99; H,
    5.39; F, 4.08; N, 6.31; S, 7.04
    Ig-16 mp 186-189° C.; 1H-NMR (d6-DMSO) δ 1.60-1.76 (m, 4H), 1.78-1.90 (m, 2H),
    2.60-2.80 (m, 4H), 3.10 (s, 3H), 4.94 (s, 2H), 6.64 (dd, J = 1.8, 8.7 Hz, 1H),
    6.85-6.89 (m, 2H), 7.03 (d, J = 1.8 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H),
    7.33-7.37 (m, 2H), 10.47 (br s, 1H), 12.96 (br s, 1H); IR (Nujol) 3400, 2924, 2853, 1722,
    1600, 1586, 1498, 1476, 1444, 1321, 1251, 1144 cm−1; Elemental analysis
    (C22H24N2O5S•0.3H2O) Calcd. (%): C, 60.90; H, 5.71; N, 6.46; S, 7.39 Found
    (%): C, 60.85; H, 5.38; N, 6.25; S, 7.18
    Ig-17 mp 264-266° C.; 1H-NMR (d6-DMSO) δ 1.96-2.07 (m, 2H), 2.97 (t, J = 6.3 Hz,
    2H), 3.13-3.20 (m, 2H), 3.17 (s, 3H), 5.02 (s, 2H), 6.82 (dd, J = 2.1, 8.7 Hz,
    1H), 7.37-7.45 (m, 3H), 7.55-7.64 (m, 3H), 7.96 (d, J = 2.1 Hz, 1H); IR (Nujol)
    3521, 3381, 2924, 2854, 1713, 1614, 1592, 1528, 1476, 1445, 1339, 1254 cm−1;
    Elemental analysis (C21H20FN3O5S•H2O) Calcd. (%): C, 54.42; H, 4.78; F,
    4.10; N, 9.07; S, 6.92 Found (%): C, 54.43; H, 4.82; F, 3.96; N, 8.83; S, 6.67
    Ig-18 mp 193-197° C.; 1H-NMR (d6-DMSO) δ 1.32-1.68 (m, 8H), 2.63-2.79 (m, 4H),
    4.85 (s, 2H), 6.73 (dd, J = 1.8, 8.7 Hz, 1H), 7.00 (d, J = 1.8 Hz, 1H), 7.17 (d, J = 8.7 Hz,
    1H), 7.31-7.37 (m, 2H), 7.70-7.75 (m, 2H), 9.79 (s, 1H); IR (Nujol)
    3280, 2924, 2853, 1703, 1594, 1475, 1331, 1291, 1244, 1167, 1153 cm−1;
    Elemental analysis (C22H23FN2O4S) Calcd. (%): C, 61.38; H, 5.39; F, 4.41; N,
    6.51; S, 7.47 Found (%): C, 61.21; H, 5.31; F, 4.29; N, 6.42; S, 7.47
    Ig-19 mp 175-177° C.; 1H-NMR (d6-DMSO) δ 1.35-1.71 (m, 8H), 2.66-2.82 (m, 4H),
    3.18 (s, 3H), 4.92 (s, 2H), 6.71 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz,
    1H), 7.26 (d, J = 8.7 Hz, 1H), 7.37-7.43 (m, 3H), 7.57-7.62 (m, 2H); IR (Nujol)
    2925, 2851, 1729, 1590, 1478, 1347, 1243, 1162, 1150 cm−1; Elemental
    analysis (C23H25FN2O4S) Calcd. (%): C, 62.14; H, 5.67; F, 4.27; N, 6.30; S,
    7.21 Found (%): C, 62.01; H, 5.72; F, 4.01; N, 6.15; S, 7.08
    Ig-20 mp 188-192° C.; 1H-NMR (d6-DMSO)) δ 1.32-1.70 (m, 8H), 2.60-2.78 (m, 4H),
    4.81 (s, 2H), 4.86 (s, 2H), 6.66 (dd, J = 1.8, 8.7 Hz, 1H), 6.90 (d, J = 2.1 Hz,
    1H), 7.15-7.29 (m, 6H), 7.43-7.46 (m, 2H), 7.70-7.75 (m, 2H); IR (Nujol) 2924,
    2853, 1713, 1596, 1474, 1343, 1164, 1153 cm−1; Elemental analysis
    (C29H29FN2O4S) Calcd. (%): C, 66.90; H, 5.61; F, 3.65; N, 5.38; S, 6.16 Found
    (%): C, 66.87; H, 5.59; F, 3.52; N, 5.37; S, 6.01
  • TABLE 65
    Compound
    No. Physical properties
    Ig-21 mp 165-175° C.; 1H-NMR (d6-DMSO) δ 2.38-2.79 (m, 6H), 3.16 (s, 3H), 4.88 (s,
    2H), 6.67 (dd, J = 2.1, 8.4 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 8.7 Hz,
    1H), 7.38-7.45 (m, 2H), 7.56-7.61 (m, 2H); IR (Nujol) 2924, 2855, 1730,
    1592, 1469, 1343, 1242, 1234, 1150 cm−1; Elemental analysis (C20H19FN2O4S)
    Calcd. (%): C, 59.69; H, 4.76; F, 4.72; N, 6.96; S, 7.97 Found (%): C, 59.73; H,
    4.72; F, 4.69; N, 6.90; S, 7.90
    Ig-22 mp 261-265° C.; 1H-NMR (d6-DMSO) δ 2.80-3.15 (m, 4H), 3.88 (d, J = 15.3 Hz,
    1H), 4.09 (d, J = 15.3 Hz, 1H), 4.90 (s, 2H), 6.75 (dd, J = 1.8, 8.7 Hz, 1H),
    7.15 (d, J = 1.8 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.29-7.39 (m, 2H),
    7.67-7.76 (m, 2H), 9.89 (br s, 1H), 13.04 (br, 1H); IR (Nujol) 3560, 3316, 3166, 3102,
    3069, 2924, 2724, 2599, 2506, 1896, 1717, 1590, 1466, 1242, 1227, 1166,
    1155 cm−1
    Ig-23 mp 239-244° C.; 1H-NMR (d6-DMSO) δ 2.90-3.15 (m, 4H), 3.17 (s, 3H), 3.90 (d,
    J = 15.3 Hz, 1H), 4.10 (d, J = 15.3 Hz, 1H), 4.97 (s, 2H), 6.75 (dd, J = 1.8, 8.7 Hz,
    1H), 7.20 (d, J = 1.8 Hz, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.40-7.47 (m, 2H),
    7.55-7.64 (m, 2H), 13.13 (br, 1H); IR (Nujol) 1718, 1590, 1479, 1348, 1234,
    1152 cm−1; Elemental analysis (C20H19FN2O5S2) Calcd. (%): C, 53.32; H, 4.25;
    F, 4.22; N, 6.22; S, 14.24 Found (%): C, 53.15; H, 4.47; F, 4.20; N, 6.19; S,
    14.23
    Ig-24 mp 251-254° C.; 1H-NMR (d6-DMSO) δ 1.96-2.05 (m, 2H), 2.93 (t, J = 6.3 Hz,
    2H), 3.11-3.20 (m, 2H), 3.76 (s, 3H), 4.94 (s, 2H), 6.92 (dd, J = 2.1, 8.7 Hz,
    1H), 6.98-7.03 (m, 2H), 7.27 (d, J = 8.7 Hz, 1H), 7.50 (t, J = 5.1 Hz, 1H),
    7.58-7.63 (m, 2H), 8.00 (d, J = 2.1 Hz, 1H), 9.73 (s, 1H); IR (Nujol) 3429,
    3171, 2924, 2853, 1745, 1595, 1577, 1481, 1450, 1269, 1154 cm−1; Elemental
    analysis (C21H21N3O6S•H2O) Calcd. (%): C, 54.65; H, 5.02; N, 9.11; S, 6.95
    Found (%): C, 54.58; H, 4.58; N, 9.05; S, 7.00
    Ig-25 mp 251-254° C.; 1H-NMR (d6-DMSO) δ 1.96-2.05 (m, 2H), 2.97 (t, J = 6.3 Hz,
    2H), 3.12 (s, 3H), 3.12-3.21 (m, 2H), 3.84 (s, 3H), 5.01 (s, 2H), 6.81 (dd, J = 2.1,
    9.0 Hz, 1H), 7.05-7.11 (m, 2H), 7.37 (d, J = 9.0 Hz, 1H), 7.44-7.49 (m,
    2H), 7.57 (t, J = 4.8 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 13.2 (br, 1H); IR (Nujol)
    3451, 3316, 2925, 2854, 1747, 1721, 1612, 1596, 1534, 1475, 1444, 1339,
    1258 cm−1; Elemental analysis (C22H23N3O6S•1.1H2O) Calcd. (%): C, 55.36; H,
    5.32; N, 8.80; S, 6.72 Found (%): C, 55.21; H, 5.10; N, 8.85; S, 6.84
    Ig-26 dp 217-219° C.; 1H-NMR (d6-DMSO) δ 1.84-2.00 (m, 2H), 2.64-2.81 (m, 4H),
    3.16 (s, 3H), 4.98 (s, 2H), 6.75 (dd, J = 2.1, 8.7 Hz, 1H), 7.35-7.61 (m, 5H),
    7.74 (d, J = 2.1 Hz, 1H), 10.39 (s, 1H), 13.0 (br, 1H); IR (Nujol) 3400, 2925,
    2854, 1705, 1605, 1590, 1476, 1459, 1418, 1377, 1316, 1231, 1170, 1157 cm−1;
    Elemental analysis (C21H20FN3O5S) Calcd. (%): C, 56.62; H, 4.53; F, 4.26; N,
    9.43; S, 7.20 Found (%): C, 56.59; H, 4.39; F, 4.37; N, 9.26; S, 7.12
  • TABLE 66
    Compound
    No. Physical properties
    Ig-27 dp 203-208° C.; 1H-NMR (d6-DMSO) δ 1.84-1.97 (m, 2H), 2.60-2.78 (m, 4H),
    3.18 (s, 3H), 3.76 (s, 3H), 4.99 (s, 2H), 6.85 (dd, J = 2.1, 8.7 Hz, 1H),
    7.38-7.66 (m, 6H), 7.74 (d, J = 2.1 Hz, 1H), 13.0 (br, 1H); IR (Nujol) 3179, 2925,
    2854, 1736, 1592, 1471, 1376, 1345, 1172, 1149 cm−1; Elemental analysis
    (C22H22FN3O5S) Calcd. (%): C, 57.51; H, 4.83; F, 4.13; N, 9.14; S, 6.98 Found
    (%): C, 57.40; H, 4.65; F, 4.18; N, 8.95; S, 7.03
    Ih-1 mp 218-222° C.; 1H-NMR (d6-DMSO) δ 1.65-1.88 (m, 4H), 2.50-2.60 (m, 4H),
    4.79 (s, 2H), 6.72 (dd, J = 1.2, 9.0 Hz, 1H), 7.03 (d, J = 1.2 Hz, 1H), 7.18 (d, J = 8.4 Hz,
    1H), 7.31-7.37 (m, 2H), 7.69-7.75 (m, 2H), 9.80 (s, 1H), 12.90 (br,
    1H); IR (Nujol) 3221, 2925, 2854, 1737, 1587, 1478, 1403, 1231 cm−1.
    Ih-2 mp 179-182° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.50-2.64 (m, 4H),
    3.17 (s, 3H), 4.86 (s, 2H), 6.69 (dd, J = 2.1, 8.4 Hz, 1H), 7.00 (d, J = 2.1 Hz,
    1H), 7.27 (d, J = 8.7 Hz, 1H), 7.39-7.49 (m, 2H), 7.58-7.63 (m, 2H); IR (Nujol)
    2926, 1725, 1592, 1492, 1476, 1347, 1237, 1149 cm−1; Elemental analysis
    (C21H21FN2O4S) Calcd. (%): C, 60.56; H, 5.08; F, 4.56; N, 6.73; S, 7.70 Found
    (%): C, 60.38; H, 5.07; F, 4.44; N, 6.73; S, 7.71
    Ih-3 mp 198-202° C.; 1H-NMR (d6-DMSO) δ 1.64-1.86 (m, 4H), 2.44-2.60 (m, 4H),
    4.80 (s, 4H), 6.64 (dd, J = 1.8, 8.7 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H),
    7.16-7.30 (m, 6H), 7.40-7.49 (m, 2H), 7.68-7.78 (m, 2H); IR (Nujol) 2924, 2854, 1727,
    1594, 1494, 1475, 1346, 1243 cm−1; Elemental analysis (C27H25FN2O4S)
    Calcd. (%): C, 65.84; H, 5.12; F, 3.86; N, 5.69; S, 6.51 Found (%): C, 65.53; H,
    5.11; F, 3.73; N, 5.63; S, 6.30
    Ih-4 mp 180-183° C.; 1H-NMR (d6-DMSO) δ 1.07 (d, J = 6.9 Hz, 3H), 1.44 (m, 1H),
    1.74-1.98 (m, 2H), 2.10 (m, 1H), 2.52-2.70 (m, 3H), 4.78 (s, 2H), 6.72 (dd, J = 2.1,
    8.7 Hz, 1H), 7.02 (d, J = 1.5 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H),
    7.30-7.40 (m, 2H), 7.68-7.78 (m, 2H), 9.80 (br s, 1H), 12.91 (br, 1H); IR (Nujol) 3217,
    2953, 2853, 2721, 1733, 1567, 1418, 1321, 1298, 1180, 1143 cm−1; Elemental
    analysis (C21H21FN2O4S) Calcd. (%): C, 60.56; H, 5.08; F, 4.56; N, 6.73; S,
    7.70 Found (%): C, 60.35; H, 5.09; F, 4.41; N, 6.66; S, 7.67
    Ih-5 mp 100-101° C.; 1H-NMR (d6-DMSO) δ 1.07 (d, J = 6.9 Hz, 3H), 1.46 (m, 1H),
    1.74-1.94 (m, 2H), 2.10 (m, 1H), 2.40-2.75 (m, 3H), 3.17 (s, 3H), 4.83 (s, 2H),
    6.67 (dd, J = 2.1, 8.4 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 9.0 Hz,
    1H), 7.38-7.48 (m, 2H), 7.55-7.63 (m, 2H), 12.90 (br, 1H); IR (Nujol) 3103,
    3068, 2854, 2726, 1726, 1619, 1475, 1346, 1293, 1235, 1171 cm−1; Elemental
    analysis (C22H23FN2O4S•0.2AcOEt) Calcd. (%): C, 61.11; H, 5.53; F, 4.24; N,
    6.25; S, 7.16 Found (%): C, 60.90; H, 5.44; F, 4.01; N, 6.43; S, 7.38
  • TABLE 67
    Compound
    No. Physical properties
    Ih-6 mp 176-178° C.; 1H-NMR (d6-DMSO) δ 1.06 (d, J = 6.9 Hz, 3H), 1.41 (m, 1H),
    1.70-1.84 (m, 2H), 2.08 (m, 1H), 2.42-2.70 (m, 3H), 4.79 (s, 4H), 6.64 (dd, J = 2.1,
    8.4 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H),
    7.14-7.30 (m, 5H), 7.40-7.50 (m, 2H), 7.66-7.76 (m, 2H), 12.99 (br, 1H); IR (Nujol)
    3106, 2854, 1717, 1594, 1494, 1291, 1251, 1235, 1188, 1165, 1154 cm−1;
    Elemental analysis (C28H27FN2O4S) Calcd. (%): C, 66.39; H, 5.37; F, 3.75; N,
    5.53; S, 6.33 Found (%): C, 66.19; H, 5.36; F, 3.52; N, 5.43; S, 6.33
    Ih-7 mp 205-210° C.; 1H-NMR (d6-DMSO) δ 1.85-1.91 (m, 4H), 2.40-2.75 (m, 4H),
    3.20 (s, 3H), 4.86 (s, 2H), 6.61 (dd, J = 2.1, 8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz,
    1H), 7.22 (dd, J = 3.6, 5.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.45 (dd, J = 1.5,
    3.6 Hz, 1H), 8.00 (dd, J = 1.5, 5.1 Hz, 1H), 12.85 (br, 1H); IR (Nujol) 3099,
    3085, 2924, 2741, 2653, 2552, 1722, 1578, 1476, 1348, 1310, 1240, cm−1;
    Elemental analysis (C19H20N2O4S2•0.2AcOEt) Calcd. (%): C, 56.42; H, 4.98;
    N, 6.93; S, 15.85 Found (%): C, 56.30; H, 5.24; N, 6.50; S, 14.88
    Ih-8 mp 134-136° C.; 1H-NMR (d6-DMSO) δ 0.86 (t, J = 7.2 Hz, 3H), 1.30-1.46 (m,
    2H), 1.58-1.70 (m, 2H), 1.72-1.90 (m, 4H), 2.54-2.66 (m, 4H), 3.03-3.12 (m,
    2H), 3.26 (s, 3H), 4.87 (s, 2H), 7.07 (dd, J = 2.1, 8.7 Hz, 1H), 7.32 (d, J = 8.7 Hz,
    1H), 7.38 (d, J = 2.1 Hz, 1H), 12.98 (br, 1H); IR (Nujol) 3042, 2923, 2739,
    2650, 2549, 1723, 1583, 1411, 1385, 1323, 1234, 1213, 1136 cm−1; Elemental
    analysis (C19H26N2O4S) Calcd. (%): C, 60.29; H, 6.92; N, 7.40; S, 8.46 Found
    (%): C, 60.41; H, 6.77; N, 7.37; S, 8.16
    Ih-9 mp 222-225° C.; 1H-NMR (d6-DMSO) δ 1.66-1.88 (m, 4H), 2.40-2.64 (m, 4H),
    4.81 (s, 4H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.97 (d, J = 2.1 Hz, 1H), 7.12 (m,
    7H), 7.57 (dd, J = 1.2, 3.6 Hz, 1H), 8.02 (dd, J = 1.2, 5.1 Hz, 1H), 12.97 (br,
    1H); IR (Nujol) 3122, 2923, 2737, 2652, 2558, 1722, 1584, 1403, 1349, 1155 cm−1.
     Ih-10 mp 143-145° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.5 Hz, 3H), 1.34-1.50 (m,
    2H), 1.66-1.89 (m, 6H), 2.50-2.60 (m, 4H), 3.11-3.22 (m, 2H), 4.81 (s, 2H),
    4.88 (s, 2H), 6.99 (dd, J = 2.1, 8.7 Hz, 1H), 7.14-7.23 (m, 6H), 7.30 (d, J = 2.1 Hz,
    1H), 12.99 (br, 1H); IR (Nujol) 3030, 2853, 2728, 2647, 1725, 1582, 1408,
    1385, 1296, 1134 cm−1; Elemental analysis (C25H30N2O4S) Calcd. (%): C,
    66.05; H, 6.65; N, 6.16; S, 7.00 Found (%): C, 65.67; H, 6.40; N, 6.21; S, 6.95
     Ih-11 mp 218-220° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.46-2.66 (m, 4H),
    4.80 (s, 2H), 6.77 (dd, J = 1.8, 8.7 Hz, 1H), 7.06-7.10 (m, 2H), 7.20 (d, J = 8.7 Hz,
    1H), 7.38 (dd, J = 2.1, 4.2 Hz, 1H), 7.82 (dd, J = 2.1, 5.4 Hz, 1H), 9.90 (br
    s, 1H), 12.96 (br, 1H); IR (Nujol) 3099, 2854, 2741, 2653, 2552, 1722, 1578,
    1508, 1439, 1385, 1348, 1310, 1240, 1151 cm−1; Elemental analysis
    (C18H18N2O4S2•0.2AcOEt) Calcd. (%): C, 55.33; H, 4.84; N, 6.86; S, 15.71
    Found (%): C, 55.14; H, 4.61; N, 7.05; S, 15.77
  • TABLE 68
    Compound
    No. Physical properties
    Ih-12 mp 174-176° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.40-2.64 (m, 4H),
    3.12 (s, 3H), 3.84 (s, 3H), 4.85 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.99 (d, J = 1.8 Hz,
    1H), 7.08 (d, J = 9.0 Hz, 2H), 7.25 (d, J = 8.7 Hz, 1H), 7.45 (d, J = 9.0 Hz,
    2H), 12.97 (br, 1H); IR (Nujol) 2925, 2746, 2662, 2563, 1727, 1709,
    1595, 1474, 1380, 1350, 1246, 1149 cm−1; Elemental analysis (C22H23FN2O4S)
    Calcd. (%): C, 61.67; H, 5.65; N, 6.54; S, 7.48 Found (%): C, 61.40; H, 5.69; N,
    6.44; S, 7.22
    Ih-13 mp 225-228° C.; 1H-NMR (d6-DMSO) δ 1.66-1.96 (m, 4H), 2.44-2.60 (m, 4H),
    4.77 (s, 2H), 6.72 (dd, J = 2.1, 8.7 Hz, 1H), 6.99 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 2.1 Hz,
    1H), 7.14 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 9.0 Hz, 2H), 9.51 (br s,
    1H), 12.99 (br, 1H); IR (Nujol) 3456, 3289, 2924, 1720, 1590, 1284, 1260,
    1145 cm−1.
    Ih-14 mp 189-194° C.; 1H-NMR (d6-DMSO) δ 1.68-1.86 (m, 4H), 2.44-2.60 (m, 4H),
    3.76 (s, 3H), 4.78 (s, 2H), 6.73 (dd, J = 1.8, 8.7 Hz, 1H), 6.97 (m, 3H), 7.08 (d,
    J = 9.0 Hz, 2H), 7.60 (d, J = 8.7 Hz, 1H), 9.52 (br s, 1H), 12.92 (br, 1H); IR
    (Nujol) 3296, 3203, 2924, 1723, 1403, 1295, 1145 cm−1; Elemental analysis
    (C21H22N2O5S•0.3AcOEt) Calcd. (%): C, 60.85; H, 5.35; N, 6.76; S, 7.74 Found
    (%): C, 60.47; H, 5.58; N, 6.35; S, 7.27
    Ih-15 mp 114-118° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.44-2.66 (m, 4H),
    3.10 (s, 3H), 4.84 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.87 (d, J = 9.0 Hz,
    2H), 6.97 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 7.34 (d, J = 9.0 Hz,
    2H), 12.99 (br, 1H); IR (Nujol) 3376, 2924, 1728, 1586, 1499, 1376, 1329,
    1283, 1226, 1147 cm−1.
    Ih-16 mp 182-185° C.; 1H-NMR (d6-DMSO) δ 0.98 (t, J = 9.9 Hz, 3H), 1.35-1.64 (m,
    4H), 1.90-2.18 (m, 2H), 2.50-2.70 (m, 3H), 4.80 (s, 2H), 6.72 (dd, J = 2.1, 8.7 Hz,
    1H), 7.04 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 7.32-7.38 (m, 2H),
    7.70-7.75 (m, 2H), 9.83 (s, 1H); IR (Nujol) 3287, 2956, 2922, 2853, 1722,
    1590, 1492, 1469, 1404, 1254, 1163, 1148 cm−1; Elemental analysis
    (C22H23FN2O4S) Calcd. (%): C, 61.38; H, 5.39; F, 4.41; N, 6.51; S, 7.45 Found
    (%): C, 61.25; H, 5.36; F, 4.30; N, 6.43; S, 7.19
    Ih-17 mp 186-188° C.; 1H-NMR (d6-DMSO) δ 0.98 (t, J = 6.9 Hz, 3H), 1.37-1.64 (m,
    4H), 1.92-2.18 (m, 2H), 2.50-2.70 (m, 3H), 3.77 (s, 3H), 4.79 (s, 2H), 6.74 (dd,
    J = 1.8, 8.7 Hz, 1H), 7.00-7.17 (m, 4H), 7.59-7.63 (m, 2H), 9.65 (s, 1H); IR
    (Nujol) 3223, 2924, 2853, 1727, 1594, 1260, 1143 cm−1; Elemental analysis
    (C23H26N2O5S) Calcd. (%): C, 62.42; H, 5.93; N, 6.33; S, 7.11 Found (%): C,
    62.21; H, 5.88; N, 6.27; S, 7.11
    Ih-18 mp 153-155° C.; 1H-NMR (d6-DMSO) δ 0.97 (t, J = 7.2 Hz, 3H), 1.35-1.68 (m,
    4H), 1.90-2.18 (m, 2H), 2.54-2.72 (m, 3H), 3.17 (s, 3H), 4.85 (s, 2H), 6.69 (dd,
    J = 2.1, 8.4 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H),
    7.38-7.45 (m, 2H), 7.57-7.62 (m, 2H); IR (Nujol) 2924, 1719, 1592, 1476, 1345,
    1237, 1146 cm−1; Elemental analysis (C23H25FN2O4S) Calcd. (%): C, 62.14; H,
    5.67; F, 4.27; N, 6.30; S, 7.21 Found (%): C, 62.38; H, 5.84; F, 4.00; N, 6.10; S,
    6.83
  • TABLE 69
    Compound
    No. Physical properties
    Ih-19 mp 119-122° C.; 1H-NMR (d6-DMSO) δ 0.97 (t, J = 6.9 Hz, 3H), 1.37-1.70 (m,
    4H), 1.92-2.18 (m, 2H), 2.50-2.74 (m, 3H), 3.13 (s, 3H), 3.84 (s, 3H), 4.85 (s,
    2H), 6.69 (dd, J = 2.1, 8.4 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 7.07-7.10 (m, 2H),
    7.24 (d, J = 8.4 Hz, 1H), 7.44-7.48 (m, 2H); IR (Nujol) 2925, 1719, 1597,
    1579, 1476, 1342, 1245, 1150 cm−1; Elemental analysis (C24H28N2O5S) Calcd.
    (%): C, 63.14; H, 6.18; N, 6.14; S, 7.02 Found (%): C, 63.30; H, 6.38; N, 5.94;
    S, 6.61
    Ih-20 mp 193-200° C.; 1H-NMR (d6-DMSO) δ 1.65-1.86 (m, 4H), 2.46-2.60 (m, 4H),
    4.78 (s, 2H), 6.73 (dd, J = 2.1, 8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.7 Hz,
    1H), 7.45-7.60 (m, 3H), 7.65-7.72 (m, 2H), 9.78 (s, 1H), 12.93 (brs,
    1H); IR (Nujol) 3206, 1765, 1735, 1584, 1478, 1459, 1448, 1435, 1398, 1366,
    1349, 1334, 1309, 1282, 1265, 1236, 1204, 1147 cm−1; Elemental analysis
    (C20H20N2O4S) Calcd. (%): C, 62.48; H, 5.24; N, 7.29; S, 8.34 Found (%): C,
    62.29; H, 5.23; N, 7.18; S, 8.24
    Ih-21 mp 182-190° C.; 1H-NMR (d6-DMSO) δ 1.67-1.87 (m, 4H), 2.30 (s, 3H),
    2.46-2.60 (m, 4H), 4.78 (s, 2H), 6.73 (dd, J = 2.1, 8.7 Hz, 1H), 7.04 (d, J = 2.1 Hz,
    1H), 7.15 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz,
    2H), 9.71 (s, 1H), 12.93 (br s, 1H); IR (Nujol) 3222, 3114, 3062, 1756, 1738,
    1596, 1478, 1456, 1417, 1404, 1381, 1365, 1346, 1322, 1303, 1291, 1280,
    1260, 1194, 1146 cm−1; Elemental analysis (C21H22N2O4S) Calcd. (%): C,
    63.30; H, 5.56; N, 7.03; S, 8.05 Found (%): C, 63.21; H, 5.53; N, 6.99; S, 7.98
    Ih-22 mp 199-205° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.44-2.64 (m, 4H),
    3.16 (s, 3H), 4.86 (s, 2H), 6.67 (dd, J = 2.1, 8.7 Hz, 1H), 6.97 (d, J = 2.1 Hz,
    1H), 7.26 (d, J = 8.7 Hz, 1H), 7.51-7.62 (m, 4H), 7.70 (m, 1H), 12.99 (br s,
    1H); IR (Nujol) 3063, 2743, 2653, 2552, 2454, 1721, 1738, 1615, 1579, 1476,
    1440, 1425, 1411, 1387, 1364, 1345, 1332, 1309 1290, 1266, 1240, 1213,
    1190, 1173 1157 cm−1; Elemental analysis (C21H22N2O4S) Calcd. (%): C,
    63.30; H, 5.56; N, 7.03; S, 8.05 Found (%): C, 63.16; H, 5.48; N, 6.95 S, 7.83
    Ih-23 mp 182-188° C.; 1H-NMR (d6-DMSO) δ 1.68-1.89 (m, 4H), 2.40 (s, 3H),
    2.45-2.64 (m, 4H), 3.14 (s, 3H), 4.86 (s, 2H), 6.66 (dd, J = 2.1, 8.7 Hz, 1H), 7.01 (d,
    J = 2.1 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz,
    2H), 12.97 (br s, 1H); IR (Nujol) 2655, 2553, 1712, 1619, 1597, 1477,
    1407, 1383, 1365, 1343, 1306, 1290, 1267, 1243, 1213, 1185, 1168, 1148,
    1121, 1110 cm−1; Elemental analysis (C22H24N2O4S) Calcd. (%): C, 64.06; H,
    5.86; N, 6.79; S, 7.77 Found (%): C, 64.14; H, 5.84; N, 6.73; S, 7.61
  • TABLE 70
    Compound
    No. Physical properties
    Ih-24 Mp 240-250° C.; 1H-NMR (d6-DMSO) δ 1.71-1.90 (m, 4H), 2.54-2.66 (m, 4H),
    3.25 (s, 3H), 4.47 (s, 2H), 4.88 (s, 2H), 6.99 (dd, J = 1.8, 8.4 Hz, 1H), 7.18 (d, J = 1.8 Hz,
    1H), 7.31 (d, J = 8.4 Hz, 1H), 7.34-7.42 (m, 5H), 12.99 (br s, 1H); IR
    (Nujol) 2657, 2557, 1710, 1620, 1603, 1582, 1496, 1479, 1456, 1440, 1412,
    1383, 1340, 1311, 1289, 1269, 1250, 1217, 1190, 1173, 1160, 1140 cm−1;
    Elemental analysis (C22H24N2O4S•0.2AcOEt) Calcd. (%): C, 63.67; H, 6.00; N,
    6.51; S, 7.45 Found (%): C, 63.75; H, 5.96; N, 6.51; S, 7.38
    Ih-25 mp 218-226° C.; 1H-NMR (d6-DMSO) δ 1.68-1.90 (m, 4H), 2.50-2.65 (m, 4H),
    3.25 (s, 3H), 4.86 (s, 2H), 7.02 (dd, J = 1.8, 8.4 Hz, 1H), 7.24 (d, J = 15.3 Hz,
    1H), 7.29-7.47 (m, 5H), 7.37 (d, J = 15.3 Hz, 1H), 7.69-7.77 (m, 2H), 12.95 (br
    s, 1H); IR (Nujol) 3057, 2662, 2568, 1721, 1616, 1578, 1478, 1451, 1410,
    1385, 1338, 1307, 1290, 1253, 1212, 1179, 1166, 1154, 1133 cm−1; Elemental
    analysis (C23H24N2O4S•0.2AcOEt) Calcd. (%): C, 64.65; H, 5.84; N, 6.34; S,
    7.25 Found (%): C, 6.45; H, 5.80; N, 6.36; S, 7.26
    Ih-26 mp 114-118° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.44-2.66 (m, 4H),
    3.10 (s, 3H), 4.84 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.87 (d, J = 9.0 Hz,
    2H), 6.97 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 7.34 (d, J = 9.0 Hz,
    2H), 12.99 (br, 1H); IR (Nujol) 3376, 2924, 1728, 1586, 1499, 1376, 1329,
    1283, 1226, 1147 cm−1
    Ih-27 mp 165-168° C.; 1H-NMR (d6-DMSO) δ 0.97 (s, 6H), 1.52-1.62 (m, 2H), 2.31 (s,
    2H), 2.50-2.60 (m, 2H), 4.80 (s, 2H), 6.71 (dd, J = 1.8, 8.7 Hz, 1H), 7.00 (d, J = 1.8 Hz,
    1H), 7.25 (d, J = 8.7 Hz, 1H), 7.30-7.39 (m, 2H), 7.68-7.76 (m, 2H),
    9.82 (br s, 1H), 12.91 (br, 1H); IR (Nujol) 3252, 2925, 1752, 1590, 1467,
    1291, 1233, 1146 cm−1; Elemental analysis (C22H23N2FO4S) Calcd. (%): C,
    61.38; H, 5.39; F, 4.41; N, 6.51; S, 7.49 Found (%): C, 61.42; H, 5.57; F, 4.20;
    N, 6.70; S, 7.17
    Ih-28 mp 122-125° C.; 1H-NMR (d6-DMSO) δ 0.98 (s, 6H), 1.54-1.64 (m, 2H), 2.33 (s,
    2H), 2.52-2.60 (m, 2H), 4.82 (s, 2H), 6.77 (dd, J = 1.8, 8.7 Hz, 1H),
    7.04-7.10 (m, 2H), 7.21 (d, J = 8.7 Hz, 1H), 7.40 (dd, J = 1.5, 3.6 Hz, 1H), 7.82 (dd, J = 1.5,
    4.8 Hz, 1H), 9.93 (br s, 1H), 12.90 (br, 1H); IR (Nujol) 3250, 3112, 2923,
    2666, 1709, 1474, 1411, 1251, 1159 cm−1
    Ih-29 mp 155-160° C.; 1H-NMR (d6-DMSO) δ 1.72-1.93 (m, 4H), 2.54-2.66 (m, 4H),
    4.30 (s, 2H), 4.86 (s, 2H), 6.96 (dd, J = 2.1, 9.0 Hz, 1H), 7.22 (d, J = 2.1 Hz,
    1H), 7.25-7.40 (m, 6H), 9.40 (s, 1H), 12.95 (br s, 1H); IR (Nujol) 3568, 3438,
    3349, 3195, 3060, 2728, 2537, 1728, 1713, 1625, 1583, 1469, 1456, 1438,
    1427, 1411, 1378, 1350, 1318, 1279, 1257, 1243, 1217, 1192, 1172, 1146,
    1130 cm−1; Elemental analysis (C21H22N2O4S) Calcd. (%): C, 63.30; H, 5.56;
    N, 7.03; S, 8.05 Found (%): C, 63.00; H, 5.75; N, 6.91; S, 7.88
  • TABLE 71
    Compound
    No. Physical properties
    Ih-30 Mp 208-213° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.50-2.62 (m, 4H),
    4.80 (s, 2H), 6.92 (dd, J = 1.8, 8.7 Hz, 1H), 7.15 (d, J = 15.3 Hz, 1H), 7.20 (d,
    J = 1.8 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.27 (d, J = 15.3 Hz, 1H),
    7.33-7.42 (m, 3H), 7.58-7.66 (m, 2H), 9.53 (s, 1H), 12.92 (brs, 1H); IR (Nujol) 3279,
    3259, 3241, 3044, 3023, 2652, 2550, 2362, 1729, 1713, 1618, 1589, 1576,
    1490, 1469, 1449, 1430, 1412, 1403, 1384, 1351, 1318, 1308, 1275, 1260,
    1237, 1214, 1198, 1175, 1136 cm−1; Elemental analysis (C22H22N2O4S) Calcd.
    (%): C, 64.37; H, 5.40; N, 6.82; S, 7.81 Found (%): C, 64.28; H, 5.50; N, 6.78;
    S, 7.56
    Ih-31 mp 112-115° C.; 1H-NMR (d6-DMSO) δ 0.99 (s, 6H), 1.54-1.66 (m, 2H), 2.34 (s,
    2H), 2.56-2.66 (m, 2H), 3.16 (s, 3H), 4.87 (s, 2H), 6.67 (dd, J = 2.1, 8.7 Hz,
    1H), 7.00 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.36-7.46 (m, 2H),
    7.57-7.66 (m, 2H), 12.95 (br, 1H); IR (Nujol) 2915, 1725, 1709, 1475, 1345,
    1308, 1291, 1239, 1166 cm−1.
    Ih-32 mp 180-184° C.; 1H-NMR (d6-DMSO) δ 0.99 (s, 6H), 1.56-1.64 (m, 2H), 2.33 (s,
    2H), 2.54-2.66 (m, 2H), 3.21 (s, 3H), 3.84 (s, 3H), 4.87 (s, 2H), 6.67 (dd, J = 2.1,
    8.7 Hz, 1H), 6.97 (d, J = 1.5 Hz, 1H), 7.08 (d, J = 9.0 Hz, 2H), 7.26 (d, J = 9.0 Hz,
    1H), 7.46 (d, J = 9.0 Hz, 2H), 12.97 (br, 1H); IR (Nujol) 3084, 2923,
    2675, 2563, 1734, 1712, 1584, 1474, 1347, 1253, 1159 cm−1; Elemental
    analysis (C24H28N2O5S) Calcd. (%): C, 63.14; H, 6.18; N, 6.14; S, 7.05 Found
    (%): C, 62.92; H, 5.98; N, 6.09; S, 6.76
    Ih-33 mp 174-180° C.; 1H-NMR (d6-DMSO) δ 0.99 (s, 6H), 1.57-1.65 (m, 2H), 2.35 (s,
    2H), 2.54-2.65 (m, 2H), 3.20 (s, 3H), 4.87 (s, 2H), 6.71 (dd, J = 2.1, 9.0 Hz,
    1H), 7.03 (d, J = 2.1 Hz, 1H), 7.21-7.32 (m, 2H), 7.45 (dd, J = 1.5, 3.6 Hz, 1H),
    8.00 (dd, J = 1.2, 2.1 Hz, 1H), 12.98 (br, 1H); IR (Nujol) 2923, 2745, 2657,
    2560, 1731, 1597, 1579, 1474, 1335, 1308, 1265, 1240, 1147 cm−1; Elemental
    analysis (C21H24N2O4S2•0.2AcOEt) Calcd. (%): C, 58.31; H, 5.59; N, 6.48; S,
    14.83 Found (%): C, 58.16; H, 5.73; N, 6.22; S, 14.25
    Ih-34 mp 146-149° C.; 1H-NMR (d6-DMSO) δ 1.90-2.18 (m, 2H), 2.57-3.02 (m, 5H),
    4.84 (s, 2H), 6.75 (dd, J = 2.1, 8.7 Hz, 1H), 7.22-7.39 (m, 8H), 7.69-7.73 (m,
    2H), 9.84 (s, 1H), 13.00 (br, 1H); IR (Nujol) 3208, 2925, 2854, 1729, 1592,
    1495, 1286, 1240, 1197, 1156, 1146 cm−1; Elemental analysis
    (C26H23FN2O4S•0.3H2O) Calcd.(%): C, 64.53; H, 4.92; F, 3.93; N, 5.79; S, 6.63
    Found (%): C, 64.52; H, 4.55; F, 3.82; N, 5.75; S, 6.48
    Ih-35 mp 152-155° C.; 1H-NMR (d6-DMSO) δ 1.90-2.19 (m, 2H), 2.53-3.02 (m, 5H),
    3.76 (s, 3H), 4.83 (s, 2H), 6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.98-7.38 (m, 9H),
    7.59-7.62 (m, 2H), 9.66 (s, 1H), 13.00 (br, 1H); IR (Nujol) 3305, 2924, 2853,
    1716, 1594, 1474, 1258, 1152 cm−1; Elemental analysis
    (C27H26N2O5S•0.3H2O) Calcd. (%): C, 65.53; H, 5.41; N, 5.65; S, 6.47 Found
    (%): C, 65.53; H, 5.28; N, 5.38; S, 6.12
  • TABLE 72
    Compound
    No. Physical properties
    Ih-36 mp 204-206° C.; 1H-NMR (d6-DMSO) δ 1.95-2.18 (m, 2H), 2.54-3.02 (m, 5H),
    3.16 (s, 3H), 4.90 (s, 2H), 6.72 (dd, J = 2.1, 9.0 Hz, 1H), 7.04 (d, J = 2.1 Hz,
    1H), 7.20-7.61 (m, 10H); IR (Nujol) 2925, 2854, 1726, 1589, 1476, 1346,
    1336, 1254, 1224, 1148 cm−1; Elemental analysis (C27H25FN2O4S) Calcd. (%):
    C, 65.84; H, 5.12; F, 3.86; N, 5.69; S, 6.513 Found (%): C, 65.542; H, 4.94; F,
    3.87; N, 5.61; S, 6.48
    Ih-37 mp 121-124° C.; 1H-NMR (d6-DMSO) δ 1.94-2.19 (m, 2H), 2.52-3.03 (m, 5H),
    3.12 (s, 3H), 3.81 (s, 3H), 4.89 (s, 2H), 6.72 (d, J = 8.7 Hz, 1H), 6.99 (s, 1H),
    7.06-7.09 (m, 2H), 7.20-7.47 (m, 8H); IR (Nujol) 2924, 2853, 1741, 1689,
    1596, 1480, 1458, 1340, 1259, 1197, 1180, 1162, 1150 cm−1
    Ih-38 mp 168-172° C.; 1H-NMR (d6-DMSO) δ 0.81 (t, J = 7.8 Hz, 6H), 1.21-1.40 (m,
    4H), 1.60 (t, J = 6.0 Hz, 2H), 2.28 (s, 2H), 2.50 (m, 2H), 3.76 (s, 3H), 4.78 (s,
    2H), 6.73 (dd, J = 2.1, 8.7 Hz, 1H), 6.97-7.03 (m, 3H), 7.15 (d, J = 8.7 Hz, 1H),
    7.57-7.62 (m, 2H), 9.62 (s, 1H), 12.95 (br, 1H); IR (Nujol) 3303, 2924, 2853,
    1719, 1598, 1498, 1486, 1469, 1404, 1254, 1155 cm−1; Elemental analysis
    (C25H30N2O5S) Calcd. (%): C, 63.81; H, 6.43; N, 5.95; S, 6.65 Found (%): C,
    63.54; H, 6.31; N, 5.90; S, 6.65
    Ih-39 mp 188-197° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.46-2.62 (m, 4H),
    4.79 (s, 2H), 6.71 (dd, J = 1.8, 8.7 Hz, 1H), 7.03 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.7 Hz,
    1H), 7.58 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 9.87 (s, 1H),
    12.90 (brs, 1H); IR (Nujol) 3208, 3084, 1755, 1736, 1581, 1474, 1419, 1404,
    1381, 1365, 1348, 1333, 1384, 1322, 1304, 1279, 1261, 1198, 1154 cm−1;
    Elemental analysis (C20H19ClN2O4S) Calcd. (%): C, 57.34; H, 4.57; Cl, 8.46;
    N, 6.69; S, 7.65 Found (%): C, 57.28; H, 4.75; Cl, 7.94; N, 6.86; S, 7.39
    Ih-40 mp 170-175° C.; 1H-NMR (d6-DMSO) δ 1.68-1.87 (m, 4H), 2.43-2.60 (m, 4H),
    4.79 (s, 2H), 6.73 (dd, J = 1.8, 8.7 Hz, 1H), 7.02 (d, J = 1.8 Hz, 1H), 7.14 (d, J = 8.7 Hz,
    1H), 7.87 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 8.7 Hz, 2H), 10.03 (s, 1H),
    12.91 (brs, 1H); IR (Nujol) 3216, 3046, 1754, 1738, 1605, 1593, 1472, 1423,
    1405, 1380, 1366, 1340, 1325, 1306, 1294, 1282, 1265, 1216, 1194, 1173,
    1154, 1110 cm−1; Elemental analysis (C21H19F3N2O4S) Calcd. (%): C, 55.75;
    H, 4.23; F, 12.60; N, 6.19; S, 7.09 Found (%): C, 55.94; H, 4.46; F, 12.31; N,
    6.46; S, 6.94
    Ih-41 mp 162-165° C.; 1H-NMR (d6-DMSO) δ 1.68-1.89 (m, 4H), 2.46-2.65 (m, 4H),
    3.17 (s, 3H), 4.86 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz,
    1H), 7.27 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz,
    2H), 12.90 (brs, 1H); IR (Nujol) 3095, 2743, 2656, 2556, 1729, 1711, 1584,
    1476, 1444, 1427, 1411, 1385, 1346, 1310, 1280, 1267, 1242, 1213, 1189,
    1173, 1156 cm−1; Elemental analysis (C21H21ClN2O4S•0.05AcOEt) Calcd.
    (%): C, 58.22; H, 4.93; Cl, 8.11; N, 6.41; S, 7.33 Found (%): C, 58.32; H, 4.94;
    Cl, 7.85; N, 6.68; S, 7.30
  • TABLE 73
    Compound
    No. Physical properties
    Ih-42 mp 181-188° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.44-2.64 (m, 4H),
    3.21 (s, 3H), 4.87 (s, 2H), 6.70 (dd, J = 1.8, 8.7 Hz, 1H), 6.99 (d, J = 1.8 Hz,
    1H), 7.29 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz,
    2H), 12.99 (brs, 1H); IR (Nujol) 3111, 3085, 3053, 2739, 2653, 2552, 1733,
    1712, 1609, 1582, 1477, 1447, 1426, 1408, 1386, 1366, 1348, 1327, 1311,
    1281, 1267, 1239, 1214, 1191, 1174, 1158, 1128, 1110 cm−1; Elemental
    analysis (C22H21F3N2O4S) Calcd. (%): C, 56.65; H, 4.54; F, 12.22; N, 6.01; S,
    6.87 Found (%): C, 56.77; H, 4.62; F, 11.93; N, 6.30; S, 6.88
    Ih-43 mp 227-232° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.46-2.64 (m, 4H),
    3.18 (s, 3H), 4.86 (s, 2H), 6.71 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz,
    1H), 7.11 (dd, J = 1.5, 5.1 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.77 (dd, J = 3.0,
    5.1 Hz, 1H), 8.03 (dd, J = 1.5, 3.0 Hz, 1H), 12.99 (brs, 1H); IR (Nujol) 3120,
    3086, 2742, 2651, 2552, 2455, 1721, 1615, 1577, 1499, 1475, 1439, 1425,
    1410, 1386, 1362, 1342, 1309, 1267, 1240, 1209, 1190, 1174, 1152, 1101 cm−1;
    Elemental analysis (C19H20N2O4S2) Calcd. (%): C, 56.42 H, 4.98; N, 6.93; S,
    15.85 Found (%): C, 56.15; H, 4.93; N, 6.87; S, 15.71
    Ih-44 mp 164-168° C.; 1H-NMR (d6-DMSO) δ 1.68-1.88 (m, 4H), 2.44-2.64 (m, 4H),
    3.21 (s, 3H), 4.87 (s, 2H), 6.70 (dd, J = 1.8, 8.7 Hz, 1H), 6.99 (d, J = 1.8 Hz,
    1H), 7.29 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz,
    2H), 12.99 (brs, 1H); IR (Nujol) 3016, 2745, 2658, 2560, 1721, 1591,
    1581, 1477, 1446, 1427, 1414, 1389, 1351, 1334, 1310, 1293, 1264, 1246,
    1212, 1190, 1162, 1102 cm−1; Elemental analysis (C22H21F3N2O5S) Calcd. (%):
    C, 54.77; H, 4.39; F, 11.81; N, 5.81; S, 6.65 Found (%): C, 54.69; H, 4.28; F,
    11.56; N, 5.82; S, 6.59
    Ih-45 mp 97-100° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.5 Hz, 6H), 1.21-1.40 (m,
    4H), 1.63 (t, J = 6.0 Hz, 2H), 2.31 (s, 2H), 2.55 (br t, 2H), 3.17 (s, 3H), 4.85 (s,
    2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz,
    1H), 7.38-7.62 (m, 4H); IR (Nujol) 2956, 2854, 1738, 1699, 1591, 1495,
    1475, 1331, 1236, 1196, 1151 cm−1.
    Ih-46 mp 103-105° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.2 Hz, 6H), 1.20-1.40 (m,
    4H), 1.63 (br t, 2H), 2.30 (s, 2H), 2.55 (br t, 2H), 3.13 (s, 3H), 3.84 (s, 3H),
    4.85 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H),
    7.07-7.10 (m, 2H), 7.24 (d, J = 8.7 Hz, 1H), 7.44-7.48 (m, 2H); IR (Nujol) 2925, 2854,
    1758, 1739, 1683, 1599, 1474, 1338, 1264, 1182, 1164, 1153 cm−1.
    Ih-47 Mp 160-163° C.; 1H-NMR (d6-DMSO) δ 1.24-1.57 (m, 10H), 1.66 (t, J = 6.0 Hz,
    2H), 2.36 (s, 2H), 2.53 (br t, 2H), 4.78 (s, 2H), 6.71 (dd, J = 2.1, 8.7 Hz, 1H),
    7.01 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 7.31-7.37 (m, 2H),
    7.70-7.75 (m, 2H), 9.79 (s, 1H), 12.9 (br, 1H); IR (Nujol) 3297, 3278, 2919, 2854, 1746,
    1720, 1590, 1468, 1251, 1162, 1151 cm−1.
  • TABLE 74
    Compound
    No. Physical properties
    Ih-48 mp 201-204° C.; 1H-NMR (d6-DMSO) δ 1.24-1.59 (m, 10H), 1.66 (t, J = 6.0 Hz,
    2H), 2.36 (s, 2H), 2.53 (br t, 2H), 3.77 (s, 3H), 4.78 (s, 2H), 6.73 (dd, J = 1.8,
    8.7 Hz, 1H), 6.99-7.16 (m, 3H), 7.15 (d, J = 8.7 Hz, 1H), 7.59-7.63 (m, 2H),
    9.62 (s, 1H), 12.5 (br, 1H); IR (Nujol) 3249, 2924, 2853, 1737, 1595, 1470,
    1329, 1262, 1154 cm−1.
    Ih-49 mp 198-205° C.; 1H-NMR (d6-DMSO) δ 1.68-1.86 (m, 4H), 2.46-2.60 (m, 4H),
    4.80 (s, 2H), 6.76 (dd, J = 1.8, 8.7 Hz, 1H), 7.03 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.7 Hz,
    1H), 7.22 (dd, J = 1.5, 5.1 Hz, 1H), 7.66 (dd, J = 3.0, 5.1 Hz, 1H),
    7.96 (dd, J = 1.5, 3.0 Hz, 1H), 9.71 (s, 1H), 12.93 (brs, 1H); IR (Nujol) 3205,
    3103, 1735, 1478, 1459, 1435, 1401, 1365, 1349, 1333, 1312, 1281, 1264,
    1206, 1146 cm−1; Elemental analysis (C18H18N2O4S2) Calcd. (%): C, 55.37; H,
    4.65; N, 7.17; S, 16.42 Found (%): C, 55.22; H, 4.56; N, 7.04; S, 16.15
    Ih-50 mp 177-181° C.; 1H-NMR (d6-DMSO) δ 0.91 (t, J = 6.9 Hz, 3H), 1.30-1.50 (m,
    6H), 1.90-2.16 (m, 2H), 2.46-2.70 (m, 3H), 4.77 (s, 2H), 6.71 (dd, J = 2.1, 8.7 Hz,
    1H), 7.01 (d, J = 2.1 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.30-7.38 (m, 2H),
    7.67-7.75 (m, 2H), 9.81 (br s, 1H); IR (Nujol) 3294, 3102, 3069, 3032, 2919,
    2667, 2573, 1722, 1590, 1470, 1403, 1341, 1293, 1254 cm−1
    Ih-51 mp 112-115° C.; 1H-NMR (d6-DMSO) δ 0.96 (s, 9H), 1.21-1.48 (m, 2H),
    2.02-2.30 (m, 2H), 2.42-2.78 (m, 3H), 4.77 (s, 2H), 6.70 (dd, J = 1.8, 8.7 Hz, 1H),
    7.05 (d, J = 1.8 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.30-7.40 (m, 2H),
    7.68-7.77 (m, 2H), 9.80 (br s, 1H); IR (Nujol) 3249, 2923, 2662, 1711, 1591, 1495,
    1477, 1414, 1339, 1295, 1241, 1194, 1156 cm−1.
    Ih-52 mp 168-171° C.; 1H-NMR (d6-DMSO) δ 0.92 (t, J = 6.6 Hz, 3H), 1.32-1.52 (m,
    6H), 1.90-2.16 (m, 2H), 2.46-2.76 (m, 3H), 3.76 (s, 3H), 4.74 (s, 2H), 6.72 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.96-7.06 (m, 3H), 7.13 (d, J = 8.7 Hz, 1H), 7.60 (d, J = 9.0 Hz,
    2H), 9.61 (s, 1H); IR (Nujol) 3302, 3017, 2923, 2669, 2563, 1720,
    1594, 1471, 1402, 1336, 1253, 1193 cm−1
    Ih-53 mp 179-181° C.; 1H-NMR (d6-DMSO) δ 0.96 (s, 9H), 1.21-1.50 (m, 2H),
    2.00-2.30 (m, 2H), 2.40-2.78 (m, 3H), 3.76 (s, 3H), 4.77 (s, 2H), 6.72 (dd, J = 1.8,
    8.7 Hz, 1H), 6.96-7.08 (m, 3H), 7.12 (d, J = 8.7 Hz, 1H), 7.59 (d, J = 8.7 Hz,
    2H), 9.61 (br s, 1H); IR (Nujol) 3665, 3297, 2923, 2666, 2570, 1718, 1594,
    1470, 1403, 1254, 1194 cm−1.
    Ih-54 mp 151-158° C.; 1H-NMR (d6-DMSO) δ 1.67-1.86 (m, 4H), 2.44-2.61 (m, 4H),
    4.79 (s, 2H), 6.73 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 7.19 (d, J = 8.7 Hz,
    1H), 7.51 (d, J = 8.7 Hz, 2H), 7.78 (d, J = 8.7 Hz, 2H), 9.89 (s, 1H),
    12.93 (brs, 1H); IR (Nujol) 3287, 3104, 3038, 1720, 1592, 1487, 1473, 1411,
    1399, 1376, 1366, 1355, 1336, 1292, 1247, 1209, 1170, 1152 cm−1.
  • TABLE 75
    Compound
    No. Physical properties
    Ih-55 mp 155-158° C.; 1H-NMR (d6-DMSO) δ 1.23-1.53 (m, 10H), 1.68 (t, J = 6.0 Hz,
    2H), 2.39 (s, 2H), 2.56 (br t, 2H), 3.17 (s, 3H), 4.86 (s, 2H), 6.68 (dd, J = 2.1,
    9.0 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 9.0 Hz, 1H), 7.38-7.63 (m,
    4H); IR (Nujol) 2917, 2854, 1725, 1590, 1478, 1342, 1233, 1146 cm−1;
    Elemental analysis (C26H29FN2O4S) Calcd. (%): C, 64.44; H, 6.03; F, 3.92; N,
    5.78; S, 6.62 Found (%): C, 64.12; H, 6.16; F, 3.59; N, 5.52; S, 6.18
    Ih-56 mp 132-135° C.; 1H-NMR (d6-DMSO) δ 1.22-1.54 (m, 10H), 1.66 (t, J = 6.0 Hz,
    2H), 2.38 (s, 2H), 2.56 (br t, 2H), 3.13 (s, 3H), 3.84 (s, 3H), 4.85 (s, 2H),
    6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 7.07-7.11 (m, 2H), 7.25 (d, J = 8.7 Hz,
    1H), 7.45-7.49 (m, 2H); IR (Nujol) 2917, 2854, 1725, 1597, 1496,
    1477, 1338, 1255, 1236, 1148 cm−1
    Ih-57 mp 161-163° C.; 1H-NMR (d6-DMSO) δ 0.92 (t, J = 6.9 Hz, 3H), 1.22-1.50 (m,
    5H), 1.62-1.78 (m, 1H), 1.90-2.18 (m, 2H), 2.46-2.74 (m, 3H), 3.17 (s, 3H),
    4.84 (s, 2H), 6.69 (dd, J = 2.1, 8.7 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz,
    1H), 7.38-7.48 (m, 2H), 7.56-7.64 (m, 2H); IR (Nujol) 2924, 2746,
    2657, 2561, 1716, 1591, 1476, 1347, 1307, 1289, 1242, 1148 cm−1; Elemental
    analysis (C24H27N2FO4S) Calcd. (%): C, 62.86; H, 5.93; F, 4.14; N, 6.11; S,
    6.99 Found (%): C, 62.92; H, 6.09; F, 3.93; N, 6.20; S, 6.69
    Ih-58 mp 162-164° C.; 1H-NMR (d6-DMSO) δ 0.97 (s, 9H), 1.28-1.58 (m, 2H),
    2.02-2.30 (m, 2H), 2.42-2.80 (m, 3H), 3.17 (s, 3H), 4.84 (s, 2H), 6.67 (dd, J = 2.1,
    8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.36-7.46 (m,
    2H), 7.56-7.64 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3100, 3080, 3049, 2924,
    2743, 2633, 1590, 1437, 1412, 1344, 1235, 1169, 1145 cm−1
    Ih-59 mp 152-155° C.; 1H-NMR (d6-DMSO) δ 0.92 (t, J = 6.9 Hz, 3H), 1.30-1.54 (m,
    6H), 1.90-2.16 (m, 2H), 2.46-2.76 (m, 3H), 3.12 (s, 3H), 3.84 (s, 3H), 4.85 (s,
    2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.97 (d, J = 2.1 Hz, 1H), 7.09 (d, J = 7.5 Hz,
    1H), 7.24 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.7 Hz, 2H), 13.00 (br s, 1H); IR
    (Nujol) 2952, 2752, 2665, 2569, 1729, 1598, 1576, 1499, 1476, 1345, 1308,
    1246, 1153 cm−1; Elemental analysis (C25H30N2O5S) Calcd. (%): C, 63.81; H,
    6.43; N, 5.95; S, 6.81 Found (%): C, 63.72; H, 6.38; N, 6.00; S, 6.68
    Ih-60 mp 140-144° C.; 1H-NMR (d6-DMSO) δ 0.97 (s, 9H), 1.24-1.50 (m, 2H),
    2.00-2.30 (m, 2H), 2.40-2.78 (m, 3H), 3.13 (s, 3H), 3.84 (s, 3H), 4.84 (s, 2H),
    6.68 (dd, J = 2.1, 8.4 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 7.09 (d, J = 9.0 Hz, 2H),
    7.22 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 8.7 Hz, 2H), 13.00 (br, 1H); IR (Nujol)
    2924, 2746, 2641, 2559, 1717, 1596, 1578, 1476, 1341, 1241, cm−1; Elemental
    analysis (C26H32N2O5S) Calcd. (%): C, 64.44; H, 6.66; N, 5.78; S, 6.66 Found
    (%): C, 64.23; H, 6.78; N, 5.90; S, 6.36
  • TABLE 76
    Compound
    No. Physical properties
    Ih-61 mp 169-171° C.; 1H-NMR (d6-DMSO) δ 0.89 (t, J = 6.9 Hz, 3H), 1.20-2.19 (m,
    12H), 2.57-2.76 (m, 3H), 3.17 (s, 3H), 4.85 (s, 2H), 6.70 (dd, J = 2.1, 8.4 Hz,
    1H), 7.00 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.38-7.46 (m, 2H),
    7.57-7.62 (m, 2H), 13.00 (br s, 1H); IR (Nujol) 2920, 2854, 1720, 1591, 1476,
    1346, 1240, 1146 cm−1; Elemental analysis (C26H31FN2O4S) Calcd. (%): C,
    64.18; H, 6.42; F, 3.90; N, 5.76; S, 6.59 Found (%): C, 64.20; H, 6.46; F, 3.66;
    N, 5.80; S, 6.52
    Ih-62 mp 157-160° C.; 1H-NMR (d6-DMSO) δ 0.89 (t, J = 6.9 Hz, 3H), 1.26-2.19 (m,
    12H), 2.54-2.76 (m, 3H), 3.13 (s, 3H), 3.84 (s, 3H), 4.85 (s, 2H), 6.69 (dd, J = 2.1,
    8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 7.06-7.12 (m, 2H), 7.25 (d, J = 8.7 Hz,
    1H), 7.43-7.48 (m, 2H), 13.00 (br s, 1H); IR (Nujol) 2924, 2854, 1721,
    1597, 1496, 1476, 1338, 1256, 1242, 1149 cm−1; Elemental analysis
    (C27H34N2O5S) Calcd. (%): C, 65.04; H, 6.87; N, 5.62; S, 6.43 Found (%): C,
    64.92; H, 6.88; N, 5.62; S, 6.42
    Ih-63 mp 183-189° C.; 1H-NMR (d6-DMSO) δ 0.95 (t, J = 7.2 Hz, 3H), 1.74-1.84 (m,
    4H), 2.51-2.60 (m, 4H), 3.55 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 4.86 (s, 2H),
    6.62 (dd, J = 2.1, 8.7 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H), 7.06-7.11 (m, 2H),
    7.27 (d, J = 8.7 Hz, 1H), 7.49-7.54 (m, 2H), 13.04 (br, 1H); IR (Nujol) 3201,
    3114, 1767, 1748, 1593, 1579, 1493, 1477, 1458, 1427, 1377, 1324, 1308,
    1257, 1189, 1154, 1084, 1065, 1057 cm−1; Elemental analysis (C23H26N2O5S)
    Calcd. (%): C, 62.42; H, 5.92; N, 6.33; S, 7.25 Found (%): C, 62.36; H, 5.91; N,
    6.32; S, 7.07
    Ih-64 mp 146-150° C.; 1H-NMR (d6-DMSO) δ 0.84 (t, J = 7.2 Hz, 3H), 1.25-1.36 (m,
    2H), 1.70-1.88 (m, 4H), 2.50-2.61 (m, 4H), 3.44 (t, J = 69 Hz, 2H), 3.84 (s,
    3H), 4.85 (s, 2H), 6.62 (dd, J = 2.1, 8.7 Hz, 1H), 6.94 (d, J = 2.1 Hz, 1H),
    7.06-7.11 (m, 2H), 7.26 (d, J = 8.7 Hz, 1H), 7.47-7.52 (m, 2H), 12.92 (br, 1H);
    IR (Nujol) 2744, 2654, 2557, 1741, 1720, 1596, 1580, 1494, 1475, 1440, 1414,
    1375, 1342, 1306, 1255, 1240, 1176, 1166, 1148, 1107, 1092, 1072, 1058,
    1033 cm−1; Elemental analysis (C24H28N2O5S•0.4AcOEt) Calcd. (%): C, 62.52;
    H, 6.39; N, 5.70; S, 6.52 Found (%): C, 62.58; H, 6.44; N, 5.76; S, 6.30
    Ih-65 mp 200-210° C.; 1H-NMR (d6-DMSO) δ 0.86 (d, J = 6.6 Hz, 6H), 1.41 (m, 1H),
    1.70-1.88 (m, 4H), 2.50-2.64 (m, 4H), 3.32 (d, J = 6.6 Hz, 2H), 3.84 (s, 3H),
    4.85 (s, 2H), 6.64 (dd, J = 2.1, 8.7 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H),
    7.05-7.10 (m, 2H), 7.26 (d, J = 8.7 Hz, 1H), 7.45-7.50 (m, 2H); IR (Nujol) 3150, 2575,
    2421, 1738, 1715, 1621, 1596, 1579, 1497, 1476, 1467, 1426, 1376, 1366,
    1320, 1307, 1265, 1211, 1180, 1146, 1090, 1069, 1055 cm−1; Elemental
    analysis (C25H30N2O5S) Calcd. (%): C, 63.81; H, 6.43; N, 5.95; S, 6.81 Found
    (%): C, 63.72; H, 6.32; N, 5.89; S, 6.55
  • TABLE 77
    Compound
    No. Physical properties
    Ih-66 mp 184-193° C.; 1H-NMR (d6-DMSO) δ 0.97 (d, J = 6.9 Hz, 6H), 1.72-1.89 (m,
    4H), 2.51-2.65 (m, 4H), 3.85 (s, 3H), 4.47 (m, 1H), 4.87 (s, 2H), 6.63 (dd, J = 2.1,
    8.7 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H), 7.08-7.13 (m, 2H), 7.29 (d, J = 8.7 Hz,
    1H), 7.62-7.67 (m, 2H); IR (Nujol) 3261, 1750, 1713, 1596, 1577, 1498,
    1476, 1378, 1364, 1338, 1318, 1303, 1265, 1217, 1183, 1146, 1112, 1086 cm−1.
    Ih-67 mp 183-186° C.; 1H-NMR (d6-DMSO) δ 0.97 (t, J = 7.2 Hz, 3H), 1.70-1.90 (m,
    4H), 2.53-2.64 (m, 4H), 3.60 (q, J = 7.2 Hz, 2H), 4.86 (s, 2H), 6.63 (dd, J = 1.8,
    8.7 Hz, 1H), 6.95 (d, J = 1.8 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.38-7.45 (m,
    2H), 7.62-7.68 (m, 2H); IR (Nujol) 2925, 2854, 1725, 1711, 1592, 1476, 1341,
    1243, 1182, 1172, 1148 cm−1; Elemental analysis (C22H23N2O4S) Calcd. (%):
    C, 61.38; H, 5.39, F, 4.41; N, 6.51; S, 7.45 Found (%): C, 61.12; H, 5.55; F,
    4.14; N, 6.33; S, 7.08
    Ih-68 mp 182-184° C.; 1H-NMR (d6-DMSO) δ 0.85 (t, J = 7.5 Hz, 3H), 1.24-1.41 (m,
    2H), 1.70-1.90 (m, 4H), 2.52-2.64 (m, 4H), 3.51 (t, J = 6.3 Hz, 2H), 4.86 (s,
    2H), 6.64 (dd, J = 1.8, 8.7 Hz, 1H), 6.95 (d, J = 1.8 Hz, 1H), 7.27 (d, J = 8.7 Hz,
    1H), 7.38-7.45 (m, 2H), 7.62-7.66 (m, 2H); IR (Nujol) 2925, 2854, 1727,
    1709, 1592, 1492, 1475, 1341, 1291, 1241, 1172, 1146 cm−1; Elemental
    analysis (C23H25N2O4S) Calcd. (%): C, 62.14; H, 5.67, F, 4.27; N, 6.30; S, 7.21
    Found (%): C, 61.94; H, 5.70; F, 4.07; N, 6.32; S, 6.96
    Ih-69 mp 165-168° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.52-2.64 (m, 4H),
    4.22 (d, J = 5.7 Hz, 2H), 4.85 (s, 2H), 4.99-5.13 (m, 2H), 5.62-5.80 (m, 1H),
    6.66 (dd, J = 2.1, 8.7 Hz, 1H), 6.97 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 8.7 Hz,
    1H), 7.39-7.46 (m, 2H), 7.64-7.69 (m, 2H); IR (Nujol) 2925, 2853, 1727, 1709,
    1592, 1493, 1477, 1344, 1243, 1166, 1154 cm−1; Elemental analysis
    (C23H23FN2O4S) Calcd. (%): C, 62.43; H, 5.24; F, 4.29; N, 6.30; S, 7.25 Found
    (%): C, 62.22; H, 5.27; F, 4.12; N, 6.32; S, 6.99
    Ih-70 mp 199-204° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.52-2.64 (m, 4H),
    3.20 (br t, 1H), 4.49 (d, J = 2.4 Hz, 2H), 4.87 (s, 2H), 6.77 (dd, J = 1.8, 8.4 Hz,
    1H), 7.08 (d, J = 1.8 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.39-7.46 (m, 2H),
    7.68-7.73 (m, 2H); IR (Nujol) 3292, 2925, 2854, 1724, 1592, 1477, 1337,
    1238, 1155 cm−1; Elemental analysis (C23H21FN2O4S) Calcd. (%): C, 62.71; H,
    4.81; F, 4.31; N, 6.36; S, 7.28 Found (%): C, 62.55; H, 4.91; F, 4.10; N, 6.32;
    S, 7.21
    Ih-71 mp 164-167° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.52-2.64 (m, 4H),
    4.55 (d, J = 9.0 Hz, 2H), 4.86 (s, 2H), 6.70 (dd, J = 2.1, 8.7 Hz, 1H), 7.00 (d, J = 2.1 Hz,
    1H), 7.29 (d, J = 8.7 Hz, 1H), 7.38-7.45 (m, 2H), 7.67-7.73 (m, 2H);
    IR (Nujol) 2920, 2854, 1724, 1710, 1593, 1495, 1478, 1344, 1240, 1167, 1155 cm−1.
  • TABLE 78
    Compound
    No. Physical properties
    Ih-72 mp 143-147° C.; 1H-NMR (d6-DMSO) δ 1.70-1.90 (m, 4H), 2.52-2.64 (m, 4H),
    3.33-3.50 (m, 2H), 3.61 (t, J = 6.3 Hz, 2H), 4.73 (br s, 1H), 4.86 (s, 2H),
    6.65 (dd, J = 2.1, 8.7 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H),
    7.38-7.45 (m, 2H), 7.63-7.69 (m, 2H); IR (Nujol) 3610, 3439, 2925, 2854,
    1724, 1710, 1591, 1493, 1476, 1341, 1238, 1166, 1153 cm−1
    Ih-73 mp 184-189° C.; 1H-NMR (d6-DMSO) δ 0.05-0.10 (m, 2H), 0.31-0.37 (m, 2H),
    1.70-1.91 (m, 4H), 2.52-2.60 (m, 4H), 3.45 (d, J = 6.9 Hz, 2H), 4.86 (s, 2H),
    6.68 (dd, J = 2.1, 8.7 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz,
    1H), 7.37-7.44 (m, 2H), 7.62-7.68 (m, 2H); IR (Nujol) 2923, 2854, 1725, 1712,
    1592, 1492, 1470, 1343, 1241, 1164, 1151 cm−1; Elemental analysis
    (C24H25FN2O4S) Calcd. (%): C, 63.14; H, 5.52; F, 4.16; N, 6.14; S, 7.02 Found
    (%): C, 63.05; H, 5.54; F, 3.95; N, 6.13; S, 6.88
    Ih-74 mp 139-144° C.; 1H-NMR (d6-DMSO) δ 1.70-1.88 (m, 4H), 2.49-2.63 (m, 4H),
    3.84 (s, 3H), 4.18 (d, 6.3 Hz, 2H), 4.84 (s, 2H), 4.98 (dd, J = 1.5, 10.2 Hz, 2H),
    5.08 (dd, J = 1.5, 17.1 Hz, 1H), 5.70 (m, 1H), 6.63 (dd, J = 2.1, 8.7 Hz, 1H),
    6.96 (d, J = 2.1 Hz, 1H), 7.06-7.11 (m, 2H), 7.23 (d, J = 8.7 Hz, 1H),
    7.50-7.55 (m, 2H), 13.00 (br, 1H); IR (Nujol) 2753, 2651, 2570, 1719, 1597, 1578, 1496,
    1477, 1464, 1444, 1417, 1377, 1341, 1308, 1252, 1179, 1155, 1092, 1060,
    1022 cm−1; Elemental analysis (C24H26N2O5S) Calcd. (%): C, 63.42; H, 5.77;
    N, 6.16; S, 7.05 Found (%): C, 63.26; H, 5.54; N, 6.19; S, 6.82
    Ih-75 mp 134-138° C.; 1H-NMR (d6-DMSO) δ 1.44 (s, 3H), 1.54 (s, 3H), 1.70-1.86 (m,
    4H), 2.49-2.63 (m, 4H), 3.84 (s, 3H), 4.31 (d, 6.9 Hz, 2H), 4.85 (s, 2H),
    5.04 (m, 1H), 6.64 (dd, J = 2.1, 8.7 Hz, 1H), 6.94 (d, J = 2.1 Hz, 1H), 7.06-7.11 (m,
    2H), 7.23 (d, J = 8.7 Hz, 1H), 7.49-7.54 (m, 2H), 13.00 (br, 1H); IR (Nujol)
    2742, 2655, 2558, 1721, 1596, 1580, 1496, 1476, 1465, 1441, 1413, 1388,
    1376, 1364, 1338, 1306, 1256, 1242, 1213, 1177, 1155, 1112, 1094, 1080,
    1036 cm−1; Elemental analysis (C26H30N2O5S) Calcd. (%): C, 64.71; H, 6.27;
    N, 5.80; S, 6.64 Found (%): C, 64.68; H, 6.04; N, 5.82; S, 6.36
    Ih-76 mp 193-202° C.; 1H-NMR (d6-DMSO) δ 1.72-1.88 (m, 4H), 2.49-2.64 (m, 4H),
    3.16 (t, J = 2.4 Hz, 1H), 3.84 (s, 3H), 4.44 (d, 2.4 Hz, 2H), 4.86 (s, 2H),
    6.74 (dd, J = 2.1, 8.7 Hz, 1H), 7.07 (d, J = 2.1 Hz, 1H), 7.05-7.10 (m, 2H), 7.27 (d, J = 8.7 Hz,
    1H), 7.53-7.58 (m, 2H), 13.02 (br, 1H); IR (Nujol) 3281, 3030, 2746,
    2657, 2562, 1721, 1597, 1580, 1499, 1477, 1462, 1438, 1426, 1413, 1388,
    1329, 1306, 1265, 1245, 1154, 1098, 1034 cm−1; Elemental analysis
    (C24H24N2O5S) Calcd. (%): C, 63.70; H, 5.35; N, 6.19; S, 7.09 Found (%): C,
    63.61; H, 5.36; N, 6.29; S, 6.89
  • TABLE 79
    Compound
    No. Physical properties
    Ih-77 mp 176-189° C.; 1H-NMR (d6-DMSO) δ 0.02-0.08 (m, 2H), 0.30-0.36 (m, 2H),
    0.77 (m, 1H), 1.70-1.88 (m, 4H), 2.49-2.64 (m, 4H), 3.41 (d, J = 6.9 Hz, 2H),
    3.84 (s, 3H), 4.86 (s, 2H), 6.67 (dd, J = 2.1, 8.7 Hz, 1H), 6.99 (d, J = 2.1 Hz,
    1H), 7.05-7.10 (m, 2H), 7.26 (d, J = 8.7 Hz, 1H), 7.49-7.54 (m, 2H), 12.96 (br,
    1H); IR (Nujol) 3146, 1739, 1594, 1579, 1496, 1477, 1442, 1426, 1397, 1377,
    1339, 1319, 1303, 1263, 1216, 1187, 1146, 1089, 1065, 1047 cm−1; Elemental
    analysis (C25H28N2O5S) Calcd. (%): C, 64.08; H, 6.02; N, 5.98; S, 6.84 Found
    (%): C, 63.97; H, 6.09; N, 6.05; S, 6.63
    Ih-78 mp 167-177° C.; 1H-NMR (d6-DMSO) δ 1.72-1.89 (m, 4H), 2.49-2.65 (m, 4H),
    3.34 (t, J = 6.6 Hz, 2H), 3.56 (t, J = 6.6 Hz, 2H), 3.84 (s, 3H), 4.68 (br, 1H),
    4.85 (s, 2H), 6.64 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H),
    7.06-7.11 (m, 2H), 7.25 (d, J = 8.7 Hz, 1H), 7.50-7.54 (m, 2H), 12.96 (br, 1H); IR (Nujol)
    3554, 3230, 1770, 1747, 1593, 1578, 1495, 1478, 1458, 1396, 1377, 1325,
    1301, 1261, 1221, 1185, 1156, 1088, 1060 cm−1; Elemental analysis
    (C23H26N2O6S) Calcd. (%): C, 60.25; H, 5.72; N, 6.11; S, 6.99 Found (%): C,
    60.09; H, 5.60; N, 6.07; S, 6.87
    Ih-79 mp 185-197° C.; 1H-NMR (d6-DMSO) δ 0.85-1.25 (m, 6H), 1.52-1.90 (m, 9H),
    2.49-2.63 (m, 4H), 3.38 (d, J = 7.2 Hz, 2H), 4.86 (s, 2H), 6.66 (dd, J = 2.1, 8.7 Hz,
    1H), 6.93 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.36-7.43 (m, 2H),
    7.57-7.63 (m, 2H), 12.99 (br, 1H); IR (Nujol) 3110, 3052, 2735, 2656, 2548,
    1734, 1710, 1593, 1492, 1472, 1423, 1407, 1384, 1343, 1289, 1234, 1169,
    1153, 1099, 1091, 1063 cm−1; Elemental analysis (C27H31FN2O4S) Calcd. (%):
    C, 65.04; H, 6.27; F, 3.81; N, 5.62; S, 6.43 Found (%): C, 64.81; H, 6.26; F,
    3.69; N, 5.58; S, 6.32
    Ih-80 mp 197-207° C.; 1H-NMR (d6-DMSO) δ 0.84-1.20 (m, 6H), 1.52-1.88 (m, 9H),
    2.49-2.63 (m, 4H), 3.34 (d, J = 6.9 Hz, 2H), 3.83 (s, 3H), 4.85 (s, 2H), 6.65 (dd,
    J = 1.8, 8.7 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 7.04-7.09 (m, 2H), 7.26 (d, J = 8.7 Hz,
    1H), 7.44-7.50 (m, 2H), 13.03 (br, 1H); IR (Nujol) 3159, 1740, 1580,
    1499, 1475, 1445, 1387, 1376, 1365, 1349, 1321, 1306, 1265, 1198, 1161,
    1142, 1091 cm−1; Elemental analysis (C28H34N2O5S) Calcd. (%): C, 65.86; H,
    6.71; N, 5.49; S, 6.28 Found (%): C, 65.79; H, 6.74; N, 5.52; S, 6.24
    Ih-81 mp 177-180° C.; 1H-NMR (d6-DMSO) δ 1.70-1.88 (m, 4H), 2.49-2.63 (m, 4H),
    3.82 (s, 3H), 4.85 (s, 2H), 5.02 (s, 2H), 6.70 (dd, J = 2.1, 8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz,
    1H), 7.26 (d, J = 8.7 Hz, 1H), 7.35-7.43 (m, 2H), 7.68-7.75 (m, 2H),
    12.99 (br, 1H); IR (Nujol) 3059, 3012, 2741, 2654, 2550, 1726, 1707, 1593,
    1496, 1478, 1444, 1426, 1410, 1387, 1338, 1296, 1235, 1213, 1179, 1156,
    1110, 1099, 1082, 1033 cm−1; Elemental analysis (C22H23FN2O5S) Calcd. (%):
    C, 59.18; H, 5.19; F, 4.26; N, 6.27; S, 7.18 Found (%): C, 59.08; H, 5.29; F,
    4.05; N, 6.19; S, 6.96
  • TABLE 80
    Compound
    No. Physical properties
    Ih-82 mp 153-157° C.; 1H-NMR (d6-DMSO) δ 1.70-1.88 (m, 4H), 2.49-2.63 (m, 4H),
    3.31 (s, 3H), 3.83 (s, 3H), 4.84 (s, 2H), 4.99 (s, 2H), 6.69 (dd, J = 2.1, 8.7 Hz,
    1H), 7.02 (d, J = 2.1 Hz, 1H), 7.03-7.08 (m, 2H), 7.25 (d, J = 8.7 Hz, 1H),
    7.55-7.60 (m, 2H), 12.99 (br, 1H); IR (Nujol) 2747, 2656, 2561, 1726, 1597,
    1579, 1498, 1476, 1442, 1414, 1386, 1338, 1307, 1260, 1242, 1178, 1157,
    1140, 1113, 1097, 1066, 1037 cm−1; Elemental analysis (C23H26N2O6S) Calcd.
    (%): C, 60.25; H, 5.72; N, 6.11; S, 6.99 Found (%): C, 60.14; H, 5.82; N, 6.09;
    S, 6.97
    Ih-83 mp 189-193° C.; 1H-NMR (d6-DMSO) δ 1.09 (d, J = 6.3 Hz, 3H), 1.30-1.45 (m,
    1H), 1.80-2.00 (m, 2H), 2.07-2.80 (m, 4H), 3.16 (s, 3H), 4.85 (s, 2H), 6.67 (dd,
    J = 2.1, 8.7 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H),
    7.39-7.62 (m, 4H), 12.91 (br, 1H); IR (Nujol) 2923, 2854, 1730, 1592, 1476, 1346,
    1237, 1150 cm−1; Elemental analysis (C22H23FN2O4S) Calcd. (%): C, 61.38; H,
    5.39; F, 4.41; N, 6.51; S, 7.45 Found (%): C, 61.34; H, 5.42; F, 4.21; N, 6.62;
    S, 7.30
    Ih-84 mp 157-161° C.; 1H-NMR (d6-DMSO) δ 1.09 (d, J = 6.6 Hz, 3H), 1.30-1.45 (m,
    1H), 1.80-2.00 (m, 2H), 2.10-2.80 (m, 4H), 3.12 (s, 3H), 3.84 (s, 3H), 4.85 (s,
    2H), 6.67 (dd, J = 2.1, 9.0 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.07-7.27 (m, 2H),
    7.45 (d, J = 9.0 Hz, 1H), 7.44-7.48 (m, 2H), 13.00 (br, 1H); IR (Nujol) 2924,
    2853, 1724, 1595, 1475, 1341, 1248, 1151 cm−1; Elemental analysis
    (C22H23FN2O4S) Calcd. (%): C, 62.42; H, 5.92; N, 6.33; S, 7.25 Found (%): C,
    62.41; H, 5.93; N, 6.48; S, 7.19
    Ii-1 1H-NMR (CDCl3) δ 5.17 (s, 2H), 7.07-7.45 (m, 7H), 7.58 (t, J = 2.1 Hz, 1H),
    7.70 (m, 1H), 7.81-7.91 (m, 3H); IR (KBr) 3249, 1730, 1610, 1591, 1495,
    1495, 1475, 1390, 1324, 1235, 1168, 1153, 1090, 1011 cm−1; Elemental
    analysis (C21H16FN3O4S•MeOH) Calcd. (%): C, 57.76; H, 4.41; N, 9.19; F,
    4.15; S, 7.01 Found (%): C, 57.72; H, 4.07; N, 8.80; F, 4.10, S, 7.06
    Ii-2 1H-NMR (CDCl3 + CD3OD) δ 4.87 (s, 2H), 6.99 (m, 1H), 7.08-7.42 (m, 9H),
    7.73 (d, J = 7.8 Hz, 1H), 7.82 (m, 2H); IR (KBr) 3254, 1726, 1607, 1590, 1550,
    1494, 1468, 1406, 1378, 1335, 1293, 1238, 1166, 1153, 1089 cm−1; Elemental
    analysis (C22H17FN2O4S•0.8MeOH) Calcd. (%): C, 60.84; H, 4.52; N, 6.22; F,
    4.22; S, 7.12 Found (%): C, 60.52; H, 4.13; N, 6.19; F, 3.85; S, 6.99
    Ii-3 1H-NMR (CD3OD) δ 3.33 (s, 3H), 5.08 (s, 2H), 7.02 (m, 1H), 7.17-7.51 (m,
    8H), 7.64-7.76 (m, 4H); IR (CHCl3) 3066, 2928, 1727, 1591, 1550, 1493, 1469,
    1380, 1349, 1293, 1234, 1175, 1151, 1087 cm−1.
    Ij-1 1H-NMR (CDCl3) δ 1.55-2.30 (m, 6H), 3.34 (m, 1H), 3.82 (m, 1H), 4.77 (br,
    1H), 4.82 (s, 2H), 6.75-7.25 (m, 6H), 7.45-7.91 (m, 3H); IR (KBr) 3275, 2955,
    1731, 1592, 1494, 1469, 1328, 1292, 1237, 1152, 1092, 1014 cm−1; Elemental
    analysis (C21H21FN2O4S•1.1H2O) Calcd. (%): C, 57.57; H, 5.38; N, 6.39; F,
    4.34; S, 7.32 Found (%): C, 57.73; H, 5.08; N, 6.11; F, 4.04, S, 6.87
  • TABLE 81
    Compound
    No. Physical properties
    Ij-2 1H-NMR (CDCl3) δ 1.59-2.18 (m, 6H), 2.70 (s, 3H), 3.25 (m, 1H), 4.56 (m,
    1H), 4.83 (s, 2H), 6.80 (s, 1H), 7.07-7.22 (m, 6H), 7.51 (m, 1H), 7.75-7.87 (m,
    2H); IR (KBr) 2952, 1729, 1591, 1493, 1469, 1335, 1292, 1233, 1152, 1087,
    1013 cm−1.
    Ij-3 1H-NMR (CDCl3) δ 1.43-2.18 (s, 6H), 3.17 (s, 1H), 4.26-4.82 (m, 5H),
    6.59-7.44 (m, 12H), 7.75-7.87 (m, 2H); IR (KBr) 3433, 2951, 1731, 1591, 1494,
    1469, 1337, 1292, 1235, 1152, 1092 cm−1.
    Ik-1 mp 165-179° C.; 1H-NMR (d6-DMSO) δ 2.09 (s, 3H), 2.23 (s, 3H), 3.17 (d, J = 0.6 Hz,
    3H), 4.90 (s, 2H), 6.68 (dd, J = 2.1, 8.7 Hz, 1H), 7.02 (d, J = 2.1 Hz,
    1H), 7.26 (d, J = 8.7 Hz, 1H), 7.39-7.44 (m, 2H), 7.57-7.62 (m, 2H), 12.97 (br,
    1H); IR (Nujol) 3211, 1766, 1739, 1590, 1492, 1481, 1461, 1418, 1377, 1326,
    1291, 1264, 1238, 1177, 1137, 1095, 1082, 1063 cm−1; Elemental analysis
    (C19H19FN2O4S) Calcd. (%): C, 58.45; H, 4.91; F, 4.87; N, 7.18; S, 8.21 Found
    (%): C, 58.46; H, 4.76; F, 4.57; N, 7.12; S, 8.18
    Ik-2 mp 206-208° C. (dec); 1H-NMR (d6-DMSO) δ 2.31 (s, 3H), 3.16 (s, 3H), 4.93 (s,
    2H), 6.72 (dd, J = 2.1, 8.4 Hz, 1H), 7.09 (d, J = 2.1 Hz, 1H), 7.29 (d, J = 8.4 Hz,
    1H), 7.38-7.44 (m, 2H), 7.55-7.60 (m, 2H); IR (Nujol) 3105, 3055, 2657,
    2566, 1721, 1591, 1556, 1494, 1480, 1453, 1399, 1349, 1338, 1294, 1241,
    1230, 1167, 1151, 1089, 1065 cm−1; Elemental analysis (C18H17FN2O4S)
    Calcd. (%): C, 57.44; H, 4.55; F, 5.05; N, 7.44; S, 8.52 Found (%): C, 57.50;
    H, 4.44; F, 4.99; N, 7.39; S, 8.47
    Ik-3 mp 172-178° C.; 1H-NMR (d6-DMSO) δ 1.02 (t, J = 7.5 Hz, 3H), 2.20 (s, 3H),
    2.53 (q, J = 7.5 Hz, 2H), 4.83 (s, 2H), 6.74 (dd, J = 2.1, 8.7 Hz, 1H), 7.01 (d, J = 2.1 Hz,
    1H), 7.18 (d, J = 8.7 Hz, 1H), 7.30-7.38 (m, 2H), 7.67-7.74 (m, 2H),
    9.77 (s, 1H), 12.98 (br, 1H); IR (Nujol) 3254, 1726, 1589, 1487, 1410, 1377,
    1333, 1289, 1246, 1233, 1167, 1088 cm−1; Elemental analysis (C19H19FN2O4S)
    Calcd. (%): C, 58.45; H, 4.91; F, 4.87; N, 7.18; S, 8.21 Found (%): C, 58.39;
    H, 4.88; F, 4.75; N, 7.21; S, 8.18
    Ik-4 mp 165-171° C.; 1H-NMR (d6-DMSO) δ 1.19 (d, J = 6.9 Hz, 6H), 2.20 (s, 3H),
    3.05 (septet, J = 6.9 Hz, 1H), 4.80 (s, 2H), 6.75 (dd, J = 1.8, 8.4 Hz, 1H),
    7.01 (d, J = 1.8 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.31-7.39 (m, 2H), 7.67-7.73 (m,
    2H), 9.72 (s, 1H), 13.00 (br, 1H); IR (Nujol) 3250, 3124, 1741, 1591, 1483,
    1377, 1318, 1293, 1200, 1146, 1088 cm−1; Elemental analysis (C20H21FN2O4S)
    Calcd. (%): C, 59.39; H, 5.23; F, 4.70; N, 6.93; S, 7.93 Found (%): C, 59.28;
    H, 5.19; F, 4.58; N, 6.93; S, 7.86
    Ik-5 mp 161-167° C.; 1H-NMR (d6-DMSO) δ 1.02 (t, J = 7.5 Hz, 3H), 2.23 (s, 3H),
    2.55 (q, J = 7.5 Hz, 2H), 3.18 (s, 3H), 4.91 (s, 2H), 6.75 (dd, J = 2.1, 8.7 Hz,
    1H), 6.96 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.38-7.45 (m, 2H),
    7.55-7.62 (m, 2H), 12.99 (br, 1H); IR (Nujol) 3185, 1766, 1478, 1328, 1180,
    1143, 1087 cm−1; Elemental analysis (C20H21FN2O4S) Calcd. (%): C, 59.39; H,
    5.23; F, 4.70; N, 6.93; S, 7.93 Found (%): C, 59.33; H, 5.16; F, 4.58; N,
    6.93; S, 7.82
  • TABLE 82
    Compound
    No. Physical properties
    Ik-6 Mp 210-217° C.; 1H-NMR (d6-DMSO) δ 1.18 (d, J = 7.2 Hz, 6H), 2.24 (s, 3H),
    3.07 (septet, J = 7.2 Hz, 1H), 3.19 (s, 3H), 4.89 (s, 2H), 6.77 (dd, J = 2.1, 9.0 Hz,
    1H), 7.01 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 9.0 Hz, 1H), 7.36-7.44 (m, 2H),
    7.56-7.62 (m, 2H), 12.99 (br, 1H); IR (Nujol) 3241, 1771, 1750, 1587, 1482,
    1324, 1178, 1086 cm−1; Elemental analysis (C21H23FN2O4S) Calcd. (%): C,
    60.27; H, 5.54; F, 4.54; N, 6.69; S, 7.66 Found (%): C, 60.04; H, 5.61; F, 4.30;
    N, 6.49; S, 7.30
    Ik-7 Mp 121-124° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.5 Hz, 3H), 1.43-1.55 (m,
    2H), 2.10 (s, 3H), 2.64 (t, J = 7.5 Hz, 2H), 3.18 (s, 3H), 4.89 (s, 2H), 6.69 (dd,
    J = 2.1, 8.7 Hz, 1H), 7.05 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H),
    7.40-7.47 (m, 2H), 7.60-7.66 (m, 2H), 12.97 (br, 1H); IR (Nujol) 3232, 1766, 1747,
    1480, 1327, 1183, 1143, 1088 cm−1; Elemental analysis (C21H23FN2O4S)
    Calcd. (%): C, 60.27; H, 5.54; F, 4.54; N, 6.69; S, 7.66 Found (%): C, 60.17; H,
    5.51; F, 4.45; N, 6.73; S, 7.53
    Ik-8 Mp 175-177° C.; 1H-NMR (d6-DMSO) δ 1.16 (t, J = 7.2 Hz, 3H), 2.58 (q, J = 7.2 Hz,
    2H), 3.18 (s, 3H), 4.92 (s, 2H), 6.80 (dd, J = 2.1, 9.0 Hz, 1H), 7.08 (d, J = 2.1 Hz,
    1H), 7.14 (s, 1H), 7.29 (d, J = 9.0 Hz, 1H), 7.39-7.45 (m, 2H),
    7.57-7.63 (m, 2H), 12.95 (br, 1H); IR (Nujol) 2655, 1730, 1711, 1591, 1481, 1389,
    1345, 1251, 1177, 1156 cm−1; Elemental analysis (C19H19FN2O4S) Calcd. (%):
    C, 58.45; H, 4.91; F, 4.87; N, 7.18; S, 8.21 Found (%): C, 58.41; H, 4.94; F,
    4.77; N, 7.03; S, 7.99
    Ik-9 Mp 225-240° C.; 1H-NMR (d6-DMSO) δ 0.79 (t, J = 7.2 Hz, 3H), 1.34-1.46 (m,
    2H), 2.18 (s, 3H), 2.48 (t, J = 7.2 Hz, 2H), 4.74 (s, 2H), 6.73 (dd, J = 2.1, 8.7 Hz,
    1H), 6.94 (d, J = 2.1 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.29-7.37 (m, 2H),
    7.66-7.72 (m, 2H), 9.73 (brs, 1H); IR (Nujol) 3265, 1754, 1712, 1590, 1484,
    1462, 1377, 1332, 1290, 1236, 1200, 1158, 1087 cm−1; Elemental analysis
    (C20H21FN2O4S•0.2H2O) Calcd. (%): C, 58.87; H, 5.29; F, 4.66; N, 6.87; S, 7.86
    Found (%): C, 58.75; H, 5.12; F, 4.46; N, 6.82; S, 7.82
    Ik-10 Mp 160-174° C.; 1H-NMR (d6-DMSO) δ 0.81 (t, J = 7.2 Hz, 3H), 1.34-1.46 (m,
    2H), 2.23 (s, 3H), 2.50 (t, J = 7.2 Hz, 2H), 3.19 (s, 3H), 4.91 (s, 2H), 6.76 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.90 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H),
    7.36-7.43 (m, 2H), 7.55-7.60 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3243, 1767, 1587,
    1482, 1325, 1178, 1140, 1085 cm−1; Elemental analysis (C21H23FN2O4S)
    Calcd. (%): C, 60.27; H, 5.54; F, 4.54; N, 6.69; S, 7.66 Found (%): C, 60.22; H,
    5.57; F, 4.32; N, 6.62; S, 7.59
  • TABLE 83
    Compound
    No. Physical properties
    Ik-11 Mp 165-173° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.5 Hz, 3H), 1.05 (t, J = 7.5 Hz,
    3H), 1.39-1.49 (m, 2H), 2.53-2.62 (m, 4H), 4.81 (s, 2H), 6.75 (dd, J = 1.8,
    8.7 Hz, 1H), 7.02 (d, J = 1.8 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 7.32-7.36 (m,
    2H), 7.70-7.75 (m, 2H), 9.79 (s, 1H); IR (Nujol) 3270, 2666, 1709, 1594, 1494,
    1479, 1466, 1427, 1408, 1379, 1361, 1329, 1290, 1239, 1195, 1163, 1091 cm−1;
    Elemental analysis (C21H23FN2O4S) Calcd. (%): C, 60.27; H, 5.54; F, 4.54; N,
    6.69; S, 7.66 Found (%): C, 60.10; H, 5.49; F, 4.43; N, 6.63; S, 7.63
    Ik-12 mp 182-190° C.; 1H-NMR (d6-DMSO) δ 0.91 (t, J = 7.5 Hz, 3H), 1.09 (t, J = 7.5 Hz,
    3H), 1.40-1.53 (m, 2H), 2.53-2.63 (m, 4H), 4.83 (s, 2H), 6.79 (dd, J = 2.1,
    8.7 Hz, 1H), 7.05-7.08 (m, 1H), 7.12 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.7 Hz,
    1H), 7.39-7.41 (m, 1H), 7.82-7.84 (m, 1H), 9.90 (s, 1H); IR (Nujol) 3249,
    3103, 3081, 2660, 1708, 1480, 1468, 1429, 1404, 1378, 1362, 1334, 1235,
    1198, 1158, 1091, 1017 cm−1; Elemental analysis (C19H22N2O4S2) Calcd. (%):
    C, 56.14; H, 5.45; N, 6.89; S, 15.78 Found (%): C, 56.05; H, 5.45; N, 6.74; S,
    15.56
    Ik-13 mp 134-137° C.; 1H-NMR (d6-DMSO) δ 0.91 (t, J = 7.5 Hz, 3H), 1.04 (t, J = 7.5 Hz,
    3H), 1.41-1.54 (m, 2H), 2.54-2.65 (m, 4H), 3.18 (s, 3H), 4.88 (s, 2H),
    6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.96 (d, J = 2.1 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H),
    7.38-7.44 (m, 2H), 7.57-7.63 (m, 2H), 13.09 (br, 1H); IR (Nujol) 3063, 2659,
    2558, 2464, 1706, 1592, 1493, 1476, 1430, 1418, 1378, 1343, 1322, 1291,
    1234, 1194, 1168, 1149, 1085, 1064 cm−1; Elemental analysis (C22H25FN2O4S)
    Calcd. (%): C, 61.09; H, 5.83; F, 4.39; N, 6.48; S, 7.41 Found (%): C, 61.05; H,
    5.79; F, 4.25; N, 6.40; S, 7.45
    Ik-14 mp 130-132° C.; 1H-NMR (d6-DMSO) δ 0.92 (t, J = 7.5 Hz, 3H), 1.07 (t, J = 7.5 Hz,
    3H), 1.42-1.54 (m, 2H), 2.54-2.66 (m, 4H), 3.21 (s, 3H), 4.89 (s, 2H),
    6.77 (dd, J = 2.1, 8.7 Hz, 1H), 7.04 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 2.1 Hz, 1H),
    7.22-7.25 (m, 2H), 7.47 (dd, J = 1.2, 3.6 Hz, 1H), 8.00 (dd, J = 1.2, 5.1 Hz,
    1H), 12.99 (br, 1H); IR (Nujol) 3102, 3075, 2654, 2554, 1723, 1477, 1422,
    1405, 1379, 1350, 1236, 1227, 1194, 1149, 1085, 1061, 1015 cm−1; Elemental
    analysis (C20H24N2O4S2) Calcd. (%): C, 57.12; H, 5.75; N, 6.66; S, 15.25
    Found (%): C, 56.90; H, 5.74; N, 6.60; S, 15.17
    Ik-15 mp 235-250° C.; 1H-NMR (d6-DMSO) δ 0.80 (t, J = 7.2 Hz, 3H), 1.34-1.47 (m,
    2H), 2.18 (s, 3H), 2.48 (t, J = 7.2 Hz, 2H), 3.75 (s, 3H), 4.69 (s, 2H), 6.72 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H), 6.96-7.01 (m, 2H), 7.11 (d, J = 8.7 Hz,
    1H), 7.52-7.57 (m, 2H), 9.52 (brs, 1H); IR (Nujol) 3254, 1744, 1596,
    1485, 1460, 1375, 1260, 1170, 1092, 1028 cm−1; Elemental analysis
    (C21H24N2O5S•0.4H2O) Calcd. (%): C, 59.53; H, 5.90; N, 6.61; S, 7.57 Found
    (%): C, 59.61; H, 5.69; N, 6.61; S, 7.57
  • TABLE 84
    Compound
    No. Physical properties
    Ik-16 mp 152-162° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.2 Hz, 3H), 1.34-1.46 (m,
    2H), 2.23 (s, 3H), 2.49 (t, J = 7.2 Hz, 2H), 3.14 (s, 3H), 3.83 (s, 3H), 4.91 (s,
    2H), 6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 7.04-7.09 (m, 2H),
    7.26 (d, J = 8.7 Hz, 1H), 7.42-7.47 (m, 2H), 12.97 (br, 1H); IR (Nujol) 3222,
    1765, 1741, 1593, 1482, 1379, 1327, 1306, 1265, 1177, 1142, 1088, 1017 cm−1;
    Elemental analysis (C22H26N2O5S) Calcd. (%): C, 61.38; H, 6.09; N, 6.51; S,
    7.45 Found (%): C, 61.26; H, 6.12; N, 6.52; S, 7.51
    Ik-17 mp 173-183° C.; 1H-NMR (d6-DMSO) δ 0.90 (t, J = 7.5 Hz, 3H), 1.05 (t, J = 7.5 Hz,
    3H), 1.38-1.51 (m, 2H), 2.53-2.61 (m, 4H), 3.76 (s, 3H), 4.80 (s, 2H),
    6.75 (dd, J = 1.8, 8.7 Hz, 1H), 6.99-7.02 (m, 2H), 7.04 (d, J = 1.8 Hz, 1H), 7.11 (d, J = 8.7 Hz,
    1H), 7.59-7.62 (m, 2H), 9.61 (s, 1H); IR (Nujol) 3241, 3170, 3013,
    1759, 1732, 1597, 1577, 1498, 1478, 1466, 1383, 1355, 1321, 1263, 1190,
    1146, 1090, 1028 cm−1; Elemental analysis (C22H26N2O5S) Calcd. (%): C,
    61.38; H, 6.09; N, 6.51; S, 7.45 Found (%): C, 61.05; H, 6.05; N, 6.51; S,
    7.32
    Ik-18 mp 114-116° C.; 1H-NMR (d6-DMSO) δ 0.92 (t, J = 7.2 Hz, 3H), 1.04 (t, J = 7.2 Hz,
    3H), 1.41-1.54 (m, 2H), 2.54-2.65 (m, 4H), 3.14 (s, 3H), 3.83 (s, 3H),
    4.88 (s, 2H), 6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.94 (d, J = 2.1 Hz, 1H), 7.07-7.09 (m,
    2H), 7.21 (d, J = 8.7 Hz, 1H), 7.45-7.48 (m, 2H); IR (Nujol) 3314, 3100, 3067,
    1767, 1742, 1596, 1579, 1497, 1480, 1465, 1377, 1342, 1318, 1302, 1263,
    1168, 1138, 1088, 1060 cm−1; Elemental analysis (C21H20F2N2O4S•0.2AcOEt)
    Calcd. (%): C, 61.85; H, 6.46; N, 6.06; S, 6.94 Found (%): C, 61.66; H, 6.47; N,
    6.08; S, 6.88
    Ik-19 mp 162-169° C.; 1H-NMR (d6-DMSO) δ 2.29 (s, 3H), 3.13 (s, 3H), 3.91 (s, 2H),
    4.95 (s, 2H), 6.78 (dd, J = 2.1, 8.7 Hz, 1H), 6.94 (d, J = 2.1 Hz, 1H),
    7.06-7.36 (m, 8H), 7.49-7.56 (m, 2H), 13.02 (br, 1H); IR (Nujol) 3149, 1739, 1590, 1476,
    1415, 1376, 1346, 1165, 1151 cm−1; Elemental analysis (C25H23FN2O4S)
    Calcd. (%): C, 64.36; H, 4.97; F, 4.07; N, 6.00; S, 6.87 Found (%): C, 64.31; H,
    4.88; F, 3.95; N, 5.97; S, 6.73
    Ik-20 mp 192-197° C.; 1H-NMR (d6-DMSO) δ 2.29 (s, 3H), 3.08 (s, 3H), 3.83 (s, 3H),
    3.92 (s, 2H), 4.94 (s, 2H), 6.75 (dd, J = 2.1, 8.7 Hz, 1H), 6.96-7.24 (m, 8H),
    7.29 (d, J = 8.7 Hz, 1H), 7.40-7.44 (m, 2H), 13.02 (br, 1H); IR (Nujol) 1703,
    1598, 1496, 1479, 1338, 1256, 1146, 1090, 1027 cm−1; Elemental analysis
    (C26H26N2O5S) Calcd. (%): C, 65.25; H, 5.48; N, 5.85; S, 6.70 Found (%): C,
    64.95; H, 5.49; N, 5.70; S, 6.35
  • TABLE 85
    Compound
    No. Physical properties
    Ik-21 mp 140-147° C.; 1H-NMR (d6-DMSO) δ 0.80 (d, J = 6.6 Hz, 6H), 1.60 (septet, J = 6.6 Hz,
    1H), 2.22 (s, 3H), 2.38 (d, J = 6.6 Hz, 2H), 3.19 (s, 3H), 4.92 (s, 2H),
    6.78 (dd, J = 2.1, 8.7 Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 1H),
    7.35-7.43 (m, 2H), 7.55-7.62 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3253, 1766,
    1587, 1481, 1324, 1177, 1139, 1085 cm−1; Elemental analysis (C22H25FN2O4S)
    Calcd. (%): C, 61.09; H, 5.83; F, 4.39; N, 6.48; S, 7.41 Found (%): C, 60.97; H,
    5.75; F, 4.23; N, 6.37; S, 7.32
    Ik-22 mp 137-142° C.; 1H-NMR (d6-DMSO) δ 0.85 (t, J = 7.2 Hz, 3H), 1.14-1.40 (m,
    4H), 2.19 (s, 3H), 2.50 (t-like, 2H), 4.84 (s, 2H), 6.76 (dd, J = 1.8, 8.7 Hz, 1H),
    6.93 (d, J = 1.8 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 7.30-7.36 (m, 2H),
    7.67-7.72 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3255, 3106, 3041, 2652, 2550, 1714, 1592,
    1484, 1466, 1407, 1378, 1351, 1332, 1290, 1233, 1199, 1169, 1159, 1091 cm−1;
    Elemental analysis (C21H23FN2O4S) Calcd. (%): C, 60.27; H, 5.54; F, 4.54; N,
    6.69; S, 7.66 Found (%): C, 60.22; H, 5.52; F, 4.39; N, 6.78; S, 7.56
    Ik-23 mp 130-140° C.; 1H-NMR (d6-DMSO) δ 0.86 (t, J = 6.9 Hz, 3H), 1.15-1.42 (m,
    4H), 2.18 (s, 3H), 2.50 (t-like, 2H), 3.76 (s, 3H), 4.82 (s, 2H), 6.75 (dd, J = 2.1,
    9.0 Hz, 1H), 6.97 (d, J = 2.1 Hz, 1H), 6.97-7.02 (m, 2H), 7.16 (d, J = 9.0 Hz,
    1H), 7.56-7.61 (m, 2H), 9.57 (s, 1H), 12.95 (br, 1H); IR (Nujol) 3248, 3076,
    2651, 2553, 1714, 1598, 1578, 1499, 1484, 1465, 1410, 1379, 1328, 1301,
    1261, 1232, 1181, 1157, 1093, 1029 cm−1; Elemental analysis (C22H26N2O5S)
    Calcd. (%): C, 61.38; H, 6.09; N, 6.51; S, 7.45 Found (%): C, 61.21; H, 6.04; N,
    6.48; S, 7.27
    Ik-24 mp 125-129° C.; 1H-NMR (d6-DMSO) δ 0.86 (t, J = 6.9 Hz, 3H), 1.17-1.40 (m,
    4H), 2.22 (s, 3H), 2.50 (t-like, 2H), 3.19 (s, 3H), 4.90 (s, 2H), 6.78 (dd, J = 2.1,
    8.7 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.36-7.43 (m,
    2H), 7.55-7.61 (m, 2H), 13.03 (br, 1H); IR (Nujol) 3253, 3121, 3091, 3074,
    1768, 1591, 1479, 1416, 1377, 1327, 1292, 1229, 1186, 1166, 1137, 1099,
    1087, 1072, 1055 cm−1; Elemental analysis (C22H25FN2O4S) Calcd. (%): C,
    61.09; H, 5.83; F, 4.39; N, 6.48; S, 7.41 Found (%): C, 61.10; H, 5.72; F, 4.31;
    N, 6.46; S, 7.39
    Ik-25 mp 140-145° C.; 1H-NMR (d6-DMSO) δ 0.86 (t, J = 7.2 Hz, 3H), 1.18-1.41 (m,
    4H), 2.22 (s, 3H), 2.50 (t-like, 2H), 3.14 (s, 3H), 3.83 (s, 3H), 4.90 (s, 2H),
    6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 7.04-7.09 (m, 2H),
    7.26 (d, J = 8.7 Hz, 1H), 7.42-7.47 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3241, 3090,
    3066, 3016, 1764, 1737, 1702, 1593, 1576, 1495, 1481, 1467, 1457, 1415,
    1378, 1328, 1305, 1264, 1172, 1141, 1087, 1017 cm−1; Elemental analysis
    (C23H28N2O5S) Calcd. (%): C, 62.14; H, 6.35; N, 6.30; S, 7.21 Found (%): C,
    62.04; H, 6.23; N, 6.29; S, 7.09
  • TABLE 86
    Compound
    No. Physical properties
    Ik-26 mp 139-147° C.; 1H-NMR (d6-DMSO) δ 0.79 (d, J = 6.6 Hz, 6H), 1.63 (m, 1H),
    2.18 (s, 3H), 2.37 (d, J = 6.6 Hz, 2H), 3.76 (s, 3H), 4.84 (s, 2H), 6.75 (dd, J = 1.8,
    8.7 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.96-7.01 (m, 2H), 7.16 (d, J = 8.7 Hz,
    1H), 7.55-7.60 (m, 2H), 9.54 (s, 1H), 12.90 (br, 1H); IR (Nujol) 3325,
    3254, 3098, 3077, 1748, 1595, 1578, 1484, 1464, 1436, 1418, 1378, 1333,
    1317, 1304, 1291, 1260, 1203, 1166, 1141, 1112, 1091 cm−1; Elemental
    analysis (C22H26N2O5S) Calcd. (%): C, 61.38; H, 6.09; N, 6.51; S, 7.45 Found
    (%): C, 61.13; H, 6.13; N, 6.55; S, 7.24
    Ik-27 mp 148-160° C.; 1H-NMR (d6-DMSO) δ 0.80 (d, J = 6.6 Hz, 6H), 1.61 (m, 1H),
    2.22 (s, 3H), 2.37 (d, J = 6.6 Hz, 2H), 3.15 (s, 3H), 3.83 (s, 3H), 4.91 (s, 2H),
    6.77 (dd, J = 2.1, 8.4 Hz, 1H), 6.84 (d, J = 2.1 Hz, 1H), 7.03-7.08 (m, 2H),
    7.26 (d, J = 8.4 Hz, 1H), 7.42-7.47 (m, 2H), 12.96 (br, 1H); IR (Nujol) 3252, 3097,
    3077, 3058, 3025, 1750, 1724, 1595, 1577, 1482, 1465, 1415, 1373, 1320,
    1305, 1270, 1212, 1188, 1163, 1144, 1091, 1053, cm−1; Elemental analysis
    (C23H28N2O5S) Calcd. (%): C, 62.14; H, 6.35; N, 6.30; S, 7.21 Found (%): C,
    62.16; H, 6.39; N, 6.32; S, 7.22
    Ik-28 mp 150-175° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.5 Hz, 3H), 0.96 (t, J = 7.2 Hz,
    3H), 1.33-1.45 (m, 2H), 2.23 (s, 3H), 2.48 (t, J = 7.5 Hz, 2H), 3.58 (q, J = 7.2 Hz,
    2H), 3.83 (s, 3H), 4.91 (s, 2H), 6.71 (dd, J = 1.8, 8.7 Hz, 1H), 6.83 (d, J = 1.8 Hz,
    1H), 7.04-7.09 (m, 2H), 7.27 (d, J = 8.7 Hz, 1H), 7.48-7.53 (m, 2H),
    12.97 (br, 1H); IR (Nujol) 3178, 1762, 1742, 1728, 1594, 1577, 1476, 1379,
    1328, 1306, 1261, 1181, 1139 cm−1; Elemental analysis (C23H28N2O5S) Calcd.
    (%): C, 62.14; H, 6.35; N, 6.30; S, 7.21 Found (%): C, 61.87; H, 6.31; N, 6.33;
    S, 6.94
    Ik-29 mp 153-165° C.; 1H-NMR (d6-DMSO) δ 0.83 (t, J = 7.5 Hz, 3H), 1.36-1.48 (m,
    2H), 2.23 (s, 3H), 2.50 (t, J = 7.5 Hz, 2H), 3.12 (s, 3H), 4.89 (s, 2H), 6.74 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.83-6.88 (m, 2H), 6.91 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.7 Hz,
    1H), 7.31-7.36 (m, 2H), 10.48 (br, 1H), 13.03 (br, 1H); IR (Nujol)
    3177, 1719, 1586, 1479, 1442, 1377, 1335, 1241, 1222, 1152 cm−1; Elemental
    analysis (C21H24N2O5S) Calcd. (%): C, 60.56; H, 5.81; N, 6.73; S, 7.70 Found
    (%): C, 60.38; H, 5.94; N, 6.52; S, 7.32
    Ik-30 mp 202-210° C.; 1H-NMR (d6-DMSO) δ 2.27 (s, 3H), 3.89 (s, 2H), 4.88 (s, 2H),
    6.75 (dd, J = 2.1, 8.4 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 7.07-7.33 (m, 8H),
    7.62-7.68 (m, 2H), 7.97 (s, 1H), 12.98 (br, 1H); IR (Nujol) 3263, 1709, 1594,
    1481, 1411, 1379, 1334, 1292, 1234, 1169 cm−1; Elemental analysis
    (C24H21FN2O4S) Calcd. (%): C, 63.70; H, 4.68; F, 4.20; N, 6.19; S, 7.09 Found
    (%): C, 63.47; H, 4.75; F, 3.93; N, 6.17; S, 6.74
  • TABLE 87
    Compound
    No. Physical properties
    Ik-31 mp 130-155° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.5 Hz, 3H), 1.33-1.45 (m,
    5H), 2.23 (s, 3H), 2.49 (t, J = 7.5 Hz, 2H), 3.14 (s, 3H), 4.10 (q, J = 7.2 Hz,
    2H), 4.90 (s, 2H), 6.76 (dd, J = 2.1, 8.7 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H),
    7.02-7.07 (m, 2H), 7.26 (d, J = 8.7 Hz, 1H), 7.40-7.45 (m, 2H), 12.93 (br, 1H);
    IR (Nujol) 3247, 1739, 1594, 1480, 1415, 1377, 1304, 1256, 1153 cm−1.
    Ik-32 mp 90-96° C.; 1H-NMR (d6-DMSO) δ 0.81 (t, J = 7.5 Hz, 3H), 1.33-1.45 (m,
    2H), 2.23 (s, 3H), 2.48 (t, J = 7.5 Hz, 2H), 3.19 (t, J = 2.4 Hz, 1H), 3.83 (s,
    3H), 4.46 (q, J = 2.4 Hz, 2H), 4.90 (s, 2H), 6.82 (dd, J = 2.1, 8.4 Hz, 1H),
    6.98 (d, J = 2.1 Hz, 1H), 7.04-7.09 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 7.53-7.58 (m,
    2H), 13.03 (br, 1H); IR (Nujol) 3588, 3310, 2642, 1733, 1707, 1687, 1599,
    1580, 1499, 1479, 1465, 1414, 1379, 1345, 1257, 1159, 1029 cm−1; Elemental
    analysis (C24H26N2O5S•0.8H2O) Calcd. (%): C, 61.47; H, 5.93; N, 5.97; S, 6.84
    Found (%): C, 61.56; H, 5.69; N, 5.87; S, 6.58
    Ik-33 mp 144-157° C.; 1H-NMR (d6-DMSO) δ 2.29 (s, 3H), 3.10 (t, J = 2.1 Hz, 1H),
    3.82 (s, 2H), 3.89 (s, 2H), 4.41 (d, J = 2.1 Hz, 2H), 4.94 (s, 2H), 6.82 (dd, J = 2.1,
    8.7 Hz, 1H), 7.00-7.24 (m, 8H), 7.31 (d, J = 8.7 Hz, 1H), 7.52-7.55 (m,
    2H), 13.06 (br, 1H); IR (Nujol) 3291, 2644, 1933, 1716, 1598, 1579, 1498,
    1475, 1346, 1335, 1262, 1240, 1158, 1095 cm−1; Elemental analysis
    (C28H26N2O5S) Calcd. (%): C, 66.91; H, 5.21; N, 5.57; S, 6.38 Found (%): C,
    66.65; H, 5.26; N, 5.56; S, 6.14
    Ik-34 mp 123-130° C.; 1H-NMR (d6-DMSO) δ 0.80 (d, J = 6.9 Hz, 6H), 1.59 (septet, J = 6.9 Hz,
    1H), 2.22 (s, 3H), 2.37 (d, J = 6.9 Hz, 2H), 3.22 (t, J = 2.4 Hz, 1H),
    4.52 (d, J = 2.4 Hz, 2H), 4.92 (s, 2H), 6.84 (dd, J = 1.8, 8.7 Hz, 1H), 6.96 (d, J = 1.8 Hz,
    1H), 7.30 (d, J = 8.7 1H), 7.35-7.42 (m, 2H), 7.67-7.72 (m, 2H),
    13.03 (br, 1H); IR (Nujol) 3307, 2654, 1732, 1592, 1493, 1475, 1379, 1350,
    1246, 1168, 1096 cm−1; Elemental analysis (C24H25FN2O4S) Calcd. (%): C,
    63.14; H, 5.52; F, 4.16; N, 6.14; S, 7.02 Found (%): C, 62.99; H, 5.36; F, 4.25;
    N, 6.13; S, 7.44
    Ik-35 mp 157-160° C.; 1H-NMR (d6-DMSO) δ 2.21 (s, 3H), 3.18 (s, 3H), 3.70 (s, 3H),
    4.90 (s, 2H), 6.77 (dd, J = 2.1, 8.7 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 7.33 (d, J = 8.7
    1H), 7.38-7.55 (m, 2H), 7.56-7.62 (m, 2H), 13.05 (br, 1H); IR (Nujol)
    1741, 1592, 1485, 1469, 1385, 1343, 1298, 1292, 1267, 1240, 1204, 1171,
    1090, 1059 cm−1; Elemental analysis (C19H19FN2O5S) Calcd. (%): C, 56.15; H,
    4.71; F, 4.67; N, 6.89; S, 7.89 Found (%): C, 56.28; H, 4.62; F, 4.37; N, 6.90;
    S, 7.70
  • TABLE 88
    Compound
    No. Physical properties
    Ik-36 mp 170-180° C.; 1H-NMR (d6-DMSO) δ 2.21 (s, 3H), 3.14 (s, 3H), 3.69 (s, 3H),
    3.83 (s, 3H), 4.90 (s, 2H), 6.77 (dd, J = 2.1, 8.7 Hz, 1H), 6.98 (d, J = 2.1 Hz,
    1H), 7.06-7.11 (m, 2H), 7.32 (d, J = 8.7 Hz, 1H), 7.43-7.48 (m, 2H), 13.03 (br,
    1H); IR (Nujol) 1726, 1597, 1498, 1479, 1415, 1383, 1338, 1305, 1266, 1254,
    1150, 1091, 1026, 1011 cm−1; Elemental analysis (C20H22N2O6S) Calcd. (%):
    C, 57.40; H, 5.30; N, 6.69; S, 7.66 Found (%): C, 56.78; H, 5.33; N, 6.64; S,
    7.30
    Ik-37 mp 142-152° C.; 1H-NMR (d6-DMSO) δ 1.04 (t, J = 7.2 Hz, 3H), 2.63 (s, 3H),
    2.72 (q, J = 7.2 Hz, 2H), 3.17 (s, 3H), 3.84 (s, 3H), 5.11 (s, 2H), 6.93 (dd, J = 2.1,
    8.7 Hz, 1H), 7.08-7.13 (m, 2H), 7.46-7.51 (m, 4H), 13.30 (br, 1H); IR
    (Nujol) 3544, 3355, 1734, 1693, 1598, 1577, 1513, 1498, 1477, 1459, 1412,
    1378, 1341, 1262, 1208, 1161, 1149, 1107, 1092, 1066, 1034 cm−1; Elemental
    analysis (C22H24N2O6S•0.4H2O) Calcd. (%): C, 58.50; H, 5.53; N, 6.20; S, 7.10
    Found (%): C, 58.43; H, 5.67; N, 6.23; S, 6.88
    Jk-38 mp 105-115° C.; 1H-NMR (d6-DMSO) δ 0.97 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.2 Hz,
    3H), 2.63 (s, 3H), 2.69 (q, J = 7.2 Hz, 2H), 3.61 (q, J = 7.2 Hz, 2H),
    3.84 (s, 3H), 5.12 (s, 2H), 6.89 (dd, J = 1.8, 8.7 Hz, 1H), 7.08-7.13 (m, 2H), 7.41 (d,
    J = 1.8 Hz, 1H), 7.49-7.57 (m, 3H), 13.32 (br, 1H); IR (Nujol) 3313, 1729,
    1631, 1596, 1576, 1509, 1496, 1479, 1461, 1446, 1412, 1378, 1337, 1260,
    1221, 1188, 1147, 1107, 1092, 1065, 1028 cm−1; Elemental analysis
    (C23H26N2O6S•0.5H2O) Calcd. (%): C, 59.09; H, 5.82; N, 5.99; S, 6.86 Found
    (%): C, 59.18; H, 5.72; N, 6.11; S, 6.99
    Ik-39 mp 169-176° C.; 1H-NMR (d6-DMSO) δ 0.81 (t, J = 7.5 Hz, 3H), 1.33-1.45 (m,
    2H), 2.23 (s, 3H), 2.49 (t, J = 7.5 Hz, 2H), 3.18 (s, 3H), 4.90 (s, 2H), 6.73 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H),
    7.51-7.59 (m, 4H), 7.70 (m, 1H), 13.00 (br, 1H); IR (Nujol) 3060, 2756, 2658, 2564,
    1729, 1708, 1584, 1480, 1447, 1415, 1380, 1335, 1307, 1246, 1170, 1146,
    1085, 1069, 1053 cm−1; Elemental analysis (C21H24N2O4S) Calcd. (%): C,
    62.98; H, 6.04; N, 6.99; S, 8.01 Found (%): C, 62.88; H, 5.76; N, 6.93; S, 7.95
    Ik-40 mp 130-136° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.2 Hz, 3H), 1.33-1.45 (m,
    2H), 2.23 (s, 3H), 2.39 (s, 3H), 2.50 (t, J = 7.2 Hz, 2H), 3.18 (s, 3H), 4.90 (s,
    2H), 6.74 (dd, J = 2.1, 8.7 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz,
    1H), 7.34-7.42 (m, 4H), 13.00 (br, 1H); IR (Nujol) 3284, 3048, 1750, 1722,
    1597, 1580, 1481, 1456, 1416, 1375, 1338, 1321, 1308, 1290, 1205, 1193,
    1166, 1146, 1087, 1055 cm−1; Elemental analysis (C22H26N2O4S) Calcd. (%):
    C, 63.75; H, 6.32; N, 6.76; S, 7.74 Found (%): C, 63.58; H, 6.05; N, 6.73; S,
    7.94
  • TABLE 89
    Compound
    No. Physical properties
    Ik-41 mp 152-159° C.; 1H-NMR (d6-DMSO) δ 0.79 (t, J = 7.2 Hz, 3H), 1.31-1.43 (m,
    2H), 2.22 (s, 3H), 2.48 (t, J = 7.2 Hz, 2H), 3.32 (s, 3H), 4.89 (s, 2H), 6.80 (dd,
    J = 2.1, 8.7 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.25-7.31 (m, 2H), 7.46-7.53 (m,
    2H), 7.73 (m, 1H), 13.01 (br, 1H); IR (Nujol) 3081, 3026, 2756, 2656, 2596,
    2562, 1730, 1709, 1596, 1475, 1448, 1416, 1380, 1350, 1269, 1244, 1211,
    1182, 1172, 1142, 1124, 1072, 1051 cm−1; Elemental analysis (C21H23FN2O4S)
    Calcd. (%): C, 60.27; H, 5.54; F, 4.54; N, 6.69; S, 7.66 Found (%): C, 60.29; H,
    5.36; F, 4.57; N, 6.63; S, 7.62
    Ik-42 mp 147-154° C.; 1H-NMR (d6-DMSO) δ 0.82 (t, J = 7.2 Hz, 3H), 1.33-1.45 (m,
    2H), 2.23 (s, 3H), 2.49 (t, J = 7.2 Hz, 2H), 3.19 (s, 3H), 4.91 (s, 2H), 6.77 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H),
    7.49-7.53 (m, 2H), 7.61-7.65 (m, 2H), 12.99 (br, 1H); IR (Nujol) 3276, 3097, 1770,
    1581, 1479, 1417, 1396, 1378, 1324, 1185, 1174, 1162, 1143, 1092, 1055,
    1011 cm−1; Elemental analysis (C21H23ClN2O4S) Calcd. (%): C, 57.99; H, 5.33;
    Cl, 8.15; N, 6.44; S, 7.37 Found (%): C, 58.05; H, 5.01; Cl, 7.79; N, 6.46; S,
    7.36
    Ik-43 mp 143-150° C.; 1H-NMR (d6-DMSO) δ 0.83 (t, J = 7.2 Hz, 3H), 1.33-1.45 (m,
    2H), 2.23 (s, 3H), 2.49 (t, J = 7.2 Hz, 2H), 3.19 (s, 3H), 4.91 (s, 2H), 6.78 (dd,
    J = 2.1, 8.7 Hz, 1H), 6.88 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H),
    7.41-7.45 (m, 2H), 7.75-7.79 (m, 2H), 12.98 (br, 1H); IR (Nujol) 3021, 2655, 1717,
    1574, 1478, 1467, 1415, 1387, 1377, 1357, 1251, 1190, 1170, 1156, 1069 cm−1;
    Elemental analysis (C21H23BrN2O4S) Calcd. (%): C, 52.61; H, 4.84; Br, 16.67;
    N, 5.84; S, 6.69 Found (%): C, 52.70; H, 4.56; Br, 16.11; N, 5.82; S, 6.67
  • Experiment 1 Binding Activity to CRTH2
  • The membrane fraction prepared with CRTH2-transfected K562 cells was used for a binding assay. To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 10 mM MgCl2) the membrane fraction (0.06 mg) and 3 nM [3H]PGD2 (172 Ci/mmol) were added, and the mixture was reacted at room temperature for 60 min. After the reaction, the mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured. The specific-binding ratio was calculated by subtracting the non-specific binding ratio which is the radioactivity similarly measured in the presence of 10 μM PGD2 from the total binding. The inhibitory activity of each compound was expressed as the concentration required for 50% inhibition (IC50), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%. The results are shown below.
  • TABLE 90
    CRTH2 inhibitory activity
    Compound No. IC50 (μM)
    Ia-15 0.037
    Ia-20 0.022
    Ia-32 0.018
    Ia-36 0.015
    Ia-39 0.045
    Ia-41 0.034
    Ia-44 0.023
    Ia-45 0.019
    Ia-47 0.051
    Ia-48 0.057
    Ia-51 0.02
    Ia-52 0.024
    Ia-55 0.042
    Ia-57 0.057
    Ia-58 0.033
    Ia-59 0.023
    Ia-61 0.045
    Ia-62 0.049
    Ia-63 0.054
    Ia-65 0.027
    Ia-66 0.037
    Ia-85 0.08
    Ib-6 0.055
    (+)-Ib-16 0.0059
    (+)-Ib-18 0.013
    (+)-Ib-20 0.0079
    Ib-21 0.012
    (+)-Ib-25 0.0036
  • TABLE 91
    CRTH2 inhibitory activity
    Compound No. IC50 (μM)
    (+)-Ib-27 0.0062
    (+)-Ib-29 0.0049
    Ib-30 0.0053
    Ib-31 0.059
    Ic-2 0.021
    Ic-6 0.0045
    Ic-14 0.0055
    Ic-24 0.068
    Ie-2 0.039
    Ie-5 0.018
    Ie-8 0.026
    If-1 0.019
    If-4 0.016
    If-9 0.012
    Ig-3 0.0097
    Ig-4 0.0078
    Ig-11 0.01
    Ig-14 0.0083
    Ig-15 0.0075
    Ig-16 0.0036
    Ig-18 0.019
    Ih-2 0.0099
    Ih-3 0.033
    Ih-4 0.024
    Ih-5 0.023
    Ih-6 0.034
    Ii-1 0.035
    Ii-2 0.035
    Ii-3 0.064
    Ij-1 0.026
    Ij-2 0.053
    Ij-3 0.053
  • TABLE 92
    CRTH2 inhibitory activity
    Compound No. IC50 (μM)
    Ik-1 0.048
    Ik-2 0.086
    Ik-3 0.051
    Ik-4 0.047
    Ik-5 0.019
  • Experiment 2 Evaluation of Antagonistic Activity to CRTH2
  • To evaluate the antagonistic activity of compounds against CRTH2, calcium mobilization assay induced by PGD2 was performed using CRTH2 transfectants.
  • The human CRTH2-transfected K562 cells were suspended at 2×106 cells/ml in assay buffer (10 mM HEPES buffer, pH 7.4, 0.1% Bovine serum albumin), and were incubated with Fura-2 AM (2 μM) for 60 min at room temperature. After washing cells were resuspended again with assay buffer, incubated at 37° C., and then treated with various concentrations of compounds for 2 min. The emitted fluorescence was measured on a calcium analyzer (CAF-110) after addition of PGD2. The antagonistic activity of each compound at 1 μM was expressed as percent inhibition of the calcium mobilization in drug-untreated cells. The results are shown below.
  • TABLE 93
    Compound No. antagonistic activity to CRTH2 (% INH)
    Ia-9 94
    Ia-51 91
    Ib-31 96
    Ib-16 100
    Ib-25 100
    Ic-6 100
    Ib-29 100
    Ia-36 89
    Ic-19 91
    Ic-31 98
    Ic-34 94
    Ic-53 60
    Ic-54 85
    Ic-55 100
    Ic-56 100
    Ic-57 100
    Ih-2 91
  • Formulation Example Formulation Example 1
  • Granules are prepared using the following ingredients.
  • Ingredients The compound represented by the formula (I)  10 mg
    Lactose 700 mg
    Corn starch 274 mg
    HPC-L  16 mg
    1000 mg 
  • The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. They are mixed by a twin shell blender. An aqueous solution of HPC-L (low mucosity hydroxypropylcellulose) is added to the mixture and the resulting mixture is kneaded, granulated (by the extrusion with pore size 0.5 to 1 mm mesh), and dried. The dried granules thus obtained are sieved by a swing sieve (12/60 mesh) to yield the granules.
  • Formulation 2
  • Powders for filling capsules are prepared using the following ingredients.
  • Ingredients The compound represented by the formula (I) 10 mg
    Lactose 79 mg
    Corn starch 10 mg
    Magnesium stearate  1 mg
    100 mg 
  • The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. These ingredients and magnesium stearate are mixed by a twin shell blender. 100 mg of the 10-fold trituration is filled into a No. 5 hard gelatin capsule.
  • Formulation 3
  • Granules for filling capsules are prepared using the following ingredients.
  • Ingredients The compound represented by the formula (I) 15 mg
    Lactose 90 mg
    Corn starch 42 mg
    HPC-L  3 mg
    150 mg 
  • The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. After mixing them, an aqueous solution of HPC-L is added to the mixture and the resulting mixture is kneaded, granulated, and dried. After the dried granules are lubricated, 150 mg of that are filled into a No. 4 hard gelatin capsule.
  • Formulation 4
  • Tablets are prepared using the following ingredients.
  • Ingredients The compound represented by the formula (I) 10 mg
    Lactose 90 mg
    Microcrystal cellulose 30 mg
    CMC-Na 15 mg
    Magnesium stearate  5 mg
    150 mg 
  • The compound represented by the formula (I), lactose, microcrystal cellulose, and CMC-Na (carboxymethylcellulose sodium salt) are made pass through a 60 mesh sieve and then mixed. The resulting mixture is mixed with magnesium stearate to obtain the mixed powder for the tablet formulation. The mixed powder is compressed to yield tablets of 150 mg.
  • INDUSTRIAL APPLICABILITY
  • The pharmaceutical composition and the compound of the present invention show superior CRTH2 receptor antagonistic activity and are useful for an agent for treating or preventing allergic diseases.

Claims (15)

1. A compound of the formula (I):
Figure US20090258922A1-20091015-C00172
wherein
a group represented by the formula:
Figure US20090258922A1-20091015-C00173
is a group represented by the formula:
Figure US20090258922A1-20091015-C00174
wherein Z3 is ═N— or ═C(—R7)—;
R4, R5, R6 and R7 are each independently hydrogen, halogen, haloalkyl, carboxy, alkyloxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, a group represented by the formula: —S(O)pR8 wherein p is an integer from 0 to 2 and R8 is alkyl or optionally substituted aryl, a group represented by the formula: —NR9R10 wherein R9 and R10 are each independently hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl or acyl, or a group represented by the formula: —OR11 wherein R11 is hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl, alkanesulfonyl, optionally substituted arylsulfonyl, optionally substituted aralkylsulfonyl, or haloalkyl;
R1 is carboxy, alkyloxycarbonyl, optionally substituted aminocarbonyl or tetrazolyl;
Z4 is —N═ or —C(—R2)═; R2 is hydrogen, alkyl or halogen;
R15 is hydrogen or alkyl;
R3 is a group represented by the formula: —(CH2)n-N(—Y)—SO2—Ar wherein n is an integer from 1 to 3; Y is hydrogen, alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl or optionally substituted arylalkenyl; and Ar is optionally substituted aryl or optionally substituted heteroaryl, a group represented by the formula:
Figure US20090258922A1-20091015-C00175
wherein r is an integer from 0 to 2; x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted aralkyl or optionally substituted arylalkenyl,
a group represented by the formula:
Figure US20090258922A1-20091015-C00176
wherein x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted aralkyl or optionally substituted arylalkenyl,
a group represented by the formula: —CR23R24—CR25R26—(CH2)y-N(—Y)—SO2—Ar wherein Ar and Y are as defined above; y is 0 or 1; one of R23 or R24 is alkyl, the other is hydrogen, alkyl, or aryl; or R23 and R24 are taken together to form a group represented by the formula: —(CH2)t- wherein t is an integer from 2 to 5; R25 and R26 are each independently hydrogen or alkyloxyalkyl,
a group represented by the formula:
Figure US20090258922A1-20091015-C00177
wherein Y and Ar are as defined above, or
a group represented by the formula:
Figure US20090258922A1-20091015-C00178
wherein Y and Ar are as defined above and u is 1 or 2; or
a group represented by the formula:
Figure US20090258922A1-20091015-C00179
is a group represented by the formula:
Figure US20090258922A1-20091015-C00180
wherein y is an integer from 1 to 3, and m, p, Y and Ar are as defined above,
a group represented by the formula:
Figure US20090258922A1-20091015-C00181
wherein m, y and Ar are as defined above, or
a group represented by the formula:
Figure US20090258922A1-20091015-C00182
wherein Y and Ar are as defined above; R20 is hydrogen or alkyl; and R21 is hydrogen or halogen; but excluding compounds 3-(4-chlorophenylsulfonylamino)-9-(2-carboxymethyl)-1,2,3,4-tetrahydrocarbazole, its ethyl ester, 3-(4-chlorophenylsulfonylaminoethyl)indole1-acetic acid, and 3-(4-chlorophenylsulfonylaminopropyl)indole acetic acid; or
R13 is hydrogen, alkyl, aralkyl, acyl or a group represented by the formula: —OR16 wherein R16 is hydrogen or alkyl, and R14 is hydrogen or alkyl: or
a group represented by the formula:
Figure US20090258922A1-20091015-C00183
is a group represented by the formula:
Figure US20090258922A1-20091015-C00184
wherein q is an integer from 0 to 3; R17 is hydrogen or alkyl; Z1 is —CH2—, —C(═O)—, —C(═NOH)—, or —C(═NOMe)-; Z2 is a group represented by the formula: —S(═O)s— wherein s is an integer from 0 to 2, a group represented by the formula: —N(—R22)— wherein R22 is hydrogen, alkyl, alkyloxycarbonyl or acyl, or a group represented by the formula: —CR18R19— wherein R18 and R19 are each independently hydrogen, alkyl or aryl; or R18 and R19 are taken together to form a group represented by the formula: —(CH2)t- wherein t is an integer from 2 to 5;
R1 and R15 are as defined above; and
a group represented by the formula:
Figure US20090258922A1-20091015-C00185
is a group represented by the formula:
Figure US20090258922A1-20091015-C00186
wherein Y, E, R20 and R21 are as defined above;
a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
2. A compound as described in claim 1, wherein a group represented by the formula:
Figure US20090258922A1-20091015-C00187
is a group represented by the formula:
Figure US20090258922A1-20091015-C00188
wherein Z3 is ═C(—R7)—; R4, R5, R6 and R7 are as defined in claim 1;
Z4 is —C(—R2)═; R2 is as defined in claim 1;
R15 is hydrogen; and
R3 is a group represented by the formula: —(CH2)n-N(—Y)—SO2—Ar wherein n is an integer from 1 to 3; Y is hydrogen, alkyl, alkenyl, optionally substituted aryl, optionally substituted aralkyl, or optionally substituted heteroarylalkyl; and Ar is optionally substituted aryl or optionally substituted heteroaryl, a group represented by the formula:
Figure US20090258922A1-20091015-C00189
wherein r is an integer from 0 to 2; x is an integer from 0 to 3; m is an integer from 1 to 3; a broken line represents the presence or absence of a bond; E is optionally substituted aryl or optionally substituted heteroaryl; or a group represented by the formula:
Figure US20090258922A1-20091015-C00190
is a group represented by the formula:
Figure US20090258922A1-20091015-C00191
wherein y is an integer from 1 to 3, and m, p, Y and Ar are as defined above, a group represented by the formula:
Figure US20090258922A1-20091015-C00192
wherein m, y and Ar are as defined above, or
a group represented by the formula:
Figure US20090258922A1-20091015-C00193
wherein Y and Ar are as defined in claim 1, and R20 and R21 are hydrogen, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
3. A compound as described in claim 1, wherein Y is alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
4. (canceled)
5. (canceled)
6. A compound as described in claim 2, wherein a group represented by the formula:
Figure US20090258922A1-20091015-C00194
is a group represented by the formula:
Figure US20090258922A1-20091015-C00195
wherein m is 2; p is 0; y is 1; Y is hydrogen, alkyl, alkenyl or aralkyl; and Ar is as defined in claim 1, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
7. (canceled)
8. (canceled)
9. A compound as described in any one of claim 1, wherein R1 is carboxy, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
10. A compound as described in claim 1, wherein R4, R5, R6 and R7 are each independently hydrogen, halogen, alkyl, alkenyl, optionally substituted aryl or optionally substituted aralkyl, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof.
11. (canceled)
12. A pharmaceutical composition containing a compound, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof as described in claim 1.
13. A pharmaceutical composition as described in claim 12, which is used for an antagonist against the CRTH2 receptor.
14. (canceled)
15. (canceled)
US12/413,503 2002-05-16 2009-03-27 Compound exhibiting pgd2 receptor antagonist Abandoned US20090258922A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/413,503 US20090258922A1 (en) 2002-05-16 2009-03-27 Compound exhibiting pgd2 receptor antagonist

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002142126 2002-05-16
JP2002-142126 2002-05-16
PCT/JP2003/006076 WO2003097598A1 (en) 2002-05-16 2003-05-15 Compound exhibiting pgd 2 receptor antagonism
US10/514,317 US7534897B2 (en) 2002-05-16 2003-05-15 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
US12/413,503 US20090258922A1 (en) 2002-05-16 2009-03-27 Compound exhibiting pgd2 receptor antagonist

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2003/006076 Division WO2003097598A1 (en) 2002-05-16 2003-05-15 Compound exhibiting pgd 2 receptor antagonism
US10/514,317 Division US7534897B2 (en) 2002-05-16 2003-05-15 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism

Publications (1)

Publication Number Publication Date
US20090258922A1 true US20090258922A1 (en) 2009-10-15

Family

ID=29544973

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/514,317 Expired - Fee Related US7534897B2 (en) 2002-05-16 2003-05-15 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
US12/413,503 Abandoned US20090258922A1 (en) 2002-05-16 2009-03-27 Compound exhibiting pgd2 receptor antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/514,317 Expired - Fee Related US7534897B2 (en) 2002-05-16 2003-05-15 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism

Country Status (5)

Country Link
US (2) US7534897B2 (en)
EP (2) EP1505061A4 (en)
JP (2) JP4484108B2 (en)
AU (1) AU2003231509A1 (en)
WO (1) WO2003097598A1 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (en) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (en) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05006701A (en) 2002-12-20 2006-03-30 Amgen Inc Asthma and allergic inflammation modulators.
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
DE10337184A1 (en) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituted 3-pyrrolidine-indole derivatives
SE0302232D0 (en) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (en) 2003-08-21 2009-11-10 استرازينيكا ايه بي Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (en) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0508540B8 (en) * 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd compound, pharmaceutical composition, and use of a compound
MXPA06013912A (en) 2004-05-29 2007-07-18 7Tm Pharma As Crth2 receptor ligands for medicinal uses.
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
BRPI0514611A (en) * 2004-08-26 2008-06-17 Actelion Pharmaceuticals Ltd use of a compound, compounds, and drug
JP5208510B2 (en) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ Phenoxyacetic acid derivatives useful for the treatment of respiratory diseases
PL1833791T3 (en) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20100113502A1 (en) * 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
CN101203491A (en) * 2005-06-24 2008-06-18 伊莱利利公司 Tetrahydrocarbazole derivatives used as androgen receptor modifier
EP2397476A3 (en) * 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
EP1911759A4 (en) * 2005-07-22 2010-07-21 Shionogi & Co Azaindole derivative having pgd2 receptor antagonistic activity
CA2618550C (en) * 2005-08-12 2013-12-17 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
JP5147401B2 (en) 2005-09-06 2013-02-20 塩野義製薬株式会社 Indolecarboxylic acid derivatives having PGD2 receptor antagonist activity
CN101273013B (en) * 2005-09-27 2013-06-12 盐野义制药株式会社 Sulfonamide derivative having PGD2 receptor antagonistic activity
KR101289995B1 (en) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Sulfonamide derivative having pgd2 receptor antagonistic activity
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
GB0614608D0 (en) * 2006-07-22 2006-08-30 Oxagen Ltd Compounds having CRTH2 antagonist activity
JP5270542B2 (en) * 2006-07-22 2013-08-21 オキサジェン リミテッド Compound having CRTH2 antagonist activity
JP5220013B2 (en) * 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド (3-Amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl) -acetic acid derivative
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2009061681A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
US20100280049A1 (en) * 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
EP2229358B1 (en) * 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
CN101903338A (en) 2007-12-19 2010-12-01 安姆根有限公司 Phenyl acetic acid derivatives as inflammation modulators
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
ES2442717T3 (en) 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compounds that have CRTH2 antagonistic activity
JP2011509990A (en) * 2008-01-22 2011-03-31 オキサジェン リミテッド Compound having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
CN101952244B (en) 2008-02-01 2014-11-05 潘米拉制药公司 N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2009099901A1 (en) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US8497381B2 (en) * 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
CN102026974B (en) * 2008-05-16 2013-08-28 伊莱利利公司 Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2010008864A2 (en) * 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
CA2728311A1 (en) * 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
WO2010018112A2 (en) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Monoaryl aminotetralines
CA2737460C (en) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
AU2009315713A1 (en) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids
WO2010055006A1 (en) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists
BRPI0921038A2 (en) 2008-11-17 2019-09-24 Hoffmann La Roche naphthylacetic acid
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
EP2401269B1 (en) 2009-02-24 2014-01-29 Merck Sharp & Dohme Corp. Indole derivatives as crth2 receptor antagonists
ES2351574B1 (en) * 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. LIBRARIES OF N-PHENETISULPHONAMIDES-N-SUBSTITUTED FOR THE DISCOVERY OF PHARMACOS
ES2351572B1 (en) * 2009-07-01 2011-11-15 Institut Univ. De Ciencia I Tecnologia S.A. LIBRARY OF N-PHENETILSULPHONAMIDES-N-SUBSTITUTED FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY.
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
US8815917B2 (en) * 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
EP2516416A1 (en) 2009-12-23 2012-10-31 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MA34094B1 (en) * 2010-03-22 2013-03-05 Actelion Pharmaceuticals Ltd 3- (HETEROARYLAMINO) -1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE PROSTAGLANDIN D2 RECEPTOR
AR088020A1 (en) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc HETEROCICLICAL COMPOUNDS AS SGC STIMULATORS
RU2013104506A (en) 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-Phenyl-substituted heterocyclyl derivatives and their use as modulators of the prostaglandin receptor D2
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CA2817319A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Triazole derivatives as sgc stimulators
US9067949B2 (en) 2011-01-19 2015-06-30 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
MX338516B (en) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
AR086931A1 (en) * 2011-06-17 2014-01-29 Merck Sharp & Dohme TETRAHYDROQUINOLINES CONDENSED WITH CYCLOALKYL AS MODULATORS OF CRTH RECEIVERS
JP6099051B2 (en) * 2011-10-25 2017-03-22 塩野義製薬株式会社 Heterocyclic derivatives having PGD2 receptor antagonist activity
CN103086943B (en) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 Indoles derivative functioning as CRTH2 receptor antagonist
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (en) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Heterocyclyl derivatives and their use as modulators of the prostaglandin D2 receptor
CN104066731B (en) 2011-12-27 2016-06-15 铁木医药有限公司 Can be used as the 2-benzyl of SGC stimulant, pyrazoles that 3-(pyrimidine-2-base) replaces
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
JP6127135B2 (en) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 1-Phenyl substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR102362835B1 (en) 2013-03-15 2022-02-14 사이클리온 테라퓨틱스, 인크. sGC STIMULATORS
JP6304877B2 (en) * 2013-04-22 2018-04-04 塩野義製薬株式会社 A pharmaceutical composition for treating and / or preventing allergic diseases, comprising a heterocycle derivative
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP3119780B1 (en) * 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (en) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Compounds as crth2 antagonist and uses thereof
MX2017003516A (en) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Pyrazole derivatives as sgc stimulators.
JP2017527604A (en) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulant
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
MX2018003202A (en) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Crystalline forms.
US10889577B2 (en) 2016-07-07 2021-01-12 Cyclerion Therapeutics, Inc. Solid forms of an sGC stimulator
MX2019000103A (en) 2016-07-07 2019-04-22 Ironwood Pharmaceuticals Inc Phosphorus prodrugs of sgc stimulators.
WO2022166638A1 (en) * 2021-02-02 2022-08-11 广东东阳光药业有限公司 Salt of indole derivative and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774240A (en) * 1985-04-24 1988-09-27 Bayer Aktiengesellschaft N-indolylethyl-sulphonic acid amides and their use
US5204374A (en) * 1990-04-10 1993-04-20 Bayer Aktiengesellschaft Cycloalkano(b)dihydroindoles and -indolesulphonamides substituted by heterocycles
US5204121A (en) * 1989-02-11 1993-04-20 Bayer Aktiengesellschaft Medicaments having controlled release of the active compound
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD264427A5 (en) 1986-02-21 1989-02-01 Bayer Ag,De PROCESS FOR PREPARING CYCLOALKANO (1.2-B) INDULSULFONAMIDES
DE3613623A1 (en) 1986-04-23 1987-10-29 Bayer Ag N-DIHYDROINDOLYLETHYL SULFONAMIDE
DE3840338A1 (en) 1988-11-30 1990-05-31 Bayer Ag NEW 2-HALOGEN-SUBSTITUTED N-INDOLYLETHYL SULPHONIC ACID AMIDES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
DE3909600A1 (en) 1989-03-23 1990-09-27 Bayer Ag Use of cycloalkano[1,2-b]indolesulphonamides in combination with plasminogen activators as drugs in thrombolytic therapy
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
TW201303B (en) 1990-07-05 1993-03-01 Hoffmann La Roche
DE4027278A1 (en) * 1990-08-29 1992-03-05 Bayer Ag HETEROCYCLICALLY SUBSTITUTED INDOLSULFONAMIDE
JP3236723B2 (en) 1993-12-21 2001-12-10 ホーチキ株式会社 Disaster prevention monitoring device
JPH08163879A (en) 1994-12-07 1996-06-21 Olympus Optical Co Ltd Ultrasonic oscillator and ultrasonic motor
JPH08157471A (en) 1994-12-07 1996-06-18 Terumo Corp 3-(benzenesulfonamidoalkyl)indole derivative
JPH08169879A (en) 1994-12-16 1996-07-02 Sagami Chem Res Center Carbazol-3, 4-dione derivative and nerve growth factor production promotor and anticataract
JP2901226B2 (en) * 1994-12-26 1999-06-07 バイエル薬品株式会社 Agent for treating allergic dermatitis
DE19506739A1 (en) 1995-02-27 1996-08-29 Bayer Ag [3-Amino] tetrahydrocarbazole propanoic acid ester
JP2002241282A (en) 1996-05-21 2002-08-28 Bayer Yakuhin Ltd Medicine for treating allergic dermatitis
ATE295360T1 (en) 1996-12-12 2005-05-15 Shionogi & Co CONDENSED HETEROCYCLIC BENZENECARBONIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING SAME
JPH11106337A (en) 1997-09-30 1999-04-20 Bayer Yakuhin Ltd Treating agent for poriasis
JPH11116477A (en) * 1997-10-15 1999-04-27 Bayer Yakuhin Ltd Treating agent for allergic conjunctival disease
JPH11343279A (en) * 1998-03-16 1999-12-14 Shionogi & Co Ltd Sulfonamide derivative and tnf-alfa production inhibitor containing the same
JPH11322600A (en) * 1998-05-07 1999-11-24 Bayer Yakuhin Ltd Chemokine production inhibitor
AU772121B2 (en) * 1999-08-23 2004-04-08 Bml, Inc. Method of identifying properties of substance to prostaglandin D receptors
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
CA2432654A1 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774240A (en) * 1985-04-24 1988-09-27 Bayer Aktiengesellschaft N-indolylethyl-sulphonic acid amides and their use
US5204121A (en) * 1989-02-11 1993-04-20 Bayer Aktiengesellschaft Medicaments having controlled release of the active compound
US5204374A (en) * 1990-04-10 1993-04-20 Bayer Aktiengesellschaft Cycloalkano(b)dihydroindoles and -indolesulphonamides substituted by heterocycles
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism

Also Published As

Publication number Publication date
EP1505061A4 (en) 2007-08-22
WO2003097598A8 (en) 2004-07-08
JP4484108B2 (en) 2010-06-16
JP2010132680A (en) 2010-06-17
EP1505061A1 (en) 2005-02-09
AU2003231509A1 (en) 2003-12-02
WO2003097598A1 (en) 2003-11-27
EP2423190A1 (en) 2012-02-29
US7534897B2 (en) 2009-05-19
US20050171143A1 (en) 2005-08-04
JPWO2003097598A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
US7534897B2 (en) Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
JP5794922B2 (en) 1,3,4-oxadiazole-2-carboxamide compound
US8106051B2 (en) Utilities of amide compounds
US6562817B1 (en) Tricyclic compound
TWI445695B (en) Sulfonamide derivatives exhibiting pgd2 receptor antagonism
EP2137158A1 (en) Small molecule inhibitors of protein arginine methyltransferases (prmts)
KR20020092348A (en) Npyy5 antagonists
WO2010004761A1 (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
IE77776B1 (en) New 5-isoquinolinesulfonamides process for preparing them and pharmaceutical compositions containing them
CN106831789A (en) Bruton's tyrosine kinase inhibitor
JP5685181B2 (en) Cyclohexane derivative having NPYY5 receptor antagonistic action
JP5392924B2 (en) Compound having NPYY5 receptor antagonistic action
MX2013001202A (en) Condensed ring pyridine compound.
AU2004263448A1 (en) Amide derivatives
JPWO2009096198A1 (en) New biaryl derivatives
TW201925211A (en) Process for preparing benzothiophen-2yl boronate
JP2003231633A (en) Medicinal composition
JP2010195688A (en) Amide and urea derivative having npyy5 receptor antagonism
CZ20002612A3 (en) Compound, pharmaceutical preparation, use of the compound, method of suppressing immune response, method of therapy and prevention of allergic diseases
JP2003055345A (en) Biphenylcarboxamide isoindoline derivative, a method of producing the same and synthetic intermediate thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION